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ABSTRACT	  
Pulmonary	   arterial	   hypertension	   (PAH)	   is	   a	   severe	   disease	   with	   limited	   therapeutic	   options	  characterised	   by	   proliferation	   of	   vascular	   cells,	   which	   in	   part	   relates	   to	   the	   presence	   of	  increased	  inflammation.	   I	  hypothesised	  that	  the	  inflammatory	  transcription	  factor	  NF-­‐kappa	  B	  (NF-­‐κB)	  was	  activated	  in	  human	  idiopathic	  PAH	  (iPAH),	  and	  that	  inhibition	  of	  NF-­‐κB	  using	  the	  synthetic	  glucocorticoid	  (GC)	  dexamethasone	  would	  reverse	  pulmonary	  hypertension	  (PH)	  and	  inflammation	   in	   the	   rat	   monocrotaline	   (MCT)	   model;	   in	   rat	   and	   human	   pulmonary	   arterial	  smooth	  muscle	  cells	  (PASMC);	  and	  in	  human	  peripheral	  blood	  mononuclear	  cells	  (PBMC).	  
Activation	   of	   NF-­‐κB	   was	   demonstrated	   in	   pulmonary	   macrophages,	   lymphocytes,	   pulmonary	  endothelial	   cells	   (EC)	   and	   PASMC	   in	   patients	   with	   severe	   iPAH,	   and	   in	   the	   rat	   MCT	   model.	  Dexamethasone	   reversed	   PH	   and	   improved	   survival	   in	   MCT-­‐induced	   PH	   in	   rats,	   with	   a	  reduction	   in	   interleukin	   (IL)-­‐6	   expression,	   and	   a	   reduction	   in	   vascular	   cell	   NF-­‐κB	   activation.	  Pulmonary	  BMPR-­‐II	  mRNA	   expression	  was	   also	   low	   in	   rats	  with	  MCT-­‐PH;	   this	  was	   increased	  following	   dexamethasone	   treatment.	   The	   dexamethasone-­‐induced	   reduction	   in	   rat	   vessel	  medial	  thickness	  was	  related	  to	  both	  a	  reduction	  in	  serum-­‐stimulated	  rat	  PASMC	  proliferation,	  and	   also	   increased	   PASMC	   apoptosis.	   I	   then	   demonstrated	   that	   dexamethasone	   inhibited	  lipopolysaccharide	   (LPS)-­‐	   and	  TNF-­‐α-­‐induced	   IL-­‐6	   and	  CXCL8	   release	   in	   an	  NF-­‐κB-­‐dependent	  manner	   in	  control	  human	  PASMC,	  whole	  blood	  and	  PBMC	  assays.	  When	  stimulated	  with	  these	  activators	   of	   NF-­‐κB,	   PBMC	   from	   PAH	   patients	   were	   relatively	   hyporesponsive	   compared	   to	  control	  cells	  in	  terms	  of	  IL-­‐6	  and	  CXCL8	  release,	  and	  were	  less	  responsive	  i.e.	  more	  resistant	  to	  dexamethasone-­‐induced	  suppression	  of	  cytokine	  release	  compared	  to	  controls.	  	  
NF-­‐κB	  activation	   is	  marked	   in	  patients	  with	   end-­‐stage	   iPAH,	   and	   reversal	   of	  NF-­‐κB	  activation	  and	  PH	  is	  possible	  in	  the	  MCT-­‐induced	  PH	  model.	  Whether	  inflammation	  might	  be	  a	  therapeutic	  target	  in	  human	  PAH	  -­‐	  and	  whether	  PAH	  is	  a	  clinically	  GC-­‐sensitive	  or	  GC-­‐resistant	  condition	  -­‐	  requires	  further	  exploration.	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CHAPTER	  1:	  INTRODUCTION	  
1.0	  General	  Introduction	  
Pulmonary	  hypertension	  (PH)	  describes	  a	  group	  of	  conditions	  with	  raised	  pulmonary	  vascular	  pressure,	   which	   are	   subdivided	   according	   to	   differences	   in	   pathophysiology	   and	   response	   to	  treatments.	   Of	   these,	   pulmonary	   arterial	   hypertension	   (PAH)	   is	   defined	   by	   PH	   in	   the	   pre-­‐capillary	  pulmonary	  arteries,	  and	  characterised	  by	  abnormal	  pulmonary	  vascular	  remodelling,	  which	  leads	  to	  a	  progressive	  increase	  in	  pulmonary	  vascular	  resistance,	  right	  ventricular	  failure	  and	   early	   death	   (Rubin,	   2006).	   PAH	   is	   rare	   disease.	   In	   the	  most	   recent	  UK	   audit	  where	  most	  (93%)	  cases	  were	  idiopathic	  PAH	  (iPAH),	  incidence	  was	  1.1	  per	  million	  and	  prevalence	  was	  6.6	  per	  million	  (Ling	  et	  al.,	  2012);	  in	  another	  survey	  where	  iPAH	  was	  less	  common	  (46%	  of	  all	  PAH	  cases)	  PAH	  prevalence	  was	  30-­‐50	  cases	  per	  million	  population	  (Peacock	  et	  al.,	  2007).	  Survival	  in	  PAH	   remains	   poor,	   despite	   the	   development	   of	   ‘advanced	   therapies’	   in	   the	   last	   twenty	   years,	  and	  the	  search	  for	  additional	  therapies	  is	  urgently	  needed.	  
A	   common	  observation	   in	  histological	   specimens,	   blood-­‐borne	   cells	   and	   circulating	  mediators	  from	  patients	  with	  PAH	  is	  the	  presence	  of	  ‘inflammation’,	  which	  can	  be	  defined	  as	  the	  presence	  of	  soluble	  factors	  and	  cells	  that	  can	  arise	  as	  a	  beneficial	   immune	  response	  to	   injury.	  However,	  persistent	  or	  uncontrolled	  inflammation	  is	  detrimental	  and	  is	  implicated	  in	  the	  pathogenesis	  of	  many	   diseases.	   	   The	   exact	   contribution	   of	   inflammation	   to	   PAH	   disease	   progression	   and	   the	  potential	   role	  of	   anti-­‐inflammatory	   therapies	   is	  not	  well	  understood.	   In	  particular,	   the	   central	  inflammatory	   transcription	   factor	  nuclear	   factor	  kappa	  B	  (NF-­‐κB)	  has	  been	   implicated	   in	  PAH	  but	  its	  precise	  role	  in	  PAH	  pathogenesis	  has	  not	  been	  explored	  in	  detail.	  	  
The	  introduction	  to	  this	  thesis	  will	  firstly	  review	  the	  basis	  of	  pulmonary	  hypertension;	  secondly	  provide	  evidence	  supporting	  a	  role	  for	  inflammation	  in	  the	  pathogenesis	  of	  PAH,	  and	  finally	  give	  an	  overview	  of	  relevant	  inflammatory	  processes	  and	  anti-­‐inflammatory	  therapies.	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1.1	  Pulmonary	  hypertension	  	  
1.1.1	  A	  Brief	  history	  of	  PH	  	  
In	   1891	   in	   Berlin,	   Germany,	   Dr	   Ernst	   von	   Romberg	   described	   the	   first	   case	   of	   ‘pulmonary	  arterial	   sclerosis’	   in	   a	   patient	   with	   an	   elevation	   in	   pulmonary	   blood	   pressure	   leading	   to	  dyspnoea	   and	   dizziness	   (Romberg,	   1891).	   The	   study	   of	   the	   pulmonary	   circulation	   advanced	  significantly	   with	   the	   advent	   of	   right	   heart	   catheterisation.	   Dr	   Werner	   Forssman,	   another	  German	  physician,	   first	   performed	   this	   technique	  upon	  himself	   in	  1929	  by	  passing	   a	   urethral	  catheter	  via	  the	  antecubital	  vein	  into	  the	  right	  atrium	  under	  fluoroscopic	  vision,	  following	  which	  the	  technique	  was	  perfected	  by	  Doctors	  André	  Cournand	  and	  Dickinson	  Richards	  in	  the	  Bellevue	  Hospital	  in	  New	  York	  in	  the	  1950s	  (and	  was	  deserving	  of	  a	  Nobel	  prize	  for	  all	  three)	  (Newman,	  2005).	   In	   1958,	   Dr	   Paul	   Wood,	   a	   cardiologist	   at	   the	   Brompton	   Hospital	   in	   London,	   defined	  pulmonary	   vascular	   resistance	   (pulmonary	   artery	   pressure	   minus	   the	   left	   atrial	   pressure	   in	  mmHg	  divided	  by	  the	  pulmonary	  blood	   flow	  in	   litres	  a	  minute,	   i.e.	  1	  (Wood)	  unit	  or	  80	  dynes	  sec/cm-­‐5),	   and	   performed	   the	   first	   pulmonary	   vasodilator	   studies	   by	   injecting	   acetylcholine	  directly	  into	  the	  pulmonary	  artery.	  He	  demonstrated	  ‘reactive’	  PH	  in	  some	  patients	  with	  mitral	  stenosis,	  and	  was	  the	  first	  to	  suggest	  the	  presence	  of	  a	  ‘vasoconstrictive	  factor’	  in	  patients	  with	  PH	  (Wood,	  1958).	  	  
Detailed	   histopathological	   study	   of	   vessel	   changes	   in	   PAH	   followed	   the	   advent	   of	   cardiac	  surgery	   in	   the	   1950s.	   In	   the	   Mayo	   Clinic,	   Professor	   Jesse	   Edwards	   and	   Dr	   Donald	   Heath	   (a	  trainee	   cardiologist	   from	   Sheffield)	   studied	   the	   pathology	   of	   patients	   with	   Eisenmenger	  syndrome	   (Heath	   and	   Edwards,	   1958),	   and	   observed	   that	   changes	  were	   reversible	   following	  corrective	   surgery	   (Heath	   et	   al.,	   1958).	   In	   1996,	   the	   pivotal	   trial	   of	   the	   first	   PAH	   ‘advanced	  therapy’	  was	  performed	  using	  epoprostenol	  (a	  synthetic	  salt	  of	  prostacyclin),	  leading	  to	  both	  an	  improvement	   in	   functional	   status	   and	   survival	   (Barst	   et	   al.,	   1996).	   The	   following	   years	   have	  seen	   significant	   advances	   in	   the	   field,	   both	   in	   the	   understanding	   of	   pathophysiology	   and	   the	  development	  of	  new	  therapies.	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1.1.2	  The	  normal	  pulmonary	  circulation	  	  
The	  pulmonary	  circulation	   is	   the	  only	  organ	  that	  receives	  the	  entire	  cardiac	  output	  at	  rest.	  To	  protect	   the	   alveolar-­‐capillary	   barrier,	   pulmonary	   vessels	   maintain	   a	   low	   basal	   tone	   and	  therefore	  a	  low	  pulmonary	  vascular	  resistance.	  In	  times	  of	  increased	  cardiac	  output,	  pulmonary	  arteries	   vasodilate	   further	   and	   further	   vessels	   are	   recruited;	   resistance	   to	   flow	   and	   pressure	  therefore	  remains	  constant.	  The	  anatomy	  of	  the	  pulmonary	  arterial	  tree	  is	  organised	  so	  that	  it	  undergoes	  a	  complex	  series	  of	  branching,	  with	  at	  least	  seventeen	  subdivisions.	  
Pulmonary	   arteries	   run	   alongside	   the	   bronchial	   tree	   in	   a	   similar	   pattern	   to	   the	   airways.	  Proximal	   large	   pulmonary	   arteries	   are	   elastic	   in	   nature,	   down	   to	   the	   level	   of	   an	   external	  diameter	  (ED)	  of	  1mm	  or	  0.5mm,	  where	  a	  transition	  to	  a	  muscular	  type	  of	  artery	  occurs,	  such	  that	  most	  arteries	  below	  500µm	  ED	  are	  completely	  muscular.	  	  
The	   muscularised	   pulmonary	   artery	   consists	   of	   three	   distinct	   layers:	   the	   intima,	   media	   and	  adventitia,	   separated	   by	   the	   internal	   and	   external	   elastic	   laminae	   (IEL	   and	   EEL)	   (Figure	   1.1).	  The	   intima	   consists	   of	   a	   single	   layer	   of	  EC	   resting	  on	   subendothelial	   collagen	  on	   the	   IEL.	  The	  media	  is	  formed	  by	  pulmonary	  arterial	  smooth	  muscle	  cells	  (PASMC)	  interposed	  with	  collagen	  and	  elastic	  fibres.	  The	  vessel	  medial	  thickness,	  measured	  between	  the	  IEL	  and	  EEL,	  is	  less	  than	  systemic	  arteries,	  and	  the	  lumen	  relatively	  wider,	  reflecting	  the	  greater	  range	  of	  flow	  and	  lower	  resistance	  of	  the	  pulmonary	  circulation.	  	  
With	   decreasing	   vessel	   size,	   muscular	   pulmonary	   arteries	   become	   partially,	   then	   completely	  non-­‐muscularised,	   forming	  arterioles	  when	   the	  ED	   is	   less	   than	  100µm	  (<80µm	   in	  rats).	  These	  vessels	  are	  usually	  ‘intra-­‐acinar’	  i.e.	  not	  accompanying	  the	  respiratory	  bronchioles.	  Cells	  found	  in	  non-­‐muscular	  arterioles	  include	  pericytes	  and	  intermediate	  cells	  which	  are	  thought	  to	  be	  the	  precursors	   of	   PASMC.	   Pericytes	   are	   stellate-­‐shaped,	   and	   lie	   within	   the	   basal	   lamina	   of	   the	  overlying	  EC;	  whereas	  intermediate	  cells	  are	  fusiform	  and	  are	  surrounded	  by	  their	  own	  lamina	  (Meyrick	   and	   Reid,	   1980b).	   In	   addition,	   the	   vessel	   wall	   also	   contains	   myofibroblasts	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Figure	  1.1:	  Components	  of	  a	  normal	  muscular	  pulmonary	  artery	  	  The	  intima	  consists	  of	  a	  single	  thin	  layer	  of	  endothelial	  cells	  resting	  on	  sub-­‐endothelial	  collagen	  and	   the	   internal	   elastic	   lamina	   (IEL),	   which	   runs	   between	   EC	   and	   the	   smooth	  muscle	  media.	  Beyond	  the	  outer	  external	  elastic	  lamina	  (EEL)	  is	  the	  adventitia,	  which	  is	  usually	  thin,	  consisting	  of	  fibroblasts	  and	  bundles	  of	  collagen.	  Photograph	  courtesy	  of	  Peter	  Dorfmuller,	  Paris.	  	  
1.1.3	  Definition	  and	  clinical	  classification	  of	  PH	  
Pulmonary	   hypertension	   (PH)	   is	   defined	   as	   an	   increase	   in	  mean	   pulmonary	   arterial	   pressure	  (mPAP)	  of	  more	  than	  25	  mmHg	  (at	  rest),	  as	  assessed	  by	  right	  heart	  catheterisation	  (Galie	  et	  al.,	  2009).	  PH	  is	   further	  subdivided	  according	  to	  the	  pulmonary	  capillary	  wedge	  pressure	  (Ppcw).	  Pre-­‐capillary	   PH	   (with	   Ppcw<15mmHg)	   includes	   clinical	   groups	   1,	   3,	   4	   and	   5	   while	   post-­‐capillary	   PH	   (Ppcw>15mmHg)	   includes	   clinical	   group	   2	   (Oudiz,	   2007).	   PAH	   is	   further	  subdivided	   into	   idiopathic	   PAH	   (iPAH),	   heritable	   PAH,	   congenital	   heart	   disease	   (CHD)-­‐associated	   PAH,	   connective	   tissue	   disease	   (CTD)-­‐associated	   PAH,	   HIV-­‐PAH,	   porto-­‐pulmonary	  hypertension	  and	  schistosomiasis-­‐associated	  PAH	  (Table	  1.1)	  (Simonneau	  et	  al.,	  2009).	  Patients	  with	  PAH	  mostly	  share	  pathological	  and	  clinical	  features	  as	  well	  as	  similarities	  in	  management.	  	  
1.1.4	  Clinical	  features	  of	  PH	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York	   Heart	   Association	   (NYHA)	   classification.	   The	   system	   takes	   into	   account	   the	   fact	   that	  syncope	  (or	  near	  syncope)	   is	  a	  marker	  of	  advanced	  PH,	  classifying	   these	  patients	  as	   ‘class	   IV',	  and	  is	  a	  strong	  mortality	  predictor	  used	  in	  clinical	  trials	  in	  PAH	  (McLaughlin	  et	  al.,	  2004).	  Clinical	  signs	  of	  PH	  include	  those	  of	   increased	  PVR	  (including	  a	  loud	  pulmonary	  component	  of	  the	  second	  heart	  sound,	  S2),	  and	  of	  right	  ventricular	  failure	  (such	  as	  fixed	  splitting	  of	  S2,	  raised	  venous	  pressure,	  pulsatile	  hepatomegaly	  and	  oedema).	  In	  patients	  without	  overt	  symptoms	  and	  signs	  of	  right	  ventricular	  failure,	  presentation	  may	  be	  non-­‐specific.	  	  	  
1.1.5	  Effects	  of	  PH	  on	  the	  right	  ventricle	  
The	  reduction	  in	  pulmonary	  vascular	  cross-­‐sectional	  area	  and	  resulting	  high	  PVR	  initially	  leads	  to	  protective	  RV	  remodelling	  and	  hypertrophy.	  However,	  ultimately	  this	  results	   in	  RV	  failure	  -­‐	  characterised	   by	   dilatation	   of	   right-­‐sided	   heart	   chambers	   and	   tricuspid	   regurgitation,	   with	  compression	   the	   left	   ventricle	   reducing	   biventricular	   function	   (Stojnic	   et	   al.,	   1992).	   Coronary	  perfusion	   of	   the	   RV,	   present	   under	   normal	   circumstances	   during	   systole	   and	   diastole,	   occurs	  only	   in	   diastole	   because	  RV	   systolic	   pressure	   is	   at	   systemic	   levels.	   In	   addition,	   coronary	   flow	  during	   diastole	   is	   reduced	   because	   the	   elevated	   RV	   diastolic	   pressure	   (due	   to	   RV	   failure)	  reduces	  the	  coronary	  perfusion	  gradient	  and	  the	  diastolic	  time	  is	  shortened	  if	  the	  heart	  rate	  is	  increased	  (Vizza	  et	  al.,	  1998).	   If	  untreated,	  a	  downward	  spiral	  of	   failing	  biventricular	   function	  further	  worsens	  coronary	  blood	  flow	  and	  ultimately	  leads	  to	  cardiovascular	  collapse	  and	  death.	  	  	  
1.1.6	  Current	  PAH	  Therapies	  
Current	   PAH	   therapies	   are	   divided	   into	   standard	   supportive	   therapy	   (including	   warfarin,	  diuretics,	  and	  calcium	  channel	  blockers	  in	  selected	  patients),	  and	  ‘advanced’	  therapies	  targeting	  specific	   PAH	   pathways,	   which	   include	   prostacyclin,	   endothelin	   receptor	   antagonists	   (e.g.	  bosentan),	  and	  inhibitors	  of	  phosphodiesterase	  type	  5	  (e.g.	  sildenafil).	  Their	  clinical	  use	   in	  the	  UK	  is	  summarised	  in	  Figure	  1.2.	  	  


















































































Figure	   1.2.	   	   Current	   UK	   evidence-­‐based	   algorithm	   for	   clinical	   management	   of	  
patients	  with	  pulmonary	  arterial	  hypertension	  (PAH).	  UK	   algorithm	   for	   the	   management	   of	   idiopathic,	   familial	   and	   anorexigen-­‐induced	   PAH.	   The	  prefixes	   1st	   and	   2nd	   indicate	   preferred	   and	   alternative	   drugs	   based	   on	   the	   quality	   and	   the	  weight	   of	   evidence	   assessed	   by	   a	   UK	   Consensus	   Meeting.	   Abbreviations:	   APAH,	   associated	  pulmonary	   arterial	   hypertension;	   FPAH,	   familial	   pulmonary	   arterial	   hypertension;	   IPAH,	  idiopathic	   pulmonary	   arterial	   hypertension;	  WHO,	  World	  Health	  Organisation.	   (Adapted	   from	  Gibbs	   et	   al	   (Gibbs,	   2008)).	  NB	   since	   this	   guideline,	   sitaxsentan	  has	   been	  withdrawn	   from	  use	  due	  to	  problems	  with	  liver	  toxicity.	  clinical deterioration which canno be rescued by restartingtherapy.
4. Synergies between agents
By exploiting molecular interrelationships between individual
therapeutic targets, it may be possible to improve overall
treatment efficacy and minimise risk of toxicity by using
reduced dosages of individual agents. PDE inhibitors are
responsible for limiting the adenylate cyclase regulated actions
of epoprostenol.156 The addition of PDE inhibitors may augment
and/or prolong the vasodilatory effects of prostanoids through
‘‘crosstalk’’ between the cyclic adenosine monophosphate
(cAMP) and cyclic guanosine monophosphate (cGMP) path-
ways. The addition of sildenafil in patients refractory to
epoprostenol is associated with enhanced levels of cAMP, an
effect mediated via inhibition of PDE-3 by cGMP.157 This effect
in turn causes upregulation of NO production and further
increases in cGMP concentrations. Sildenafil, when added to
aerosolised iloprost, causes a greater reduction in PVR than
either drug alone.147 158 Co-treatment with sildenafil and
beraprost may also result in greater increases in plasma
concentrations of cAMP and cGMP than with either drug
alone.159 Bosentan and sildenafil have synergistic effects on
haemodynamics and mortality in animal models.160 Since
endothelin suppresses NO production,110 161 ERAs upregulate
NO production and synergise sildenafil.147 162
6.4.6.2 Clinical evidence for use of combination therapy
To date there have been relatively few prospective trials
conducted to appraise the merits of combining drugs with
different modes of action for the treatment of PAH. Many
authors have reported successful outcomes with this approach
in animal models of PH as well as in observational series and
non-randomised studies. Most of the studies currently available
are of a retrospective or observational nature, describing
experiences with small numbers of heterogeneous patients
(often from a single centre) without matched controls
characterised. Investigators have mostly chosen to investigate
IPAH, CTD APAH or anorexigen induced APAH, limiting the
applicability of results to other categories of PH. A number of
well-designed studies are now underway (Appendix 1) that
should help clarify the potential benefits of a variety of different
combination strategies in the next 1–3 years.
A comprehensive listing of published studies is included in
this manuscript (tables 4–11). There are only four possible
combinations of currently available agents: ERAs and prosta-
noids, ERAs and PDE 5 inhibitors, PDE 5 inhibitors and
prostanoids, or all three drug types together. Because there are
four types of prostanoids and two ERAs the combinations can
become complex within these four groups.
6.4.6.3 Approaches to combination therapy
Given the limited amount of conclusive data pertaining to
combination treatment, published guidelines have so far made
no specific recommendation to guide clinicians on the next step
to impr ve the status of their patients who fail monotherapy.
The most commonly applied combination therapy approach
to date has involved the addition of a second drug where
patients deteriorate (or fail to sufficiently improve) despite
optimal doses of an initial therapy. The algorithms in figs 4 and
5 indicate commonly used clinical criteria for considering
combination therapy. These criteria were chosen because they
indicate a particularly poor prognosis and can be documented.
For patients who present in WHO functional class III the
most common combination is the addition of a second oral
agent (sildenafil to an ERA or an ERA to sildenafil). In the UK
this accounts for 65% of combination therapy prescriptions. In
small studies this approach has been shown to be effective in
improving functional class, 6MWT distance and peak oxygen
consumption.149 163 164
The addition of a parenteral prostanoid to the original oral
therapy increases the complexity of administering treatment. It
is indicated in the event of rapid deterioration, especially when
expected survival time is limited. The combination of a
prostanoid plus sildenafil accounts for 23% of combination
therapy prescriptions in the UK and confers added clinical
benefits to monotherapy compared with either class of drugs
alone.147 148 158 165
Figure 4 Algorithm for the management of idiopathic, familial and
anorexogen-induced pulmonary arterial hypertension. The prefixes 1st
and 2 d indicate preferred and alternative drugs based on the quality and
t weight of evidence assessed by the Consensus Meeting. APAH,
associated pulmonary arterial hypertension; FPAH, familial pulmonary
arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension;
WHO, World Health Organization.
Pulmonary hypertension
ii26 Thorax 2008;63(Suppl II):ii1–ii41. doi:10.1136/thx.2007.090480
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1.1.7	  Survival	  in	  PAH	  
In	  the	  1980s,	  survival	  in	  patients	  with	  PAH	  at	  1,	  2	  and	  3	  years	  was	  68,	  48	  and	  34%	  respectively	  (D'Alonzo	  et	  al.,	  1991).	  Recent	  registries	  since	  the	  advent	  of	  advanced	  therapies	  suggest	  this	  has	  improved	  although	  registries	  differ	  slightly	  (Humbert	  et	  al.,	  2010,	  Benza	  et	  al.,	  2010,	  Ling	  et	  al.,	  2012).	   In	  a	  UK	  registry	  of	   incident,	   treatment-­‐naive	  patients	  (93%	  idiopathic),	  1,	  2	  and	  3-­‐year	  survival	   was	   93,	   84	   and	   73%	   overall.(Ling	   et	   al.,	   2012)	   In	   the	   French	   registry	   of	   idiopathic	  (87%),	   heritable	   and	   anorexigen-­‐PAH	   patients,	   1,	   2	   and	   3	   year	   survival	  was	   83,	   67	   and	   58%	  respectively	   (Humbert	   et	   al.,	   2010).	   In	   the	   USA,	   a	   registry	   of	   over	   2500	   patients	   assessed	   a	  larger	  spectrum	  of	  associated	  PAH	  cases	  (47%	  idiopathic),	  of	  whom	  91%	  were	  alive	  at	  one	  year	  (Benza	   et	   al.,	   2010).	   It	   is	   important	   to	   note	   that	   survival	   is	   worse	   in	   certain	   PAH	   subtypes:	  Eisenmenger-­‐PAH	   survival	   exceeds	   idiopathic	   PAH,	   which	   is	   superior	   to	   systemic	   sclerosis-­‐associated	   PAH	   (Hurdman	   et	   al.,	   2012).	   In	   addition,	   the	   presence	   of	   BMPR-­‐II	  mutations	   (see	  below)	  leads	  to	  an	  earlier	  and	  more	  severe	  clinical	  presentation	  (Sztrymf	  et	  al.,	  2008).	  
 
1.2	  Pathogenesis	  of	  pulmonary	  arterial	  hypertension	  	  
The	  key	  pathological	  finding	  in	  PAH	  is	  pulmonary	  vascular	  remodelling.	  Endothelial	  cell	  damage	  is	   thought	   to	  be	   an	   initiating	   event	   in	   its	   development,	  with	   evidence	   for	   loss	   of	   endothelium	  dependent	  vasodilatation	   in	  patients	  with	  PAH	  (Brett	  et	  al.,	  1996).	  Loss	  of	   the	  EC	  barrier	  may	  allow	  the	  underlying	  smooth	  muscle	  to	  come	  into	  contact	  with	  mediators	  and	  other	  cells	  leading	  to	  release	  of	  mediators	  and	  growth	  factors;	  endothelial	  damage	  leads	  to	  a	  disturbed	  vasoactive	  mediator	  balance;	   these	  events	   result	   in	  a	  host	  of	   intracellular	   signalling	  events	   that	  promote	  PASMC	   growth	   such	   as	   tyrosine	   kinases,	   calcium	   and	   protein	   kinases.	   In	   addition	   there	   is	  evidence	   for	  coagulation	  abnormalities	   in	  PAH	  (Welsh	  et	  al.,	  1996).	  The	  sequence	  of	  events	   is	  not	   certain	   but	   certain	   risk	   factors	   have	   been	   identified.	   Some	   but	   not	   all	   patients	   harbour	  germline	  mutations;	  additional	  acquired	  factors	  are	  recognised	  including	  exposure	  to	  drugs	  and	  toxins,	  infections,	  shear	  stress,	  hypoxia,	  and	  inflammation.	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1.2.1	  Pulmonary	  vascular	  remodelling	  
Pulmonary	  vascular	  remodelling	  defines	  the	  characteristic	  fibrotic	  and	  proliferative	  lesions	  that	  occur	   in	   muscular	   pulmonary	   arteries	   <	   500μM	   ED	   in	   PAH.	   This	   is	   a	   maladaptive	   response	  where	   vessel	   walls	   thicken	   in	   response	   to	   genetic	   abnormalities,	   endothelial	   dysfunction,	  vasoactive	  mediator	  and	  growth	  factor	  imbalance,	  and	  other	  factors,	  leading	  to	  a	  sustained	  rise	  in	   intravascular	   pressure.	   The	   findings	   originally	   described	   in	   patients	   with	   congenital	   heart	  disease	   included	   early	   ‘reversible’	   lesions	   were	   medial	   hypertrophy,	   arteriolar	  neomuscularisation,	   intimal	   proliferation	   and	   fibrosis;	   ‘irreversible’	   later	   lesions	   including	  fibrinoid	  necrosis	  and,	  in	  some,	  plexiform	  lesions	  (Wagenvoort	  CA.,	  1989).	  	  	  
In	   medial	   hypertrophy,	   both	   an	   increase	   in	   number	   (hyperplasia)	   and	   an	   increase	   in	   size	  (hypertrophy)	  of	  PASMC	  occurs	  (Dorfmuller,	  2010).	  In	  early	  stages	  of	  disease	  in	  all	  types	  of	  PH,	  neomuscularisation	   of	   pulmonary	   arterioles	   also	   occurs,	   thought	   to	   follow	   transformation	   of	  pericytes	   and	   intermediate	   cells	   in	  partially	  muscular	   arterioles	   into	   smooth	  muscle	   like	   cells	  (Meyrick	   and	  Reid,	   1980a).	   Fibrotic	   intimal	   thickening	   is	   also	   common	   in	   human	  PAH	  due	   to	  proliferation	   and	   recruitment	   of	   fibroblasts	   and	   myofibroblasts,	   and	   consequent	   collagen	  deposition	  and	  potential	  vessel	  occlusion	  (Dorfmuller,	  2010).	  Finally,	  complex	  lesions	  including	  plexiform	   lesions	   occur	   in	   15%	   of	   idiopathic	   cases,	   and	   in	   other	   PAH	   subtypes	   (Tuder	   et	   al.,	  1994).	   These	   develop	   beyond	   branching	   points	   in	   small	   pulmonary	   arteries	   due	   to	   a	  proliferating	   clone	   of	   apoptosis-­‐resistant	   EC,	   neoangiogenesis	   and	   the	   accumulation	   of	  inflammatory	  progenitor	  cells,	  myofibroblasts	  in	  a	  collagen-­‐rich	  matrix	  (Tuder	  et	  al.,	  1994,	  Lee	  et	  al.,	  1998).	  	  




Figure	   1.3.	   	   Histology	   showing	   remodeled	   pulmonary	   arteries	   in	   idiopathic	  
pulmonary	  arterial	  hypertension	  (iPAH).	  Photographs	  of	  paraffin-­‐embedded	  haematoxylin	  and	  eosin-­‐stained	  human	   lung	  sections	   from	  patients	   with	   iPAH	   following	   lung	   transplantation.	   Medium	   sized	   pulmonary	   arteries	   with	  medial	   hypertrophy	   and	   intimal	   proliferation	   (A)	   and	   plexiform	   lesions	   (B).	   Thank	   you	   to	  Dr	  Peter	  Dorfmuller,	  Paris.	  	  
1.2.2	  Genetic	  susceptibility	  to	  PAH	  
Patients	   with	   heritable	   PAH	   (HPAH)	   have	   provided	   great	   insight	   into	   mechanisms	   of	   PH.	   In	  1997,	   a	  gene	   for	  PAH	  was	   localised	   to	   chromosome	  2p31-­‐32	   (Nichols	  et	  al.,	  1997),	   soon	  after	  which	   two	   groups	   identified	   the	   mutated	   gene	   to	   be	   bone	   morphogenetic	   type	   2	   receptor	  (BMPR-­‐II)	   (Deng	   et	   al.,	   2000,	   Lane	   et	   al.,	   2000).	   Less	   often,	   patients	   with	   HPAH	   harbour	  mutations	   of	   other	  members	   of	   the	   TGF-­‐β	   superfamily,	   activin-­‐like	   kinase-­‐type	   1	   (ALK1)	   and	  endoglin	  (ENG),	  which	  are	  associated	  with	  hereditary	  haemorrhagic	  telangiectasia	  (Machado	  et	  al.,	  2009).	  
BMPR-­‐II	   is	   a	   cell	   surface	   serine/threonine	  kinase	   receptor,	   a	  member	  of	   the	   receptors	   for	   the	  TGF-­‐β	  superfamily.	  BMPR-­‐II	  binds	  BMP	  proteins	  with	  high	  affinity	  (although	  it	  binds	  TGF-­‐β	  less	  well);	   the	   second	   messengers	   are	   the	   Smad	   proteins,	   which	   translocate	   to	   the	   nucleus	   and	  influence	  the	  transcription	  of	  genes	  that	  regulate	  cell	  growth,	  differentiation	  and	  migration.	  For	  example,	  BMP-­‐2,	  -­‐4	  and	  -­‐7	  usually	  inhibit	  proliferation	  and	  induce	  apoptosis	  in	  control	  PASMC,	  whereas	   PASMC	   isolated	   from	   patients	  with	   BMPR-­‐II	  mutations	   are	   resistant	   to	   these	   effects	  
A" B"
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(Yang	   et	   al.,	   2005b),	   suggesting	   that	   normal	   BMP	   signalling	   is	   critical	   in	  maintaining	   normal	  pulmonary	  vascular	  cell	  numbers.	  
Mutations	   that	   result	   in	   loss	   of	   function	  of	   the	   gene	   encoding	  BMPR-­‐II	   have	  been	   reported	   in	  30%	  of	  patients	  with	  iPAH	  and	  over	  75%	  of	  those	  with	  HPAH	  (Machado	  et	  al.,	  2006).	  However,	  as	   lifetime	  penetrance	   is	   only	  10-­‐20%	   (Machado	  et	   al.,	   2009),	   it	   is	   thought	   that	   a	   ‘second	  hit’	  must	   be	   needed	   to explain	   the	   onset	   of	   PH	   –	   which	   could	   include	   an	   inflammatory	   stimulus	  (Song	  et	  al.,	  2005,	  Hagen	  et	  al.,	  2007).	  In	  addition,	  it	  is	  important	  that	  even	  patients	  without	  the	  germline	  mutation	  have	   reduced	  BMPR-­‐II	   lung	  protein	   levels	   (Atkinson	  et	   al.,	   2002).	  This	  has	  also	   been	   reported	   in	   rats	   with	   MCT-­‐induced	   PH	   (Morty	   et	   al.,	   2007).	   This	   implies	   that	  dysfunctional	  BMPR-­‐II	  signalling	  is	  a	  common	  feature	  in	  PAH.	  	  
1.2.3	  Endothelial	  dysfunction	  in	  PAH	  
Normal	   pulmonary	   endothelium	   creates	   a	   smooth	   anti-­‐thrombogenic	   barrier,	   providing	  important	   metabolic	   functions	   and	   control	   of	   leukocyte	   trafficking.	   Endothelial	   cells	   (EC)	  maintain	   vascular	   tone	   through	   release	   of	   pulmonary	   vasodilators	   (nitric	   oxide	   (NO),	  prostaglandin	   (PG)-­‐I2,	   (prostacyclin)),	   and	   vasoconstrictors	   (such	   as	   endothelin-­‐1	   (ET-­‐1),	  serotonin	  and	  thromboxane	  A2).	  In	  PAH,	  endothelial	  injury	  due	  to	  hypoxia,	  shear	  stress,	  drugs	  and	   toxins	   leads	   to	   an	   imbalance	   of	   these	   vasoactive	   substances,	   with	   resulting	   pulmonary	  vasoconstriction,	   as	   well	   as	   altered	   control	   of	   vascular	   cell	   proliferation	   and	   migration.	  Prostacyclin,	  NO	  and	  ET-­‐1	  and	  selected	  additional	  pathways	  are	  briefly	  discussed.	  	  	  
1.2.3.1	  Vasoactive	  mediator	  imbalance	  in	  PAH	  
Prostacyclin	   is	   the	  major	  metabolite	  of	  arachidonic	  acid	  produced	   in	  EC.	  Through	  binding	  cell	  surface	  or	  nuclear	   receptors,	   it	   acts	   on	  PASMC,	   circulating	  platelets	   and	  other	   cells	   to	   elevate	  intracellular	   cyclic	   adenosine	   monophosphate	   (cAMP),	   causing	   vasodilatation,	   inhibition	   of	  platelet	  aggregation	  and	  inhibition	  of	  PASMC	  proliferation	  (Vane	  and	  Corin,	  2003,	  Friedman	  et	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al.,	  1997).	   In	  patients	  with	  PAH,	  prostacyclin	  synthase	   levels	  are	  reduced	  (Tuder	  et	  al.,	  1999).	  Administration	   of	   prostacyclin	   reduces	   PASMC	   proliferation	   in	   vitro	   (Wharton	   et	   al.,	   2000);	  decreases	   experimental	   PH	   (Archer	   et	   al.,	   1986,	   Leffler	   and	   Hessler,	   1979,	   Max	   et	   al.,	   1999,	  Miyata	   et	   al.,	   1996,	   Yuki	   et	   al.,	   1994),	   and	   these	   formed	   the	   basis	   for	   the	   clinical	   trial	   of	  epoprostenol	  (Barst	  et	  al.,	  1996).	  
NO	   is	   produced	   in	  EC	   from	  L-­‐arginine	  by	   endothelial	  NO	   synthase	   (eNOS)	   and	   causes	   soluble	  guanylate	   cyclase	   (sGC)	   to	   form	   cyclic	   GMP	   (cGMP)	   in	   PASMC.	   cGMP	   leads	   to	   vasodilatation,	  inhibition	   of	   SMC	   proliferation	   and	   migration	   (Sarkar	   et	   al.,	   1996,	   Tsihlis	   et	   al.,	   2011,	  Zuckerbraun	   et	   al.,	   2007).	   In	   PAH,	   NO	   bioavailability	   is	   reduced	   by	   several	  mechanisms	   (e.g.	  reduced	  NO	  synthase	  (NOS)	  expression	  (Giaid	  and	  Saleh,	  1995)	  (thereby	  lowering	  tissue	  cGMP	  levels),	  and	  increased	  expression	  of	  phosphodiesterase	  type	  5	  (PDE5)	  (which	  degrades	  cGMP)	  in	   PASMC	   (Wharton	   et	   al.,	   2005)	   and	   in	   the	   right	   ventricle	   (Nagendran	   et	   al.,	   2007).	   Indeed,	  PDE-­‐5	  inhibition	  (e.g.	  using	  sildenafil)	  is	  a	  therapeutic	  strategy	  for	  PAH	  (Galie	  et	  al.,	  2005).	  	  
ET-­‐1	   is	   a	   vasoconstrictor	   peptide	   and	   smooth	  muscle	  mitogen	  whose	   levels	   are	   increased	   in	  patients	  with	  PAH	  (Giaid	  et	  al.,	  1993).	  ET-­‐1	  is	  primarily	  made	  by	  EC,	  and	  also	  by	  macrophages	  (Ehrenreich	   et	   al.,	   1990)	   and	  PASMC	   (Woods	   et	   al.,	   1999,	  Giaid	   et	   al.,	   1993).	   Stimuli	   for	  ET-­‐1	  release	  include	  vessel	  wall	  stretch,	  cytokines	  and	  other	  inflammatory	  mediators	  (e.g.	  endotoxin)	  (Woods	  et	  al.,	  1999,	  Wort	  et	  al.,	  2009).	  Through	  the	  ETA	  receptor,	  ET-­‐1	  causes	  vasoconstriction	  and	   induces	  PASMC	  proliferation	  (Davie	  et	  al.,	  2002).	  Several	  studies	  show	  that	  ET-­‐1	  receptor	  blockade	   reverses	   PH	   in	   experimental	   models,	   which	   formed	   the	   basis	   for	   clinical	   studies	   in	  human	  iPAH	  (Price	  and	  Howard,	  2008).	  	  
1.2.4	  Role	  of	  pulmonary	  arterial	  smooth	  muscle	  cells	  (PASMC)	  	  
In	  normal	  circumstances,	  adult	  PASMC	  undergo	  minimal	  basal	  cell	  division.	  By	  contrast,	  PASMC	  from	   patients	   with	   PH	   undergo	   increased	   proliferation	   (Eddahibi	   et	   al.,	   2001).	   In	   addition,	  PASMC	   take	   on	   a	   ‘synthetic	   phenotype’	   i.e.	   they	   make	   more	   collagen	   and	   elastin	   in	   culture	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(Crouch	   et	   al.,	   1989),	   produce	  more	   DNA	   (e.g.	   in	   response	   to	   vascular	   stretch	   (Weiser	   et	   al.,	  1995),	  and	  release	  vasoactive	  mediators	  normally	  produced	  by	  the	  endothelium.	  These	  include	  ET-­‐1,	   (which	  may	   follow	   inflammatory	   activation	   of	   PASMC	   (Woods	   et	   al.,	   1999,	  Wort	   et	   al.,	  2009);	   nitric	   oxide	   and	   cytokines	   (which	  may	   be	   due	   to	   an	   increase	   in	   inducible	   isoforms	   of	  nitric	  oxide	  synthase	  (NOS)	  and	  cyclooxygenase,	  respectively)	  (Bishop-­‐Bailey	  et	  al.,	  1997).	  
As	  outlined	  above,	  several	  extrinsic	  factors	  influence	  PASMC	  proliferation	  including	  vasoactive	  mediators	  (above),	  as	  well	  as	  the	  effects	  of	  growth	  factors.	   In	  addition,	  changes	  in	  ion	  channel	  activity	   (e.g.	   sustained	   Ca2+	   flux)	   also	   exerts	  mitogenic	   effects	   via	   Ca2+–calmodulin-­‐dependent	  stimulation	   of	   the	   cell	   cycle,	   activation	   of	   mitogen-­‐activated	   protein	   (MAP)	   kinase	   pathways,	  and	   stimulation	   of	   activator	   protein	   (AP)-­‐1	   (Burg	   et	   al.,	   2008).	   ET-­‐1	   and	   5-­‐HT	   pathways	   are	  upregulated	   in	   PAH	   and	   these	   mediators	   increase	   PASMC	   proliferation	   (Davie	   et	   al.,	   2002)	  (Eddahibi	  et	  al.,	  2001).	  Several	  other	  growth	  factors	  are	  implicated	  in	  PAH	  bind	  and	  activate	  cell	  surface	   tyrosine	   kinase	   receptors,	   and	   activate	   intracellular	   signalling	   cascades,	   resulting	   in	  PASMC	   proliferation,	   migration,	   as	   well	   as	   resistance	   to	   apoptosis.	   Such	   growth	   factors	  implicated	   in	   PAH	   include	   vascular	   endothelial	   growth	   factor	   (VEGF)	   (expressed	   in	   epithelial	  cells,	  EC	  and	  macrophages)	  (Voelkel	  et	  al.,	  1996),	  platelet-­‐derived	  growth	  factor	  (PDGF),	  which	  is	  a	  potent	  PASMC	  mitogen	  (Yu	  et	  al.,	  2003)	  upregulated	   in	  perivascular	  macrophages	   in	  PAH	  patients	  (Humbert	  et	  al.,	  1998),	  and	  basic	  fibroblast	  growth	  factor	  (Benisty	  et	  al.,	  2004).	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1.2.5	  Normal	  regulation	  of	  cell	  survival	  	  
The	  balance	  of	  cell	  proliferation	  and	  apoptosis	   is	   important	   for	  both	  development	  and	  normal	  tissue	  homeostasis.	  Normal	  regulation	  of	  cell	  growth	  is	  briefly	  considered	  here.	  	  
1.2.5.1	  Control	  of	  proliferation	  	  
Cell	   proliferation	   i.e.	   an	   increase	   in	   the	   number	   of	   cells	   as	   a	   result	   of	   growth	   and	   division	   is	  controlled	  by	  highly	  regulated	  events	  during	  the	  cell	  cycle.	  The	  cell	  cycle	  has	  two	  main	  phases:	  interphase,	   the	   phase	   between	   mitotic	   events,	   and	   the	   mitotic	   phase.	   Interphase	   has	   three	  distinct	  stages:	  G1,	  S	  and	  G2.	  During	  G1,	  the	  first	  stage,	  cells	  “monitor”	  their	  environment,	  and	  following	  appropriate	  stimuli,	  make	  RNA	  and	  proteins	  to	  induce	  growth.	  Cells	  then	  enter	  S	  stage	  and	  replicate	  their	  chromosomal	  DNA.	  Finally	   in	  G2	  phase,	  cells	  grow	  and	  prepare	  for	  mitosis.	  To	  facilitate	  DNA	  replication,	  histone	  modification	  occurs,	  opening	  the	  chromatin	  to	  allow	  entry	  of	  replication	  machinery	  (Lodish,	  1995).	  	  
1.2.5.2	  Control	  of	  apoptosis	  
Damaged	   or	   unrequired	   cells	   undergo	   apoptosis	   (programmed	   cell	   death).	   This	   is	   a	   normal	  physiological	   process	   characterised	   by	   changes	   in	   the	   plasma	   membrane	   (such	   as	   loss	   of	  membrane	   symmetry),	   condensation	   of	   the	   cytoplasm	   and	   nucleus,	   protein	   cleavage	   and	  internucleosomal	  DNA	  cleavage.	  In	  the	  final	  stages,	  apoptotic	  cells	  become	  fragmented	  and	  are	  phagocytosed	   without	   significant	   inflammatory	   damage	   to	   surrounding	   cells	   -­‐	   in	   contrast	   to	  necrosis,	   which	   results	   in	   local	   tissue	   damage	   (Hedrick	   et	   al.,	   2010).	   Apoptotic	   signalling	  consists	  of	  extrinsic	  and	  intrinsic	  pathways.	  The	  extrinsic	  pathway	  is	  activated	  by	  TNF	  receptors	  (‘death	   receptors’),	   which	   activate	   caspase-­‐8,	   of	   which	   FAS	   ligand	   is	   the	   prototype;	   others	  include	   TNFR1.	   The	   intrinsic	   pathway	   is	   triggered	   by	   non-­‐receptor	   stimuli	   including	   growth	  factor	   deprivation,	   DNA	   damage	   and	   cytotoxic	   stress,	   as	   well	   as	   death	   receptors.	   Intrinsic	  apoptosis	  is	  characterised	  by	  the	  permeabilisation	  of	  the	  outer	  mitochondrial	  membrane,	  which	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releases	   pro-­‐apoptotic	   factors	   from	   the	   inner	  mitochondria	   into	   the	   cytoplasm.	   These	   factors	  activate	   caspase-­‐3	   and	   the	   ‘executioner	   caspases’,	  which	   activate	   endonucleases	   and	   result	   in	  DNA	  fragmentation.	  The	  intrinsic	  pathway	  is	  co-­‐ordinated	  by	  B	  cell	  lymphoma	  (Bcl-­‐2)	  proteins,	  which	   contain	  pro-­‐apoptotic	   (e.g.	  Bad,	  Bax)	  and	  anti-­‐apoptotic	  members:	   the	  balance	  of	   these	  determines	  the	  onset	  of	  apoptosis	  (Brenner	  and	  Mak,	  2009).	  	  
The	  role	  of	  NF-­‐κB	  in	  controlling	  proliferation	  and	  apoptosis	  has	  been	  studied	  in	  cancers,	  where	  NF-­‐κB	   is	   constitutively	   activated:	   NF-­‐κB	   can	   both	   positively	   and	   negatively	   influence	   tumour	  growth	   by	   several	   mechanisms	   (DiDonato	   et	   al.,	   2012).	   For	   example,	   NF-­‐κB	   mediated	   anti-­‐apoptotic	  effects	   in	  a	  solid	   tumour	  model	   through	   induction	  of	  Bcl-­‐XL	  (Greten	  et	  al.,	  2004).	   In	  addition,	   IKK2	   (IKKβ)-­‐driven	   NF-­‐κB	   activation	   contributed	   to	   the	   release	   of	   growth	   factors	  including	   IL-­‐6	   from	   tissue	   macrophages,	   which	   stimulated	   the	   proliferation	   of	   premalignant	  cancer	   cells	   through	   activation	   of	   signal	   transducer	   and	   activator	   of	   transcription	   3	   (STAT3)	  (Greten	  et	  al.,	  2004)	  (see	  IL-­‐6	  section	  below).	  
 
1.3	  Monocrotaline-­‐induced	  PH	  in	  rats	  
There	   are	   several	   models	   of	   PH,	   none	   of	   which	   completely	   recapitulate	   human	   disease	  (Stenmark	   et	   al.,	   2009).	  We	   selected	   to	   study	  monocrotaline	   (MCT)-­‐induced	  PH	   in	   this	   thesis	  because	  it	  has	  a	  well-­‐described	  inflammatory	  component.	  MCT	  is	  a	  toxic	  alkaloid	  derived	  from	  the	  crotalaria	   specibilis	  plant.	   Ingestion	  of	  a	  crotalaria	  plant	  caused	  severe	  fatal	  PH	  in	  a	  boy	   in	  Tanzania	   in	  1975	  (Heath	  et	  al.,	  1975),	  and	  a	  single	   injection	  of	  MCT	  was	   found	  to	  cause	  rapid	  and	  reproducible	  PH	  in	  rats(Bruner	  et	  al.,	  1983,	  Hilliker	  et	  al.,	  1982)	  (see	  Chapter	  4),	  following	  early	  EC	  injury,	  with	  development	  of	  lung	  oedema	  (Sugita	  et	  al.,	  1983)	  then	  PASMC	  proliferation	  and	   marked	   RV	   hypertrophy	   (Rosenberg	   and	   Rabinovitch,	   1988)	   (Sugita	   et	   al.,	   1983).	   This	  model	   has	   been	   extensively	   studied	   over	   the	   last	   40	   years	   and	   although	   has	   limitations,	   has	  been	  essential	   in	  preclinical	  studies	  of	  PAH	  therapies.	  Limitations	  of	   the	  model	  however	  exist,	  such	  as	  that	  it	  does	  not	  recapitulate	  all	  the	  histological	  features	  of	  human	  PAH	  including	  intimal	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proliferation	  and	  complex	  lesions;	  in	  addition,	  most	  prophylactic	  treatments	  are	  able	  to	  prevent	  MCT-­‐induced	   PH	   (Stenmark	   et	   al.,	   2009).	   Despite	   this,	   it	   remains	   a	   useful,	   reproducible	   and	  frequently	  used	  model,	  with	  a	  marked	  inflammatory	  component.	  	  	  
1.3.1	  Mechanism	  of	  MCT-­‐induced	  PH	  
MCT	  is	  activated	  in	  the	  liver	  by	  cytochrome	  P450	  to	  monocrotaline	  pyrrole	  (MCTP),	  and	  direct	  administration	   of	   this	   metabolite	   onto	   EC	   monolayers	   causes	   progressive	   endothelial	   injury	  (Reindel	   and	   Roth,	   1991).	   It	   is	   thought	   that	   in	   rats,	  MCTP	   reaches	   the	   pulmonary	   circulation	  where	   it	   initiates	   EC	   injury,	   vascular	   leak	   and	   chemokine	   release,	   thus	   recruiting	   mainly	  mononuclear	  cells,	  and	  a	  sequence	  of	  events	  that	  result	  in	  vascular	  remodelling	  (summarised	  in	  Figure	  1.4).	  Of	  note,	  an	  early	  (day	  0-­‐14)	  influx	  of	  perivascular	  inflammatory	  cells	  occurs	  (mainly	  of	  macrophages	   (Sahara	  M,	   2007)	   and	   immature	   dendritic	   cells	   (Perros	   et	   al.,	   2007b),	  with	   a	  minority	   of	   lymphocytes).	   Pulmonary	   artery	   medial	   hypertrophy	   and	   vascular	   remodelling	  follows	   this	   early	   inflammatory	   phase,	   with	   a	   significant	   increase	   in	   pulmonary	   arterial	  muscularisation	  after	  14	  days	  (Guignabert	  et	  al.,	  2005).	  NF-­‐κB-­‐dependent	  chemokines	  including	  fracktalkine	  (Perros	  et	  al.,	  2007a),	  RANTES	  (Dorfmuller	  et	  al.,	  2002)	  and	  MCP-­‐1	  (Guignabert	  et	  al.,	  2005);	  and	  cytokines	  including	  IL-­‐1β	  (Voelkel	  et	  al.,	  1994),	  IL-­‐6	  (Steiner	  et	  al.,	  2009,	  Savale	  et	  al.,	  2009,	  Bhargava	  et	  al.,	  1999,	  Miyata	  et	  al.,	  1995),	  IL-­‐10	  (Ito	  et	  al.,	  2007)	  and	  TNF-­‐α	  (Wang	  et	  al.,	  2012)	  are	  implicated	  in	  this	  model.	  Of	  note,	  an	  early	  peak	  then	  a	  later	  rise	  in	  lung	  MCP-­‐1	  and	   IL-­‐1	   mRNA	   occurs,	   and	   IL-­‐6	   is	   prominent	   from	   day	   10	   (Guignabert	   et	   al.,	   2005).	   Anti-­‐inflammatory	   approaches	   have	   indeed	   been	   shown	   to	   prevent	  MCT-­‐induced	   PH,	   such	   as	   IL-­‐1	  blocking	  antibodies	  (Voelkel	  et	  al.,	  1994)	  and	  blockade	  of	  stromal-­‐derived	  factor	  (SDF)-­‐1	  -­‐	  thus	  inflammatory	  cell	  recruitment	  (Savai	  et	  al.,	  2012b).	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Figure	   1.4.	   	   Contributing	   mechanisms	   in	   monocrotaline-­‐induced	   pulmonary	  
hypertension.	  Abbreviations:	  MCT	  monocrotaline,	  VCAM	  vascular	   cell	   adhesion	  molecule,	   ICAM	   intracellular	  adhesion	  molecule,	   SMCs	   smooth	  muscle	   cells,	  MMP	  matrix	  metalloproteinase,	   PDGF	  platelet-­‐derived	  growth	  factor.	  Thank	  you	  to	  Dr	  Lan	  Zhao,	  Hammersmith	  Hospital,	  London	  UK.	  	  	  
1.4	  An	  overview	  of	  Inflammation	  
Inflammation	   is	   the	   normal	   response	   of	   a	   body,	   particularly	   vascular	   tissues,	   to	   exogenous	  noxious	  or	  deleterious	  stimuli	  such	  as	  pathogens,	  damaged	  cells,	  or	  irritants.	  	  The	  classical	  signs	  of	  acute	  inflammation	  are	  pain,	  heat,	  redness,	  swelling,	  and	  loss	  of	  function,	  which	  represent	  the	  actions	  of	  the	  organism	  to	  remove	  the	  injurious	  stimuli	  and	  to	  initiate	  the	  healing	  process.	  	  The	  response	   is	   not	   dependent	   upon	   the	   specific	   stimulus	   and,	   as	   such,	   is	   part	   of	   the	   innate	  response.	   	   The	   immune	   response	   is	   divided	   into	   innate	   and	   adaptive	   components.	   Innate	  immunity	  describes	  an	  immediate,	  non-­‐specific	  response	  to	  a	  pathogen	  or	  object	  recognised	  as	  ‘non-­‐self’	   e.g.	   antigens	   (antibody-­‐generators).	   The	   adaptive	   immune	   response	   is	   the	   second	  layer	   of	   protection	   that	   is	   activated	   by	   the	   innate	   immune	   response,	   and	   retained	   as	  immunological	   memory.	   Both	   immune	   systems	   have	   humoral	   (antibody-­‐mediated)	   and	   cell-­‐mediated	  components	  (Roitt.	  I,	  1993).	  The	  components	  of	  innate	  immunity	  form	  an	  immediate	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barrier	  (e.g.	  cilia;	  epithelium;	  gut	  flora);	  the	  process	  of	  acute	  inflammation	  (including	  activation	  of	  coagulation	  to	  attempt	  to	  contain	  the	  insult);	  and	  activation	  of	  the	  complement	  system	  (e.g.	  by	   opsonisation:	   the	   priming	   of	   pathogens	   for	   destruction).	   The	   cells	   of	   the	   innate	   immune	  response	  are	   those	  without	   immune	  memory	  and	   include	  natural	  killer	   (NK)	  cells;	  mast	   cells;	  eosinophils;	  basophils	  and	  phagocytes	  (e.g.	  macrophages,	  neutrophils	  and	  dendritic	  cells	  (DCs)).	  These	   cells	   release	   cytokines;	   recruit	   immune	   cells	   to	   the	   site	  of	   injury;	   activate	   complement;	  and	   some	   (e.g.	   dendritic	   cells)	   activate	   the	   adaptive	   immune	   system	   by	   antigen	   presentation	  (Roitt.	  I,	  1993).	  	  
The	   principle	   of	   adaptive	   immunity	   is	   the	   recognition	   by	   T	   cells	   of	   ‘non-­‐self’,	   through	  presentation	   of	   antigen	   by	   a	   major	   histocompatibility	   complex	   (MHC)	  molecule.	   MHC	   class	   I	  molecules	   are	   expressed	   on	   all	   nucleated	   cells	   and	   bind	   (e.g.	   viral)	   peptides	   generated	   from	  proteasomal	   degradation	   of	   cytosolic	   proteins;	   the	   peptide	   and	  MHC	   I	  membrane	   complex	   is	  then	  presented	  to	  cytotoxic	  T	  (Tc)	  cells.	  In	  contrast,	  MHC	  class	  II	  molecules	  are	  expressed	  only	  on	  ‘professional’	  APCs	  and	  lymphocytes,	  classed	  as	  such	  because	  they	  are	  extremely	  efficient	  at	  internalising	   antigen	   by	   expressing	   co-­‐stimulatory	   molecules	   (for	   example,	   macrophages	  express	  CD80/86).	  Foreign	  proteins	  (e.g.	  bacteria)	  undergo	  phagocytosis	  or	  receptor-­‐mediated	  endocytosis,	   and	   the	   antigen	   fragment	   binds	   to	   the	   class	   II	  MHC	  molecule	   on	   the	  membrane.	  Class	   II	   molecules	   then	   interact	   with	   CD4+	   ("helper")	   T	   cells	   to	   help	   trigger	   an	   appropriate	  immune	   response,	   e.g.	   involving	   phagocyte	   recruitment	   or	   activation	   of	   memory	   B	   cells	   to	  induce	  an	  antibody	  response	  (Roitt.	   I,	  1993).	  However,	  this	   is	  a	   fairly	  simplistic	  view:	  a	  recent	  review	  suggests	  an	  additional	  role	  for	  innate	  lymphoid	  cells,	  which	  as	  well	  as	  a	  role	  in	  immunity,	  may	  play	  a	  role	  in	  tissue	  homeostasis	  and	  remodelling	  (Leavy,	  2013).	  
Inflammation	   is	   part	   of	   the	   complex	   programmed	   response	   in	   vascular	   tissue	   to	   attempt	   to	  remove	  injurious	  stimuli.	  It	  is	  defined	  as	  acute	  or	  chronic	  depending	  on	  the	  time	  course	  and	  the	  cells	  involved	  (Table	  1.2),	  and	  can	  cause	  destruction	  as	  well	  as	  tissue	  healing,	  thus	  it	  is	  usually	  a	  closely	  regulated	  process.	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   Acute	   Chronic	  
Causative	  agent	   Bacterial	  pathogens,	  injured	  tissues	   Persistent	  acute	  inflammation	  due	  to	  non-­‐degradable	  pathogens,	  viral	  infection,	  persistent	  foreign	  bodies,	  or	  autoimmune	  reactions	  
Major	  cells	  involved	   Neutrophils	  (primarily),	  basophils	  (inflammatory	  response),	  and	  eosinophils	  (worms	  and	  parasites),	  mononuclear	  cells	  (monocytes,	  macrophages)	  
Mononuclear	  cells	  (monocytes,	  macrophages,	  lymphocytes,	  plasma	  cells),	  fibroblasts	  
Primary	  mediators	   Vasoactive	  amines,	  eicosanoids	  (prostaglandins	  &	  leukotrienes)	   IFN-­‐γ	  and	  other	  cytokines,	  growth	  factors,	  reactive	  oxygen	  species,	  hydrolytic	  enzymes	  
Onset	   Immediate	   Delayed	  
Duration	   Few	  days	   Months	  or	  years	  
Outcomes	   Resolution,	  abscess	  formation,	  chronic	  inflammation	   Tissue	  destruction,	  fibrosis,	  necrosis	  
Table	  1.2.	  	  Features	  of	  acute	  and	  chronic	  inflammation.	  Adapted	  from	  Roitt’s	  Essential	  Immunology	  (Roitt.	  I,	  1993).	  	  
1.5	  Evidence	  for	  inflammation	  in	  PAH	  
Several	  lines	  of	  evidence	  implicate	  the	  role	  of	  inflammation	  in	  PAH.	  These	  include	  the	  presence	  of	   increased	   perivascular	   inflammatory	   cells;	   elevated	   circulating	   and	   tissue	   cytokines,	  chemokines	   and	   autoantibodies;	   and	   the	   association	   of	   inflammatory	   conditions	   and	   their	  treatment	   with	   PAH	   and	   (in	   some	   cases)	   its	   regression,	   respectively.	   These	   features	   are	  discussed	  in	  turn.	  	  
1.5.1	  Inflammatory	  cells	  in	  PAH	  
In	   histological	   studies,	   a	   mononuclear	   cell	   inflammatory	   infiltrate	   is	   observed	   around	  remodelled	  vessels,	   including	  plexiform	  lesions	   in	  human	  PAH	  (Figure	  1.5).	  The	  cells	   involved	  are	  T	  cells,	  monocytes/macrophages,	  and,	  to	  a	  lesser	  extent,	  B	  cells	  (Cool	  et	  al.,	  1997,	  Tuder	  et	  al.,	   1994,	   Hall	   et	   al.,	   2009,	   Pinto	   et	   al.,	   2004,	   Heath	   and	   Edwards,	   1958,	   Savai	   et	   al.,	   2012b).	  Perivascular	   mast	   cells	   have	   also	   been	   observed	   in	   iPAH	   and	   CHD-­‐PAH	   (Heath	   and	   Yacoub,	  1991,	   Mitani	   et	   al.,	   1999)	   (Hamada	   et	   al.,	   1999).	   Perivascular	   dendritic	   cells	   (DC)	   are	   also	  present	   in	   human	   iPAH	   (Perros	   et	   al.,	   2007b);	   increased	   circulating	  DC	   are	   found	   in	   patients	  with	   iPAH	  and	  portopulmonary	  hypertension	   (J	  Le	  Pavec,	  2009);	  and	   these	  express	   increased	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activation	   markers	   (Perros	   et	   al.,	   2007b).	   Savai	   et	   al	   recently	   quantified	   the	   increase	   in	  perivascular	  CD14+	  monocytes	  and	  macrophages	  in	  human	  iPAH	  (Savai	  et	  al.,	  2012b),	  although	  no	  studies	  have	  yet	  assessed	  the	  function	  of	  these	  cells	  in	  PAH.	  Cells	  of	  monocyte/macrophage	  origin,	   then	   cells	   of	   lymphoid	   origin	   (including	   lymphocytes	   and	   natural	   killer	   (NK)	   cells)	  implicated	   in	   PAH,	   are	   briefly	   discussed.	   Monocytes	   and	   macrophages	   are	   then	   discussed	   in	  more	  detail	  in	  section	  1.6.	  
T-­‐cell	   subsets	   are	   subdivided	   into	   CD4+	   T	   helper	   (Th)	   cells,	   CD4+CD25hiFoxP3+CD127low	   T	  regulatory	  (Treg)	  cells	  and	  CD8+	  cytotoxic	  T	  (Tc)	  cells.	  CD4+	  T	  cells	  are	  further	  subdivided	  into	  Th1,	  Th2	  and	  Th17	  (IL-­‐17-­‐producing)	  cells.	  Overall,	  Th	  cells	  stimulate	  B	  cell	  differentiation	  and	  macrophage	  activation;	  Tc	  cells	  bind	  to	  MHC	  class	  1	  molecules	  and	  kill	  infected	  cells;	  and	  Treg	  cells	   are	   important	   in	   balancing	   Th1	   and	   Th2	   responses,	   maintaining	   self-­‐tolerance	   and	  controlling	  autoimmunity.	  Several	  lines	  of	  evidence	  support	  a	  role	  for	  T	  cells	  in	  the	  development	  of	  PAH.	  	  In	  animal	  models,	  the	  athymic	  nude	  rat	  (without	  T	  cells)	  developed	  PAH	  more	  readily	  than	  those	  with	  intact	  T	  cell	  production	  (Taraseviciene-­‐Stewart	  et	  al.,	  2007).	  In	  the	  MCT	  model,	  depletion	  of	  T	  cells	  ameliorated	  PAH,	  again	  suggesting	  the	   importance	  of	  a	  Th2	  antigen-­‐driven	  immune	   response	   (Daley	   et	   al.,	   2008).	   Indeed,	  T	   cell	   infiltrates	   are	   increased	   in	  patients	  with	  iPAH	  (Tuder	  et	  al.,	  1994).	  An	   increase	   in	  CD8+	  and	  CD3+	  T	  cells	   subsets	   (Austin	  et	  al.,	  2010),	  whereas	  in	  peripheral	  blood,	  a	  decrease	  in	  cytotoxic	  (CD8+)	  Tc	  cells	  is	  seen	  –	  perhaps	  reflecting	  their	   uptake	   to	   the	   lung.	   In	   addition,	   PAH	   patients	   have	   an	   increase	   in	   circulating	   Treg	   cells	  which	   may	   represent	   a	   systemic	   response	   attempting	   to	   suppress	   pro-­‐inflammatory	   activity	  (Ulrich	  et	  al.,	  2008).	  Several	  studies	  have	  suggested	  B	  lymphocytic	  dysfunction	  in	  PAH	  patients.	  Indeed,	  B-­‐lymphocytes	  are	  seen	  around	  diseased	  vessels	  (Tuder	  et	  al.,	  1994,	  Savai	  et	  al.,	  2012a,	  Perros	  et	  al.,	  2012);	  levels	  of	  antinuclear	  antibodies	  are	  increased	  in	  patients	  with	  PAH	  (Rich	  et	  al.,	   1986),	   with	   autoantibodies	   directed	   against	   endothelial	   cells	   (Tamby	   et	   al.,	   2005)	   and	  fibroblasts	   (Tamby	   et	   al.,	   2006).	   These	   autoantibodies	  may	   play	   a	   role	   by	   inducing	   adhesion	  molecule	  expression	  (Carvalho	  et	  al.,	  1996),	  or	   through	   inducing	  EC	  apoptosis	   (Bordron	  et	  al.,	  1998)	   thereby	   contributing	   to	   their	   apoptosis-­‐resistant	   phenotype.	   Finally,	   NK	   cells	   are	  
Laura	  Price	  PhD:	  Inflammation	  in	  Pulmonary	  Arterial	  Hypertension	   41	  













Figure	  1.5.	  	  Pulmonary	  vascular	  inflammation	  in	  a	  lung	  section	  from	  a	  patient	  
with	  idiopathic	  pulmonary	  arterial	  hypertension	  	  (iPAH).	  A	  pulmonary	  arterial	  lesion	  from	  a	  patient	  with	  iPAH,	  illustrating	  the	  perivascular	  mononuclear	  cell	   (mainly	   lymphocytic)	   infiltrate	   (in	   centre),	   a	   small	   pulmonary	   artery	   (left	   side)	   and	   a	  bronchiole	  to	  the	  right.	  Magnification	  x200.	  	  
1.5.2	  Inflammatory	  mediators	  in	  PAH	  
A	   second	   important	   observation	   is	   that	   patients	   with	   PAH	   have	   elevated	   plasma	   and	   tissue	  levels	  of	  cytokines	  and	  chemokines.	  These	  include	  the	  cytokines	  IL-­‐1-­‐β	  and	  IL-­‐6	  (Humbert	  et	  al.,	  1995,	  Soon	  et	  al.,	  2010),	  and	  chemokines	  such	  as	  CXCL8/IL-­‐8	  (Soon	  et	  al.,	  2010),	  CCL2/MCP-­‐1	  (Sanchez	   et	   al.,	   2007),	   CCL5/regulated	   and	   normal	   T	   cell	   expressed	   and	   secreted	   (RANTES)	  (Dorfmuller	  et	  al.,	  2002),	  and	  CXC3CL1	  fractalkine	  (Balabanian	  et	  al.,	  2002).	  These	  are	  detailed	  further	  below.	  In	  addition,	  the	  circulating	  marker	  of	  inflammation	  and	  tissue	  damage,	  C-­‐reactive	  protein	   (CRP)	   is	   also	   increased	   in	  patients	  with	  PAH	   (Quarck	  et	   al.,	   2009)	   (and	  even	   in	   those	  with	  CHD-­‐PAH	  (Diller	  et	  al.,	  2008));	  high	  CRP	  levels	  are	  predictive	  of	  worse	  outcomes	  (Quarck	  et	   al.,	   2009).	   Elevated	   levels	   of	   inflammatory	   cytokines	   are	   characteristic	   of	   all	   PAH	   subtypes	  including	  CTD-­‐PAH	  (Okawa-­‐Takatsuji	  M,	  1999),	  HIV-­‐associated	  PAH	  (Humbert	  et	  al.,	  1998)	  and	  PAH	  associated	  with	  sickle	  cell	  disease	  (Niu	  et	  al.,	  2009),	  suggesting	  that	  the	  increased	  levels	  of	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such	  mediators	  are	  common	  to	  the	  pathology	  of	  PAH	  per	  se	  and	  not	  restricted	  to	  one	  particular	  sub-­‐type.	  Finally,	  these	  mediators	  have	  been	  shown	  to	  have	  important	  prognostic	  value	  (Soon	  et	  al.,	  2010,	  Gourh	  et	  al.,	  2009,	  Selimovic	  et	  al.,	  2009)	  (Eddahibi	  et	  al.,	  2006)	  (Niu	  et	  al.,	  2009).	  In	  the	   largest	   of	   these	   studies,	   plasma	   IL-­‐6,	   CXCL8,	   IL-­‐10	   and	   IL-­‐12p70	   were	   independently	  associated	   with	   worse	   survival	   in	   patients	   with	   PAH,	   and	   were	   even	   more	   sensitive	   than	  conventional	  haemodynamics	  or	  6-­‐minute	  walk	  distance	  (Soon	  et	  al.,	  2010).	  	  
Further	   to	   circulating	   mediators,	   tissue	   chemokines	   are	   elevated	   in	   PAH.	   For	   example,	  fracktalkine	  (CX3CL1)	  is	  a	  soluble	  or	  membrane-­‐bound	  chemokine	  whose	  effects	  are	  mediated	  through	  the	  CX3CR1	  receptor,	  expressed	  by	  many	  cells.	  Soluble	  CX3CR1	   levels	  are	  elevated	   in	  patients	  with	  PAH	  (Balabanian	  et	  al.,	  2002),	  upregulated	  on	  both	  CD4+	  and	  CD8+	  T	  lymphocytes	  in	  PAH	  (Balabanian	  et	  al.,	  2002).	  Monocyte	  chemotactic	  protein	  (MCP)-­‐1	  (CCL2)	  is	  a	  chemokine	  produced	   by	   vascular	   cells	   that	   stimulates	   monocytes/macrophage	   activation	   and	   migration,	  with	  actions	  mediated	  via	   the	  CCR2	  receptor.	  Further	   to	  elevated	  serum	  MCP-­‐1	   levels,	  PASMC	  and	   EC	   from	   patients	   with	   iPAH	   overexpress	   MCP-­‐1	   and	   CCR2,	   and	   exhibit	   exaggerated	  migratory	   and	   proliferative	   responses	   to	   MCP-­‐1	   (Sanchez	   et	   al.,	   2007).	   Finally,	   RANTES	   is	  released	   from	   EC	   in	   PAH	   (Dorfmuller	   et	   al.,	   2002),	   which	   is	   likely	   to	   induce	   recruitment	   of	  inflammatory	  cells	  (e.g.	  CD8+	  T	  cells)	  (Galkina	  et	  al.,	  2005).	  	  
1.5.3	  Clinical	  evidence	  for	  inflammation	  in	  PAH	  
PAH	   is	   a	   recognised	   complication	   of	   a	   number	   of	   “inflammatory”	   conditions	   including	   the	  syndrome	   of	   polyneuropathy,	   organomegaly,	   endocrinopathy,	   monoclonal	   gammopathy	   and	  skin	   changes	   (POEMS	   syndrome)	   (Lesprit	   et	   al.,	   1998),	   connective	   tissue	   diseases	   (including	  scleroderma,	  mixed	  connective	  tissue	  disease	  (MCTD)	  and	  systemic	  lupus	  erythematosus	  (SLE))	  (Hachulla	   et	   al.,	   2005,	   Asherson,	   1990,	   Fagan	   and	   Badesch,	   2002),	   Hashimoto’s	   thyroiditis	  (Thurnheer	  R,	  1997)	  and	  Castleman’s	  disease	  (Montani	  et	  al.,	  2005).	  PAH	  is	  also	  associated	  with	  infections	  including	  schistosomiasis	  (Graham	  et	  al.,	  2010)	  and	  HIV	  (Nunes	  et	  al.,	  2003).	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Immunosuppression	  of	   these	  underlining	  conditions	  has	  been	  observed	  to	   improve	  associated	  PAH	   in	   some	   cases	   of	   SLE	   (Karmochkine	   et	   al.,	   1996,	   Tanaka	   et	   al.,	   2002,	   Jais	   et	   al.,	   2008,	  Goupille	  et	  al.,	  1994)	  MCTD	  (Jais	  et	  al.,	  2008,	  Dahl	  et	  al.,	  1992),	  POEMS	  (Jouve	  et	  al.,	  2007)	  and	  Castleman’s	  disease	  (Montani	  et	  al.,	  2005).	  Improvements	  are	  however	  unusual	  in	  scleroderma-­‐associated	  PAH	  (Sanchez	  et	  al.,	  2006)	  for	  reasons	  that	  may	  include	  a	  more	  pronounced	  fibrotic	  vascular	   disease	   and	   the	   presence	   of	   major	   comorbidities.	   Hemodynamic	   improvement	   is	  reported	   in	   some	   cases	   of	   HIV-­‐associated	   PAH	   following	   anti-­‐retroviral	   therapy	   (Zuber	   et	   al.,	  2004,	  Barnier	   et	   al.,	   2009).	   Recent	   studies	   however	   suggest	   that,	   compared	   to	   advanced	  PAH	  therapies,	  anti-­‐retroviral	  therapy	  treatment	  is	  not	  associated	  with	  hemodynamic	  improvements	  (Degano	  et	  al.,	  2010),	  and	  that	  the	  prevalence	  of	  HIV-­‐related	  PAH	  in	  fact	  remains	  similar	  to	  that	  prior	  to	  the	  era	  of	  antiretroviral	  therapy	  (Sitbon	  et	  al.,	  2008).	  Finally,	  it	  is	  unclear	  as	  to	  whether	  immunosuppression	  would	  improve	  iPAH.	  There	  have	  been	  no	  clinical	  trials	  but	  sporadic	  case	  reports	   suggest	   haemodynamic	   and	   clinical	   improvement	   following	   the	   use	   of	   prednisolone	  alone	  (Ogawa	  et	  al.,	  2011)	  and	  in	  combination	  with	  methotrexate	  (Bellotto	  et	  al.,	  1999).	  	  	  
1.5.4	  How	  inflammation	  may	  contribute	  to	  vascular	  remodelling	  in	  PAH	  
Inflammation	   is	   likely	   to	   contribute	   to	   PAH	   through	   multiple	   mechanisms.	   It	   may	   initiate	  vascular	  remodelling	  (i.e.	  be	  an	  “initial	  hit”),	  be	  integral	  in	  its	  propagation	  (a	  “secondary	  hit”)	  or	  just	   be	   reactive	   to	   on-­‐going	   remodelling	   (“bystander”	   phenomenon).	   Chemokines	   such	   as	  RANTES,	   MCP-­‐1	   and	   fracktalkine	   all	   contribute	   to	   inflammatory	   cell	   recruitment,	   as	   well	   as	  causing	  PASMC	  proliferation	  (Perros	  et	  al.,	  2007a,	  Sanchez	  et	  al.,	  2007).	   In	  addition,	  cytokines	  implicated	   in	   PAH	   (e.g.	   IL-­‐6)	   can	   directly	   influence	   PASMC	   proliferation	   (Ikeda	   et	   al.,	   1991).	  Inflammatory	   stimuli	   also	   activate	   vascular	   cells	   to	   release	   more	   chemokines,	   cytokines	   and	  growth	   factors	   (e.g.	   ET-­‐1	   (Wort	   et	   al.,	   2009)),	   leading	   to	   propagation	   of	   inflammation	   and	  vascular	  cell	  growth	  (see	  later	  for	  more	  on	  IL-­‐6,	  CXCL8	  and	  TNF-­‐α).	  A	  summary	  of	  inflammatory	  pathways	  contributing	  to	  PAH	  is	  proposed	  in	  Figure	  1.6.	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Figure	   1.6.	   	   Schematic	   to	   illustrate	   how	   inflammatory	   mechanisms	   might	  
contribute	  to	  the	  pathophysiology	  of	  pulmonary	  arterial	  hypertension	  (PAH).	  Pathways	  through	  which	  inflammation	  may	  propagate	  pulmonary	  vascular	  remodelling	  in	  PAH	  are	   summarised.	   Initial	   inflammatory	   triggers	  may	   include	   infections,	   drugs	   or	   toxins,	   which	  may	  act	  as	  a	  ‘second	  hit’	  in	  concert	  with	  another	  risk	  factor	  such	  as	  BMPR-­‐II	  dysfunction,	  which	  may	   alter	   the	   subsequent	   inflammatory	   response.	   Whatever	   the	   exact	   relationship,	   there	   is	  evidence	   for	   activation	   of	   both	   the	   innate	   immune	   system	   (e.g.	   through	   activation	   of	  macrophages/monocytes)	   and	   of	   adaptive	   immunity	   (e.g.	   through	   specific	   T-­‐cell	   and	   B	   cell	  receptors).	   	   Subsequent	   production	   of	   cytokines	   and	   chemokines	   may	   propagate	   further	  inflammatory	   processes	   and	   on	   their	   own,	   or	   through	   production	   of	   growth	   factors,	   drive	  vascular	   remodelling	   processes.	   B	   cell	   production	   of	   autoantibodies	   may	   favour	   an	   anti-­‐apoptotic	  phenotype	  of	  endothelial	  cells.	  
	  
1.6	  Cells	  of	  the	  monocyte	  /	  macrophage	  lineage	  	  
Cells	  of	  the	  monocyte/macrophage	  lineage	  originate	  as	  myeloid	  progenitor	  cells,	  which	  give	  rise	  to	   pro-­‐monocytes	   in	   the	   bone	   marrow	   then	   differentiate	   into	   a	   circulating	   pool	   of	   blood	  monocytes.	  They	  migrate	  through	  blood	  vessel	  walls	  to	  become	  tissue	  macrophages,	  which	  form	  the	   mononuclear	   phagocyte	   system.	   These	   cells	   function	   as	   1)	   professional	   phagocytic	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macrophages	   (which	   with	   endothelial	   cells	   and	   polymorphs	   from	   the	   reticular	   activating	  system)	  and	  2)	  professional	  antigen	  presenting	  cells.	  Of	  note,	  CD68	  is	  a	  glycoprotein	  present	  in	  cytoplasmic	  granules	  of	  monocytes/macrophages	  and	  a	  commonly	  used	  immunohistochemical	  marker	  for	  cells	  of	  this	  lineage	  (Pulford	  et	  al.,	  1990).	  	  
1.6.1	  Blood	  monocytes	  
Circulating	  monocytes	  are	  described	  as	  “inflammatory”	  or	  “resident”	  monocytes.	  Inflammatory	  monocytes	  express	  the	  chemokine	  receptor	  CCR2,	  and	  are	  recruited	  to	   inflamed	  tissues	  e.g.	   in	  response	  to	  MCP-­‐1	  (CCL2)	  (Geissmann	  et	  al.,	  2003).	  They	  can	  differentiate	  into	  inflammatory	  DC	  (Geissmann	  et	  al.,	  2003)	  and	  replenish	  resident	  cell	  compartments	  (Varol	  et	  al.,	  2007).	  Resident	  monocytes	   are	   found	   both	   in	   resting	   and	   inflamed	   tissues;	   those	   on	   resting	   endothelium	   are	  thought	   to	   patrol	   healthy	   tissue,	   allowing	   rapid	   tissue	   invasion	   at	   the	   site	   of	   infection	   and	  differentiation	   into	   tissue	   macrophages	   (Auffray	   et	   al.,	   2007).	   In	   humans,	   inflammatory	  monocytes	  express	  CD14+	  CD16–	  and	  resident	  monocytes	  express	  CD14+	  CD16+	  (Auffray	  et	  al.,	  2007,	   Passlick	   et	   al.,	   1989).	   Alveolar	   macrophages	   are	   predominantly	   derived	   from	   the	  ‘resident’	   subtype	   (Passlick	   et	   al.,	   1989):	   this	   CD16+	   marginal	   pool	   resides	   on	   endothelial	  surfaces	  and	  can	  be	  rapidly	  mobilised	  (Steppich	  et	  al.,	  2000).	  	  
1.6.1.1	  Monocytes	  in	  PAH	  
Savai	   et	   al	   demonstrated	   an	   increase	   in	   CD14+	   monocytes	   in	   the	   adventitia	   of	   pulmonary	  arteries	  in	  iPAH	  patients	  compared	  to	  controls	  (Savai	  et	  al.,	  2012b).	  In	  addition,	  plasma	  and	  lung	  tissue	   levels	   of	   monocyte	   chemoattractants	   were	   elevated	   in	   patients	   with	   iPAH	   –	   including	  MCP-­‐1	  (Itoh	  et	  al.,	  2006),	  fracktalkine	  (Balabanian	  et	  al.,	  2002)	  and	  RANTES	  (Dorfmuller	  et	  al.,	  2002)	  -­‐	  localised	  to	  CD4+	  and	  CD8+	  T	  lymphocytes	  (Balabanian	  et	  al.,	  2002),	  pulmonary	  arterial	  EC,	  and	  to	  a	  lesser	  extent,	  PASMC	  (Balabanian	  et	  al.,	  2002,	  Dorfmuller	  et	  al.,	  2002).	  In	  the	  case	  of	  MCP-­‐1,	   Sanchez	   et	   al	   showed	   that	   although	   monocyte	   MCP-­‐1	   levels	   were	   similar	   between	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patients	   and	   control	   subjects,	   EC	   released	   twice	   as	  much	  MCP-­‐1	   than	   PASMC,	   and	  monocyte	  migration	  was	  markedly	  increased	  in	  the	  presence	  of	  ECs	  from	  patients	  with	  iPAH	  (Sanchez	  et	  al.,	  2007).	  These	  findings	  therefore	  suggest	  that	  recruitment	  and	  activation	  of	  monocytes	  play	  a	  key	   role	   in	   iPAH.	   Indeed,	   Savai	   et	   al	   blocked	   monocyte	   recruitment	   in	   the	   MCT-­‐induced	   PH	  model	   and	   demonstrated	   a	   regression	   of	   PH	   (Savai	   et	   al.,	   2012b).	   There	   have	   been	   several	  microarray	  studies	  of	  gene	  expression	  profiles	  of	  PBMC	  from	  PAH	  patients,	  confirmed	  by	  PCR,	  for	   example	   showing	   that	   over	   100	   genes	   including	   those	   involved	   in	   inflammation	   and	   cell	  proliferation	   that	   discriminated	   patients	   with	   PAH	   from	   controls	   (Bull	   et	   al.,	   2004).	   Other	  studies	   suggested	   that	   circulating	   monocytes	   and	   monocyte-­‐derived	   DCs	   from	   PAH	   patients	  were	   hyporesponsive	   in	   vitro	   compared	   to	   cells	   from	   control	   subjects	   (Wang	   et	   al.,	   2009,	  Raychaudhuri	  et	  al.,	  2002a)	  –	  these	  are	  discussed	  in	  chapter	  6.	  	  	  
1.6.2	  Dendritic	  Cells	  
Dendritic	   cells	   (DC)	   are	   mononuclear	   phagocytes	   derived	   from	   blood	   monocytes,	   and	   act	   as	  professional	   APCs.	   They	   form	   a	   bridge	   between	   the	   innate	   and	   adaptive	   immune	   systems	   as	  they	   make	   contact	   with	   T	   and	   B	   cells	   in	   lymph	   nodes.	   Human	   DC	   subsets	   include	   CD11c+	  myeloid	   DCs,	   CD141+	   myeloid	   DCs	   and	   CD303+	   plasmacytoid	   DCs.	   These	   human	   monocyte	  subsets	   differentiate	   into	   DC	   in	   the	   presence	   of	   granulocyte/	  macrophage	   colony-­‐stimulating	  factor	   (GM-­‐CSF)	   and	   IL-­‐4,	   and	   mature	   further	   in	   the	   presence	   of	   TNF-­‐α	   (Sallusto	   and	  Lanzavecchia,	  1994).	  An	  increase	  in	  infiltrating	  DC	  in	  pulmonary	  arteries	  has	  been	  documented	  in	   the	   adventitia	   of	   all	   sizes	   of	   pulmonary	   arteries	   in	   both	  human	   iPAH	   (Perros	   et	   al.,	   2007b,	  Savai	  et	  al.,	  2012b)	  and	  in	  MCT-­‐induced	  PH	  (Perros	  et	  al.,	  2007b).	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1.6.3	  Tissue	  macrophages	  	  
Tissue	   macrophages	   have	   a	   broad	   role	   in	   the	   maintenance	   of	   tissue	   homeostasis	   through	  phagocytosis	   and	   remodelling	   and	   repair	   of	   tissue.	   Of	   these,	   alveolar	   macrophages	   (AM)	   are	  responsible	  for	  the	  clearance	  of	  particulate	  matter	  inhaled	  during	  normal	  breathing.	  They	  have	  a	   particularly	   high	   expression	   of	   pattern	   recognition	   and	   scavenger	   receptors,	   important	   in	  clearing	   microorganisms,	   viruses	   and	   environmental	   particles	   in	   the	   lung	   (Palecanda	   et	   al.,	  1999).	  
Activated	  macrophages	  interact	  with	  and	  induce	  proliferation	  of	  T	  cells;	  they	  also	  interact	  with	  SMC	   and	  EC,	  maintaining	   cell	   viability,	   preventing	   apoptosis	   and	   causing	   further	  macrophage	  activation	   and	   replication.	   In	   addition,	   SMC	   and	   EC	   can	   present	   antigens	   and	   secrete	  macrophage	  chemokines	  (MCP-­‐1),	  as	  well	  as	  IL-­‐1	  and	  TNF-­‐α	  that	  activate	  further	  macrophages.	  Following	   activation,	   the	  most	   important	  monocyte/macrophage-­‐derived	   cytokine	   released	   is	  TNF-­‐α;	  others	  include	  IL1-­‐β,	  IL-­‐6,	  CXCL8,	  IL-­‐10	  and	  IFN-­‐α/β	  (Ross,	  1993).	  
Macrophages	   are	   subdivided	   according	   to	   function,	   depending	   upon	   their	   activation	   stimuli,	  based	  on	  their	  activation	  state	  into	  M1	  (‘classical’)	  and	  M2	  (‘alternative’)	  macrophages,	  and	  the	  more	  recently	  described	   ‘regulatory’	  macrophages,	  which	  release	  high	   levels	  of	   IL-­‐10	  (Saraiva	  and	   O'Garra,	   2010,	   Gordon	   and	   Taylor,	   2005).	   M1	   macrophages	   are	   primed	   by	   IFN-­‐γ	   and	   a	  second	  signal	  such	  as	  a	  microbial	  product	  (e.g.	  LPS)	  or	  a	  pro-­‐inflammatory	  cytokine	  (e.g.	  TNF-­‐
α).	   They	   are	   pro-­‐inflammatory	   and	   highly	   phagocytic,	   releasing	   reactive	   oxygen	   and	  nitrogen	  species,	   chemokines	   and	   pro-­‐inflammatory	   cytokines	   such	   as	   TNF-­‐α	   and	   IL-­‐6	   that	   direct	  endothelial	  injury.	  Conversely,	  alternatively	  activated	  M2	  macrophages	  phagocytose	  poorly,	  and	  have	   anti-­‐inflammatory	   functions	   such	   as	   extracellular	   matrix	   deposition	   and	   resolution	   of	  tissue	   injury	   (Gordon	   and	   Taylor,	   2005).	   Inhibition	   of	   NF-­‐κB	   in	   bone-­‐marrow-­‐derived	  macrophages	  (BMDMs)	  resulted	  in	  reduced	  levels	  of	  LPS-­‐induced	  TNF-­‐α	  but	  no	  effect	  on	  IL-­‐10	  release	   (Wilson	  et	   al.,	   2005).	   	  Glomerular	   infiltration	  and	  activation	  of	  host	  macrophages	  was	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significantly	  reduced	  when	  labelled	  dominant-­‐negative	  IκB	  BMDMs	  were	  injected	  into	  a	  model	  of	  nephritis	  presence	  (Wilson	  et	  al.,	  2005).	  	  
1.6.3.1	  Tissue	  macrophages	  in	  PAH	  
An	   increase	   in	   CD68+	   tissue	   macrophages	   in	   human	   iPAH	   lung	   sections	   was	   recently	  demonstrated	   by	   Savai	   et	   al	   (Savai	   et	   al.,	   2012b).	   In	   2002,	   Raychaudhuri	   et	   al	   demonstrated	  increased	   NF-­‐κB	   activation	   in	   (unstimulated)	   human	   alveolar	   macrophages	   obtained	   from	  bronchoalveolar	   lavage	   from	   patients	   with	   PAH	   compared	   to	   controls	   without	   PAH	  (Raychaudhuri	  et	  al.,	  1999).	  The	  role	  of	  macrophages	  in	  PAH	  is	  discussed	  further	  in	  chapter	  3.	  	  
1.7	  Inflammatory	  signalling	  in	  PAH	  
Of	  the	   inflammatory	  transcription	   factors,	   there	   is	  preliminary	  evidence	   implicating	  activation	  of	  nuclear	   factor-­‐kappa	  B	  (NF-­‐κB)	   in	  MCT-­‐induced	  PH;	   in	  alveolar	  macrophages	   from	  patients	  with	  iPAH	  (Raychaudhuri	  et	  al.,	  2002b);	  and	  in	  cytokine-­‐mediated	  release	  of	  ET-­‐1	  from	  PASMC	  (Wort	  et	  al.,	  2009).	  NF-­‐κB	  was	  therefore	  selected	  to	  study	  in	  this	  thesis.	  In	  this	  section,	  canonical	  NF-­‐κB	   signalling	   is	   described;	   thereafter	  major	   activators	   of	   this	   pathway	   (Toll-­‐like	   receptor	  signalling	   and	   TNF-­‐α	   (also	   a	   product	   of	   NF-­‐κB	   activation));	   and	   finally	   relevant	   downstream	  products	  of	  NF-­‐κB	  activation	  including	  CXCL8	  and	  IL-­‐6,	  and	  what	  is	  known	  regarding	  their	  role	  in	  PAH.	  Additional	   interesting	   transcription	   factors	   in	  PAH	  might	   include	   JNK,	   JAK,	  STATs	  and	  AP-­‐1,	  however	  were	  not	  the	  subject	  of	  this	  thesis.	  	  
1.7.1	  Nuclear	  factor	  kappa	  B	  (NF-­‐κB)	  
NF-­‐κB/Rel	   transcription	   factors	   are	   key	   regulators	   of	   the	   majority	   of	   genes	   involved	   in	  inflammatory	   and	   proliferative	   cellular	   responses.	   NF-­‐κB	  was	   first	   detected	   as	   a	   protein	   that	  formed	  complexes	  with	  the	  light	  chain	  gene	  enhancer	  in	  B-­‐lymphocytes.	  It	  was	  found	  to	  exist	  in	  most	  cells,	  and	  that	  movement	  of	  the	  inactive	  cytoplasmic	  form	  to	  the	  nucleus	  led	  to	  specific	  and	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proteins	   bind	   to	  NF-­‐κB	   dimers	   and	  mask,	   and	   thereby	   inhibit,	   the	  NF-­‐κB	   nuclear	   localization	  signal	  (NLS)	  (Karin	  and	  Ben-­‐Neriah,	  2000).	  The	  first	  step	  is	  activation	  of	  the	  IKK	  complex,	  which	  occurs	  in	  response	  to	  a	  variety	  of	  activating	  stimuli	  (Table	  1.3).	  The	  mechanisms	  by	  which	  the	  IKK	  complex	   is	  activated	  are	  different	   for	  each	   type	  of	   receptor	  activated	  (examples	   including	  Toll-­‐like	   receptor	   signalling	   and	   TNF-­‐α	   are	   discussed	   below).	   The	   IKK	   complex	   contains	   two	  catalytic	  subunits,	  IKKα	  (IKK-­‐1)	  and	  IKKβ	  (IKK-­‐2),	  and	  a	  non-­‐catalytic	  regulatory	  subunit	  called	  NEMO	  (NF-­‐κB	  essential	  modulator).	   IKK-­‐1	  and	   IKK-­‐2	  usually	  heterodimerise	  with	   IKKα-­‐IKKβ-­‐NEMO	  in	  a	  1:1:2	  ratio	  (Hacker	  and	  Karin,	  2006).	  Once	  receptors	  have	  engaged,	  the	  activated	  IKK	  complex	   phosphorylates	   IκBα	   on	   Ser332	   and	   Ser36,	   which	   leads	   to	   its	   ubiquitination	   and	  degradation	  by	  the	  26S	  proteasome	  (Karin	  and	  Ben-­‐Neriah,	  2000).	  Thus	  the	  NF-­‐κB	  heterodimer	  is	  released;	  and	  it	  translocates	  to	  the	  nucleus	  to	  bind	  specific	  DNA	  response	  elements	  of	  target	  genes	  to	  activate	  gene	  expression.	  Of	  the	  catalytic	  IKK	  subunits,	  IKKβ	  or	  IKK-­‐2	  is	  responsible	  for	  the	  majority	   of	   IκB	   kinase	   activity	   in	  most	   cell	   types	   (Vallabhapurapu	   and	  Karin,	   2009).	   This	  description	  of	  classical	  or	  canonical	  NF-­‐κB	  signalling	  is	  illustrated	  in	  Figure	  1.7.	  




	  	  	  	  	  	  	  	  	  
	  
	  
Figure	  1.7.	  	  Figure	  illustrating	  simplified	  canonical	  (classical)	  NF-­‐κB	  signalling	  	  In	  resting	  quiescent	  cells,	  the	  p50-­‐p65	  (RelA)	  NF-­‐κB	  heterodimer	  is	  maintained	  in	  the	  cytosol	  by	  forming	  a	  complex	  with	  the	  inhibitory	  protein,	  IκB.	  In	  response	  to	  many	  stimuli,	  the	  IκB	  kinase	  (IKK)	  enzyme	  complex	  is	  activated,	  and	  phosphorylates	  IκBα	  at	  two	  conserved	  serine	  residues	  (serines	   32	   and	   36).	   This	   leads	   to	   phosphorylation	   and	   dissociation	   of	   IκB	   (which	   results	   in	  ubiquitination,	   dissociation	   of	   IκBα	   from	   NF-­‐κB,	   and	   eventual	   degradation	   of	   IκB	   by	   the	  proteasome).	  Activated	  unimpeded	  NF-­‐κB	  then	  translocates	   into	  the	  nucleus	  where	  p65	  binds	  to	  specific	  DNA	  response	  elements	  of	  multiple	   target	  genes.	  The	  DNA/NF-­‐κB	  complex	  recruits	  other	  proteins	  such	  as	  co-­‐activators	  and	  RNA	  polymerase,	  which	   transcribe	  downstream	  DNA	  into	  mRNA,	  thus	  inducing	  gene	  transcription	  of	  target	  genes.	  	  Abbreviations:	  NF-­‐κB	  -­‐	  nuclear	  factor-­‐κB,	  P	  -­‐	  phosphate	  group,	  IκBα	  -­‐	  inhibitor	  of	  NF-­‐κB,	  IKK	  -­‐	  IκB	  kinase,	  (IKKα/IKK-­‐1),	  IKKβ/IKK-­‐2),	  and	  NEMO	  -­‐	  NF-­‐κB	  essential	  modulator.	  	  
1.7.1.1	  Regulation	  of	  NF-­‐κB	  transcriptional	  activity	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associated	  with	  histone	  acetylation,	  which	  controls	  p65	  activity.	  Many	  of	  the	  co-­‐activators	  that	  NF-­‐κB	   recruits	   following	   DNA	   binding	   (e.g.	   CBP)	   possess	   a	   histone	   acetyltransferase	   (HAT)	  domain.	   These	   induce	   acetylation	   of	   histone	   lysine	   residues,	   thereby	   allowing	   increasing	  transcription	  factor	  access	  to	  DNA,	  usually	  correlating	  with	  gene	  activation	  (Calao	  et	  al.,	  2008).	  HAT	   activity	   is	   balanced	   by	   histone	   deacetylase	   (HDAC)	   enzymes,	   which	   deacetylate	   lysine	  residues	  and	  render	  the	  nucleosomal	  DNA	  less	  accessible	  to	  the	  transcriptional	  machinery,	  thus	  inhibiting	   NF-­‐κB	   gene	   regulation.	   For	   example,	   the	   interaction	   of	   p65	   with	   HDAC-­‐1	   and	   2	  inhibits	  NF-­‐κB-­‐induced	  transcription	  of	  CXCL8	  (Ashburner	  et	  al.,	  2001).	  These	  acetylation	  and	  deacetylation	  events,	  through	  the	  involvement	  of	  substrate-­‐specific	  HDACs	  and	  HATs,	  modulate	  both	  NF-­‐κB-­‐signalling	  and	  the	  transcriptional	  transactivation	  of	  NF-­‐κB-­‐dependent	  genes.	  	  
1.7.2	  Toll-­‐like	  receptor	  (TLR)	  signalling	  
TLRs	   are	  pattern	   recognition	   receptors	   that	   recognise	  bacterial	   components	   and	  patterns	  not	  expressed	   by	   eukaryotic	   cells.	   Their	   discovery	   over	   15	   years	   ago	  was	   recognised	   in	   2011	   by	  award	  of	  the	  Nobel	  Prize.	  TLR	  signalling	  is	  a	  core	  feature	  of	  the	  innate	  immune	  response,	  and	  a	  prerequisite	   for	   the	   induction	   of	   acquired	   immunity	   (Akira	   et	   al.,	   2001).	   TLRs	   are	   either	  activated	   by	   microbial	   ligands	   (pathogen-­‐associated	   molecular	   patterns,	   PAMPs)	   or	   non-­‐infectious	   ligands	   (damage-­‐associated	   molecular	   pattern	   molecules,	   DAMPs).	   TLRs	   are	  expressed	  on	  all	   immune	  cells,	  and	  also	  on	  vascular	  cells	   including	  human	  pulmonary	  arterial	  endothelial	  and	  PASMC	  (George	  et	  al.,	  2012,	  Yang	  et	  al.,	  2005a).	  Over	  thirteen	  different	  specific	  TLRs	  have	  been	  described	  (O'Neill	  et	  al.,	  2013).	  Of	  these,	  TLR4	  is	  mainly	  activated	  by	  bacterial	  endotoxin	  (lipopolysaccharide,	  LPS),	  and	  will	  be	  discussed	  here.	  
Activation	   of	   the	   common	   Toll/IL-­‐1	   receptor	   (TIR)	   domain	   of	   TLRs	   mainly	   activates	   the	  canonical	  NF-­‐κB	  pathway	  and	  MAP	  kinase	  pathways	  (e.g.	  JNK	  and	  thereafter	  AP-­‐1)	  (Zhang	  and	  Ghosh,	   2001).	   TLR	   activation	   occurs	   through	   both	   ‘MyD88-­‐dependent	   signalling’	   (through	  recruitment	  of	  the	  adapter	  protein,	  myeloid	  differentiation	  primary	  response	  gene-­‐88,	  MyD88)	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and	   through	   MyD88-­‐independent	   pathways.	   In	   the	   former,	   MyD88	   associates	   with	   the	   TIR	  domain	   death	   domain	   to	   recruit	   downstream	   IL-­‐1	   receptor–associated	   kinase	   (IRAK)	   to	   the	  receptor	   complex	   (O'Neill	   and	   Greene,	   1998).	   IRAK	   is	   then	   autophosphorylated;	   dissociates	  from	  the	  receptor	  complex	  and	  recruits	  TNF	  receptor–associated	  factor	  6	  (TRAF6)	  that	  in	  turn	  activates	   downstream	   kinases	   including	   NF-­‐κB–inducing	   kinase	   (NIK)	   and	   mitogen-­‐activated	  protein	   kinase/ERK	   kinase	   kinase	   1	   (MEKK1)	   (Karin	   and	   Ben-­‐Neriah,	   2000).	   NIK	   can	   be	  phosphorylated	  and	  activated	  by	  TGF-­‐β–activated	  kinase	  1	  (TAK1);	  and	  both	  activated	  MEKK1	  and	   NIK	   activate	   the	   IKK	   complex	   (Zhang	   and	   Ghosh,	   2001).	   Subsequently,	   IκB	   is	  phosphorylated	  and	  degraded	   leading	   to	  nuclear	   translocation	  of	  NF-­‐κB	  and	   initiation	  of	  gene	  transcription.	   In	   MyD88-­‐independent	   signalling,	   adaptor	   proteins	   (e.g.	   TIRAP	   or	   MyD88-­‐adapter-­‐like	  protein	  -­‐	  MAL)	  directly	  activate	  IKK	  (Akira	  et	  al.,	  2001).	  	  
LPS	  is	  unique	  as	  it	  uses	  both	  these	  signalling	  pathways	  (Figure	  1.8).	  Early	  studies	  showed	  that	  TLR4-­‐deficient	  mice	  were	  hyporesponsive	  to	  LPS	  (Hoshino	  et	  al.,	  1999),	  and	  later	  translated	  to	  patients	  with	  TLR4	  mutations	  who	  were	  hyporesponsive	  to	  endotoxin	  (Arbour	  et	  al.,	  2000).	  LPS	  signalling	   through	   TLR4	   requires	   both	   CD14	   (a	   glycoprotein	   which	   may	   be	   soluble	   or	  membrane-­‐bound);	  MD-­‐2	   (a	   small	  molecule	   in	   serum),	   and	   LPS	   binding	   protein	   (LBP),	  which	  acts	  as	  a	  shuttle	  to	  transfer	  microbial	  products	  to	  CD14	  (Zhang	  and	  Ghosh,	  2001).	  





	  	  	  	  	  	  
Figure	   1.8.	   	   Figure	   illustrating	   Toll-­‐like	   receptor	   signalling	   through	   MyD88-­‐
dependent	  and	  independent	  pathways.	  Lipopolysaccharide	   (LPS)	   or	   Gram-­‐negative	   bacterial	   endotoxin	   signals	   through	   the	   adaptor	  molecule	   myeloid	   differentiation	   factor	   88	   (MyD88)	   and	   also	   recruits	   a	   MyD88-­‐like	   adaptor	  molecule	   (MAL)	   resulting	   in	   the	   activation	   of	   NF-­‐κB	   via	   IκB	   kinase	   (IKK).	   NF-­‐κB	   thereafter	  translocates	   to	   the	  nucleus	   and	  binds	   to	  κB	  promoter	   elements	   resulting	   in	   the	   expression	  of	  inflammatory	  cytokines.	  	  Abbreviations:	  TLR	   -­‐	  Toll-­‐like	   receptor,	  TIR	  –	  Toll/IL-­‐1	   receptor,	  TRIF	   -­‐	  TIR-­‐domain-­‐containing	  adapter-­‐inducing	   interferon-­‐β,	   TRAM	   -­‐	   TRIF-­‐related	   adaptor	   molecule,	   MyD88	   -­‐	   Myeloid	  differentiation	   primary	   response	   gene	   88,	   IRF	   -­‐	   Interferon	   Regulatory	   Factor,	   IRAK	   -­‐	  Interleukin-­‐1	   receptor-­‐associated	   kinase,	   IFN	   -­‐	   Interferon,	  TNFα	   -­‐	  Tumour	  Necrosis	   Factor	  α.,	  IFN	  -­‐	  interferon.	  	  	  
1.7.3	  Tumour	  necrosis	  factor	  (TNF)-­‐α	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(TNFR1),	  a	  ubiquitous	  surface	  receptor;	  and	  TNFR2,	  whose	  expression	  is	  restricted	  to	  immune	  and	   endothelial	   cells.	   Both	   receptors	   activate	   NF-­‐ĸB	   (by	   different	  mechanisms)	   (Thommesen	  and	   Laegreid,	   2005),	   for	   example,	   through	   the	   cytoplasmic	   domain	   of	   TNFR1	   binding	   the	  adapter	   protein	   TNFR-­‐associated	   death	   domain	   (Wajant	   et	   al.,	   2003).	   Finally,	   a	   distinct	  signalling	   pathway,	  which	   requires	   internalisation	   of	   the	   TNF/TNFR1	   complex	   into	   endocytic	  vesicles	   and	   activation	   of	   the	   Fas	   associated	   death	   domain	   (FADD)	   of	   the	   receptor,	   leads	   to	  caspase-­‐8-­‐	  and	  caspase-­‐3-­‐dependent	  apoptosis	  (Micheau	  and	  Tschopp,	  2003).	  	  	  	  
1.7.3.1	  Role	  of	  TNF-­‐α	  in	  PAH	  
Circulating	  levels	  of	  TNF-­‐α	  are	  elevated	  in	  human	  PAH	  (Lei	  et	  al.,	  2002,	  Pendergrass	  et	  al.,	  2010,	  Soon	  et	   al.,	   2010)	  and	  predict	   adverse	  outcomes	   (Soon	  et	   al.,	   2010).	  TNF-­‐α	  expression	   is	   also	  elevated	  in	  MCT-­‐induced	  PH	  (Wang	  et	  al.,	  2012)	  and	  overexpression	  of	  TNF-­‐α	  caused	  severe	  PH	  in	   a	   mouse	   model	   of	   emphysema	   (Fujita	   et	   al.,	   2001).	   In	   addition,	   the	   TNF-­‐α	   antagonist	  etanercept	  prevented	  and	  reversed	  MCT-­‐induced	  PH	  (Sutendra	  et	  al.,	  2011).	  Interestingly,	  TNF-­‐α	  reduces	  BMPR-­‐II	  expression	  in	  cultured	  osteoblasts	  (Singhatanadgit	  et	  al.,	  2006);	  and	  ongoing	  studies	   by	   Hurst	   et	   al	   show	   that	   TNF-­‐α	   indeed	   reduced	   BMPR-­‐II	   signalling	   in	   human	   PASMC	  (Hurst	   L.,	   2012).	   This	   creates	   a	   ‘chicken	   and	   egg’	   hypothesis	   i.e.	   in	   addition	   to	   BMPR-­‐II	  dysfunction	  promoting	  an	   inflammatory	  phenotype	  (Hagen	  et	  al.,	  2007,	  Davies	  et	  al.,	  2012),	   it	  seems	  that	  inflammation	  itself	  can	  also	  negatively	  regulate	  BMPR-­‐II	  signalling.	  	  
1.7.4	  Interleukin	  (IL)-­‐6	  
IL-­‐6	   was	   originally	   identified	   as	   a	   T	   cell-­‐derived	   cytokine	   that	   promoted	   B	   cell	   maturation	  (Hirano	  et	  al.,	  1985).	  It	  is	  now	  recognised	  as	  a	  multi-­‐functional	  cytokine	  produced	  by	  many	  cell	  types	  (Table	  1.4),	  and	  belongs	  to	  a	  family	  of	  structurally	  related	  cytokines	  (e.g.	  cardiotrophin-­‐1,	  CT-­‐1)	  that	  share	  the	  trans-­‐membrane	  gp130	  protein	  (Kishimoto	  et	  al.,	  1995).	  The	  plasma	  half-­‐life	  of	  IL-­‐6	  is	  about	  2	  minutes,	  following	  which	  it	  is	  degraded	  in	  the	  liver	  (Castell	  et	  al.,	  1988).	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Transcription	   (STATs),	   notably	   STAT3	   (Heinrich	   et	   al.,	   1998).	   STATs	   translocate	   into	   the	  nucleus	   and	  bind	   specific	   enhancer	   sequences,	   and	   activate	   transcription	   of	   IL-­‐6	   target	   genes	  (Heinrich	  et	  al.,	  1998).	   Interestingly,	   STAT3	  nuclear	  binding	  sites	   lie	   close	   to	  binding	  sites	   for	  other	   transcription	   factors	   including	  nuclear	   factor	   (NF)–IL-­‐6,	  NF-­‐κB,	  activator	  protein	   (AP)-­‐1	  and	  GR,	  allowing	  interaction	  with	  these,	  at	  least	  in	  certain	  cell	  types	  (Heinrich	  et	  al.,	  1998).	  For	  example,	   in	   a	   murine	   plasmacytoma	   cell	   line,	   where	   IL-­‐6	   is	   a	   potent	   stimulator	   of	   tumour	  growth,	   the	   rapid	   induction	   of	   the	   acute	   phase	   gene	   junB	   by	   IL-­‐6	   resulted	   from	   co-­‐ordinated	  DNA	  binding	  of	  STAT3	  and	  p65	  (Brown	  et	  al.,	  1995).	  This	   ‘cross-­‐talk’	  with	  other	  transcription	  factors	  is	  believed	  to	  be	  one	  of	  the	  mechanisms	  through	  which	  the	  ubiquitous	  gp130\JAK\STAT	  pathway	   exerts	   cell-­‐specific	   responses.	   In	   addition,	   IL-­‐6	   has	   been	   shown	   to	   induce	   more	  upstream	  activation	  of	  NF-­‐κB,	  for	  example	  in	  epithelial	  cells	  where	  IL-­‐6	  caused	  degradation	  of	  cytoplasmic	   IκBα	   at	   1	   hour,	   then	   increased	   p65	   nuclear	   translocation	   and	   DNA	   binding	   at	   2	  hours	  (Wang	  et	  al.,	  2003).	  This	  is	  summarised	  in	  Figure	  1.9.	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Further	  to	  mediating	  the	  acute	  phase	  response	  (Ramadori	  and	  Christ,	  1999),	  IL-­‐6	  is	  implicated	  in	   the	  regulation	  of	  cell	  growth,	  differentiation,	  proliferation	  and	  apoptosis	   in	  many	  cell	   types	  (Table	  1.3).	  For	  example,	   IL-­‐6	   induces	  macrophage	  differentiation	  (Chomarat	  et	  al.,	  2000)	  and	  MCP-­‐1	  release	  from	  mononuclear	  cells	  and	  vascular	  SMC	  (Biswas	  et	  al.,	  1998).	  In	  addition,	  IL-­‐6	  induces	  PASMC	  migration	  (Savale	  et	  al.,	  2009),	  proliferation	  of	  SMC	  (Ikeda	  et	  al.,	  1991)	  and	  EC	  (Steiner	  et	  al.,	  2009).	  IL-­‐6	  also	  causes	  proliferation	  and	  inhibits	  apoptosis	  in	  cancer	  cells,	  where	  elevated	   plasma	   IL-­‐6	   levels	   are	   adversely	   prognostic;	   indeed	   IL-­‐6	   is	   a	   novel	   target	   for	   cancer	  therapies	  (Guo	  et	  al.,	  2012).	  	  
1.7.4.1	  Role	  of	  IL-­‐6	  in	  PAH	  	  
Circulating	  IL-­‐6	  levels	  are	  elevated	  in	  human	  idiopathic	  PAH	  (Soon	  et	  al.,	  2010,	  Itoh	  et	  al.,	  2006).	  IL-­‐6	   is	   also	   raised	   in	   lung	   specimens	   in	   several	   experimental	   PH	   models	   including	   hypoxia-­‐induced	  PH	   (Savale	   et	   al.,	   2009),	  MCT-­‐induced	  PH	   (Steiner	   et	   al.,	   2009,	  Bhargava	   et	   al.,	   1999,	  Miyata	   et	   al.,	   1995,	   Savale	   et	   al.,	   2009)	   and	   in	   ovalbumin	   and	   VEGF	   antagonist-­‐induced	   PH,	  where	  whole	  lung	  IL-­‐6	  correlated	  with	  mPAP	  (Mizuno	  et	  al.,	  2012).	  The	  increase	  in	  IL-­‐6	  is	  likely	  to	  reflect	  increased	  production	  by	  both	  vascular	  cells	  and	  inflammatory	  cells	  (Savale	  et	  al.,	  2009,	  Mizuno	  et	  al.,	  2012)	  -­‐	  including	  EC	  (Mizuno	  et	  al.,	  2012)	  and	  PASMC	  (Davies	  et	  al.,	  2012).	  In	  turn,	  IL-­‐6	   affects	   inflammatory	   and	   vascular	   cells	   to	   promote	   vascular	   remodelling.	   These	   effects	  include	  accumulation	  of	  perivascular	  T	  lymphocytes	  (Steiner	  et	  al.,	  2009),	  stimulation	  of	  EC	  to	  produce	  chemokines	  such	  as	  CX3CL1/fracktalkine	  (Imaizumi	  et	  al.,	  2004)	  and	  the	  promotion	  of	  PASMC	   and	   EC	   proliferation	   (Savale	   et	   al.,	   2009,	   Steiner	   et	   al.,	   2009).	   Importantly,	   pro-­‐proliferative	   factors	   e.g.	   vascular	   endothelial	   growth	   factor	   (VEGF),	   extracellular	   signal-­‐regulated	  kinase	  (ERK)	  and	  the	  pro-­‐proliferative	  transcription	  factors	  c-­‐MYC	  and	  MAX	  and	  anti-­‐apoptotic	   factors	   e.g.	   Bcl-­‐2	   and	   survivin	   are	   activated	   in	   IL-­‐6	   transgenic	   mice	   showing	   a	  muscularised	  pulmonary	  arteriopathy	  (Steiner	  et	  al.,	  2009).	  	  In	  addition,	  a	  feedback	  loop	  exists	  between	   BMPR-­‐II	   and	   IL-­‐6,	   such	   that	   disordered	   BMPR-­‐II	   signalling	   may	   cause	   cytokine	  dysregulation	  (Hagen	  et	  al.,	  2007).	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1.7.5	  Chemokine	  (CXC	  motif)	  ligand	  (CXCL)-­‐8	  
CXCL8	  is	  a	  prototype	  CXC	  chemokine,	  and	  classically	  considered	  a	  neutrophil	  chemoattractant.	  Baseline	   CXCL8	   release	   is	   minimal	   in	   most	   cells;	   it	   is	   rapidly	   released	   by	   many	   cell	   types	  including	  EC	  and	  macrophages	  in	  response	  to	  a	  wide	  range	  of	  stimuli	  such	  as	  TNF-­‐α	  and	  IL-­‐1β	  (Matsushima	   and	   Oppenheim,	   1989),	   bacterial	   (Brightbill	   et	   al.,	   1999)	   and	   viral	   products	  (Johnston	  et	  al.,	  1997)	  and	  oxidative	  stress	  (DeForge	  et	  al.,	  1993)	  as	  a	  result	  of	  NF-­‐κB	  activation	  (Brightbill	  et	  al.,	  1999).	   In	  EC,	  CXCL8	  may	  also	  be	  stored	  for	  rapid	  release	  from	  Weibel	  Palade	  bodies	  (Utgaard	  et	  al.,	  1998).	  The	  effects	  of	  CXCL8	  are	  mediated	  through	  two	  surface	  G	  protein-­‐coupled	   receptors,	   CXCR1	   and	   CXCR2,	   expressed	   by	   several	   cell	   types.	   CXCR1	   receptors	   are	  CXCL8-­‐specific,	  whereas	  CXCR2	  is	  activated	  by	  multiple	  CXC-­‐	  chemokines	  (Schraufstatter	  et	  al.,	  2001).	   Following	   receptor	   activation	   and	   interaction	   with	   G	   proteins,	   CXCL8	   signals	   through	  multiple	  pathways	  to	  promote	  protein	  translation	  and	  regulate	  the	  activity	  of	  a	  range	  of	  many	  transcription	   factors	   involved	   in	   cell	   proliferation	   and	   survival,	   cell	   metabolism,	   and	  angiogenesis.	   For	   example,	   CXCL8-­‐induced	   cytoskeletal	   structural	   changes	   (and	   thereafter	  chemotaxis)	   are	  mediated	   by	   phosphatidyl-­‐inositol-­‐3	   (PI3)-­‐kinase	   (Knall	   et	   al.,	   1997).	   CXCL8	  can	  also	  signal	  through	  MAP	  kinases,	  and	  the	  JAK2-­‐STAT3	  pathway,	  e.g.	  in	  systemic	  EC	  (Gharavi	  et	   al.,	   2007).	   In	  many	   cases,	   CXCL8-­‐induced	   gene	   transcription	   appears	   to	   occur	   through	   co-­‐operative	  activation	  of	  both	  NF-­‐κB	  and	  AP-­‐1	  (Yasumoto	  et	  al.,	  1992,	  Mastronarde	  et	  al.,	  1998).	  	  	  
1.7.5.1	  Role	  of	  CXCL8	  in	  PAH	  
In	  PAH,	  circulating	  plasma	  CXCL8	  levels	  are	  elevated	  and	  associated	  with	  an	  adverse	  prognosis	  (Soon	  et	  al.,	  2010).	  There	  are	   few	  mechanistic	   studies	  of	  CXCL8	   in	  PAH,	  and	  as	  yet	  none	  with	  immunostaining	   to	   indicate	   which	   cell	   types	   might	   be	   involved.	   Davies	   et	   al	   implicated	   this	  chemokine	  in	  HPAH	  PASMC,	  where	  anti-­‐CXCL8	  antibodies	  restored	  the	  antiproliferative	  effects	  of	   TGF-­‐β	   (Davies	   et	   al.,	   2012).	   Studies	   in	   systemic	   vascular	   EC	   showed	   that	   CXCL8	   directly	  enhanced	  cell	  proliferation	  in	  association	  with	  an	  upregulation	  of	  matrix	  metalloproteinases	  (Li	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et	  al.,	  2003).	   In	  addition,	  CXCL8	  is	  an	   important	  pro-­‐angiogenic	  chemokine	  through	  its	  actions	  on	   endothelial	   CXCR2.	  Dysregulation	   of	   angiogenesis	   is	   associated	  with	   chronic	   inflammatory	  and	  fibroproliferative	  disorders,	  as	  well	  as	  with	  tumour	  growth	  (Strieter	  et	  al.,	  2007).	  	  
1.8	  Anti-­‐	  inflammatory	  therapies	  
With	   increasing	   evidence	   implicating	   inflammation	   as	   a	   driver	   of	   PAH,	   the	   concept	   of	  introducing	   anti-­‐inflammatory	   therapies	   is	   potentially	   attractive.	   This	   might	   include	   broadly	  acting	  agents	   including	  glucocorticoids	  (GC),	  selective	   inhibitors	  of	   inflammatory	  transcription	  factors	   e.g.	  NF-­‐κB,	   as	  well	   as	  more	   specific	   cytokine	   inhibition,	   for	   example,	   using	   a	   clinically	  available	  monoclonal	  antibody	  directed	  at	  IL-­‐6	  (e.g.	  tocilizumab)	  (Arita	  et	  al.,	  2010).	  This	  thesis	  explored	  the	  use	  of	  the	  synthetic	  GC	  dexamethasone	  and	  a	  specific	  inhibitor	  of	  NF-­‐κB.	  	  	  
1.8.1	  Glucocorticoids	  
Naturally	  occurring	  GC	   include	  cortisol	   (hydrocortisone)	  and	  cortisone	  (converted	   to	  cortisol)	  made	   from	   cholesterol	   in	   the	   zona	   fasciculata	   of	   the	   adrenal	   cortex;	   dexamethasone	   is	   a	  synthetic	  GC.	  Cortisone	  was	  identified	  in	  the	  1930s	  by	  the	  chemist	  Dr	  Edward	  Kendall.	  Synthetic	  cortisone	  was	  produced	  soon	  after	  this	  by	  Merck	  in	  1949;	  shortly	  followed	  by	  hydrocortisone.	  Even	   in	   these	   early	   days,	   the	   side	   effects	   relating	   to	   the	   high	   doses	   needed	   to	   suppress	  rheumatic	  symptoms	  inspired	  the	  search	  for	  superior	  agents.	  	  The	  structural	  configuration	  responsible	  for	  GC	  action	  is	  the	  delta-­‐4,3-­‐keto-­‐11-­‐beta,17-­‐alpha,21-­‐trihydroxyl	  configuration	  (Figure	  1.10).	  Dexamethasone	  has	  a	  16α-­‐hydroxyl	  side	  group,	  which	  gives	   it	   more	   anti-­‐inflammatory	   activity	   (and	   relatively	   less	   mineralocorticoid	   activity)	   by	  increasing	  lipophilicity	  therefore	  receptor	  affinity,	  and	  a	  shorter	  plasma	  half-­‐life	  (Table	  1.5).	  In	  practical	  terms,	  0.75mg	  of	  dexamethasone	  promotes	  a	  therapeutic	  response	  equivalent	  to	  that	  of	  4mg	  methylprednisolone,	  5mg	  prednisolone	  and	  20mg	  hydrocortisone	  (Christy,	  1988).	  
Laura	  Price	  PhD:	  Inflammation	  in	  Pulmonary	  Arterial	  Hypertension	   62	  
	  
	  	  	  	  	  	  	  	  	  	  
	  	  	  
	  
Figure	  1.10.	  	  The	  chemical	  structure	  of	  glucocorticoids:	  effects	  on	  function.	  	  	  Structures	   of	   cortisol,	   cortisone,	   and	   several	   of	   the	   more	   commonly	   prescribed	   synthetic	  glucocorticoids.	  The	  delta-­‐4,3-­‐keto-­‐11-­‐beta,17-­‐alpha,21-­‐trihydroxyl	   configuration	   is	  present	   in	  all	   GC.	   The	   introduction	   of	   a	   double	   bond	   between	   the	   1	   and	   2	   positions	   of	   hydrocortisone	  (cortisol)	   yields	   prednisolone	   (delta-­‐1-­‐hydrocortisone),	   which	   has	   about	   four	   times	   more	  glucocorticoid	   activity	   than	   cortisol.	   Dexamethasone	   is	   based	   on	   the	   cortisol	   structure	   but	  differs	  in	  three	  positions	  (extra	  double	  bond	  in	  the	  A-­‐ring	  between	  carbons	  1	  and	  2	  and	  addition	  of	  a	  9-­‐α-­‐fluoro	  group	  and	  a	  16-­‐α-­‐methyl	  substituent).	  It	  therefore	  binds	  more	  powerfully	  to	  the	  glucocorticoid	  receptor	  than	  cortisol.	  	  	  
1.8.1.1	  Mechanisms	  of	  GC	  action	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Figure	  1.11.	  	  Mechanisms	  of	  action	  of	  glucocorticoids	  (GC).	  Cortisol	   freely	   diffuses	   across	   the	   plasma	   membrane	   and	   binds	   to	   the	   cytosolic	   GC	   receptor	  (GR).	   	   The	   cortisol–GR	   complex	   then	   translocates	   into	   the	   nucleus,	   where	   it	   binds	   as	   a	  homodimer	   to	  DNA	  sequences	  called	  glucocorticoid-­‐responsive	  elements.	  Secondly,	   regulation	  of	   other	   glucocorticoid-­‐responsive	   genes	   involves	   interactions	   between	   the	   cortisol–GR	  complex	   and	   other	   transcription	   factors,	   such	   as	   nuclear	   factor-­‐κB	   (NF-­‐κB).	   The	   third	  mechanism	   is	   GC	   signalling	   through	  membrane-­‐associated	   receptors	   and	   second	  messengers	  (so-­‐called	  non-­‐genomic	  pathways).	  Abbreviations:	  TNF-­‐α	  -­‐	  tumour-­‐necrosis	  factor	  α,	  HSP	  -­‐	  heat-­‐shock	  protein,	  mRNA	  -­‐	  messenger	  RNA,	   and	   P	   -­‐	   phosphate.	   The	   three	  mechanisms	   are	   non-­‐genomic	   activation,	   DNA-­‐dependent	  regulation,	   and	   protein	   interference	  mechanisms	   (e.g.,	   NF-­‐κB	   elements).	   Black	   arrows	   denote	  activation,	   the	   red	   line	   inhibition,	   the	   red	   dashed	   arrow	   repression,	   and	   the	   red	   X	   lack	   of	  product	  (i.e.	  no	  mRNA).	  Adapted	  from	  Rhen	  et	  al	  (Rhen	  and	  Cidlowski,	  2005).	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1.8.1.1.1	  Genomic	  effects	  of	  glucocorticoids:	  transactivation	  and	  transrepression	  	  
The	   first	   major	   mechanism	   of	   GC	   action	   involves	   transactivation	   of	   anti-­‐inflammatory	   target	  genes.	  Following	  translocation	  into	  the	  nucleus,	  the	  GR-­‐ligand	  complex	  dimerises	  and	  binds	  to	  specific	   DNA	   sequences	   (glucocorticoid-­‐response	   elements,	   GRE)	   to	   induce	   transcription	   i.e.	  transactivation	   of	   anti-­‐inflammatory	   genes,	   such	   as	   IκB	   (the	   gatekeeper	   that	   limits	   NF-­‐κB	  migration	   into	   the	   nucleus)	   (Scheinman	   et	   al.,	   1995),	   IL-­‐10	   and	  MAPK	   phosphatase	   1	   (which	  leads	  to	  inactivation	  of	  MAP	  kinases)	  (Lasa	  et	  al.,	  2002).	  	  
A	  second	  and	  more	  important	  mechanism	  by	  which	  GC	  suppress	  inflammation	  is	  through	  direct	  GR	  protein-­‐protein	  interaction	  thus	  inhibition	  of	  pro-­‐inflammatory	  mediators,	  i.e.	  the	  process	  of	  transrepression.	  This	  mutual	  inhibition	  of	  DNA	  binding	  was	  first	  described	  by	  GR	  inhibition	  of	  AP-­‐1	   directed	   pro-­‐inflammatory	   gene	   transcription	   (Yang-­‐Yen	   et	   al.,	   1990)	   and	   was	   later	  similarly	  described	  for	  GR	  and	  p65	  (Ray	  and	  Prefontaine,	  1994).	  Transrepression	  explains	  the	  GC-­‐mediated	  inhibition	  of	  many	  inflammatory	  cytokines	  (e.g.	  IL-­‐6,	  IL-­‐1β,	  TNF-­‐α),	  enzymes	  (e.g.	  iNOS,	  COX2	  and	  MMPs)	  and	  adhesion	  molecules,	  which	  all	  have	  NF-­‐κB	  and/or	  AP-­‐1	  elements	  in	  their	   gene	   promoter	   regions	   (Liberman	   et	   al.,	   2007).	   Additional	   more	   recently	   described	  transcription	   factors	   shown	   to	  be	   transrepressed	  by	  GR	   include	  CREB,	  NFAT,	   STAT	  and	  T-­‐bet	  (De	  Bosscher	  and	  Haegeman,	  2009).	  Transrepression	  of	  pro-­‐inflammatory	  transcription	  factors	  is	   thought	   to	   largely	   explain	   the	   clinical	   success	   of	   GC	   as	   effective	   anti-­‐inflammatory	   agents	  (Adcock	  et	  al.,	  2004);	  while	  transactivation	  contributes	  largely	  to	  adverse	  metabolic	  effects	  (De	  Bosscher	  and	  Haegeman,	  2009).	  	  
1.8.1.1.2	  Non-­‐genomic	  effects	  of	  glucocorticoids	  
GC	  also	  undergo	  non-­‐genomic	   interaction	  with	  cytoplasmic	  or	  membrane	  GR.	  These	  can	  exert	  much	   more	   rapid	   actions	   (within	   minutes)	   as	   they	   are	   not	   mediated	   by	   changes	   in	   gene	  expression,	  and	  illustrate	  the	  diversity	  of	  GC	  targets	  (Rhen	  and	  Cidlowski,	  2005).	  Through	  such	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a	   rapid,	   non-­‐transcriptional	   mechanism	   by	   the	   GR,	   an	   increase	   in	   endothelial	   nitric	   oxide	  synthase	  was	  demonstrated	  in	  systemic	  EC,	  and	  administration	  of	  GC	  in	  mice	  reduced	  vascular	  inflammation	  and	  myocardial	  infarct	  size	  (Hafezi-­‐Moghadam	  et	  al.,	  2002).	  	  
1.8.1.1.3	  Transcriptional	  regulation	  by	  GC	  
GC	  regulate	  gene	  transcription	  by	  recruiting	  coactivator	  proteins	  (such	  as	  CBP,	  cAMP	  response	  element	  binding	  (CREB)-­‐binding	  protein	  p300),	  which	  possess	  histone	  acetyl	  transferase	  (HAT)	  activity.	  Histone	   acetylation	   facilitates	   assembly	   of	   the	   basal	   transcription	  machinery	   and	   the	  initiation	   of	   transcription	   by	   RNA	   polymerase	   II,	   thus	   increasing	   the	   transcription	   of	   anti-­‐
inflammatory	  genes	  (Ogryzko	  et	  al.,	  1996).	  In	  addition,	  the	  activated	  GR	  can	  recruit	  co-­‐repressor	  proteins	  including	  histone	  deacetylases	  (HDACs)	  to	  the	  activated	  transcription	  complex,	  altering	  chromatin	   structure,	   and	   reducing	   transcription	  of	   inflammatory	   genes	   (Ito	   et	   al.,	   2000)	   (also	  see	  Figure	  1.10).	  It	   is	  proposed	  that	  the	  balance	  between	  HAT	  and	  HDAC	  activity	  is	  associated	  with	  the	  level	  of	  inflammation.	  Indeed,	  imbalance	  of	  this	  mechanism	  is	  one	  of	  the	  mechanisms	  postulated	  in	  patients	  who	  have	  resistance	  to	  GC	  effects:	  For	  example,	  a	  reduction	  in	  pulmonary	  HDAC	  and	  an	  increase	  in	  HAT	  expression	  is	  seen	  in	  patients	  with	  asthma	  and	  COPD	  (Ito	  et	  al.,	  2005,	   Ito	  et	  al.,	  2002),	  and	   in	  asthmatics	   treated	  with	  GC,	   these	  changes	  were	  partly	   reversed	  (Ito	  et	  al.,	  2002).	  	  	  
1.8.1.2	  Glucocorticoid	  side	  effects	  	  
GC	  side	  effects	   arise	  mainly	   from	   the	  GR-­‐mediated	   transactivation	  of	   target	   genes	   involved	   in	  the	  metabolism	  of	  sugar,	  protein,	  fat,	  muscle	  and	  bone	  (De	  Bosscher	  and	  Haegeman,	  2009).	  Side	  effects	  are	  dose-­‐dependent;	  related	  to	  the	  half-­‐life	  of	  the	  drug;	  the	  frequency	  of	  administration;	  the	  time	  of	  day	  and	  the	  route	  of	  administration.	  Of	  note,	  dexamethasone	  has	  a	  similar	  tendency	  to	  produce	  facial	  mooning,	  acne	  and	  nervous	  excitation	  as	  prednisolone;	  peripheral	  oedema	  is	  
Laura	  Price	  PhD:	  Inflammation	  in	  Pulmonary	  Arterial	  Hypertension	   67	  
unusual	   (7%)	   and	   mild;	   excessive	   appetite,	   weight	   gain	   and	   abdominal	   distension	   are	   more	  common	  (David	  A.	  Williams,	  2002).	  	  	  
1.8.1.3	  Evidence	  supporting	  the	  use	  of	  GC	  in	  asthma	  and	  COPD	  
The	  basis	  for	  the	  use	  of	  GC	  in	  certain	  chronic	  diseases	  is	  based	  on	  the	  fact	  that	  inflammation	  is	  present	  both	  during	  stable	  disease	  periods	  and/or	  during	  exacerbations	  of	  disease;	  that	  NF-­‐κB	  is	   activated	   and	   has	   a	   direct	   relevance	   to	   disease	   pathogenesis,	   and	   that	   the	   use	   of	   steroids	  improves	   these	  end	  points	   in	  studies	  of	   relevant	  cells	  or	   tissue	  as	  well	  as	  clinical	   studies.	  The	  basis	  for	  their	  use	  in	  asthma	  and	  COPD	  will	  be	  outlined,	  as	  an	  example	  of	  a	  GC	  sensitive	  and	  GC	  resistant	  condition	  respectively.	  
Both	  these	  conditions	  are	  characterised	  by	  chronic	   inflammation	  of	   the	  respiratory	  tract,	  with	  recruitment	  of	   inflammatory	  cells	  (Barnes,	  2011).	  Activation	  of	  NF-­‐κB	  is	  characteristic	   in	  both	  asthma	  (Hart	  et	  al.,	  1998,	  Gagliardo	  et	  al.,	  2003)	  and	  COPD	  (Di	  Stefano	  et	  al.,	  2002,	  Caramori	  et	  al.,	  2003).	  However,	  despite	  the	  similarities	  in	  activation	  of	  inflammatory	  genes	  between	  these	  conditions,	   there	   are	   differences	   in	   their	   GC	   responsiveness.	   In	   asthma,	   GC	   are	   effective	   at	  reducing	   airway	   inflammatory	   cell	   recruitment	   (notably	   eosinophils,	  T	   lymphocytes	   and	  mast	  cells)	  with	  a	  reduction	  in	  chemotactic	  mediators	  and	  adhesion	  molecules	  (Barnes,	  2011).	  Indeed	  in	  stable	  asthmatics,	  inhaled	  GC	  increased	  GR–DNA	  binding	  and	  reduced	  NF-­‐κB	  DNA	  binding	  in	  bronchial	  biopsies	  (Hancox	  et	  al.,	  1999).	  By	  contrast,	  in	  COPD	  (where	  chronic	  activation	  of	  NF-­‐κB	  in	  stable	  disease	  is	  further	  increased	  during	  exacerbations	  (Caramori	  et	  al.,	  2003)),	  even	  high	  dose	  GC	  failed	  to	  suppress	  airway	  inflammation	  in	  sputum	  (Keatings	  et	  al.,	  1997)	  and	  alveolar	  macrophages	  (Culpitt	  et	  al.,	  2003).	  
The	  clinical	  correlate	  to	  this	  is	  that	  most	  patients	  with	  asthma	  are	  successfully	  treated	  with	  GC;	  indeed	  the	  use	  of	   inhaled	  corticosteroids	  (ICS)	  reduces	  asthma	  exacerbations	  and	  has	  reduced	  asthma	  morbidity	   and	   mortality	   (Pauwels	   et	   al.,	   1997),	   and	   they	   are	   first	   line	   treatment	   for	  persistent	  asthma	  (BTS,	  2011).	  Most	  patients	  (apart	  from	  1%	  of	  ‘GC-­‐dependent’	  asthmatics)	  can	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be	   weaned	   from	   oral	   GC	   to	   ICS,	   with	   short	   courses	   of	   oral	   GC	   reserved	   for	   exacerbations	  (Barnes,	  2011).	  	  
GC	  are	  less	  effective	  in	  COPD,	  with	  clinical	  studies	  showing	  a	  failure	  to	  reduce	  COPD	  progression	  (Yang	  et	  al.,	  2007),	  and	  a	  large	  study	  demonstrating	  a	  failure	  to	  reduce	  mortality	  (Calverley	  et	  al.,	   2003).	   These	   results	   are	   thought	   to	   reflect	   GC	   resistance	   in	   COPD	   (see	   below),	   and	   only	  limited	   GC	   use	   is	   suggested	   in	   COPD	   patients	  with	   FEV1	   <	   50%	   predicted	  with	  more	   than	   2	  annual	   exacerbations	   (Barnes,	   2011).	   Of	   note,	   exacerbations	   of	   both	   asthma	   and	   COPD	   are	  difficult	   to	   treat	   with	   GC,	   which	   is	   not	   well	   understood	   as	   inflammatory	   triggers	   for	  exacerbations	  activate	  NF-­‐κB	  and	  therefore	  should	  be	  a	  target	  of	  GC	  (Edwards	  et	  al.,	  2009).	  In	  addition,	   the	   lack	   of	   effect	   of	   GC	   in	   COPD	   is	   likely	   to	   be	   selective,	   since	   those	   subjects	   are	  subjected	  to	  GC	  side	  effects.	  	  
1.8.2	  Specific	  inhibitors	  of	  NF-­‐κB	  	  	  
Several	  specific	  inhibitors	  of	  NF-­‐ĸB	  have	  been	  developed,	  with	  the	  aim	  of	  reducing	  off-­‐target	  GC	  side	  effects.	  There	  are	  also	  many	  drugs	  where	  although	  NF-­‐ĸB	  is	  not	  the	  primary	  target,	  in	  part	  act	   through	  inhibition	  of	  NF-­‐ĸB,	   including	  statins	  and	  aspirin	  (which	   inhibit	   the	  breakdown	  of	  IĸB,	   to	   a	   greater	  degree	  with	   certain	   statins	   e.g.	   simvastatin	  more	   than	  pravastatin)	   (McCarty	  and	   Block,	   2006)	   (Hilgendorff	   et	   al.,	   2003).	   A	   potential	   advantage	   of	   specific	   targeted	   NF-­‐ĸB	  inhibition,	  at	  least	  in	  patients	  with	  COPD/asthma	  with	  documented	  GC	  resistance,	  would	  be	  to	  bypass	  problems	  associated	  with	  GC	  (e.g.	  Cushing’s	  Disease)	  without	  suppressing	  inflammation	  (Adcock	  et	  al.,	  1995c).	  A	  major	  concern	  of	  complete	  or	  irreversible	  blockade	  of	  NF-­‐ĸB,	  however,	  is	   the	   likely	   widespread	   effects	   on	   immune	   regulation.	   In	   addition,	   mice	   with	   a	   deletion	   in	  RelA/p65	  were	  susceptible	  to	  a	  lethal	  liver	  injury	  (Geisler	  et	  al.,	  2007).	  There	  is	  currently	  little	  clinical	   trial	   data	   from	  other	  diseases,	   although	  one	   cancer	   trial	   using	   a	   proteasome	   inhibitor	  does	   suggest	   the	  presence	  of	   significant	   side	   effects	   (see	  below).	  The	   sites	   of	   action	  of	  NF-­‐ĸB	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inhibitors	   are	   summarised	   in	   Figure	   1.12,	   and	   some	   of	   the	   specific	   inhibitors	   are	   discussed	  briefly,	  with	  PAH-­‐relevant	  studies	  if	  available.	  	  
	  
Figure	  1.12.	  	  Inhibitors	  of	  NF-­‐ĸB	  and	  their	  main	  sites	  of	  action.	  Small	   molecule	   or	   peptide	   inhibitors	   of	   IKK-­‐β	   prevent	   IKK-­‐β	   phosphorylation,	   proteasome	  inhibitors	   prevent	   IκB	   processing,	   antisense	   and	   siRNA	   act	   on	   NF-­‐κB	   mRNA	   and	   limit	  subsequent	   protein	   expression,	   decoy	   oligonucleotides	   compete	   for	   the	   κB	   sites	   within	  promoters	  of	  affected	  genes	  preventing	  their	  transcriptional	  activation.	  GCs	  may	  act	  by	  binding	  activated	   NF-­‐κB	   family	   members	   and	   preventing	   their	   association	   with	   κB	   sites	   (trans-­‐repression)	  or	  by	  recruiting	  HDACs,	  thus	  preventing	  chromatin	  disassociation.	  	  Abbreviations:	   NF-­‐κB	   -­‐	   nuclear	   factor	   κB,	   IκB	   -­‐	   inhibitor	   of	   κB,	   IKK-­‐β	   -­‐	   IκB	   kinase-­‐β,	   HDAC	   -­‐	  histone	  deacetylation,	  GC	  -­‐	  glucocorticoid,	  MEKK	  -­‐	  mitogen-­‐activated	  protein	  kinase/ERK	  kinase	  kinase,	  CBP	  -­‐	  cAMP	  response	  element	  binding	  (CREB)-­‐binding	  protein	  p300,	  mRNA	  -­‐	  messenger	  RNA,	  siRNA	  -­‐	  small	  interfering	  RNA.	  	  From:	  Edwards	  et	  al	  (Edwards	  et	  al.,	  2009).	  	  	  
1.8.2.1	  IκB	  kinase–β	  (IKK2)	  inhibitors	  
Several	  small	  molecule	  or	  peptide	  inhibitors	  targeting	  IKK-­‐β	  (IKK2)	  have	  undergone	  phase	  I	  and	  II	  clinical	  trials	  in	  cancer,	  as	  well	  as	  in	  pre-­‐clinical	  trials	  in	  asthma	  and	  COPD	  (Karin	  et	  al.,	  2004).	  There	   are	   currently	   at	   least	   eight	   such	   inhibitors	   commercially	   available	   which	   include	   2-­‐[(aminocarbonyl)	  amino]-­‐5-­‐[4-­‐fluorophenyl]-­‐3-­‐thiophenecarboxamide)	  (TCPA)	  and	  AS206686.	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The	  anti-­‐inflammatory	  activity	  of	   IKK2	  inhibitors	  has	  been	  shown	  in	  several	  cell	   types	  using	  a	  range	   of	   stimuli.	   For	   example,	   two	   different	   IKK2	   inhibitors	   (TCPA	   and	   SC-­‐514)	   blocked	  cytokine	   release	   from	   human	   airway	   smooth	   muscle	   cells,	   even	   more	   effectively	   than	   GC	  including	   dexamethasone	   (Birrell	   et	   al.,	   2005).	   In	   a	   COPD	   model,	   the	   IKK2	   inhibitor	   PF-­‐184	  prevented	   neutrophilia	   and	   reduced	   GC-­‐insensitive	   inflammation	   in	   vitro	   (Sommers	   et	   al.,	  2009).	  Although	  there	  has	  been	  no	  in	  vivo	  study	  of	  IKK2	  inhibitors	  in	  PH	  models	  as	  yet,	  a	  study	  of	  PASMC	  isolated	  from	  HPAH	  patients	  (where	  NF-­‐κB	  was	  constitutively	  activated,	  and	  IL-­‐6	  and	  CXCL8	   release	   from	  PASMC	  higher	   than	   controls),	   neutralisation	   of	   these	   cytokines	   using	   the	  IKK2	   inhibitor	  BMS-­‐345541	  (and	   the	  peptide	   inhibitor	  of	  NF-­‐κB	  nuclear	   translocation,	  SN-­‐50)	  restored	  the	  anti-­‐proliferative	  effects	  of	  TGF-­‐β1	  in	  PASMC	  (Davies	  et	  al.,	  2012).	  
 
1.8.2.2	  Proteasome	  inhibitors	  
The	   proteasome	   system	   is	   central	   to	   the	   regulation	   of	   NF-­‐κB	   activity	   by	   de-­‐ubiquitination,	  unfolding	   and	   destruction	   of	   IκB	   proteins.	   Several	   classes	   of	   reversible	   and	   irreversible	  inhibitors	   target	   the	  20S	  proteasome.	   In	   a	  model	   of	   COPD,	   the	  proteasomal	   inhibitor	  MG-­‐132	  prevented	   cigarette	   smoke-­‐induced	   IκBα	   degradation	   (Karimi	   et	   al.,	   2006).	   Clinical	   studies	   of	  proteasomal	  inhibitors	  (e.g.	  using	  bortezomib	  in	  multiple	  myeloma)	  have	  however	  highlighted	  potential	   side	   effects	   including	   thrombocytopenia,	   fatigue,	   peripheral	   neuropathy	   and	  neutropenia	  (Richardson	  et	  al.,	  2003).	  There	  have	  been	  no	  studies	  of	  these	  agents	  in	  PH.	  	  
1.8.2.3	  Other	  agents	  
Other	  inhibitors	  of	  NF-­‐κB	  include	  decoy	  oligonucleotides,	  antisense,	  and	  small	  interfering	  RNA	  (siRNA).	   Decoy	   oligonucleotides	   competitively	   bind	   activated	   Rel	   proteins	   and	   prevent	   their	  binding	   nuclear	   targets;	   antisense	   technology	   uses	   stabilised	   oligonucleotides	   to	   bind	   to	  complementary	  mRNA,	  thus	  blocking	  translation;	  siRNA	  transiently	  silences	  gene	  expression	  by	  directing	   sequence-­‐specific	   degradation	   of	   a	   target	   mRNA	   by	   an	   endogeneous	   RNA-­‐induced	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silencing	  complex	  (Edwards	  et	  al.,	  2009).	  These	  agents	  have	  mainly	  been	  studies	   in	  models	  of	  asthma	  where,	  for	  example,	  a	  p65	  antisense	  oligonucleotide	  reduced	  lung	  NF-­‐κB	  activation	  and	  airway	   inflammatory	   cell	   recruitment	   (Choi	   et	   al.,	   2004);	   and	   epithelial	   cells	   transfected	  with	  siRNA	  against	  p65	  demonstrated	   reduced	  TNF-­‐α	   induced	   IL-­‐6	  and	  CXCL8	  release	   (Platz	  et	  al.,	  2005).	   In	   the	   MCT-­‐induced	   model	   of	   PH,	   a	   study	   by	   Kimura	   et	   al	   showed	   that	   a	   decoy	  oligonucleotide	  was	  effective	  at	  reversing	  PH	  (Kimura	  et	  al.,	  2009),	  and	  two	  studies	  show	  some	  success	  in	  the	  same	  model	  using	  pyrrolidine	  dithiocarbamate	  (Huang	  et	  al.,	  2008,	  Sawada	  et	  al.,	  2007)	  (PDTC,	  an	  anti-­‐oxidant	  and	  non-­‐specific	  inhibitor	  of	  NF-­‐κB).	  These	  studies	  are	  discussed	  in	  more	  detail	  in	  Chapter	  4.	  	  
1.9	  Hypothesis	  	  
That	  NF-­‐κB	  drives	   the	   inflammatory	   response	   in	  PAH	  and	   that	   inhibition	  of	   this	  pathway	  will	  reverse	  vascular	  remodelling,	  and	  may	  provide	  novel	  treatments	  in	  PAH.	  	  
1.10	  Aims	  
To	  determine:	  1. Evidence	   for	  activation	  of	   the	  NF-­‐κB	  pathway	   in	  histological	  sections	  of	  patients	  with	  PAH	  (monocytes/macrophages	  and	  vascular	  cells),	  compared	  to	  normal	  subjects.	  	  2. The	  effect	  of	  dexamethasone	  on	  monocrotaline-­‐induced	  NF-­‐κB-­‐associated	  inflammation	  and	  pulmonary	  haemodynamics	  in	  vivo.	  3. Mechanisms	  by	  which	  dexamethasone	   treatment	  alters	  pulmonary	  arterial	   smooth	  muscle	  cell	  survival	  in	  monocrotaline-­‐induced	  PH.	  	  4. How	  circulating	  monocytes	  from	  patients	  with	  PAH	  differ	  in	  their	  response	  to	  LPS	  and	  TNF-­‐α	   stimulation	   and	   measured	   cytokine	   release,	   compared	   to	   controls,	   with	   respect	   to	  inhibition	  of	  NF-­‐κB;	  and	  steroid	  responsiveness.	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CHAPTER	  2:	  METHODS	  AND	  MATERIALS	  
2.1	  CLINICAL	  METHODS	  
2.1.1	  Patient	  cohorts	  
Immunohistochemistry	   study:	   Lung	   sections	   were	   obtained	   from	   patients	   following	   lung	  transplantation	   for	   idiopathic	   PAH	   at	   the	   Antoine	   Béclère	   Hospital,	   France.	   Controls	   were	  normal	   lung	   resected	   from	   patients	   with	   lung	   cancer	   undergoing	   lobectomy	   surgery	   at	   the	  University	   of	   Ferrara	   Hospital.	   Patients	   had	   routine	   clinical	   data	   collected.	   The	   study	   was	  approved	  by	  the	  Research	  Ethics	  Committees	  of	  both	  hospitals.	  
Human	   blood	   study:	   Patients	   with	   idiopathic	   PAH	   were	   selected	   from	   those	   known	   to	   the	  Royal	   Brompton	   Pulmonary	   Hypertension	   Service,	   and	   healthy	   volunteer	   controls	   were	   age-­‐matched.	  The	  study	  was	  approved	  by	  the	  Royal	  Brompton	  Hospital	  Cardiovascular	  Biomedical	  Research	  Unit	  Tissue	  Bank	  Ethics	  Committee,	  reference	  09/H0504/104.	  	   	  
2.1.2	  Measured	  and	  recorded	  variables	  
Demographic	  details	  were	   recorded	   including	  age,	   sex,	  past	  medical	  history	  and	  drug	  history.	  The	   results	   of	   invasive	   pulmonary	   haemodynamic	   variables	  were	   from	   the	  most	   recent	   right	  heart	   catheterisation	   (RHC).	   Results	   of	   routinely	   measured	   laboratory	   assays	   were	   also	  recorded	   including	   full	   blood	   count	   (white	   blood	   cell	   count,	   neutrophil	   count,	   haemoglobin	  concentration,	  platelet	  count),	  brain	  natriuretic	  peptide	  (BNP)	  and	  C-­‐reactive	  protein.	  
2.1.3	  Definitions	  and	  scores	  
PAH	   was	   determined	   at	   right	   heart	   catheterisation	   by	   a	   mean	   pulmonary	   arterial	   pressure	  (mPAP)	   >25mmHg	   and	   a	   pulmonary	   arterial	   occlusion	   pressure	   <15mmHg.	   Clinical	   PAH	  severity	  was	  assessed	  by	  the	  6-­‐minute	  walk	  distance	  and	  the	  NYHA/WHO	  functional	  class	  score	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Table	  2.1.	  	  Functional	  assessment	  of	  pulmonary	  arterial	  hypertension.	  The	  New	  York	  Heart	  Association	  (NYHA)	  for	  patients	  with	  cardiac	  disease	  was	  devised	  in	  1928	  and	   has	   been	   updated	   numerous	   times,	   most	   recently	   in	   1994.	   In	   1998,	   the	   World	   Health	  Organisation	  (WHO)	  revised	  this	  to	  reflect	  the	  unique	  physiology	  of	  pulmonary	  hypertension.	  In	  practice,	  the	  two	  classification	  systems	  are	  used	  interchangeably	  (Rubin,	  2004).	  	  
2.1.4	  Patient	  sample	  acquisition	  and	  preparation	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2.2	  IN	  VIVO	  METHODS	  
2.2.1	  Monocrotaline	  model	  
All	   experiments	   using	   the	  monocrotaline	   (MCT)	  model	   were	   performed	   following	   training	   at	  Imperial	  College	  London	  then	  on	  a	  placement	  at	  the	  Antoine	  Béclère	  Hospital	  in	  Clamart	  (Paris,	  France)	  under	  the	  supervision	  of	  Professor	  Marc	  Humbert.	  Male	  6-­‐week	  old	  Wistar	  rats	  (100g	  body	   weight)	   were	   maintained	   in	   a	   temperature-­‐controlled	   room	   with	   a	   12:12-­‐h	   light-­‐dark	  
cycle	  with	  access	  to	  standard	  rat	  chow	  and	  water.	  Rats	  received	  a	  single	  subcutaneous	  injection	  of	  60mg/kg	  monocrotaline	  (MCT)	  (Sigma-­‐Aldrich,	  Lyon,	  France),	  which	  was	  the	  standard	  dose	  used	  in	  this	  model.	  Following	  right-­‐heart	  catheterisation	  28	  or	  35	  days	  after	  MCT	  exposure,	  rats	  were	  killed	  by	  lethal	  injection	  of	  pentobarbitone	  (Sigma	  Aldrich),	  and	  lung	  tissue	  was	  prepared	  for	   later	   analysis.	   Local	   and	   UK	   Home	   Office	   protocols	   were	   followed	   at	   all	   times.	   For	   all	  
Figure	  2.1.	  	  The	  monocrotaline	  PAH	  model.	  Figure	   shows	   (A)	   preparation	   of	   intraperitoneal	   anaesthesia;	   (B)	   isolation	   of	   the	   right	  external	   jugular	   vein;	   (C)	   the	   set-­‐up	   for	   haemodynamic	   measurement	   and	   (D)	   a	   pressure	  curve	  for	  right	  ventricular	  systolic	  pressure.	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experiments,	  end-­‐points	  were	  body	  weight,	  pulmonary	  haemodynamics,	  right	  ventricular	  mass	  (see	  below)	  and	  survival.	  	  	  
2.2.1.1	  Anaesthesia	  	  
Rats	  were	   anaesthetised	  with	   an	   intraperitoneal	   injection	   of	   a	  mixture	   of	   35mg/kg	   ketamine	  (250mg/5ml,	   Vibrac,	   France),	   4mg/kg	   xylazine	   (Rompun	   2%,	   Bayer	   Health,	   France)	   and	  0.5mg/kg	  acepromazine	  (injectable	  Calmivet	  solution,	  Lure,	  France)	  (Figure	  2.1B).	  The	  depth	  of	  anaesthesia	  was	  assessed	  by	  pedal	  withdrawal	  reflex	  before	  commencement	  of	  procedures,	  and	  at	   regular	   intervals	   during	   the	   procedure.	   If	   top-­‐up	   anaesthesia	  was	   required,	   this	  was	   given	  using	  the	  mixture	  described,	  at	  doses	  of	  50%	  of	  that	  required	  to	  induce	  anaesthesia.	  	  
2.2.1.2	  Hemodynamic	  assessment	  
A	  3.5	  French	  umbilical	  vessel	  catheter	  (Tyco,	  Plaisir,	  France),	  angled	  to	  90°	  over	  the	  distal	  1	  cm	  and	  curved	  slightly	  at	  the	  tip,	  was	  introduced	  into	  the	  exposed	  right	  external	  jugular	  vein	  of	  rats	  (not	  the	  internal	  jugular	  vein,	  as	  is	  used	  in	  humans,	  due	  to	  the	  presence	  of	  a	  valve	  in	  the	  external	  vein)	   (Figure	   2.1B).	   With	   the	   angle	   directed	   anteriorly,	   the	   catheter	   was	   inserted	   2.5cm	  proximally,	  which	  placed	  the	  catheter	  in	  the	  right	  atrium.	  The	  catheter	  was	  rotated	  90°	  counter	  clockwise	  and	  inserted	  1.0cm	  further,	  which	  placed	  the	  catheter	  in	  the	  right	  ventricle,	  and	  when	  advanced	   an	   additional	   1.5cm,	   in	   the	   pulmonary	   artery.	   Following	   connection	   to	   a	   standard	  haemodynamic	   connection	   using	   heparinised	   saline	   and	   a	   3-­‐way	   connection	   (Figure	   2.1C),	  placement	   at	   each	   stage	   was	   confirmed	   by	   respective	   pressure	   contours	   (Figure	   2.1D).	  Hemodynamic	   values	   were	   automatically	   calculated	   by	   the	   physiological	   data	   acquisition	  system	   Cardiomax	   III	   (Phymep,	   Paris,	   France).	   Following	   exsanguination,	   the	   lungs	   were	  distended	   by	   infusion	   of	  OCT	   compound	   (Miles,	   Epernon,	   France)	   diluted	   in	   sterile	   PBS	   (1:1)	  into	  the	  trachea;	  quick-­‐frozen	  in	  isopentane	  (Sigma,	  France)	  on	  dry	  ice	  and	  stored	  at	  -­‐80°C.	  To	  obtain	  Fulton’s	  index	  of	  right	  ventricular	  hypertrophy,	  the	  ratio	  of	  the	  right	  ventricular	  weight	  to	   left	   ventricular	   plus	   septal	  weight	   (RV/LV+S)	  was	   calculated.	   Figure	   2.2	   shows	   the	   normal	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Figure	  2.2.	  Pressure	  waveforms	  using	  flow-­‐directed	  pulmonary	  arterial	  catheter.	  Following	   right-­‐heart	   catheterisation	   (RHC)	   of	   the	   right	   external	   jugular	   vein	   in	   the	   rat,	   the	  catheter	  measures	  right	  atrial	  pressure	  (RAP),	  right	  ventricular	  systolic	  pressure	  (RVSP)	  in	  the	  right	  ventricle,	  and	  finally	  pulmonary	  artery	  pressure	  (PAP).	  The	  wedging’	  of	  the	  catheter	  tip	  to	  obtain	  the	  pulmonary	  arterial	  occlusion	  or	  ‘wedge’	  pressure	  (PAWP),	  which	  is	  a	  useful	  reflection	  of	  left	  ventricular	  end-­‐diastolic	  pressure	  (LVEDP)	  and	  LV	  function	  in	  humans,	  is	  not	  possible	  to	  perform	   in	   rats,	   at	   least	   using	   this	   system.	   Of	   note,	   the	   absolute	   pressure	   readings	   in	   the	   rat	  model	  are	  very	  similar	  to	  the	  values	  in	  human	  RHC.	  
	  
Figure	   2.3.	   	   Isolation	   of	   heart	   showing	  monocrotaline-­‐induced	   right	   ventricular	  
hypertrophy.	  Compared	   to	   control	   rats	   (A),	   monocrotaline	   (MCT)	   induced	   severe	   right	   ventricular	  hypertrophy,	   demonstrated	   in	   B	   (paraffin-­‐embedded	   eosin	   stained	   slides,	   courtesy	   of	   Dr	  Frederic	  Perros,	  France)	  and	  C	  (in	  a	  heart	  in	  transverse	  section,	  dissected	  following	  right-­‐heart	  catheterisation).	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2.3	  LABORATORY	  METHODS	  
2.3.1	  Cell	  culture	  techniques	  
2.3.1.1	  Primary	  PASMC	  isolation	  and	  culture	  
Similar	  methods	  were	  used	  for	  both	  rat	  and	  human	  PASMC	  digestion	  and	  culture,	  according	  to	  the	  protocol	  used	  by	  Eddahibi	  et	  al	  (Eddahibi	  et	  al.,	  1999).	  Briefly,	  proximal	  pulmonary	  arteries	  were	   immediately	  dissected	   from	  the	  heart-­‐lung	  block	   from	  rats	   (or	   lung	  section	   from	  human	  lung)	  in	  a	  sterile	  petri	  dish	  in	  sterile	  saline.	  Vessels	  were	  cut	  using	  microdissection	  scissors	  and	  the	  intimal	  cell	  layer	  and	  the	  adventitial	  tissue	  stripped	  off	  using	  forceps.	  The	  denuded	  vessels	  were	  cut	  into	  small	  pieces	  and	  transferred	  into	  cell-­‐culture	  flasks.	  To	  allow	  the	  PASMC	  to	  grow	  out,	  the	  vessel	  tissues	  were	  incubated	  in	  DMEM	  supplemented	  with	  20%	  FCS,	  2mM	  L-­‐glutamine,	  and	   antibiotics	   (100	   U/ml	   penicillin	   and	   0.1	   mg/ml	   streptomycin	   (Invitrogen,	   UK)).	   After	   2	  weeks	   of	   incubation,	   the	   PASMC	   collected	   in	   the	   culture	  medium	   and	   the	   vessel	   tissues	  were	  transferred	  into	  new	  cell-­‐culture	  flasks.	  Cultured	  PASMC	  were	  used	  between	  passages	  1	  and	  3.	  Explants	  from	  the	  same	  pulmonary	  artery	  were	  usually	  transferred	  several	  times.	  
	  
2.3.1.2	  Characterisation	  of	  cultured	  PASMC	  	  
To	  determine	  phenotypic	   characteristics,	   PASMC	  were	   assessed	   for	   expression	  of	   the	  muscle-­‐specific	   contractile	   and	   cytoskeletal	   proteins	   including	   smooth	   muscle	   α-­‐actin	   using	  immunofluorescence.	   For	   the	   human	   PASMC	   experiments,	   previous	   immunofluorescence	  studies	  in	  our	  London	  group	  showed	  that	  all	  cultured	  PASMC	  from	  patients	  with	  PAH	  and	  from	  controls	  showed	  a	  similar	  level	  of	  positive	  staining	  with	  antibodies	  against	  smooth	  muscle	  cell	  α−actin,	   desmin,	   and	   vinculin	   (Wort,	   2002).	   Similar	   rat	   PASMC	   experiments	   using	   α−smooth	  muscle	  actin	  (Sigma,	  reactive	  in	  both	  rat	  and	  human	  tissue)	  were	  performed	  with	  the	  help	  of	  Dr	  Ingrid	  Durand-­‐Gasselin	  in	  Clamart,	  France.	  Cells	  were	  grown	  with	  10%	  FCS/DMEM	  on	  Lab-­‐Tek	  chamber	   slides	   were	   fixed	   in	   absolute	   methanol	   at	   –20°C	   for	   10	   minutes	   and	   processed	   for	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immunostaining	  by	   incubation	   for	  60	  minutes	  with	   anti–smooth	  muscle	   cell	   α-­‐actin	   antibody.	  The	   slides	   were	   then	   exposed	   for	   1	   hour	   to	   FITC-­‐conjugated	   secondary	   Ab’s	   (Dako,	   France)	  diluted	  1:200	  (Figure	  2.4).	  	  
 
Figure	  2.4.	  	  Cultured	  rat	  pulmonary	  arterial	  smooth	  muscle	  cells	  (PASMC)	  staining	  
positively	  for	  α-­‐smooth	  muscle	  actin.	  Photograph	  of	  Labtek	  slides	  showing	  immunofluorescence	  staining	  of	  PASMC	  stained	  with	  alpha	  smooth	  muscle	  actin	  (green),	  counterstained	  with	  DAPI	  (blue,	  nuclei).	  Magnification	  x	  400.	  	  
2.3.1.3	  General	  cell	  counting	  
Cells	   (PBMCs	   and	   PASMs)	  were	   counted	   using	   a	   haematocytometer	   under	   an	   inverted	   phase	  contrast	  microscope	  (CK40,	  Olympus,	  UK)	  or	  a	  conventional	  upright	  light	  microscope	  (Olympus	  CH30,	  x100-­‐x400	  objective).	  The	  total	  numbers	  of	  cells	  within	  the	  boundaries	  each	  of	  the	  four	  (1mm3)	  larger	  corner	  squares	  (or	  partially	  overlapping	  the	  upper	  or	  left	  borders)	  were	  counted.	  The	   total	   number	   of	   cells	  was	   estimated	   as	   the	   (total	   cell	   count	   for	   4	   squares	   /	   4)	   x	   dilution	  factor	  x	  104	  cells	  per	  millilitre	  of	  suspension.	  	  
2.3.1.4	  Centrifugation	  
Centrifugation	  of	  small	  volumes	  of	  cells	  (less	  than	  2ml)	  used	  a	  fixed	  angle	  bench	  top	  centrifuge	  (e.g.	  the	  Boeco	  M-­‐240	  R	  (Hettich,	  Germany)	  centrifuge).	  For	  larger	  volumes	  a	  Hettich	  Rotina	  46R	  centrifuge	   was	   used	   with	   swing-­‐out	   buckets	   (Hettich,	   Germany).	   Centrifugation	   speeds	   are	  quoted	  as	  relative	  centrifugal	  force	  (RCF	  or	  x	  g)	  or	  rotor	  speed	  in	  revolutions	  per	  minute	  (RPM)	  with	  independent	  variables	  including	  time,	  temperature	  and	  brake.	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2.3.1.5	  Assessment	  of	  cell	  viability	  
2.3.1.5.1	  Measurement	  of	  cell	  respiration	  using	  the	  MTT	  assay	  	  
The	   effect	   of	   the	   various	   treatments	   on	   PASMC	   viability	   was	   assessed	   by	   measuring	   the	  mitochondrial-­‐dependent	   reduction	   of	   yellow	   3-­‐[4,5-­‐dimethylthiazol-­‐2-­‐yl]-­‐2,5-­‐diphenyltetrazolium	   bromide	   (MTT;	   Sigma	   Aldrich))	   to	   formazan	   (purple).	   At	   the	   end	   of	   the	  experiments,	   media	   was	   removed	   from	   cells	   and	   frozen	   at	   -­‐20°C	   for	   subsequent	   mediator	  release	  by	  ELISA.	  	  100	  µl	  of	  MTT	  solution	  (0.5	  mg/ml	  in	  the	  10%	  ward	  DMEM)	  was	  added	  to	  the	  empty	  wells	   and	   incubated	   for	  4	  hours.	  MTT	  solution	  was	   then	   removed,	   solubilised	   in	  100µl	  dimethyl	  sulfoxide	  (DMSO;	  Sigma,	  UK)	  per	  well,	  and	  the	  plate	  tapped	  to	  mix.	  The	  optical	  density	  at	  550nm	  was	  measured	  using	  a	  plate	  reader.	  	  
2.3.1.5.2	  Trypan	  blue	  exclusion	  stain	  
Trypan	   blue	   exclusion	   was	   used	   to	   determine	   the	   number	   of	   viable	   peripheral	   blood	  mononuclear	  cells	   (PBMC)	   in	  suspension.	  An	  equal	  volume	  of	   cells	  and	  0.4%	  w/v	   trypan	  blue	  were	  mixed	   and	   counted	   using	   a	   haemocytometer.	   Dead	   cells	   fail	   to	   exclude	   trypan	   blue	   and	  stain	   dark	   blue;	   whereas	   live	   cells	   with	   an	   intact	   membrane	   exclude	   the	   stain,	   and	   were	  expressed	  as	  a	  percentage	  of	  the	  total	  number.	  Viability	  was	  defined	  as	  >	  80%	  cell	  viability	  i.e.	  cells	  excluding	  the	  blue	  dye.	  	  
2.3.1.5.3	  Alamar	  blue	  assay	  
Viability	   of	   PBMC	   was	   assessed	   using	   Alamar	   Blue	   (Invitrogen,	   UK)	   as	   a	   more	   quantifiable	  viability	  assay	  whose	  active	  ingredient	  is	  resazurin,	  a	  non-­‐toxic,	  cell	  permeable	  compound	  that	  is	  blue	  in	  colour	  and	  virtually	  non-­‐fluorescent.	  Upon	  entering	  viable	  cells,	  resazurin	  is	  reduced	  to	  a	  red	  compound	  that	  is	  highly	  fluorescent.	  A	  1:10	  dilution	  of	  Alamar	  blue	  was	  prepared	  with	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the	   PBMCs	   remaining	   in	   96-­‐well	   plates	   following	   aspiration	   of	   180μl	   supernatant	   (i.e.	   10μl	  Alamar	   blue	   and	   70μl	  warm	  10%	  FCS/RMPI	  was	   added	   to	   the	   remaining	   20μl,	   to	  makeup	   to	  100μl).	  The	  PBMC	  were	   left	  at	  37°C	   in	  5%	  CO2	   for	  4	  hours	  and	  the	  quantification	  of	  reduction	  (from	  blue	  to	  red	  in	  live	  cells)	  measured	  using	  a	  plate	  reader	  set	  at	  570nm.	  	  	  
2.3.2	  Enzyme	  linked	  immunosorbent	  assays	  	  
The	  presence	  of	  IL-­‐6	  and	  CXCL8	  in	  cell	  supernatants	  was	  detected	  using	  commercially	  available	  ELISA	  Duoset	  kits	  exactly	  as	  described	  by	  the	  manufacturer	  (R&D	  Systems,	  Abingdon,	  UK).	  	  
2.3.2.2	  Sandwich	  ELISA	  protocol	  
A	  capture	  antibody	  was	  attached	  to	  the	  plastic	  of	  a	  96	  well	  plate	  by	  passive	  adsorption.	  Surplus	  antibody	  was	  washed	  away	  and	  a	  blocking	  buffer	   containing	   a	  high	   concentration	  of	   albumin	  used	  to	  fill	  excess	  non-­‐specific	  binding	  sites.	  Samples	  were	  then	  added	  to	  the	  wells,	  and	  antigen	  bound	  by	  the	  immobilised	  specific	  primary	  ‘capture’	  antibody.	  After	  washing	  away	  any	  unbound	  substances,	  a	  second	  ‘detection’	  antibody	  labelled	  with	  biotin	  and	  directed	  at	  a	  different	  epitope	  on	  the	  antigen	  of	  interest	  was	  added	  which	  binds	  to	  the	  now	  immobilised	  analyte.	  After	  further	  washing,	  streptavidin	  horseradish	  peroxidase	  (HRP)	  was	  added.	  Streptavidin	  binds	  to	  biotin	  on	  the	   detection	   antibody.	   Thus,	   the	   amount	   of	   HRP	   present	   is	   in	   proportion	   to	   the	   amount	   of	  antigen	   in	   the	  original	   sample.	  HRP	  was	  quantified	  by	   the	   colorimetric	   reaction	   following	   the	  addition	   of	   HRP	   substrate	   3,	   3’,	   5,	   5’	   tetramethylbenzidine	   (Reagent	   B,	   OptEIATM,	   Becton	  Dickenson,	   UK)	   in	   the	   presence	   of	   hydrogen	   peroxide	   (Reagent	   A,	   OptEIATM).	   	   The	   colour	  develops	   in	   proportion	   to	   the	   amount	   of	   antigen	  present	   in	   the	   initial	   step.	   The	   reaction	  was	  terminated	  at	  20-­‐30	  minutes	  by	  acidification	  with	  H2SO4.	  The	  developed	  colour	  was	  then	  read	  by	  a	  plate-­‐reader	  set	  at	  450nm.	  	  
All	   ELISA	   reactions	   were	   performed	   in	   duplicate.	   Each	   plate	   included	   eight	   conditions	   (also	  plated	  in	  duplicate)	  representing	  serial	  dilutions	  of	  a	  known	  concentration	  of	  standard	  analyte	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Reagents	  Maxisorp	  96	  well	  microtitre	  plates	  Appropriate	  antibodies	  (capture	  and	  detection),	  standards	  and	  streptavidin-­‐HRP	  from	  kit.	  Wash	  buffer	   	   PBS	  (5	  tablet	  /	  1000ml	  H2O)	  	   	   	   0.05%	  Tween	  20	  (0.5ml/1000mls)	  	  Blocking	  buffer	   	   PBS	  (1	  tablet/200ml	  H2O)	  	   	   	   1%	  BSA	  (2g/200ml)	  	   	   	   0.05%	  NaN3	  (0.1g/200ml)	  Reagent	  	  diluent	  	   Tris	  buffered	  saline	  (20mM	  Trizma	  base-­‐	  1.211g	  /500ml,	  150mM	  NaCl-­‐	  	  	   	   	   4.38g	  /500ml)	  	   	   	   0.1%	  BSA-­‐0.5g/500ml	  	   	   	   0.05%	  Tween	  20	  0.25ml/500ml	  	   	   	   pH	  7.3.	  Store	  2-­‐8°C,	  use	  within	  7	  days	  Substrate	  solution	   50%	  Reagent	  A	  (H2O2)	  	   	   	   50%	  Reagent	  B	  (Tetramethylbenzidine)	  Stop	  solution	   	   1M	  H2SO4	  Protocol	  1. Coat	   wells	   of	   Maxisorp	   96	   well	   microtitre	   plate	   with	   100µl	   capture	   antibody.	   	   Seal	   and	  incubate	  overnight	  at	  room	  temperature.	  2. Wash	  each	  well	  3	  times	  with	  400µl	  wash	  buffer.	  	  Invert	  plate	  and	  tap	  dry	  on	  paper	  towel.	  3. Add	   300µl/well	   blocking	   buffer	   and	   incubate	   for	   a	   minimum	   of	   1h	   at	   room	   temperature.	  	  During	  this	  stage	  prepare	  standards	  and	  sample	  dilutions	  using	  reagent	  diluent.	  4. Wash	  3	  times	  and	  tap	  dry.	  5. Add	  100µl	   of	   control	   /standard	  /	   sample	   to	   appropriate	  wells.	   	   Seal	   and	   incubate	   for	  2h	  at	  room	  temperature	  6. Wash	  3	  times	  and	  tap	  dry.	  7. Add	  100µl/well	  of	  detection	  antibody,	  seal	  and	  incubate	  for	  2hrs	  at	  room	  temperature.	  8. Wash	  3	  times	  and	  tap	  dry.	  9. Add	   100µl/well	   Streptavidin	   HRP,	   seal	   and	   incubate	   for	   20	   minutes	   at	   room	   temperature	  avoiding	  direct	  light.	  10. Wash	  3	  times	  and	  tap	  dry.	  11. Add	   100µl/well	   substrate	   solution,	   seal	   and	   incubate	   for	   20minutes	   at	   room	   temperature	  avoiding	  direct	  light.	  12. Add	  50µl/well	  stop	  solution.	  	  13. Read	  O.D.	  at	  450nm	  (correction	  of	  570nm)	  within	  30	  minutes	  
Figure	  2.6.	  	  	  Details	  of	  generic	  sandwich	  ELISA	  protocol	  (R&D	  Systems).	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2.3.3	  Quantitative	  real-­‐time	  reverse	  transcription	  polymerase	  chain	  
reaction	  (RT-­‐qPCR)	  	  
To	  investigate	  changes	  in	  the	  levels	  of	  messenger	  RNA	  (mRNA),	  reverse	  transcription	  (RT)-­‐PCR	  was	   performed	   on	   PASMC	   and	  whole	   lung	   homogenates.	   Following	   RNA	   extraction	   from	   the	  DNA,	   protein	   and	   other	   cellular	   components,	   the	   RNA	   was	   reversed	   transcribed	   and	  complementary	  DNA	  (cDNA)	  detected	  using	  real	  time	  RT-­‐PCR	  (Figure	  2.7).	  	  	  	  
2.3.3.1	  RNA	  Extraction	  
RNA	  was	   extracted	   from	  homogenised	   rat	   lungs	  with	   the	   total	   RNA	   isolation	  minikit	   (Agilent	  technologies,	   Paris,	   France),	   or	   from	   rat	   PASMC	   (plated	   at	   5x103	   cells/well	   in	   96-­‐well	   plates)	  using	   the	  RNeasy	  Mini	  Kit	   (Qiagen,	  Courtaboeuf,	   France)	  with	  on-­‐column	  DNase,	   according	   to	  the	  manufacturer’s	  instructions.	  	  	  
2.3.3.2	  Reverse	  transcription	  
The	   isolated	   RNA	  was	   first	   non-­‐specifically	   transcribed	   into	   cDNA	   prior	   to	   PCR	   (Figure	   2.5).	  Mature	  mRNA	  has	  a	  chain	  of	  adenosine	  nucleotides	  on	  the	  3’	  end	  –the	  Poly-­‐A	  tail.	  The	  RT	  primer	  used	  in	  this	  thesis	  was	  an	  oligo-­‐(dT)	  that,	  by	  complementarity,	  hybridizes	  with	  the	  poly-­‐A	  end	  of	  mRNA.	   Polymerization	   starts	   from	   this	   primer,	   and	   proceeds	   until	   a	   complete	   cDNA	  transcription	  of	  the	  mRNA	  has	  formed.	  	  
After	  DNA	  digestion,	  extracted	  RNA	  was	  reverse-­‐transcribed	  to	  cDNA	  using	  Omniscript	  Reverse	  Transcription	   kit	   (Qiagen)	   (for	   whole	   rat	   lung	   samples)	   or	   a	   cDNA	   reverse	   transcription	   kit	  (Applied	   Biosystems,	   Warrington,	   Cheshire,	   UK)	   for	   cells,	   according	   to	   the	   manufacturer’s	  protocol.	  
	  







Figure	  2.7.	  	  Principle	  of	  reverse	  transcription	  and	  Polymerase	  chain	  reaction.	  	  
2.3.3.3	  Amplification:	  Quantitative-­‐PCR	  
Real	  time	  qPCR	  is	  based	  on	  conventional	  PCR,	  with	  the	  advantage	  that	  it	  allows	  more	  accurate,	  quantitative	   measurements	   of	   PCR	   product	   concentrations	   after	   each	   cycle	   using	   the	  incorporation	   of	   a	   fluorescent	   dye	   or	   oligonucleotide	   probe.	   	   We	   used	   the	   addition	   of	   a	  fluorescent	   DNA	   binding	   dye,	   SYBR	   Green,	   into	   the	   reaction	   mixture.	   SYBR	   Green	   fluoresces	  when	  it	  binds	  to	  the	  minor	  groove	  of	   the	  double	  stranded	  DNA,	  emitting	  a	   low	  signal	  when	  in	  solution,	  but	  a	  much	  higher	  signal	  when	  bound	  to	  DNA.	  Thus,	  as	  the	  reaction	  proceeds	  there	  is	  a	  corresponding	  increase	  in	  signal	  intensity	  (Figure	  2.8).	  	  	  
TaqMan	   Gene	   Expression	   Assays	   were	   used	   for	   rat	   IL-­‐6,	   BMPR-­‐II	   and	   actin.	   (β-­‐actin	  [Rn00667869_m1],	   BMPR-­‐II	   [Rn01437210_m1],	   IL-­‐6	   [Rn00561420_m1].	   Constitutively	  expressed	  β-­‐actin	  was	  selected	  as	  an	  internal	  housekeeping	  gene.	  	  We	  were	  unable	  to	  obtain	  the	  primer	  sequences	  of	  these	  pre-­‐designed	  primers	  purchased	  from	  Qiagen.	  
PCR	  reactions	  were	  set	  up	  in	  duplicate	  in	  0.1	  ml	  Thermo-­‐PCR	  tubes,	  containing	  SYBR	  Green	  PCR	  Master	  Mix,	  forward	  primer,	  reverse	  primer,	  template	  cDNA	  and	  RNAse	  free	  water	  and	  loaded	  into	   the	   PCR	  machine	   (Rotor-­‐Gene	   6000,	   Corbett,	   USA).	   The	   PCR	   conditions	  were	   95˚	   for	   15	  minutes,	  95˚	  for	  15	  seconds,	  60˚	  for	  20	  seconds,	  and	  72˚	  for	  20	  seconds.	  
1-2 Introduction
Purpose of the Kit
RNA Detection The TaqMan® EZ RT-PCR Kit provides a system for the detection and 
analysis of RNA. Direct detection of the reverse transcription 
polymerase chain reaction (RT-PCR) product with no downstream 
processing is accomplished by monitoring the increase in fluorescence 
of a dye-labeled DNA probe. This method makes it possible to analyze 
thousands of samples per day with high sample-to-sample 
reproducibility.
Using a single-tube, single-enzyme system, RNA is reverse transcribed 
to cDNA and amplified using the PCR process (Figure 1-1). Reverse 
transcription and DNA polymerization take place without the addition of 
subsequent enzymes or buffers.
Figure 1-1 Schematic representation of RT-PCR using the TaqMan EZ 
RT-PCR Kit. Hybridization of the TaqMan pr be is not shown.
Basics of the 5´
Nuclease Assay
The RT-PCR reaction exploits the 5´ nuclease activity of the rTth DNA 
Polymerase to cleave a TaqMan probe during PCR. The TaqMan probe 
contains a reporter dye at the 5´ end of the probe and a quencher dye 
at the 3´end of the probe. During the reaction, the reporter dye and 
quencher dye become separated, resulting in increased fluorescence of 
the reporter. Accumulation of PCR products is detected directly by 
monitoring the increase in fluorescence of the reporter dye.
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Figure	  2.8.	  	  Fluorescence	  of	  polymerase	  chain	  reactions	  (PCR).	  Individual	   PCR	   reactions	  were	  monitored	   by	   tracking	   the	   increase	   in	   fluorescence	   over	   time.	  Coloured	   lines	   represent	   a	   single	   condition/reaction/tube	   within	   the	   machine.	   The	   x-­‐axis	   is	  cycle	   number	   and	   the	   y-­‐axis	   is	   fluorescence	   intensity.	   The	   red	   horizontal	   line	   represents	   the	  threshold.	   It	   can	   be	   seen	   that	   the	   first	   black	   line	   crosses	   the	   threshold	   earlier	   than	   the	   other	  lines,	  this	  indicates	  it	  had	  a	  greater	  quantity	  of	  cDNA	  specific	  for	  the	  primer	  in	  that	  tube	  than	  the	  other	  samples	  had	  of	  their	  respective	  primers.	  	  Individual	  reactions	  are	  characterised	  by	  the	  PCR	  cycle	  at	  which	  fluorescence	  first	  rises	  above	  background	   levels.	   It	   is	   at	   this	   point	   that	   PCR	   amplification	   becomes	   exponential,	   termed	   the	  threshold	  cycle	  (Ct).	  The	  more	  target	  DNA	  present	  in	  the	  starting	  material	  the	  lower	  the	  Ct.	  The	  correlation	  between	  fluorescence	  and	  the	  amount	  of	  amplified	  product	  enables	  quantification	  of	  target	  molecules	  over	  a	  wide	  range.	  	  	  
Analysis	  of	  relative	  expression	  and	  Ct	  values	  was	  with	  Rotor-­‐gene	  6000	  software	  (version	  1.7),	  followed	   by	   use	   of	   Excel	   software	   to	   implement	   the	   delta-­‐delta	   CT	   method	   (Pfaffl,	   2001)	   to	  compare	  the	  difference	  in	  expression	  relative	  to	  the	  mean	  change	  in	  the	  reference	  gene,	  β-­‐actin.	  Relative	   transcript	  abundance	   is	  expressed	  as	  ΔCt	  value	   (ΔCt	  =	  Ct	   reference	  –	  Ct	   target),	  with	  higher	   ΔCt	   values	   indicate	   higher	   transcript	   abundances,	   and	   negative	   ΔCt	   values	   represent	  genes	  that	  are	  less	  expressed	  compared	  with	  the	  reference	  gene.	  	  	  
2.3.4	  Cell	  proliferation	  assays	  
Proliferation	   experiments	   used	   in	   this	   thesis	   included	   direct	   manual	   cell	   counting,	   and	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assessment	  of	   incorporation	  of	   tritiated	  methyl	   thymidine	   into	   the	  DNA	   fraction	  of	   cells.	   This	  latter	  technique	  is	  frequently	  used	  and	  a	  quick	  convenient	  way	  to	  assess	  proliferation.	  Increased	  thymidine	   uptake	   may	   reflect	   increased	   synthesis	   of	   enzymes	   or	   proteins	   involved	   in	  proliferation,	   although	   it	   is	   not	   a	   true	   reflection	   of	   changes	   in	   cell	   number,	   therefore	   both	  techniques	  were	  used.	  	  	  
2.3.4.1	  Manual	  cell	  counting	  
To	   assess	   the	   effects	   on	   10%	   serum-­‐stimulated	   cell	   counts,	   cells	   were	   seeded	   at	   2.5x104	  cells/well	   to	   achieve	   90%	   confluence	   in	   8-­‐well	   permanox	   Lab-­‐Tek	   slides	   (Nalge	   Nunc	  International,	   Naperville,	   IL)	   and	   allowed	   to	   adhere	   overnight.	   The	  media	  was	   replaced	  with	  fresh	  media	  containing	  treatments	  for	  24	  hours.	  Slides	  were	  immunostained	  with	  DAPI;	  images	  were	  captured	  and	  saved	  using	  a	  fluorescence	  microscope,	  and	  manual	  cell	  counting	  performed	  on	  8-­‐10	  fields	  per	  condition	  by	  an	  assessor	  blinded	  to	  the	  treatment	  groups.	  	  
2.3.4.2	  [Methyl-­‐3H]-­‐thymidine	  uptake	  
To	  assess	  the	  effects	  of	  dexamethasone	  on	  10%FCS/DMEM-­‐stimulated-­‐rat	  PASMC	  proliferation,	  DNA	  synthesis	  was	  measured	  by	  [methyl-­‐3H]-­‐thymidine	  (Sigma	  Aldrich)	  incorporation	  over	  24	  hours.	  Rat	  PASMC	  were	  seeded	  in	  96-­‐well	  plates	  (5000	  cells/well),	  allowed	  to	  adhere	  overnight	  in	  DMEM/10%FCS,	   and	   then	   quiesced	   in	   0.1%	  DMEM	   for	   24	   hours.	   Cells	  were	  washed	   twice	  with	  PBS	   then	   incubated	   in	   fresh	  medium	  containing	  0.25μCi/well	   [methyl-­‐3H]-­‐thymidine	  and	  in	  the	  presence	  and	  absence	  of	  dexamethasone	  (see	  chapter	  5).	  After	   incubation	  for	  24	  hours,	  the	   cells	   were	   washed	   twice	   with	   PBS,	   treated	   by	   ice-­‐cold	   10%	   trichloroacetic	   acid	   (Sigma	  Aldrich),	   and	   dissolved	   in	   0.1	   N	   NaOH	   (0.5	   ml/well)	   (Sigma	   Aldrich).	   The	   incorporated	  radioactivity	  was	  counted,	  with	  [3H]	  thymidine	  incorporation	  into	  DNA	  reported	  as	  counts	  per	  minute	  per	  well.	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2.3.5	  Apoptosis	  assays	  
2.3.5.1	  Hoescht	  staining	  
Hoechst	  33342	  is	  a	  water-­‐soluble,	  blue	  fluorescent	  dye	  that	  targets	  DNA	  in	  live	  cells	  and	  stains	  condensed	   apoptotic	   condensed	   nuclei	   with	   a	   characteristic	   high	   intensity.	   It	   is	   more	   cell-­‐permeable	  and	  less	  toxic	  to	  cells	  than	  DAPI.	  Cells	  were	  stained	  according	  to	  the	  manufacturer’s	  protocol	   (see	   chapter	   5),	   and	   the	   number	   of	   apoptotic	   cells	   expressed	   as	   a	   proportion	   of	   the	  total	  cells.	  	  
2.3.5.2	  DNA	  Fragmentation	  ELISA	  	  
The	  Cell	  Death	  Detection	  ELISA	  Plus	  kit	  (Roche	  Applied	  Science,	  Indianapolis,	  USA)	  was	  used	  to	  detect	   cytoplasmic	   histone-­‐associated-­‐DNA	   fragments,	   according	   to	   the	   manufacturers’	  instructions.	   	   This	   is	   a	   sandwich	   ELISA	   using	   mouse	   monoclonal	   antibodies	   directed	   against	  DNA	  and	  histones,	  which	  detects	  mono-­‐	  and	  oligonucleosomes	   released	   into	   the	   cytoplasm	  of	  cells	   that	   die	   from	   apoptosis.	   Briefly,	   5	   x	   104	   PASMC	  were	   plated	   in	   24	  well	   plates	   in	   500ul.	  Conditions	  are	  described	   in	   chapter	  5.	  Cells	  were	   lysed	  with	   lysis	  buffer;	   centrifuged;	  and	   the	  supernatant	  (cell	  lysate)	  analysed	  to	  determine	  apoptotic	  nucleosomes:	  The	  samples	  are	  placed	  into	  a	   streptavidin-­‐coated	  microplate	  and	   incubated	  with	  a	  mixture	  of	   anti-­‐histone-­‐biotin	  and	  anti-­‐DNA-­‐peroxidase.	   During	   incubation,	   nucleosomes	   will	   be	   captured	   via	   their	   histone	  component	   by	   the	   anti-­‐histone-­‐biotin	   antibody,	   while	   binding	   to	   the	   streptavidin-­‐coated	  microplate.	   Simultaneously,	   anti-­‐DNA-­‐peroxidase	   binds	   to	   the	   DNA	   part	   of	   the	   nucleosomes.	  After	   removal	   of	   the	   unbound	   antibodies,	   the	   amount	   of	   peroxidase	   retained	   in	   the	  immunocomplex	  is	  photometrically	  determined	  with	  ABTS	  (a	  compound	  often	  used	  in	  ELISAs	  to	  determine	  reaction	  kinetics)	  as	  the	  substrate,	  using	  a	  plate	  reader	  set	  at	  450	  nm.	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2.3.6	  Peripheral	  blood	  mononuclear	  cell	  (PBMC)	  isolation	  
Experiments	   in	   the	   final	   results	   chapter	   of	   this	   thesis	   used	  both	   human	   ‘whole	   blood’	   assays,	  and	   also	   PBMC	   assays.	   PBMC	   were	   isolated	   from	   whole	   blood	   using	   the	   principle	   that	   a	  hydrophilic	  polysaccharide	  (e.g.	  Ficoll	  or	  Histopaque)	  separates	  layers	  of	  blood	  into	  a	  top	  layer	  of	   plasma,	   followed	   by	   a	   layer	   of	   PBMCs	   and	   a	   bottom	   fraction	   of	   polymorphonuclear	   cells	  (granulocytes)	   (such	   as	   neutrophils	   and	   eosinophils)	   and	   erythrocytes	   (Figure	   2.9).	   During	  centrifugation,	  erythrocytes	  are	  aggregated	  by	  the	  polysucrose	  and	  rapidly	  sediment;	  whereas	  lymphocytes	   and	   other	   mononuclear	   cells	   remain	   at	   the	   plasma-­‐Ficoll/Histopaque	   layer	  interface.	  Due	  to	  the	  increased	  density	  of	  granulocytes,	  these	  do	  not	  band	  with	  the	  mononuclear	  cells,	  but	  move	  to	  the	  bottom	  of	  the	  tube.	  Therefore	  the	  PBMC	  layer	  can	  be	  carefully	  separated	  from	  erythrocytes	  and	  granulocytes.	  In	  this	  thesis	  I	  used	  two	  different	  methods	  of	  PBMC	  isolation.	  In	  preliminary	  experiments,	  I	  used	  pre-­‐filled	   Ficoll-­‐containing	   50ml	   falcons	   (UNISept,	   Abcys,	   Jerusalem,	   Israel).	   These	   were	  effective	  but	  more	  costly.	  Secondly,	  I	  used	  a	  technique	  involving	  layering	  Histopaque	  (a	  form	  of	  Ficoll)	   onto	   diluted	   whole	   blood.	   I	   selected	   the	   latter	   method	   for	   the	   final	   experiments,	   as	  described	  below.	  
 
Figure	  2.9.	  	  Layers	  of	  blood	  following	  Ficoll	  separation.	  
Plasma	  layer 
PBMC	  &	  basophils Ficoll	  or	  Histopaque	  layer Packed	  erythrocytes	   /	  granulocytes 
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2.3.6.1	  Histopaque	  gradient	  PBMC	  isolation	  
Histopaque	  1077	  (Sigma	  Aldrich,	  UK)	   is	  a	  Ficoll	  gradient	  solution	  containing	  a	  polysaccharide	  and	  a	  radiopaque	  contrast	  medium.	  Fresh	  citrated	  blood	  (15-­‐20ml	  per	  subject)	  was	  mixed	  1:1	  in	  50ml	   falcons	   with	   warm	   RPMI	   (without	   supplements).	   Following	   this,	   6ml	   of	   the	   1:1	   blood:	  RPMI	   mix	   was	   carefully	   layered	   onto	   3ml	   Histopaque	   pre-­‐prepared	   in	   a	   15ml	   falcon,	   and	  centrifuged	  (400g,	  low	  brake,	  22°C)	  for	  30	  min.	  The	  PBMC	  layer	  was	  aspirated	  into	  fresh	  15ml	  falcons	   carefully	  using	   a	  Pasteur	  pipette,	   and	  7ml	  of	  PBMC	   layer	  made	  up	   to	  14ml	  with	   fresh	  RPMI	  (0%	  FCS).	  The	  first	  of	  the	  lower	  speed	  washes	  was	  then	  performed,	  to	  remove	  platelets:	  PBMCs	  were	  washed	  with	  warm	  RPMI	  1640	  (0%	  FCS)	   (200g	   for	  15	  minutes,	  with	  break),	   the	  supernatant	  discarded,	   the	  pellet	   resuspended	   into	  20ml	   fresh	  RPMI	   in	  a	  50ml	   falcon.	  After	   a	  final	  wash,	  the	  pellet	  was	  resuspended	  in	  10ml	  RMPI/10%	  FCS.	  Cells	  were	  counted	  (with	  trypan	  blue	   diluted	   1:1)	   and	   106	   cells/ml	   (in	   10%	   RPMI)	   plated	   in	   100μl	   into	   a	   96-­‐well	   plate	   (105	  cells/well).	  Cells	  were	  incubated	  at	  37°C	  for	  2	  hours,	  before	  treatments	  were	  added.	  	  
2.3.7	  Nuclear	  factor	  κB	  transcription	  factor	  assays	  
These	   assays	   were	   performed	   on	   PASMC	   with	   the	   assistance	   of	   Dr	   Elen	   Jazwari	   (Airways	  Disease,	  NHLI),	  and	  repeated	  in	  PBMC	  with	  Dr	  Chao	  Meng	  (Critical	  Care,	  NHLI).	  
	  
2.3.7.1	  Preparation	  of	  nuclear	  extracts	  
Nuclear	   extraction	   of	   PMBC	   and	   PASMC	   was	   performed	   according	   to	   the	   manufacturer’s	  instructions	  (Active	  Motif	  ®).	  PASMC	  or	  PBMC	  (1	  and	  2	  million	  cells	  per	  condition	  respectively)	  were	  placed	  in	  2ml	  vials	  for	  1	  hour,	  with	  TNF-­‐α	  (0-­‐10ng/ml)	  ±	  dexamethasone	  (10-­‐7M).	  After	  an	  hour,	  the	  experiment	  was	  stopped	  with	  ice-­‐cold	  PBS	  to	  limit	  further	  protein	  modifications	  (e.g.	  dephosphorylation).	   Cells	   were	   then	   resuspended	   in	   hypotonic	   buffer	   to	   increase	  membrane	  fragility,	   and	   detergent	   was	   added	   to	   induce	   leakage	   of	   the	   cytoplasmic	   proteins	   into	   the	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supernatant.	   After	   collection	   of	   the	   cytoplasmic	   fraction,	   nuclei	   were	   lysed	   and	   the	   nuclear	  proteins	  solubilized	  in	  the	  lysis	  buffer,	  in	  the	  presence	  of	  a	  protease	  inhibitor	  cocktail.	  Nuclear	  and	  cytoplasmic	  fractions	  were	  then	  frozen	  at	  -­‐80°C	  for	  later	  use.	  	  
2.3.7.2	  Measurement	  of	  protein	  content:	  The	  Bradford	  assay	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2.3.7.3	  NF-­‐κB	  transcription	  factor	  p65	  TransAM	  assay	  








Figure	  2.11.	  	  Protocol	  for	  the	  p65	  TransAM®	  Assay.	  	  
2.4	  STATISTICAL	  METHODS	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Distribution	   Groups	   Paired	   Test	  Parametric	   2	   No	   Student	  t-­‐	  test	  Non-­‐parametric	   2	   No	   Mann	  Whitney	  U	  test	  Parametric	   >2	   No	   ANOVA	  with	  Bonferroni’s	  correction	  	  (Dunnett’s	  test	  to	  compare	  all	  to	  control)	  Non-­‐parametric	   >2	   No	   Kruskal-­‐Wallis	  test	  with	  Dunn’s	  multiple	  comparisons	  test	  correction	  Parametric	   2	   Yes	   Paired	  t-­‐test	  Non-­‐parametric	   2	   Yes	   Wilcoxon	  matched	  pairs	  test	  	  Parametric	   >2	   Yes	   Repeated	  measures	  ANOVA	  with	  Bonferroni’s	  correction	  
 
Table	  2.2.	  	  Statistical	  tests	  used	  for	  paired	  and	  grouped	  comparisons.	  	  Power	  calculations	  were	  performed	  using	  a	  set	  power	  of	  0.80,	  and	  an	  alpha	  value	  of	  0.05.	  Single	  comparisons	  were	  made	  using	  Students	  t-­‐test	  or	  Mann	  Whitney	  tests,	  and	  multiple	  comparisons	  tested	  using	  one-­‐way	  ANOVA	  or	  Friedman’s	  test	  or	  Kruskal	  Wallis	  test,	  followed	  by	  appropriate	  post-­‐tests,	  for	  normal	  /	  non-­‐parametric	  data	  respectively.	  For	  ranked	  data,	  the	  Wilcoxon	  signed	  rank	   or	   signed	   pairs	   tests,	   for	   normal	   /	   non-­‐parametric	   data	   respectively.	   Differences	   at	   a	  probability	  value	  (p)	  of	  <0.05	  were	  considered	  significant.	  Data	  were	  entered	  in	  Microsoft	  Excel	  prior	  to	  statistical	  analysis	  using	  Prism	  version	  5.0	  (GraphPad	  software,	  La	  Jolla,	  CA,	  USA).	  For	  correlations,	  if	  data	  were	  parametric	  in	  distribution,	  Pearson’s	  correlation	  was	  used;	  if	  non-­‐parametric,	   Spearman’s	   rank	   correlation.	   In	   both	   cases,	   a	   value	   is	   stated	   for	   r	   (degree	   of	  correlation)	  and	  p	  (statistical	  significance),	  r	  values	  of	  >0.3	  or	  <-­‐0.3	  are	  considered	  significant	  when	  associated	  with	  a	  p	  value	  of	  <0.05.	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2.5	  MATERIALS	  &	  REAGENTS	  
2.5.1	  General	  reagents	  
Reagent	   Cat	  #	   Supplier	  Bovine	  Serum	  Albumin	  	   A7030	   Sigma	  Aldrich	  Distilled	  water	  purification	  system	   -­‐	   MilliporeTM	  ELISA	  substrates	  A	  and	  B,	  OptEIA	   555214	   BD	  biosciences	  Endotoxin	  free	  water	   W50-­‐100	   Lonza	  Phosphate	  buffered	  saline	   D8537	   Sigma	  Aldrich	  Sodium	  chloride	   S7653	   Sigma	  Aldrich	  Sodium	  Citrate	   S5770	   Sigma	  Aldrich	  Trizma	  base	  DMSO	  Tritiated	  methyl	  thymidine	  Tween	  20	  
T6066	  D2650	  TRK418	  9005-­‐64-­‐5	  
Sigma	  Aldrich	  Sigma	  Aldrich	  Amersham	  Sigma	  Aldrich	  
	  
2.5.2	  Cells	  and	  cell	  culture	  
Reagent	   Cat	  #	   Supplier	  Dulbecco’s	  modified	  eagle’s	  medium	   D6546	   Sigma	  Aldrich	  Fetal	  calf	  serum	   12664025	   Invitrogen	  L-­‐Glutamine	  200mM	  MEM/Non-­‐essential	  amino	  acids	   25030081	  11140	   Invitrogen	  GIBCO	  Penicillin	  &	  Streptomycin	   1507063	   Invitrogen	  RPMI	  medium	  1640	  Trypsin	  0.25%	  CryoSFM	  
R8758	  25200056	  C-­‐29910	  
Sigma	  Aldrich	  Life	  Technologies	  Promocell	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2.5.3	  Stimuli,	  reagents	  and	  recombinant	  proteins	  
Reagent	   Cat	  #	   Supplier	  E.	  Coli	  LPS	  026:B6	  TNF-­‐α	   L4391	  210TA-­‐010	   Sigma	  Aldrich	  R&D	  Systems	  
	  
2.5.4	  Antibodies	  and	  reagents	  for	  immunostaining	  
Target	   Host	  
species	  
Cat	  #	   Supplier	  
Human	  p65	   Rabbit	   Sc-­‐372	   Santa	  Cruz	  Rabbit	  IgG	   Goat	   BA-­‐1000	   Vector	  labs	  Rat	  α-­‐smooth	  muscle	  actin	  (IF)	   Mouse	   A2547	   Sigma	  Aldrich	  Rat	  caspase-­‐3	   Rabbit	   Ab2302	   Abcam	  Rat	  p65	  Rat	  anti-­‐phospho-­‐IKKα/β	  Normal	  rabbit	  IgG	  Diaminobenzidine	  (DAB)	  liquid	  Peroxidase	  blocking	  solution	  
Rabbit	  Rabbit	  -­‐	  
C22B4	  C2967	  Sc-­‐2027	  D3467	  
Cell	  Signalling	  Cell	  Signalling	  Santa	  Cruz	  DAKO	  DAKO	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2.5.5	  ELISAs	  and	  related	  assays	  	  
Reagent	   Cat	  #	   Supplier	  Cell	  death	  detection	  ELISA	  Hoechst	  stain	  33342,	  trihydrochloride	  Alamar	  blue	  Assay	  4′,6-­‐Diamidino-­‐2-­‐phenylindole	  dihydrochloride	  (DAPI)	  	  
11774425001	  H21492	  DAL1025	  D9542	  T8154	  
Roche	  Invitrogen	  Invitrogen	  Sigma	  Aldrich	  Sigma	  Aldrich	  
2.5.6	  qRT-­‐PCR	  
Reagent	   Cat	  #	   Supplier	  5xFirst	  strand	  buffer	   Y02321	   Invitrogen	  dNTP	  (dATP,	  dCTP,	  dGTP	  and	  dTTP)	   088K6003	   Sigma	  Aldrich	  Dithiothreitol (DTT)	   Y00147	   Invitrogen	  M-­‐MLV	  Reverse	  transcriptase	   28025-­‐013	   Invitrogen	  OligoDT12-­‐18	   58862	   Invitrogen	  PCR	  tubes-­‐	  capped	  0.1ml	   LW2590	   Corbett	  Primer	  assay:	  β-­‐actin	   Rn00667869_m1	   Applied	  Biosystems	  Primer	  assay:	  BMPR-­‐II	   Rn01437210_m1	   Applied	  Biosystems	  Primer	  assay:	  IL-­‐6	   Rn00561420_m1	   Applied	  Biosystems	  RNasine,	  0.5U/µl	   N261B	   Promega	  RNeasy	  Kit	   74106	   Qiagen	  Reverse	  Transcriptase	  buffer	   18057-­‐018	   Invitrogen	  SYBR	  green	  PCR	  kit	   204141	   Qiagen	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2.5.7	  Equipment	  
	   	   Supplier	  EL800	  plate	  reader	  with	  Gen	  5	  (Biotek)	  software	   	   Biotek	  Rotorgene-­‐6000	  RT-­‐PCR	  machine	   	   Corbett	  pH	  meter	   	   Hanna	  instruments	  pH	  buffers	  (pH	  4	  and	  10)	   	   Fisher	  Scientific	  Cardiomax	  III	  cardiac	  catheterisation	  monitor	   	   Phymep,	  Paris,	  France	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CHAPTER	  3:	  NUCLEAR	  FACTOR-­‐κB	  ACTIVATION	  IN	  
IDIOPATHIC	  PULMONARY	  ARTERIAL	  HYPERTENSION	  
	  
3.1	  Rationale	  
Several	   lines	   of	   evidence	   support	   the	   hypothesis	   that	   NF-­‐κB	  might	   be	   activated	   in	   idiopathic	  PAH.	   Transcription	   of	   pro-­‐inflammatory	   genes	   upregulated	   in	   human	   iPAH,	   including	  chemokines	   (e.g.	   IL-­‐8/CXCL-­‐8,	   MCP-­‐1/CCL2,	   RANTES/CCL5,	   fracktalkine/CX3CL1)	   and	  cytokines,	   (e.g.	   IL-­‐1-­‐β,	   IL-­‐6	   and	   TNF-­‐α)	   is	   coordinated	   by	   nuclear	   factor-­‐kappa	   B	   (NF-­‐κB)	  activation	  (Lenardo	  and	  Baltimore,	  1989,	  Siebenlist	  et	  al.,	  1994).	  In	  addition,	  cytokines	  (TNF-­‐α	  and	  IL-­‐1-­‐β)	   implicated	   in	   iPAH	  (Soon	  et	  al.,	  2010,	  Humbert	  et	  al.,	  1995)	  positively	   feedback	  to	  activate	  NF-­‐κB	  itself	  (Osborn	  et	  al.,	  1989).	  Recognised	  inflammatory	  triggers	  in	  PAH	  which	  are	  also	   activators	   of	   NF-­‐κB	   (Lenardo	   and	   Baltimore,	   1989)	   include	   viral	   infections	   (Cool	   et	   al.,	  2003)	   and	   oxidative	   stress	   (Dorfmuller	   et	   al.,	   2011)	   as	   well	   as	   alveolar	   hypoxia	   (Rius	   et	   al.,	  2008,	  Fitzpatrick	  et	  al.,	  2011).	  	  
Activation	   of	   NF-­‐κB	   is	   a	   feature	   of	   many	   chronic	   inflammatory	   conditions	   including	   asthma	  (Hart	   et	   al.,	   1998),	   chronic	   obstructive	   pulmonary	   disease	   (Di	   Stefano	   et	   al.,	   2002)	   and	  rheumatoid	  arthritis	   (Marok	  et	  al.,	  1996)	  as	  well	  as	   in	  (non-­‐lymphoid)	  malignancies	  (Wang	  et	  al.,	  1999).	  In	  asthma	  and	  COPD,	  activation	  of	  NF-­‐κB	  correlates	  with	  disease	  severity,	  suggesting	  a	  direct	  role	  in	  pathogenesis	  (Hart	  et	  al.,	  1998,	  Di	  Stefano	  et	  al.,	  2002).	  In	  atherosclerosis,	  NF-­‐κB	  activation	   is	   seen	   within	   macrophages,	   endothelial	   and	   vascular	   smooth	   muscle	   cells	   within	  atherosclerotic	   plaques	   (Brand	   et	   al.,	   1996):	   the	   degree	   of	   activation	   is	   positively	   associated	  with	  symptoms	  of	  unstable	  angina	  (Wilson	  et	  al.,	  2002,	  Ritchie,	  1998).	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There	  are	  several	   lines	  of	  supportive	  evidence	  for	  a	  role	  for	  NF-­‐κB	  in	  PAH.	  Gene	  array	  studies	  showed	  that	  lymphocytes	  from	  patients	  with	  PAH	  have	  distinct	  NF-­‐κB-­‐associated	  gene	  profiles	  (including	  Toll-­‐like	  receptor	  4	  and	  CD14)	  (Bull	  et	  al.,	  2004).	  Our	  group	  previously	  showed	  that	  the	  production	  of	   endothelin-­‐1	   (ET-­‐1)	   released	   from	  human	  PASMC	   in	   response	   to	   IFN-­‐γ	   and	  TNFα,	  in	  vitro,	  is	  under	  NF-­‐κB	  control	  (Wort	  et	  al.,	  2009).	  NF-­‐κB	  activation	  was	  demonstrated	  in	  endothelial	   cells	   in	   rats	   with	   MCT-­‐induced	   PH,	   and	   NF-­‐κB	   blockade	   using	   several	   agents	  prevented	   the	   onset	   of	   PH	   in	   this	   model	   (Kimura	   et	   al.,	   2009,	   Huang	   et	   al.,	   2008).	   In	   2002,	  Raychaudhuri	  et	  al	  demonstrated	  increased	  NF-­‐κB	  activation	  in	  (unstimulated)	  human	  alveolar	  macrophages	   obtained	   from	   bronchoalveolar	   lavage	   from	   patients	   with	   PAH	   compared	   to	  controls	  without	  PAH	  (Raychaudhuri	  et	  al.,	  1999).	  More	  recently,	  an	   interesting	  study	  showed	  that	   NF-­‐κB	  was	   constitutively	   activated	   in	   cultured	   PASMC	   from	   patients	  with	   heritable	   PAH	  compared	  to	  control	  PASMC	  (Davies	  et	  al.,	  2012).	  	  
No	   study	   has	   previously	   examined	   NF-­‐κB	   activation	   in	   lung	   tissue	   or	   vascular	   cells	   from	  idiopathic	  PAH	  patients.	  We	  therefore	  performed	  a	  detailed	   immunohistochemical	  assessment	  of	  lung	  stained	  for	  the	  p65	  subunit	  of	  NF-­‐κB,	  as	  well	  as	  specific	  inflammatory	  cell	  markers.	  Our	  hypothesis	  was	  that	  NF-­‐κB	  activation	  in	  both	  inflammatory	  and	  pulmonary	  vascular	  cells	  was	  a	  feature	  of	  idiopathic	  PAH.	  
	  
Laura	  Price	  PhD:	  Inflammation	  in	  Pulmonary	  Arterial	  Hypertension	   99	  
3.2	  Methods	  	  
3.2.1	  Selection	  of	  subjects	  
Specimens	   from	   control	   subjects	   (n=14)	  were	   obtained	   from	   lung	   resected	   during	   lobectomy	  surgery;	   for	   patients	   with	   idiopathic	   PAH	   (n=12),	   specimens	   were	   obtained	   following	   lung	  transplantation.	   Demographics,	   co-­‐morbidities,	   drug	   history	   and	   inflammatory	  markers	   were	  recorded,	  as	  well	  as	  clinical,	  haemodynamic	  status	  and	  PAH	  therapies	  prior	  to	  transplantation.	  Local	  hospital	  ethics	  committees	  approved	  the	  study	  with	  all	  patients	  giving	  informed	  consent	  to	   participate	   (Comité	   de	   Protection	   des	   Personnes	   Ile-­‐de-­‐France,	   Paris	   VII;	   University	   of	  Ferrara).	  	  
3.2.2	  Lung	  tissue	  processing	  
Lung	  tissue	  preparation	  was	  performed	  by	  Dr	  Peter	  Dorfmuller	  in	  Paris	  for	  PAH	  specimens,	  and	  Professor	  Gaetano	  Caramori	  in	  Italy	  (for	  controls).	  Two	  to	  four	  randomly	  selected	  blocks	  of	  lung	  tissue	  (2	  x	  2.5cm)	  were	  taken	  from	  the	  sub-­‐pleural	  parenchyma	  of	  the	  lobe	  obtained	  at	  the	  time	  of	  surgery,	  avoiding	  areas	  involved	  by	  tumour	  in	  controls.	  Fresh	  lung	  tissue	  was	  gently	  inflated	  through	   the	   bronchi	   using	   an	   automated	   formalin-­‐pump	   (Microm,	   France)	   and	   eventually	  immersed	  in	  buffered	  formalin	  for	  24	  hours.	  All	  lobes	  were	  sampled.	  Samples	  were	  fixed	  in	  4%	  formaldehyde	  in	  phosphate	  buffered	  saline	  (PBS)	  at	  pH	  7.2,	  embedded	  in	  paraffin	  and	  4µm	  thick	  sections	  were	  obtained.	  	  
3.2.3	  Immunoperoxidase	  staining	  in	  lung	  sections	  
All	  double	   immunohistochemical	  staining	  was	  performed	   in	  Ferrara,	   Italy,	  by	  collaborators	  Dr	  Paulo	   Casolari	   and	  Professor	  Gaetano	  Caramori.	   Sections	  were	   dewaxed	   and	   rehydrated	   then	  heat-­‐mediated	   antigenic	   retrieval	   performed	   using	   pH	   6.0	   citrate	   buffer.	   Endogenous	  peroxidase	  activity	  was	  quenched	  by	   incubation	  of	   the	  slides	   in	  3%	  hydrogen	  peroxide	   for	  30	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minutes;	   cell	   membranes	   were	   permeabilised	   by	   0.1%	   saponin	   in	   PBS,	   and	   non-­‐specific	  labelling	  blocked	  by	  5%	  normal	  horse	  serum	  in	  PBS	  for	  20	  minutes,	  at	  room	  temperature	  (as	  for	  all	   the	   following	  steps).	  After	  washing	   in	  PBS,	  sections	  were	   incubated	   for	  1	  hour	  with	  mouse	  anti-­‐human	   CD68	   (Dako)	   at	   a	   1:100	   dilution	   (160μg/ml).	   For	   negative	   control	   slides,	   normal	  mouse	  non-­‐specific	  immunoglobulins	  (Santa	  Cruz	  Biotechnology)	  were	  used	  at	  the	  same	  protein	  concentration	   as	   the	   primary	   antibody.	   After	   repeated	   PBS	  washing,	   sections	  were	   incubated	  with	   anti-­‐mouse	   biotinylated	   antibody	   (Vector	   ABC	   Kit,	   Vector	   Laboratories)	   for	   30	  minutes.	  Sections	  were	   then	   incubated	  with	  ABC	   reagent	   (Vector	   ABC	  Kit,	   Vector	   Laboratories)	   for	   30	  minutes	   and	   stained	  with	   chromogen-­‐fast	   diaminobenzidine	   (DAB)	   for	   1–5	  minutes.	   Selected	  slides	   were	   incubated	   with	   anti-­‐CD20	   (Diagnostic	   BioSystems,	   Pleasanton,	   USA)	   anti-­‐CD45	  (Thermo	  Fisher	  Scientific,	  Cheshire,	  UK).	  
For	  CD68-­‐p65	  double	  staining,	   the	  process	  was	  repeated	  again	  on	  the	  same	  slides	   for	  staining	  p65	  using	  a	  rabbit	  anti	  human	  p65	  (Santa	  Cruz	  Biotechnology)	  at	  a	  dilution	  of	  1:50	  (200μg/ml)	  or	  using	  a	  normal	  rabbit	  non-­‐specific	   immunoglobulin	  (Santa	  Cruz	  Biotechnology)	  at	  the	  same	  protein	   concentration	   as	   the	   primary	   antibody	   as	   a	   negative	   control.	   Finally,	   the	   slides	  were	  stained	   with	   chromogen	   fast	   red	   for	   10–20	   minutes,	   counterstained	   in	   haematoxylin	   and	  mounted	  on	  aqueous	  mounting	  medium.	  	  
3.2.4	  Microscopy	  
I	  performed	  microscopy	  with	  the	  assistance	  of	  Mr	  Stephen	  Rothery	  in	  the	  Facility	  for	  Imaging	  by	  Light	   Microscopy	   (FILM)	   at	   Imperial	   College	   London.	   Red-­‐yellow-­‐green	   (RGB)	   images	   were	  recorded	   using	   10x	   objective	   on	   a	   Zeiss	   Axiovert	   200	   inverted	  microscope	  with	   a	  motorized	  stage,	   controlled	   by	   Improvision	   Volocity	   acquisition	   software.	   Absolute	   numbers	   of	   CD68+	  macrophages/mm2	   were	   counted	   from	   composite	   stitched	   images	   using	   image	   analysis	  software,	  also	  obtaining	  smooth	  muscle	  layer	  area	  measurements.	  Analysis	  was	  also	  performed	  by	  Dr	  Jie	  Zhu	  (JZ)	  (Department	  of	  Histology,	  Royal	  Brompton	  Hospital).	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3.2.5	  Morphometric	  analysis	  
Paraffin-­‐embedded	   slides	   were	   stained	   with	   haematoxylin	   and	   eosin	   and	   were	   blinded	   to	  assessors.	  Pulmonary	  vascular	  morphometric	  end	  points	  were	  measured	  using	  a	  conventional	  upright	   light	   microscope	   (Olympus,	   CH30,	   x100-­‐x400	   objective)	   and	   Image	   J	   (FIJI)	   Image	  analysis	   software	   used	   in	   the	   histopathology	   labs	   at	   the	   Royal	   Brompton	   Hospital.	  Measurements	   (in	   µm)	   included	   external	   diameter	   (distance	   between	   EEL),	  medial	   thickness	  (between	  the	   internal	  and	  external	  elastic	   lamina,	  and	  the	  smooth	  muscle	  area	   in	  µm2.	  Medial	  thickness	  may	  be	  described	  as	  normal	  if	  5	  (3-­‐7)	  %	  of	  the	  ED	  (3-­‐7%	  of	  the	  ED),	  mild	  (7-­‐10%	  ED);	  moderate	  (10-­‐15%	  ED)	  and	  severe	  (>15%	  ED)	  (Wagenvoort	  CA.,	  1989).	  	  	  
3.2.5.1	  Anatomical	  considerations	  
It	   was	   important	   to	   recognise	   the	   relevant	   vessels	   during	   lung	   histological	   analysis.	   Caveats	  include	   the	   exclusion	   bronchial	   arteries	   from	   analysis	   of	   pulmonary	   arteries,	   recognition	   of	  pulmonary	   arterioles	   and	   venules.	   Bronchial	   arteries	   accompany	   the	   bronchi;	   their	   medial	  thickness	   lies	   between	   that	   of	   pulmonary	   and	   systemic	   arteries;	   their	   calibre,	   however,	   is	  smaller	  than	  that	  of	  a	  pulmonary	  artery	  accompanying	  the	  same	  bronchus.	  They	  show	  a	  distinct	  IEL	   but	   the	   EEL	   is	   often	   absent.	   In	   addition,	   non-­‐muscular	   intra-­‐acinar	   arterioles	   are	  indistinguishable	   from	   pulmonary	   venules	   without	   tracing	   their	   course	   in	   serial	   sections.	  Finally,	   pulmonary	   veins	   are	   difficult	   to	   distinguish	   from	   intra-­‐acinar	   non-­‐muscularised	  arterioles	  without	  tracing	  serial	  lung	  sections	  (Wagenvoort	  CA.,	  1989).	  	  
3.2.5.2	  Scoring	  of	  pulmonary	  vascular	  cells	  
For	  pulmonary	  arterial	  endothelial	  cells	   (EC)	  and	  PASMC,	   individual	  cells	   in	  10-­‐20	  pulmonary	  arteries	   (external	   diameter	   [ED]	   100-­‐500µm)	   per	   subject	   were	   analysed	   under	   high-­‐power	  magnification	   (x400).	   One	   slide	  was	   available	   per	   subject.	   For	  macrophages,	   every	   cell	   (in	   at	  least	  20	   fields	  of	  view)	  was	  counted	   (at	  200-­‐400	  x	  magnification)	  and	   the	  average	  value	  used	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per	  subject.	  For	  vascular	  cells,	   every	  cell	   in	  all	   suitable	  vessels	  was	   included	  with	   the	  average	  value	   again	   being	   used	   per	   subject	   for	   further	   analyses.	   Total	   area	   per	   tissue	   sample	   was	  measured	   using	   analysis	   of	   stitched	   images	   obtained	   using	   the	   10x	   objective	   on	   the	   Zeiss	  inverted	  microscope.	  Additional	   standard	  morphometric	  data	   included	  pulmonary	   arterial	  ED	  (µm)	  and	  percentage	  smooth	  muscle	  medial	  thickness	  (single	  medial	  thickness/ED	  x100).	  	  	  




















































































Figure	  3.1.	  	  Inter-­‐	  and	  Intra-­‐observer	  variability.	  To	   ensure	   methodological	   consistency,	   measurements	   were	   repeated	   both	   for	   the	   same	  observer	  on	  different	  dates	  (intra)	  and	  between	  observers	  (inter)	   for	  one	  of	   the	  standard	  end	  points,	  overall	  p65+	  positivity	  in	  macrophages.	  These	  data	  represent	  mean±SEM	  for	  n=3-­‐5	  per	  group.	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3.2.6	  Immunofluorescence	  
Confocal	  immunofluorescence	  staining	  was	  performed	  on	  5µm	  acetone	  fixed	  frozen	  sections	  by	  Dr	   Natacha	   Gambaryan	   (post-­‐doctoral	   fellow,	   Imperial	   College	   London).	   The	   sections	   were	  incubated	   for	  1	  hour	   in	  10%	  human	  serum	   to	  block	  non-­‐specific	  protein-­‐protein	   interactions.	  The	  sections	  were	  then	  incubated	  with	  primary	  anti-­‐NF-­‐κB	  p65	  (acetyl	  K310)	  antibody	  (Abcam,	  ab52175)	   at	   a	   1/100	   dilution	   overnight	   at	   4°C.	   AlexaFluor488-­‐conjugated	   goat	   anti-­‐rabbit	  secondary	  antibody	  (Invitrogen)	  was	  used	  and	  DAPI	  was	  used	  to	  stain	  the	  cell	  nuclei.	  	  
3.2.7	  Statistical	  analysis	  
The	  sample	  size	  (n=12	  per	  group)	  was	  selected	  with	  the	  scope	  of	  detecting	  a	  difference	  in	  total	  CD68+	   cell	   (macrophage)	   count	   between	   the	   two	   groups	   of	   1.5	   standard	   deviations	   at	   a	  significance	  level	  of	  0.01	  and	  power	  of	  80%,	  and	  based	  on	  a	  similar	  previous	  study	  (Caramori	  et	  al.,	  2003).	  Numeric	  data	  were	  expressed	  as	  mean	  ±	  standard	  error	  of	  the	  mean	  (SEM)	  or	  median	  (interquartile	   range).	   Comparisons	   in	   continuous	   variables	   between	   groups	   were	   performed	  using	   Student’s	   t	   test	   for	   normally	   distributed	   data	   and	   Mann-­‐Whitney	   U	   test	   for	   non-­‐parametric	   data.	   Linear	   regression	   was	   used	   for	   assessing	   the	   relation	   between	   continuous	  variables.	  Correlation	  analyses	  used	  Pearson’s	  or	  Spearman’s	  r	  for	  parametric	  /	  non-­‐parametric	  data	  as	  appropriate.	  A	  p-­‐value	  <0.05	  was	  considered	   indicative	  of	  statistical	  significance	  using	  GraphPad	  Prism	  5.0	  (La	  Jolla,	  California).	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3.3	  Results	  
3.3.1	  Demographics	  	  
Both	   groups	   had	   a	   female	   predominance.	   Patients	   with	   idiopathic	   PAH	   were	   younger	   than	  patients	   undergoing	   lung	   cancer	   surgery.	   None	   were	   current	   smokers.	   At	   the	   time	   of	  preoperative	   assessment,	   controls	   had	   no	   evidence	   of	   airway	   disease	   with	   respect	   to	   lung	  function	   and	   none	   were	   taking	   corticosteroid-­‐based	   therapy,	   including	   inhalers	   (Table	   3.1).	  There	  was	  no	   evidence	  of	   elevated	   inflammatory	  markers	   including	  C-­‐reactive	  protein	   (CRP);	  total	  or	  differential	  peripheral	  blood	  white	  cell	  counts	  (Figure	  3.2).	  	  	   	   Controls	  (n=14)	   PAH	  patients	  (n=12)	  Age	  (years)*	   68	  (2)	   36	  (10)***	  M/F	   4/10	   5/7	  Smoking	  history	  (NS/FS)	   11/3	   0	  CRP	  (mg/L)	   NA	   <10	  (<10-­‐47)	  Peripheral	  WCC	  (absolute)	  Total	  count	  (x10-­‐9/L)	   6.93	  (6.25-­‐9.19)	   7.90	  (5.80-­‐9.25)	  
	  
Table	  3.1.	  	  Demographic	  and	  biochemical	  characteristics	  of	  study	  subjects.	  *At	  pre-­‐transplantation	  assessment	  (for	  all	  measurements).	  ***p<0.001	  between	  groups.	  Values	  are	  mean	   (SEM)	   or	  median	   (IQR).	   Abbreviations:	  M	   -­‐	  male,	   F	   -­‐	   female,	  NS	   -­‐	   non-­‐smoker,	   FS	   -­‐	  former	  smoker,	  CRP	  -­‐	  C-­‐reactive	  protein,	  WCC	  -­‐	  white	  cell	  count	  (differential	  counts	  displayed	  in	  Figure	  3.2),	  NA	  -­‐	  data	  not	  available.	  








	  	  	  	  	  
	  
Figure	  3.2.	  	  Peripheral	  total	  and	  differential	  white	  blood	  cell	  count.	  Differential	   white	   cell	   counts	   were	   measured	   using	   laboratory	   blood	   samples	   at	   the	   time	   of	  transplantation	   or	   surgery.	   All	   results	   were	   within	   normal	   range	   for	   standard	   lab	   values	   (Total	  white	  cell	  count	  (WCC)	  4-­‐11	  x109/litre	  (L);	  Neutrophils	  (neut)	  2.5-­‐7.5	  x109/L;	  Lymphocytes	  (lymph)	  1-­‐4	  x109/L;	  Monocytes	  (mono)	  0.1-­‐1	  x109/L;	  Eosinophils	  (eos)	  0-­‐0.5	  x109/L;	  Basophils	  (baso)	  0-­‐0.2	  x109/L).	  Results	  represent	  controls	  (n=14)	  vs.	  PAH	  (n=12).	  Groups	  compared	  by	  1-­‐way	  ANOVA	  and	  Bonferroni’s	  post-­‐test	  analysis.	  
	  
3.3.2	  Clinical	  characteristics	  of	  PAH	  patients	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   PAH	  patients	  (n=12)	  Age	  at	  diagnosis,	  years	   31	  (3)	  Years	  from	  diagnosis	  to	  transplantation	   4.8	  (1.6)	  NYHA	  functional	  class	  (III/IV,	  n)*	   5/7	  6MWD	  (m)	  (n=6)	   391	  (33)	  BNP	  (ng/L)	   259	  (86.1)	  
BMPR2	  mutation	  (mutant/wild	  type)	  (n=10)	   2/8	  RAP	  (mmHg)	   8	  (1.7)	  mPAP	  (mmHg)	   62	  (15.4)	  PCWP	  (mmHg)	  (n=10)	   8	  (1.6)	  CO	  L/min	   4.80	  (0.70)	  CI	  L/min/kg/m2	   2.80	  (0.31)	  PVRI	  (n=10)	  (Wood	  units-­‐m2)	  	   21.1	  (2.7)	  PAH	  therapies	  (n)	   Epoprostenol	  (12),	  bosentan	  (12),	  sildenafil	  (7)	  
 
Table	  3.2.	  	  Clinical	  characteristics	  of	  idiopathic	  PAH	  patients.	  *At	  last	  assessment	  prior	  to	  lung	  transplantation	  (for	  all	  measurements).	  All	  values	  are	  presented	  as	  mean	  (SEM).	  Abbreviations:	  NYHA	  -­‐	  New	  York	  Heart	  Association,	  BNP	  -­‐	  brain	  natriuretic	  peptide,	  BMPR-­‐II	  	  -­‐	  bone	   morphogenetic	   protein	   receptor	   type	   2,	   RAP	   -­‐	   right	   atrial	   pressure,	   mPAP	   -­‐	   mean	  pulmonary	  artery	  pressure,	  PCWP	  -­‐	  pulmonary	  capillary	  wedge	  pressure,	  CO	  -­‐	  cardiac	  output,	  CI	  -­‐	  cardiac	  index,	  PVRI	  -­‐	  pulmonary	  vascular	  resistance	  index.	  	  
3.3.3	  Pulmonary	  artery	  morphometric	  assessment	  
PAH	  patients	  had	  greater	  smooth	  muscle	  medial	  thickness	  compared	  to	  controls	  in	  vessels	  with	  an	  external	  diameter	  (ED)	  of	  100-­‐250µm	  (34.0±1.2%	  vs.	  20.5±1.5%	  in	  controls,	  p<0.0001)	  and	  in	   vessels	  with	   and	   ED	   of	   250-­‐500µm	   (25.6±1.1%	   vs.	   18.9±1.5%	   in	   controls,	   p<0.01)	   (Figure	  3.3).	  It	  is	  worthy	  of	  comment	  that	  the	  control	  vessels	  are	  not	  as	  thin-­‐walled	  as	  controls	  in	  other	  series;	  this	  might	  reflect	  the	  significantly	  increased	  age	  of	  the	  control	  subjects	  and	  potential	  co-­‐morbidities.	  








































Figure	   3.3.	   	   Increased	   pulmonary	   arterial	   smooth	   muscle	   medial	   thickness	   in	  
patients	  with	  pulmonary	  arterial	  hypertension	  (PAH).	  Percentage	  medial	  thickness	  (%	  smooth	  muscle	  medial	  thickness/mean	  external	  diameter	  (ED))	  was	  measured	  in	  pulmonary	  arteries	  on	  lung	  sections	  stained	  with	  haematoxylin	  &	  eosin	  by	  an	  observer	   blinded	   to	   the	   groups.	   Vessels	   were	   subdivided	   according	   to	   their	   size.	   Medial	  thickness	   was	   significantly	   increased	   in	   all	   groups	   compared	   to	   controls.	   Results	   represent	  mean	  ±	  SEM	  of	  12	  PAH	  patients	  and	  14	  control	  samples.	  **p<0.01	  ****p<0.0001.	  	  
3.3.4	  Macrophage	  analysis	  	  
Scoring	   of	   CD68+	   and	   p65+	   stained	  macrophages	   showed	   an	   absolute	   increase	   in	   CD68+	   cell	  count	   in	   PAH	   patients	   compared	   to	   controls	   (49.0±4.5	   vs.	   7.95±1.9	  macrophages/100mm2	   of	  lung	   parenchyma,	   p<0.0001).	   In	   addition,	   the	   percentage	   of	   ‘overall	   p65+’	   and	   ‘nuclear	   p65+’	  macrophages	   (expressed	   as	   a	   fraction	   of	   the	   total	   cells	   counted)	  was	   higher	   in	   PAH	   patients	  compared	   to	   control	   subjects	   (71.6±2.98%	   vs.	   52.4±2.15%,	   p<0.001	   and	   16.9±2.5%	   vs.	  3.5±1.25%,	  p<0.001,	  respectively)	  (Figure	  3.4).	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Figure	   3.4.	   	   Increased	  macrophage	   numbers	   and	   NF-­‐κB	   activation	   in	   idiopathic	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3.3.5	  Correlations	  between	  macrophage	  p65-­‐positivity	  and	  pulmonary	  
arterial	  morphological	  data	  	  
A	   significant	   correlation	   was	   found	   between	   p65	   nuclear	   positivity	   in	   macrophages	   and	  pulmonary	   arterial	   medial	   thickness	   (r=0.45,	   p=0.02,	   Figure	   3.5A)	   and	   between	   overall	  macrophage	   p65+	   staining	   with	   pulmonary	   arterial	   medial	   thickness	   (r=0.46,	   p=0.02,	   Figure	  3.5B).	  However,	   there	  was	  no	  significant	   correlation	  seen	  when	   the	  analysis	  was	   restricted	   to	  
within	  each	  group,	  therefore	  suggesting	  that	  these	  may	  not	  be	  true	  correlations.	  
	  
r=0.45, p=0.02









































Figure	   3.5.	   Correlations	   between	   lung	   macrophage	   nuclear	   and	   overall	   p65	  
positivity	  (p65+)	  and	  pulmonary	  arterial	  medial	  thickness.	  Morphometric	   analysis	  was	   performed	  on	   lung	   sections	   in	   both	  PAH	  patients	   and	   controls	   of	  double-­‐immunostained	   for	   CD68	   and	   p65,	   with	   haematoxylin	   &	   eosin	   counterstaining,	   by	   2	  independent	   blinded	   observers.	   Correlations	   were	   seen	   between	   macrophage	   nuclear	   p65+	  staining	   and	   percentage	   smooth	  muscle	   vessel	   medial	   thickness	   (A)	   and	  macrophage	   overall	  p65+	  staining	  and	  percentage	  smooth	  muscle	  vessel	  medial	  thickness	  (B).	  Unfilled	  round	  points	  represent	   controls;	   Solid	   squares	   points	   are	   PAH	   patients.	   Data	   represent	   the	   Pearson	  correlation	  co-­‐efficient	  (r)	  for	  n=12	  (PAH)	  or	  n=14	  (controls).	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3.3.6	  Correlations	  between	  macrophage	  counts,	  macrophage	  p65+	  and	  
clinical	  severity	  of	  PAH	  	  
Macrophage	  counts	  significantly	  correlated	  with	  BNP,	  a	  marker	  that	  is	  elevated	  with	  increasing	  right	   ventricular	   dysfunction,	   and	   SvO2	   which	   falls	   with	   worsening	   cardiac	   function	   (r=0.75,	  p=0.01	   for	   BNP	   and	   r=-­‐0.83,	   p=0.02	   with	   SvO2),	   although	   not	   6-­‐minute	   walk	   disease,	   mPAP,	  cardiac	  index	  or	  right	  atrial	  pressure	  (Figure	  3.6	  A-­‐D).	  Importantly,	  none	  of	  the	  clinical	  severity	  parameters	  correlated	  with	  macrophage	  nuclear	  p65-­‐positivity	  (Figure	  3.6	  A-­‐D).	  	  
	  
Figure	  3.6.	   	  Correlations	  between	  macrophage	  counts	  and	  clinical	  parameters	  in	  
patients	  with	  PAH	  (pulmonary	  arterial	  hypertension).	  Morphometric	  analysis	  was	  performed	  to	  assess	  macrophage	  counts	  on	  lung	  sections	  from	  PAH	  patients	  double-­‐immunostained	  for	  CD68	  and	  p65,	  with	  haematoxylin	  &	  eosin	  counterstaining,	  by	  2	  independent	  blinded	  observers.	  Correlations	  were	  made	  with	  clinical	  parameters	  including	  6-­‐minute	   walk	   distance	   (A);	   brain	   natriuretic	   peptide	   (BNP)	   (B);	   oxygen	   saturations	   in	   the	  central	   vein	   (SvO2)	   (C);	  mean	  pulmonary	  arterial	  pressure	   (mPAP)	   (D);	   cardiac	   index	   (E)	   and	  right	   atrial	   pressure	   (F).	   Correlations	  were	   significant	   only	   for	  BNP	   and	   SvO2.	  Data	   represent	  Pearson’s	  correlation	  co-­‐efficient	  (r)	  for	  up	  to	  12	  patients	  per	  group.	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Figure	   3.7.	   	   No	   significant	   correlations	   seen	   between	   macrophage	   nuclear	  
positivity	   (p65+)	   and	   clinical	   parameters	   in	   patients	   with	   PAH	   (pulmonary	  
arterial	  hypertension).	  Morphometric	  analysis	  was	  performed	  to	  assess	  macrophage	  counts	  on	  lung	  sections	  from	  PAH	  patients	  double-­‐immunostained	  for	  CD68	  and	  p65,	  with	  haematoxylin	  &	  eosin	  counterstaining,	  by	  2	  independent	  blinded	  observers.	  Correlations	  were	  made	  with	  clinical	  parameters	  including	  6-­‐minute	   walk	   distance	   (A);	   brain	   natriuretic	   peptide	   (BNP)	   (B);	   oxygen	   saturations	   in	   the	  central	   vein	   (SvO2)	   (C);	  mean	  pulmonary	  arterial	  pressure	   (mPAP)	   (D);	   cardiac	   index	   (E)	   and	  right	  atrial	  pressure	  (F).	  No	  correlation	  was	  found	  for	  macrophage	  nuclear	  p65+	  with	  any	  of	  the	  recorded	  clinical	  parameters	  in	  the	  PAH	  patient	  group.	  Data	  represent	  Pearson’s	  correlation	  co-­‐efficient	  (r)	  for	  up	  to	  12	  patients	  per	  group.	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3.3.7	  p65	  immunohistochemistry	  in	  pulmonary	  arterial	  vascular	  cells	  








	  	  	  	  	  
	  
Figure	   3.8.	   	   Increased	   NF-­‐κB	   p65	   positive	   staining	   in	   pulmonary	   arterial	  
endothelial	   cells	   (EC)	   and	   smooth	   muscle	   cells	   (PASMC)	   in	   pulmonary	   arterial	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Figure	  3.9.	  	  Pulmonary	  arterial	  endothelial	  (EC)	  and	  smooth	  muscle	  cells	  (PASMC)	  
stained	   positively	   for	   nuclear	   p65	   in	   patients	   with	   pulmonary	   arterial	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Figure	  3.10.	   	  p65-­‐positive	   immunostaining	   in	  perivascular	  B	  and	  T	   lymphocytes	  
around	   a	   remodeled	   pulmonary	   artery	   in	   a	   patient	   with	   pulmonary	   arterial	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3.3.8	  Nuclear	  p65	  staining	  was	  prominent	  in	  patients	  with	  BMPR-­‐II	  
mutations	  




Figure	   3.11.	   	   Marked	   p65-­‐positivity	   in	   several	   cell	   types	   including	   endothelial	  
cells	   (EC)	   and	   macrophages	   in	   a	   patient	   with	   a	   known	   mutation	   in	   the	   gene	  
encoding	  bone	  morphogenetic	  protein	  receptor	  type	  2	  (BMPR-­‐II).	  This	  wide-­‐field	  light	  microscopy	  photograph	  is	  a	  composite	  stitched	  image	  of	  lung	  parenchyma,	  with	  p65/CD68	   immunohistochemical	   staining	  and	  H&E	  counterstaining.	   Increased	  density	  of	  CD68+	   cells	   is	   seen	   (macrophages,	   staining	   brown)	   and	   dense	   pulmonary	   arterial	   EC	   p65+	  (pink)	   staining	   in	   an	   idiopathic	   PAH	   patient	   carrying	   a	   mutation	   in	   BMPR-­‐II.	   	   Magnification	  x100.	   Figure	   is	   representative	   of	   2	   similar	   patients	   both	   with	   BMPR-­‐II	   mutations.	   Scale	   bar	  represents	  200µm.	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3.3.9	  Correlation	  of	  p65	  in	  vascular	  cells	  with	  pulmonary	  arterial	  
morphological	  data	  	  
When	   analysed	   across	   all	   subjects,	   the	   percentage	   of	   p65+	   pulmonary	   artery	   vascular	   cells	  correlated	  with	  vessel	  medial	   thickness	   for	  nuclear	  EC	  p65+	  (r=0.54,	  p<0.0001,	  Figure	  3.12A)	  and	  for	  PASMC	  (r=0.45,	  p<0.0001,	  Figure	  3.12B).	  However,	  there	  was	  no	  significant	  correlation	  seen	   when	   the	   analysis	   was	   restricted	   within	   each	   group;	   these	   are	   therefore	   not	   true	  correlations.	   This	   may	   reflect	   the	   lack	   of	   heterogeneity	   in	   disease	   severity,	   as	   samples	   were	  unavailable	  from	  patients	  with	  less	  severe	  disease.	  	  
	  	  
Figure	  3.12.	  	  Correlation	  between	  vascular	  cell	  p65+	  and	  vessel	  medial	  thickness.	  Correlations	  were	  seen	  across	  groups	  when	  comparing	  (A)	  percentage	  endothelial	  cell	  nuclear	  p65+	  staining	  and	  smooth	  muscle	  vessel	  medial	  thickness	  and	  (B)	  percentage	  p65+	  staining	  in	  pulmonary	  arterial	  smooth	  muscle	  cells	  smooth	  muscle	  vessel	  medial	  thickness	  and.	  However,	  no	   significant	   correlations	  were	   seen	  within	   groups.	   Unfilled	   round	   points	   represent	   controls	  (n=12);	  solid	  square	  points	  are	  PAH	  patients	  (n=14).	  	  
Laura	  Price	  PhD:	  Inflammation	  in	  Pulmonary	  Arterial	  Hypertension	   117	  
3.3.10	  No	  correlation	  of	  p65	  in	  vascular	  cells	  with	  markers	  of	  PAH	  
clinical	  severity	  	  
No	  significant	  correlations	  were	  seen	  between	  p65+	  in	  both	  pulmonary	  arterial	  EC	  (Figure	  3.13)	  and	   PASMC	   (Figure	   3.14)	  with	   any	  markers	   of	   PAH	   clinical	   severity	   including	   6-­‐minute	  walk	  distance,	   BNP,	   and	   right-­‐heart	   catheterisation	   data	   (including	   SvO2,	  mean	   pulmonary	   arterial	  pressure,	  cardiac	  index	  and	  right	  atrial	  pressure).	  
	  
Figure	  3.13.	  	  No	  correlation	  of	  endothelial	  cell	  nuclear	  p65	  positivity	  (p65+)	  with	  
clinical	   severity	   parameters	   in	   patients	   with	   pulmonary	   arterial	   hypertension	  
(PAH).	  No	  significant	  correlation	  was	  found	  for	  endothelial	  cell	  p65+	  with	  any	  of	  the	  recorded	  clinical	  parameters	  in	  the	  PAH	  patient	  group	  including	  6-­‐minute	  walk	  distance	  (A);	  BNP	  (B);	  SvO2	  (C);	  mean	   pulmonary	   arterial	   pressure	   (D);	   cardiac	   index	   (E);	   and	   right	   atrial	   pressure	   (F).	   Solid	  squares	  points	  are	  PAH	  patients.	  Data	  represent	  Pearson’s	  correlation	  co-­‐efficient	  (r)	  for	  up	  to	  14	  patients	  per	  group.	  





Figure	  3.14.	  	  	  No	  correlation	  of	  PASMC	  p65	  positivity	  (p65+)	  with	  clinical	  severity	  
parameters	  in	  patients	  with	  pulmonary	  arterial	  hypertension	  (PAH).	  No	   significant	   correlation	   was	   found	   for	   PASMC	   p65+	   with	   any	   of	   the	   recorded	   clinical	  parameters	  in	  the	  PAH	  patient	  group	  including	  6-­‐minute	  walk	  distance	  (A);	  BNP	  (B);	  SvO2	  (C);	  mean	   pulmonary	   arterial	   pressure	   (D);	   cardiac	   index	   (E);	   and	   right	   atrial	   pressure	   (F).	   Solid	  squares	  points	  are	  PAH	  patients.	  Data	  represent	  Pearson’s	  correlation	  co-­‐efficient	  (r)	  for	  up	  to	  14	  patients	  per	  group.	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3.3.11	  Confocal	  immunofluoresence	  images	  
Confocal	   immunofluorescence	   staining	   experiments	   demonstrated	   an	   intense	   increase	   in	  nuclear	  p65	  staining	  in	  pulmonary	  vascular	  cells	  compared	  to	  cells	  from	  control	  lung	  specimens	  (Figure	  3.15A).	  These	  were	  PASMC	  and	  endothelial	  cells,	  as	  identified	  either	  side	  of	  the	  elastic	  tunica	  media	  (Figure	  3.15B	  and	  D).	  Antibody	  negative	  control	  staining	  is	  shown	  in	  Figure	  3.15C.	  
 
Figure	   3.15.	   	   Confocal	   immunofluorescence	   NF-­‐κB	   p65	   staining	   in	   pulmonary	  
arterial	  vascular	  cells.	  Confocal	   immunofluorescence	   staining	   of	   acetone-­‐fixed	   frozen	   lung	   specimens	   using	   NF-­‐κB	  KAC310	   AlexaFluor488	   (cyan-­‐green),	   and	   DAPI	   (blue)	   counterstaining,	   showed	   little	   positive	  nuclear	  staining	  in	  control	   lung	  specimens	  (A),	  and	  marked	  nuclear	  staining	  in	  idiopathic	  PAH	  (B	  and	  D).	  Antibody	  negative	  control	  staining	  of	  a	  control	  specimen	  is	  shown	  in	  C.	  Some	  green	  autofluorescence	  is	  seen	  with	  collagen	  fibres.	  	  Magnification	  x400	  (insert	  x2400).	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3.3.12	  NF-­‐κB	  activation	  in	  smaller	  vessels:	  arterioles	  and	  veins	  








Figure	  3.16.	   	   Increased	  NF-­‐κB	  p65	  positive	  staining	  in	  pulmonary	  arteriolar	  and	  
vein	   endothelial	   cells	   (EC)	   and	   smooth	   muscle	   cells	   (PASMC)	   in	   pulmonary	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3.4	  Discussion	  
In	   this	   chapter,	   I	   demonstrate	   increased	  NF-­‐κB	   activation	   in	   lung	  macrophages,	   lymphocytes,	  pulmonary	  arterial	  endothelial	  and	  smooth	  muscle	  cells	  in	  human	  idiopathic	  PAH	  compared	  to	  controls.	   NF-­‐κB	   activation	   was	   accompanied	   by	   an	   increase	   in	   absolute	   numbers	   of	   lung	  macrophages.	   These	   findings	   in	   this	   cohort	   of	   patients	   with	   end	   stage	   iPAH	   provide	   novel	  human	  data	   to	  support	  a	  role	   for	  NF-­‐κB	  activation	   in	  cells	  relevant	   to	  vascular	  remodelling	   in	  PAH.	  	  
There	  is	  an	  increasing	  literature	  supporting	  a	  role	  for	  inflammation	  in	  the	  pathogenesis	  of	  PAH	  (Dorfmuller	  et	  al.,	  2003,	  Hassoun	  et	  al.,	  2009,	  Price	  et	  al.,	  2012,	  Quarck	  et	  al.,	  2009).	  Perivascular	  inflammatory	   infiltrates	   are	   prominent	   (Tuder	   et	   al.,	   1994,	   Perros	   et	   al.,	   2012,	   Heath	   and	  Yacoub,	   1991,	   Savai	   et	   al.,	   2012b,	  Montani	   et	   al.,	   2011),	  with	   involvement	   of	   both	   the	   innate	  (Ormiston	   et	   al.,	   2012)	   and	   the	   adaptive	   (Perros	   et	   al.,	   2012)	   immune	   systems	   implicated.	  Circulating	  cytokines	  and	  chemokines	  are	  elevated	  in	  patients	  with	  iPAH	  (Humbert	  et	  al.,	  1995,	  Pendergrass	  et	  al.,	  2010,	  Itoh	  et	  al.,	  2006,	  Soon	  et	  al.,	  2010,	  Selimovic	  et	  al.,	  2009)	  and	  confer	  a	  worse	  prognostic	  outcome	  (Soon	  et	  al.,	  2010,	  Selimovic	  et	  al.,	  2009).	  Indeed,	  activation	  of	  NF-­‐κB	  is	   a	   central	   or	   parallel	   process	   in	  many	   chronic	   inflammatory	   disorders	   (Hart	   et	   al.,	   1998,	  Di	  Stefano	  et	  al.,	  2002,	  Marok	  et	  al.,	  1996)	  (Wang	  et	  al.,	  1999,	  Brand	  et	  al.,	  1996).	   In	  the	  rat	  MCT	  model	   of	   PH,	   NF-­‐κB	   activation	   was	   increased	   in	   EC	   in	   rats	   treated	   with	   MCT	   compared	   to	  controls	  (Huang	  et	  al.,	  2008,	  Sawada	  et	  al.,	  2007),	  and	  was	  associated	  with	  loss	  of	  EC	  integrity	  (Huang	  et	  al.,	  2008).	  NF-­‐κB	  blockade	  using	  the	  antioxidant	  pyrrolidine	  dithiocarbamate	  at	  early	  stages	   in	   this	  model	   prevented	   pulmonary	   vascular	   remodelling	   and	  PH	   (Huang	   et	   al.,	   2008),	  and	  reduced	  macrophage	   infiltration.	   (Sawada	  et	  al.,	  2007).	  Reversal	  of	  PH	  was	  demonstrated	  using	  therapeutic	  treatment	  with	  a	  nanoparticle-­‐mediated	  NF-­‐κB	  oligonucleotide	  decoy	  NF-­‐κB	  inhibitor	  3	  weeks	  after	  MCT	  insult	  after	  the	  establishment	  of	  PH	  (Kimura	  et	  al.,	  2009).	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Endothelial	  cell	  p65	  nuclear	  staining	  was	  increased	  in	  iPAH	  patients	  in	  this	  study.	  Interestingly,	  as	   all	   patients	  had	   end-­‐stage	  disease,	   this	  might	   imply	   a	  persistent	   stimulus	   for	   inflammation	  and	   cell	   activation	   throughout	   the	   disease	   process,	   and	   not	   just	   at	   initiation	   of	   endothelial	  damage,	   as	  has	  been	  previously	   suggested	   (Huang	  et	   al.,	   2008).	  Disease-­‐relevant	   activators	  of	  NF-­‐κB	  include	  oxidants	  (Dorfmuller	  et	  al.,	  2011),	  viruses	  (Cool	  et	  al.,	  2003),	  bacterial	  endotoxin	  (Meyrick	  and	  Brigham,	  1986),	   thrombin	  (Djordjevic	  et	  al.,	  2004),	  alveolar	  hypoxia	  (Fitzpatrick	  et	   al.,	   2011)	   and	   abnormal	   vascular	   flow	   (Cuhlmann	   et	   al.,	   2011).	   Key	   targets	   of	   NF-­‐κB	   in	  (systemic)	  EC	  include	  vascular	  cell	  adhesion	  molecule	  (VCAM)-­‐1	  (the	  inducible	  adhesive	  protein	  present	   on	   circulating	   monocytes	   and	   lymphocytes),	   and	   MCP-­‐1/CCL2,	   which	   coordinate	   to	  promote	   monocyte	   adhesion	   and	   transendothelial	   migration	   (Springer,	   1994).	   Indeed,	  downstream	  products	  of	  NF-­‐κB	  activation	  including	  MCP-­‐1/CCL2	  as	  well	  as	  IL-­‐6	  (e.g.	  in	  a	  model	  of	   SU5416	   and	   ovalbumin)	   are	   localised	   to	   pulmonary	   arterial	   EC	   by	   immunohistochemical	  studies	  in	  models	  of	  PH	  (Kimura	  et	  al.,	  2001,	  Mizuno	  et	  al.,	  2012).	  
In	   this	   study	   I	   demonstrated	   an	   increase	   in	   the	   absolute	  number	  of	   lung	   tissue	  macrophages.	  This	   is	   supported	   by	   a	   recent	   histological	   study,	   which	   also	   demonstrated	   an	   increase	   in	  perivascular	  monocytes	  and	  dendritic	  cells	  (Savai	  et	  al.,	  2012b).	  Furthermore,	  we	  demonstrated	  increased	   NF-­‐κB	   activation	   within	   these	   macrophages.	   This	   observation	   in	   lung	   tissue	   is	  consistent	   with	   the	   finding	   in	   alveolar	   macrophages	   from	   PAH	   patients	   obtained	   at	  bronchoscopy	   (Raychaudhuri	   et	   al.,	   1999),	   while	   circulating	   monocytes	   showed	   evidence	   of	  immune	   hyporesponsiveness	   (Raychaudhuri	   et	   al.,	   2002a).	   Together	   these	   findings	   add	   to	   an	  evolving	   story	  where	   inflammatory	  cell	   subsets	   including	  dendritic	   cells	   (Perros	  et	  al.,	  2007b,	  Wang	  et	   al.,	   2009)	  and	   lymphocytes	   (Perros	  et	   al.,	   2012)	  also	   show	   lung	   tissue	  activation	  but	  reduced	   activation	   or	   desensitization	   in	   the	   circulating	   cell	   population,	   suggesting	   that	  recruitment	  of	  activated	  inflammatory	  cells	  might	  be	  occurring	  to	  the	  lungs	  in	  PAH	  (see	  Chapter	  6).	   Activation	   of	   macrophages	   leads	   to	   release	   of	   cytokines,	   chemotaxins,	   reactive	   oxygen	  species	   and	   vasoactive	   mediators,	   including	   ET-­‐1	   (Ehrenreich	   et	   al.,	   1990),	   all	   of	   which	   are	  implicated	  in	  the	  pathogenesis	  of	  PAH.	  Indeed,	  perivascular	  macrophages	  have	  been	  shown	  to	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stain	  avidly	  for	  ET-­‐1	  in	  histological	  sections	  from	  patients	  with	  PAH	  (Talati	  et	  al.,	  2010,	  Giaid	  et	  al.,	  1993).	  Furthermore,	  macrophages	  from	  mice	  with	  mutated	  BMPR2,	  and	  from	  humans	  with	  heritable	   PAH	   (HPAH),	   were	   shown	   to	   have	   reduced	   ETA/ETB	   receptor	   gene	   expression,	   and	  greater	  ET-­‐1	  release,	  and	  stimulation	  of	  macrophages	  with	  ET-­‐1	  activated	  NF-­‐κB,	  suggesting	  a	  positive	  feedback	  loop	  (Talati	  et	  al.,	  2010).	  	  
An	   increase	   in	   NF-­‐κB	   activation	   was	   also	   demonstrated	   in	   PASMC	   in	   diseased	   pulmonary	  arteries	  and	  arterioles,	  although	   less	  pronounced	   than	   in	  EC.	  Apart	   from	  their	  obvious	  role	   in	  vessel	  wall	  remodelling,	  PASMC	  are	  implicated	  in	  the	  synthesis	  of	  vasoactive	  mediators,	  growth	  factors	   and	   cytokines.	   Human	   PASMC	   stimulated	   with	   TNF-­‐α	   and	   IFN-­‐γ	   released	   ET-­‐1	   in	   a	  synergistic	  manner	  due	  to	  enhanced	  NF-­‐κB	  binding	  and	  histone	  acetylation	  at	  specific	  κB	  sites	  (Wort	  et	  al.,	  2009).	  Further	  direct	  evidence	  for	  a	  role	  of	  NF-­‐κB	  signalling	  in	  human	  PASMC	  was	  demonstrated	   in	   a	   study	   that	   associated	   a	   single	   nucleotide	   polymorphism	   in	   the	   TRPC	  (transient	   receptor	   potential	   channel)	   gene	   promoter	   region	  with	   a	   functional	  NF-­‐κB	  binding	  site	   in	   268	   patients	   with	   iPAH.	   PASMC	   from	   these	   patients	   showed	   that	   activation	   of	   NF-­‐κB	  upregulated	   TRPC6	   expression	   and	   increased	   PASMC	   proliferation;	   this	   was	   attenuated	  following	  inhibition	  of	  NF-­‐κB	  (Yu	  et	  al.,	  2009).	  In	  our	  study,	  both	  EC	  and	  PASMC	  p65+	  correlated	  significantly	  with	  vessel	  medial	  thickness,	  suggesting	  a	  role	  in	  pathogenesis.	  However,	  whether	  NF-­‐κB	  activation	  is	  a	  primary	  event	  in	  these	  cells	  or	  a	  consequence	  of	  remodelling	  is	  not	  clear.	  	  Examination	  of	  cells	  from	  patients	  with	  different	  disease	  severities	  may	  help	  address	  this	  issue.	  
Interestingly,	  I	  observed	  the	  most	  widespread	  and	  most	  intense	  nuclear	  p65	  staining	  in	  the	  two	  subjects	  with	  known	  BMPR2	  mutations.	  	  Larger	  studies	  are	  required	  to	  confirm	  this	  preliminary	  observation.	   BMPR-­‐II	   dysfunction	   is	   an	   important	   contributor	   to	   remodelling	   in	   PAH,	   both	   in	  patients	  with	  and	  without	  germline	  mutations	  (Davies	  and	  Morrell,	  2008).	   In	  support	  of	   these	  findings,	  Davies	  et	  al	  recently	  demonstrated	  increased	  constitutive	  nuclear	  phosphorylation	  of	  p65	   in	   PASMC	   from	   patients	   with	   heritable	   PAH	   (harbouring	   BMPR2	   mutations)	   in	   vitro	  compared	   to	   control	  PASMC,	   leading	   to	   the	  hypothesis	   that	   inappropriate	  NF-­‐κB	  activation	   in	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cells	   from	   patients	   with	   heritable	   PAH	   may	   contribute	   to	   enhanced	   IL-­‐6	   and	   CXCL8	   release	  (Davies	  et	  al.,	  2012).	  	  
My	   final	   observation	   was	   that	   NF-­‐κB	   activation	   was	   increased	   in	   B	   and	   T	   perivascular	  lymphocytes,	  which	  were	   numerous	   in	   perivascular	   cell	   infiltrates.	   As	   outlined	   in	   the	   general	  introduction,	  lymphocytes	  have	  been	  implicated	  in	  the	  pathogenesis	  of	  PAH.	  	  Indeed,	  Perros	  et	  
al	   showed	   in	   lung	   from	  patients	  with	   iPAH	  that	   tertiary	   lymphoid	   follicles	  develop	  and	  highly	  express	   lymphocyte	   survival	   factors,	   with	   concomitant	   reduction	   in	   activated	   circulating	  lymphocytes,	   and	   a	   stromal	   network	   of	   channels	   connecting	   the	   lymphoid	   follicles	   to	  remodelled	  vessels	  (Perros	  et	  al.,	  2012).	  	  
Despite	   my	   histological	   observations,	   there	   were	   few	   significant	   correlations	   with	   either	  morphological	   PH	   severity	   (assessed	   by	   medial	   thickness)	   or	   clinical	   markers	   of	   disease	  severity.	   The	   only	   correlations	   were	  with	  macrophage	   numbers	   and	   BNP,	   and	   also	   inversely	  with	  SvO2,	  which	  is	  interesting	  and	  suggests	  that	  increased	  macrophage	  numbers	  reflect	  worse	  cardiac	  function.	  However,	  no	  other	  relationship	  was	  found.	  Reasons	  for	  this	  could	  relate	  to	  the	  fact	  that	  the	  sample	  only	  represented	  patients	  with	  end	  stage	  disease:	  as	  mentioned,	  if	  patients	  with	  more	  heterogeneous	  disease	  stages	  were	  included,	  correlations	  might	  have	  been	  apparent.	  In	  addition,	   the	  study	  was	  not	  sufficiently	  powered	  to	  detect	  clinically	   important	  changes.	  For	  example,	  the	  detection	  of	  a	  5mmHg	  difference	  in	  mPAP	  (with	  a	  standard	  deviation	  of	  10mmHg)	  would	  need	  a	  sample	  size	  of	  50	  patients	  per	  group.	  	  	  	  
3.4.1	  Study	  limitations	  	  
Firstly,	   this	   study	  was	   limited	   by	   its	   observational	   nature.	   Secondly,	   the	   age	   between	   groups,	  predetermined	   by	   differences	   in	   age	   of	   presentation	   of	   PAH	   and	   lung	   cancer,	   was	   markedly	  different.	  However,	   there	  was	  no	  correlation	  between	  NF-­‐κB	  activation	  and	  age	   in	  our	  cohort,	  and	   increasing	   age	   has	   been	   shown	   to	   increase	   NF-­‐κB	   activation	   and	   cytokine	   release	   from	  vascular	   endothelial	   cells	   (Donato	   et	   al.,	   2008),	   which	   if	   anything	   would	   increase	   the	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significance	  of	  my	  results.	  Thirdly,	  comparisons	  were	  limited	  by	  a	  lack	  of	  invasive	  hemodynamic	  data	  in	  the	  control	  subjects.	  Although	  the	  clinical	  notes	  were	  not	  examined	  it	  is	  highly	  unlikely	  that	  these	  patients	  undergoing	  lung	  resection	  for	  cancer	  would	  have	  significant	  PH,	  as	  it	  would	  be	   a	   contra-­‐indication	   for	   surgery.	   Finally,	   all	   the	   patients	   had	   a	   similar	   level	   of	   advanced	  disease	   and	   were	   on	   advanced	   therapies	   that	   included	   prostanoids,	   phosphodiesterase	  inhibitors	  and	  endothelin	  receptor	  antagonists.	  These	  medications	  may	  of	  course	  influence	  NF-­‐κB	   signalling	   although	   the	  majority	   of	   in	   vitro	   evidence	  would	   suggest	   that	   they	   cause	   down	  regulation	  of	  NF-­‐κB	  activation	  status.	  	  For	  instance,	  treprostinil	  blocks	  nuclear	  translocation	  of	  NF-­‐κB	  and	  cytokine	  release	  (Raychaudhuri	  et	  al.,	  2002b)	  and	  nitric	  oxide	  blocked	  reduction	  of	  the	  NF-­‐κB	   inhibitory	  protein	   IκB-­‐α	   from	  LPS-­‐stimulated	  alveolar	  macrophages	   (Raychaudhuri	  et	  al.,	  1999)	  both	  of	  which	  would	  result	  in	  decreased	  NF-­‐κB	  activation.	  	  However,	  it	  is	  clear	  from	  my	  data	  that	  even	  in	  end-­‐stage	  patients	  on	  advanced	  therapies	  there	  was	  evidence	  of	  increased	  NF-­‐κB	   activation.	   The	   failure	   to	   detect	   a	   correlation	   between	   p65	   staining	   and	   clinical	   and	  haemodynamic	   indices	  may	   reflect	   the	   similarity	   of	   disease	   status	   of	   the	   patients:	   analysis	   of	  NF-­‐κB	  activation	  in	  patients	  with	  milder	  disease	  will	  be	  informative.	  	  
3.4.2	  Conclusion	  
In	  conclusion,	  I	  provide	  novel	  observations	  by	  direct	  examination	  of	  human	  lung	  tissue	  that	  NF-­‐
κB	   is	   activated	   in	   pulmonary	   macrophages,	   lymphocytes	   and	   pulmonary	   vascular	   cells	   in	  patients	  with	  end	  stage	  idiopathic	  PAH.	  Although	  observational	  in	  nature,	  these	  results	  support	  previous	   animal	   work	   suggesting	   that	   therapies	   directed	   at	   NF-­‐κB	   signalling	   may	   form	  therapeutic	  option	  in	  the	  future.	  	  	  
I	   proceeded	   in	   the	   following	   chapter	   to	   test	   the	   hypothesis	   that	   using	   the	   synthetic	  glucocorticoid	  dexamethasone	   to	   inhibit	  NF-­‐κB	  signalling	   in	  an	  experimental	  model	  of	  PH,	  PH	  would	  be	  reversed.	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CHAPTER	  4:	  THE	  EFFECT	  OF	  DEXAMETHASONE	  IN	  
MONOCROTALINE-­‐INDUCED	  PULMONARY	  
HYPERTENSION	  IN	  RATS	  
	  
4.1	  Rationale	  
Following	   from	   the	   previous	   chapter	  where	   increased	  NF-­‐κB	   activation	  was	   demonstrated	   in	  human	   idiopathic	   PAH,	   I	   hypothesised	   that	   NF-­‐κB	   inhibition,	   using	   dexamethasone,	   would	  reverse	   established	   PH	   in	   an	   experimental	   model.	   Of	   PH	   models,	   we	   selected	   to	   use	   MCT-­‐induced	  PH	  (Bruner	  et	  al.,	  1983,	  Hilliker	  et	  al.,	  1982).	  MCT-­‐induced	  PH	   is	   characterised	  by	  an	  initial	   ‘inflammatory	  phase’	  with	  perivascular	   inflammatory	   cell	   (predominantly	  macrophage)	  infiltrates,	   followed	  by	   a	   vascular	   cell	   ‘proliferative	  phase’	   during	  which	   vascular	   remodelling	  and	   subsequent	   PH	   develops	   (Rosenberg	   and	   Rabinovitch,	   1988)	   (Sugita	   et	   al.,	   1983).	   Using	  electron	  microscopy,	  EC	  injury	  has	  been	  shown	  to	  occur	  as	  early	  as	  4	  days	  after	  MCT	  injection	  (Rosenberg	   and	   Rabinovitch,	   1988)	   (Sugita	   et	   al.,	   1983),	   followed	   by	   interstitial	   oedema	  (Rosenberg	  and	  Rabinovitch,	  1988)	  and	  increased	  pulmonary	  vascular	  leakage,	  which	  precedes	  RV	   hypertrophy	   (Sugita	   et	   al.,	   1983).	   Extension	   of	   smooth	   muscle	   into	   normally	   non-­‐muscularised	   arterioles	   develops	   after	   the	   first	   week,	   followed	   by	   further	   extension	   of	  muscularisation	   and	   hypertrophy	   of	   muscular	   arteries	   from	   2	   weeks	   with	   an	   associated	  increase	   in	   PA	   pressure	   (Rosenberg	   and	   Rabinovitch,	   1988).	   Indeed,	   pathological	   changes	   in	  MCT-­‐induced	   PH	   such	   as	   medial	   hypertrophy	   are	   similar	   to	   human	   PAH,	   however	   there	   are	  several	   important	   differences,	   including	   that	   rats	   with	   MCT-­‐induced	   PH	   do	   not	   develop	  occlusive	   intimal	   lesions	   or	   plexiform	   lesions	   that	   are	   characteristic	   of	   the	   plexogenic	  arteriopathy	  of	  the	  later	  phase	  of	  human	  PAH	  (Stenmark	  et	  al.,	  2009).	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NF-­‐κB	  activation	  has	  been	  shown	  to	  be	  a	  feature	  of	  MCT-­‐induced	  PH.	  Sawada	  et	  al	  showed	  that	  p65	   expression	   was	   increased	   in	   endothelial	   cells	   and	   mononuclear	   cells	   from	   day	   8-­‐22	  following	  MCT,	  although	  not	  on	  days	  0-­‐4	  (Sawada	  et	  al.,	  2007).	  They	  also	  noted	  that	  infiltration	  of	  ED-­‐1-­‐positive	  cells	  (rat	  macrophages)	  increased	  from	  day	  4,	  suggesting	  that	  the	  MCT-­‐induced	  endothelial	  damage	  might	  precede	  the	  activation	  of	  NF-­‐κB	  in	  these	  cells.	  (Sawada	  et	  al.,	  2007).	  Huang	  et	  al	  showed	  that	  the	  NF-­‐κB	  inhibitory	  subunit,	  IκB-­‐α,	  was	  significantly	  and	  persistently	  reduced	  from	  day	  14-­‐28;	  and	  that	  NF-­‐κB	  binding	  was	  increased	  at	  day	  14	  then	  was	  reduced	  at	  21-­‐28	  days,	  despite	  progressive	  PAH	  (Huang	  et	  al.,	  2008).	  Most	  recently,	  Kimura	  et	  al	   showed	  p65	  activation	   in	  alveolar	  macrophages	  and	  weak	  staining	   in	  pulmonary	  vascular	   lesions,	  and	  that	   NF-­‐κB	   DNA	   binding	   peaked	   at	   day	   3	   and	   was	   reduced	   by	   day	   7	   (Kimura	   et	   al.,	   2009).	  Together	   these	   studies	   document	  NF-­‐κB	   activation	   in	   vascular	   cells	   and	  mononuclear	   cells	   in	  MCT-­‐induced	  PH,	  with	  evidence	  suggesting	  that	  p65	  nuclear	  binding	  is	  activated	  transiently	  and	  early	  on	  in	  the	  model,	  although	  the	  reduction	  in	  the	  inhibitory	  subunit	  IκB-­‐α	  from	  2	  weeks	  may	  be	  more	  persistent.	  
Clinically,	   glucocorticoids	   (GC)	   remain	   one	   of	   the	  most	   effective	   treatments	   for	  many	   chronic	  inflammatory	   conditions	   (Barnes	   and	   Adcock,	   1993).	   The	   suggestion	   that	   treatment	   with	   GC	  and/or	   immunosuppressants	  may	  dramatically	   improve	  PAH	  stems	   from	  case	  studies	  (and	  no	  controlled	  trials)	  reporting	  the	  improvement	  seen	  in	  PAH	  in	  associated	  inflammatory	  conditions	  including	   systemic	   lupus	   erythematosus	   and	  mixed	   connective	   tissue	   disease	   (Sanchez	   et	   al.,	  2006,	   Jais	   et	   al.,	   2008).	   The	   use	   of	   GC	   clinically	   in	   idiopathic	   PAH	   is	   untested,	   although	   one	  report	   demonstrated	   that	   high	   dose	   prednisolone	   inhibited	   PDGF-­‐stimulated	   proliferation	   of	  PASMC	  from	  PAH	  patients	  (Ogawa	  et	  al.,	  2005)	  and	  that	  this	  was	  associated	  with	  reduced	  NF-­‐κB	  nuclear	   translocation	   (Ogawa	   et	   al.,	   2008a). There	   have	   been	   several	   studies	   where	   anti-­‐inflammatory	   therapies	   have	   been	   used	   in	   MCT-­‐induced	   PH	   to	   target	   the	   early	   phase	   of	   the	  model,	  and	  some	  also	  targeting	  the	  later	  phase	  once	  remodelling	  has	  begun	  (Voelkel	  et	  al.,	  1994)	  (Kimura	   et	   al.,	   1998)	   (Bonnet	   et	   al.,	   2007,	   Nishimura	   et	   al.,	   2001).	   In	   early	   studies,	   co-­‐
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administration	  of	  an	  IL-­‐1	  receptor	  antagonist	  prevented	  the	  onset	  of	  MCT-­‐induced	  PAH	  (Voelkel	  et	   al.,	   1994)	   and	   the	   co-­‐administration	   of	   anti-­‐MCP-­‐1	   antibodies	   prevented	   the	   infiltration	   of	  macrophages	   (which	   were	   maximal	   from	   day	   14-­‐21),	   and	   reduced	   PAH	   severity	   at	   day	   28	  (Kimura	   et	   al.,	   1998).	   More	   recently,	   immunosuppressive	   agents	   including	   rapamycin	  (Nishimura	   et	   al.,	   2001)	   and	   cyclosporin	   (Bonnet	   et	   al.,	   2007)	   have	   been	   shown	   to	   attenuate	  established	  MCT-­‐induced	  PAH	  (Bonnet	  et	  al.,	  2007,	  Nishimura	  et	  al.,	  2001).	  Several	  groups	  have	  studied	  the	  effects	  of	  GC	  in	  MCT-­‐induced	  PAH.	  Of	  these,	  all	  administered	  GC	  with	  or	  shortly	  after	  MCT	   and	   showed	   an	   amelioration	   of	   PH	   (Langleben	   and	   Reid,	   1985,	   Bhargava	   et	   al.,	   1999,	  Tanabe	   et	   al.,	   1981,	   Hilliker	   and	   Roth,	   1984)	   with	   an	   associated	   reduction	   in	   IL-­‐6	   activity	  (Bhargava	  et	  al.,	  1999).	  However,	  no	  studies	  have	  yet	  shown	  that	  GC	  might	  reverse	  established	  MCT-­‐induced	  PAH,	   once	   remodelling	   and	  haemodynamic	   evidence	   of	   PAH	   is	   present	   (beyond	  day	  14).	  	  
I	   therefore	  hypothesised	   that	   in	   rats	  with	  established	  monocrotaline-­‐induced	  PH	  (beyond	  day	  14),	   dexamethasone	   would	   significantly	   reduce	   and	   possibly	   normalise	   pulmonary	  hypertension	  and	  pulmonary	  vascular	  remodelling	  induced	  by	  NF-­‐κB	  and	  also	  improve	  survival.	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4.2	  Methods	  
4.2.1	  MCT-­‐induced	  PH	  model	  	  
All	  experiments	  using	  the	  MCT	  model	  were	  performed	  after	  in	  vivo	  training	  at	  Imperial	  College	  London	  then	  on	  a	  placement	  at	  the	  Hôpital	  Antoine-­‐Béclère	  in	  Clamart	  (Paris,	  France)	  under	  the	  supervision	   of	   Professor	   Marc	   Humbert.	   Further	   experimental	   details	   of	   the	   model	   are	  described	   in	   chapter	   2.	   Male	   6-­‐week	   old	   Wistar	   rats	   (100g	   body	   weight)	   received	   a	   single	  subcutaneous	  injection	  of	  60mg/kg	  MCT	  (Sigma	  Aldrich),	  which	  was	  the	  standard	  dose	  used	  in	  this	  model.	  MCT	  was	  dissolved	  in	  1M	  HCl,	  and	  the	  pH	  was	  adjusted	  to	  7.4	  with	  1M	  NaOH,	  with	  0.5ml	   volumes	   injected	   per	   rat	   (so	   6mg	   MCT	   in	   0.5	   ml	   injected	   into	   100g	   rats).	   Rats	   were	  anaesthetised	   with	   an	   intraperitoneal	   injection	   of	   a	   mixture	   of	   35mg/kg	   ketamine,	   4mg/kg	  xylasine	   and	   0.5mg/kg	   acepromazine,	   which	   are	   not	   known	   to	   have	   effects	   on	   inflammatory	  gene	  transcription	  unlike	  e.g.	  etomidate	  which	  suppresses	  adrenal	  steroidogenesis	  even	  after	  a	  single	  bolus	  (Jackson,	  2005).	  Following	  obvious	  haemodynamic	  instability	  during	  anaesthesia	  in	  preliminary	  experiments,	  presumed	  relative	  adrenal	  suppression	  was	  managed	  using	  a	  5mg/kg	  dose	   of	   intraperitoneal	   dexamethasone	   prior	   to	   induction	   of	   anaesthesia.	   This	   was	   for	   a	  maximum	  of	  15	  minutes	  prior	  to	  harvesting	  of	  tissues	  and	  was	  felt	  unlikely	  to	  have	  a	  significant	  impact	  on	  gene	  transcription.	  In	  addition,	  it	  was	  essential	  as	  indeed	  without	  it	  the	  rats	  perished	  as	  soon	  as	  anaesthesia	  was	   induced.	  Right-­‐heart	  catheterisation	  was	  performed	  28	  or	  35	  days	  after	  MCT	  exposure,	  then	  rats	  were	  killed	  by	  lethal	  injection	  of	  pentobarbitone	  and	  lung	  tissue	  was	  prepared	  for	  later	  analysis.	  Local	  and	  UK	  Home	  Office	  protocols	  were	  followed	  at	  all	  times.	  	  	  
4.2.2	  Dexamethasone	  treatment	  of	  MCT	  exposed	  rats	  
A	   water-­‐soluble	   clinically	   available	   formulation	   of	   dexamethasone	   (Merck,	   France)	   was	  prepared	  for	  intraperitoneal	  injection	  (i.p.)	  diluted	  in	  0.9%	  normal	  saline.	  Rats	  were	  randomly	  divided	   into	   a	   1)	   saline-­‐treated	   control	   group	   (n=10);	   2)	   an	   MCT-­‐exposed	   group	   (n=20);	   3)	  MCT-­‐exposed	   and	   dexamethasone-­‐treated	   from	   day	   14	   to	   day	   28	   groups	   in	   3	   dose	   ranges:	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5mg/kg/day,	  2.5mg/kg/48-­‐hourly	  and	  1.25mg/kg/48-­‐hourly)	  (10	  rats	  per	  group)	  and	  4)	  MCT-­‐exposed	  and	  5mg/kg/day	  dexamethasone-­‐treated	  day	  21	  to	  day	  35	  group	  (n=10).	  These	  doses	  of	   dexamethasone	  were	   selected	   based	   on	   a	   previous	   similar	   study	   by	   Bhargava	   et	   al	   where	  dexamethasone	   (1mg/kg/day)	   was	   administered	   on	   days	   1-­‐14	   before	   assessment	   at	   day	   14	  (Bhargava	   et	   al.,	   1999).	   We	   wished	   to	   repeat	   this	   and	   design	   a	   ‘treatment’	   rather	   than	  ‘preventative’	   study,	  with	   the	  assessment	  at	  day	  28	  or	  35.	  We	  selected	  a	  higher	  dose	   thinking	  this	  might	  be	  needed	  to	  reverse	  established	  disease.	  In	  addition,	  we	  gave	  two	  doses	  on	  alternate	  days	  to	  reduce	  the	  risk	  of	  adrenal	  suppression	  and	  side	  effects.	  Finally,	  we	  intentionally	  chose	  to	  not	  include	  a	  dexamethasone-­‐alone	  treatment	  group	  (see	  limitations	  at	  end	  of	  discussion).	  	  
4.2.3	  Tissue	  preparation	  
Following	   right-­‐heart	   catheterisation,	   the	   heart	   and	   lung	   block	   was	   dissected.	   The	   right	  ventricle	  was	  separated	  from	  the	  left	  heart	  and	  septum,	  and	  these	  parts	  weighed	  to	  calculate	  the	  relative	  cardiac	  weights	  (Fulton’s	  index).	  The	  trachea	  then	  right	  main	  bronchus	  was	  canulated	  and	   a	   50:50	   Optimum	   Cutting	   temperature	   (OCT)	   compound	   (Tissue-­‐Tek®)	   mixed	   with	  phosphate-­‐buffered	  saline	  gently	  instilled	  into	  the	  right	  lung.	  The	  right	  main	  bronchus	  was	  tied	  and	   the	   left	   uninflated	   lung	  dissected	  and	   separated	   from	   the	   left	   lung	  and	   trachea.	  The	   right	  lung	  was	   then	  quick-­‐frozen	   in	   liquid	  nitrogen	   and	   stored	   at	   -­‐80°C	   for	   later	  RT-­‐qPCR.	   The	   left	  lungs	  were	   immersed	   in	  paraffin	  and	   these	  were	   later	  embedded	   in	  paraffin	  and	  stained	  with	  haematoxylin	  and	  eosin	  for	  morphometric	  analysis.	  	  
4.2.4	  Pulmonary	  artery	  morphometry	  	  
Sections	  of	  paraffin-­‐embedded	  lungs	  were	  prepared	  and	  stained	  with	  hematoxylin	  and	  eosin	  by	  the	   Antoine	   Béclère	   Hospital	   Pathology	   department.	   The	   slides	   were	   blinded	   using	  computerised	   number	   generation,	   and	   evaluated	   using	   light	   microscopy	   for	   the	   extent	   of	  vascular	   remodelling	   in	   at	   least	   three	  whole	   left	   lung	   sections	   from	   each	   rat.	   The	   percentage	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medial	   wall	   thickness	   (media	   x1	   µm/external	   diameter	   (E.D.)	   µm	   x100)	   and	   adventitial	  thickness	  (adventitia	  x1	  µm/E.D.	  µm	  x100)	  of	  fully	  muscularised	  pre-­‐acinar	  pulmonary	  arteries	  was	   measured,	   using	   10	   randomly	   chosen	   vessels	   from	   each	   of	   3	   sections	   for	   each	   rat.	   For	  arterioles	  (<80	  µm	  E.D.),	  the	  degree	  of	  muscularisation	  was	  determined	  as	  ‘no	  muscularisation,	  not	  occluded’;	  ‘muscularisation,	  not	  occluded’	  or	  ‘muscularised	  and	  fully	  occluded’.	  	  	  
4.2.5	  Statistical	  analysis	  
This	  was	  performed	  as	  described	  in	  Chapter	  2.	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4.3	  Results	  and	  Figures	   	  
4.3.1	  Dexamethasone	  (day	  14-­‐28)	  treatment	  reduced	  haemodynamics	  
and	  right	  ventricular	  hypertrophy	  in	  established	  MCT-­‐induced	  PAH	  
Compared	  to	  control	  animals,	  MCT-­‐treated	  rats	  had	  severe	  PH	  demonstrated	  by	  elevated	  mean	  pulmonary	  arterial	  pressure	  (mPAP)	  (16.4±0.7	  vs.	  38.5±2.02	  mmHg,	  p<0.01,	  Figure	  4.1A),	  right	  ventricular	   systolic	   pressure	   (RVSP,	   35.2±1.1	   vs.	   86.3±3.8	   mmHg,	   p<0.001,	   Figure	   4.1B)	   and	  Fulton’s	   index	  of	   the	   right	   ventricular	  weight	   to	   left	   ventricular	  plus	   septal	  weight	   (RV/LV+S,	  0.26±0.02	  vs.	  0.58±0.02,	  p<0.001,	  Figure	  4.1C)	  at	  day	  28.	  Dexamethasone	   treatment	   from	  day	  14	   to	   28	   after	   MCT	   administration	   reduced	   haemodynamic	   severity	   at	   all	   3	   concentrations	  chosen	   (1.25	   mg/kg/48	   hourly	   (Dex1.25);	   2.5mg/kg/48	   hourly	   (Dex2.5)	   and	   5mg/kg/day	  (Dex5))	   in	   a	   dose-­‐dependent	   manner	   compared	   to	   MCT	   alone	   (mPAP:	   from	   38.5±2.02	   to	  28.7±3.9	   (p=0.066),	   24.9±1.4	   and	   23.08±0.9	   mmHg	   (both	   p<0.01);	   RVSP	   (from	   86.3±3.8	   to	  64.3±8.7	   (p=NS),	   52.2±2.5	   (p<0.001)	   and	   47.8±2.37	   mmHg	   (p<0.001);	   RV/LV+S:	   from	  0.58±0.02	  to	  0.37±0.034,	  0.36±0.02	  and	  0.32±0.01	  (p<0.001	  for	  all	  doses).	  With	  Dex5,	  this	  was	  a	  reduction	  to	  59.9%	  (mPAP),	  55.5%	  (RVPS)	  and	  55.2%	  (RV/LVS)	  of	  the	  values	  seen	  with	  MCT-­‐alone,	   with	   no	   difference	   compared	   to	   control	   values	   for	   both	   higher	   dexamethasone	   doses	  (Dex2.5	  and	  Dex5).	  Finally,	  the	  weights	  of	  the	  rats	  were	  markedly	  reduced	  (Figure	  4.1D)	  despite	  dose	  adjustment	  of	  dexamethasone.	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Figure	   4.1.	   	   Dose-­‐dependent	   improvements	   in	   pulmonary	   haemodynamics	   in	  
monocrotaline-­‐induced	   pulmonary	   hypertension	   in	   rats	   following	   day	   14-­‐28	  
dexamethasone	  treatment.	  Monocrotaline	  (MCT)	  was	  administered	  to	  rats	  at	  day	  0	  followed	  by	  daily	  dexamethasone	  in	  3	  dose	  regimens:	  1.25mg/kg	  and	  2.5mg/kg	  48-­‐hourly	  and	  5mg/kg	  per	  day	  from	  day	  14-­‐28.	  At	  day	  28,	  rats	  were	  anaesthetised	  and	  right-­‐heart	  catheterisation	  performed	  followed	  by	  assessment	  of	  Fulton’s	   index	  of	  RV	  weight.	  Mean	  pulmonary	  artery	  pressure	  (mPAP)	  was	  elevated	  in	  MCT	  alone	  vs.	   controls	   then	  reduced	  compared	   to	  MCT	  alone	  with	  all	  doses	  of	  dexamethasone	   (A).	  Right	  ventricular	  systolic	  pressure	  (RVSP)	  was	  similarly	  elevated	  following	  MCT	  and	  reduced	  by	  dexamethasone	   (B).	   Fulton’s	   index	   was	   increased	   by	   MCT	   and	   reduced	   significantly	   by	   all	  dexamethasone	  doses	  used	  (C).	  Weights	  at	  day	  28	  were	  decreased	  in	  the	  MCT	  group	  and	  even	  further	   in	   all	   dexamethasone-­‐treated	   groups	   (despite	   dose	   adjustment/alternate	   dosing	   to	  account	  for	  weight	  loss	  with	  dexamethasone)	  (D).	  Results	  represent	  mean	  ±	  SEM	  for	  n=10	  per	  group,	  compared	  using	  1-­‐way	  ANOVA	  and	  Bonferroni’s	  post	  test.	  **p<0.01,	  ***p<0.001.	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4.3.2	  Dexamethasone	  given	  therapeutically	  (day	  21-­‐35)	  reduced	  
haemodynamics	  and	  right	  ventricular	  hypertrophy	  in	  established	  MCT-­‐
induced	  PAH	  
Dexamethasone	  (5mg/kg/day)	  given	  from	  day	  21-­‐35	  after	  the	  initiation	  of	  MCT	  treatment	  also	  significantly	   reduced	   pulmonary	   haemodynamics	   in	   rats	   with	   MCT-­‐induced	   PAH.	   At	   day	   35,	  dexamethasone	   reduced	   invasive	   haemodynamic	   severity	   compared	   to	   baseline	   without	  dexamethasone	  in	  terms	  of	  mPAP	  (38.5±3.5	  vs.	  20.8±2.03mmHg,	  p<0.001),	  RVSP	  (86.0±6.1	  vs.	  43.5±5.94mmHg	  (p<0.001))	  and	  RV/LV+S	  (0.58±0.03	  vs.	  0.39±0.032,	  p<0.001))(Figure	  4.2A-­‐C).	  mPAP	   and	   RVSP	  measurements	   were	   no	   different	   to	   controls	   after	   dexamethasone	   although	  RV/LV+S	   in	   dexamethasone-­‐treated	   MCT	   rats	   remained	   higher	   than	   controls	   (0.26±0.02	   vs.	  0.39±0.032,	  p<0.01)	  (Figure	  4.2C).	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Figure	   4.2.	   	   Dose-­‐dependent	   improvements	   in	   pulmonary	   haemodynamics	   in	  
monocrotaline-­‐induced	   pulmonary	   hypertension	   in	   rats	   following	   day	   21-­‐35	  
dexamethasone	  treatment.	  Monocrotaline	   (MCT)	   was	   administered	   to	   rats	   at	   day	   0	   followed	   by	   daily	   dexamethasone	  treatment	  (5mg/kg	  per	  day)	  from	  day	  21-­‐35.	  At	  day	  35,	  rats	  were	  anaesthetised	  and	  right-­‐heart	  catheterisation	   performed	   followed	   by	   assessment	   of	   Fulton’s	   index	   of	   RV	   weight.	   Mean	  pulmonary	   artery	   pressure	   (mPAP)	   was	   elevated	   in	   MCT	   alone	   vs.	   controls	   then	   reduced	  compared	   to	  MCT	   alone	  with	   dexamethasone	   (A).	   Right	   ventricular	   systolic	   pressure	   (RVSP)	  was	   similarly	   elevated	   following	  MCT	  and	   reduced	  by	  dexamethasone	   (B).	   Fulton’s	   index	  was	  increased	  by	  MCT	  and	   reduced	   significantly	  by	  dexamethasone	   (C).	  Results	   represent	  mean	  ±	  SEM	  for	  n=10	  per	  group,	  compared	  using	  1-­‐way	  ANOVA	  and	  Bonferroni’s	  post	   test.	  **	  p<0.01,	  ***	  p<0.001.	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4.3.4	  Dexamethasone	  treatment	  reversed	  pulmonary	  vascular	  
remodelling	  







Figure	  4.3.	  	  Photographs	  of	  paraffin-­‐embedded	  lung	  sections	  showing	  progression	  
of	  inflammation	  in	  monocrotaline-­‐induced	  pulmonary	  hypertension	  	  Lung	   sections	   were	   stained	   with	   ED-­‐1	   staining	   (red,	   macrophages/monocytes)	   with	  hematoxylin	   (blue)	   counterstaining.	   Figure	   A	   shows	   a	   control	   rat	   with	   thin-­‐walled	   smooth	  muscle	  media,	  without	  adventitial	  inflammatory	  infiltrate	  or	  parenchymal	  inflammation	  (x100).	  Three	   days	   after	   monocrotaline	   (MCT)	   administration,	   a	   perivascular	   infiltration	   of	  macrophages/monocytes	   with	   infiltration	   of	   ED-­‐1-­‐positive	   cells	   was	   seen	   (B	   x200).	   At	   day	   7	  following	   MCT	   the	   principal	   perivascular	   inflammatory	   cells	   remain	   (ED-­‐1+	  macrophages/monocytes	  with	  some	  lymphocytes)	  and	  perivascular	  oedema	  is	  still	  present	  (C,	  x200).	   At	   day	   14	   there	   was	   moderate	   medial	   hypertrophy	   and	   a	   less	   marked	   inflammatory	  infiltrate	  (D	  x100).	  A	  pulmonary	  arteriole	  at	  day	  21	  has	  marked	  medial	  hypertrophy	  (x200,	  E).	  At	   day	   28	   there	   was	   significant	   medial	   hypertrophy	   and	   relatively	   little	   perivascular	  inflammation	  (F,	  x100).	  Dr	  Frederic	  Perros	  kindly	  prepared	  and	  gave	  me	  these	  images.	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When	  pulmonary	  vascular	  morphometry	  of	  pre-­‐acinar	  pulmonary	  arteries	  within	  lung	  sections	  was	   performed	   at	   day	   28	   following	   MCT,	   the	   percentage	   medial	   thickness	   was	   increased	  compared	  to	  controls	  (10.8±4.93	  vs.	  31.4±10.1,	  p<0.001)(Figure	  4.4A);	  the	  adventitial	  thickness	  was	   similarly	   thickened	   (8.83±4.95	   vs.	   36.5±34.3%,	   p<0.001)(Figure	   4.4B).	   Both	   of	   these	  parameters	  were	  significantly	  reduced	  by	  dexamethasone	  in	  a	  dose-­‐dependent	  manner	  (Figure	  4.4).	   	   In	   detail,	   the	   percentage	  medial	   thickness	  was	   reduced	   in	   Dex1.25-­‐,	   Dex2.5-­‐	   and	  Dex5-­‐treated	   rats	   (31.4±10.1	   vs.	   20.7±9.47,	   18.8±7.7	   and	   14.7±7.46%	   respectively,	   p<0.001	   for	   all	  groups,	  Figure	  4.4A)	  and	  the	  pulmonary	  arterial	  adventitial	  thickness	  (36.5±34.3	  vs.	  24.0±12.6,	  16.3±10.4	   and	   9.47±5.39%	   respectively,	   p<0.001	   for	   all	   groups,	   Figure	   4.4B)	   at	   day	   28	  compared	  to	  MCT	  alone.	  Further	  to	  these	  arterial	  changes,	  there	  was	  also	  a	  significant	  increase	  in	  pulmonary	  arteriolar	  muscularisation	  at	  day	  28,	  with	  an	   increase	  seen	   in	   the	  percentage	  of	  both	   non-­‐occluded	   and	   occluded	   arterioles	   compared	   to	   control	   rats	   (p<0.001),	   which	   was	  reduced	   in	   a	   dose-­‐dependent	   manner	   following	   day	   14-­‐28	   dexamethasone	   treatment	   in	   all	  dexamethasone-­‐treated	  groups	  (p<0.001)	  (Figure	  4.4C).	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Figure	  4.4.	  	  Dose-­‐dependent	  improvements	  in	  pulmonary	  vascular	  remodelling	  in	  
monocrotaline-­‐induced	  pulmonary	  hypertension	  in	  rats	  following	  day	  14-­‐28	  
dexamethasone	  treatment.	  Monocrotaline	  (MCT)	  was	  administered	  to	  rats	  at	  day	  0	  followed	  by	  daily	  dexamethasone	  (Dex,	  1.25,	  2.5	  and	  5mg/kg	  per	  day)	   from	  day	  14-­‐28.	  At	  day	  28,	   lung	  tissue	  was	  paraffin-­‐embedded	  and	  stained	  with	  haematoxylin	  and	  eosin	  for	  pulmonary	  vascular	  morphometric	  assessment	  by	  an	  observer	  blinded	  to	  the	  groups.	  MCT	  significantly	  increased	  the	  percentage	  medial	  thickness	  of	  pre-­‐acinar	  pulmonary	  arteries	  (expressed	  as	  media	  /	  external	  diameter	  x	  100)	  compared	  to	  controls	   and	   was	   reduced	   in	   all	   dexamethasone-­‐treated	   groups	   compared	   to	   MCT	   alone,	  although	  remaining	  greater	  than	  control	  levels	  (A).	  Pulmonary	  arterial	  adventitial	  thickness	  was	  also	   increased	   following	  MCT	  compared	   to	  control	   rats	  and	  was	  significantly	   reduced	  with	  all	  dexamethasone	  doses,	  although	  not	  back	  to	  control	  levels	  (B).	  Muscularisation	  of	  arterioles	  was	  also	   increased	   following	   MCT	   and	   was	   reduced	   at	   all	   dexamethasone	   doses	   (C).	   Results	  represent	  mean	  ±	  SEM	  of	  8-­‐10	  rats	  per	  group,	  compared	  using	  1-­‐way	  ANOVA	  and	  Bonferroni’s	  post-­‐test	  (A	  and	  B)	  and	  a	  2-­‐way	  ANOVA	  (C).	  *	  p<0.05	  ***	  p<0.001.	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4.3.3	  Dexamethasone	  improved	  survival	  in	  established	  monocrotaline-­‐
induced	  PH	  







Figure	  4.5.	  	  Dexamethasone	  improved	  on	  survival	  in	  rats	  with	  monocrotaline-­‐
induced	  pulmonary	  arterial	  hypertension	  (PAH)	  at	  day	  28.	  Monocrotaline	   (MCT)	   was	   administered	   to	   rats	   at	   day	   0	   followed	   by	   daily	   dexamethasone	  5mg/kg	   per	   day	   from	   day	   14-­‐28,	  when	   survival	  was	   assessed	   using	   a	   Kaplan	  Meier	   analysis.	  Rats	   treated	   with	   dexamethasone	   (solid	   line)	   had	   significantly	   improved	   survival	   at	   day	   28	  compared	   to	   MCT-­‐PAH	   rats	   without	   dexamethasone	   treatment	   (broken	   line).	   Kaplan	   Meier	  curves	  compared	  using	  a	   log-­‐rank	   test	   (n=20	   for	  MCT	  alone;	  n=10	   for	  dexamethasone-­‐treated	  group).	  **p<0.001.	  
!
!
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4.4	  Discussion	  
The	   main	   findings	   from	   chapter	   4	   were	   that	   1)	   dexamethasone	   improved	   MCT-­‐induced	   PH	  haemodynamic	   severity	   in	   a	   dose-­‐dependent	   manner,	   with	   normalisation	   at	   the	   two	   higher	  dexamethasone	   doses	   used;	   2)	   dexamethasone	   significantly	   reduced	   (although	   did	   not	  normalise)	   all	   indices	   of	   pulmonary	   vascular	   remodelling	   and	  3)	   dexamethasone	   significantly	  improved	  survival	  in	  rats	  with	  established	  MCT-­‐induced	  PH.	  
In	   response	   to	   a	   standard	   dose	   of	   MCT,	   I	   reproduced	   severe	   PH,	   with	   both	  mPAP	   and	   RVSP	  increasing	  approximately	  2.5	  times	  above	  control	  values,	  accompanied	  by	  a	  marked	  increase	  in	  RV	  hypertrophy	  and	  RV	  weight.	  These	  values	  obtained	   from	  my	  experiments	   in	   keeping	  with	  previous	  studies	  of	  the	  MCT	  model	  (Schermuly	  et	  al.,	  2005,	  Guignabert	  et	  al.,	  2005).	  My	  results	  using	  dexamethasone	  showed	  that	  further	  to	  previous	  studies	  in	  the	  1980s	  where	  GC	  prevented	  pulmonary	  vascular	   remodelling	  and	  PH	  when	  administered	  early	   in	   the	  model,	   I	  was	  able	   to	  treat	   rats	  with	   established	  PH	  and	   reverse	  PH	  at	  much	   later	   time	  points.	   Previous	  GC	   studies	  include	   those	   by	   Langleben	   et	   al	   where	   methylprednisolone	   (5mg/kg,	   ‘low	   dose’)	   was	   co-­‐administered	   with	   MCT	   at	   day	   0	   then	   daily	   for	   21	   days;	   and	   ‘high	   dose’	   (30mg/kg)	  methylprednisolone	  pulses	  were	  given	  either	  side	  of	  MCT	  at	  day	  0	  (Langleben	  and	  Reid,	  1985);	  and	   by	   Bhargava	   et	   al	   where	   dexamethasone	   (1mg/kg/day)	   was	   given	   on	   days	   1-­‐14	   before	  assessment	   at	   day	   14	   (Bhargava	   et	   al.,	   1999).	   Interestingly,	   the	   study	   by	   Langleben	   et	   al	  demonstrated	  that	  methylprednisolone	  at	   lower	  and	  more	   ‘chronic’	  dosing	  was	  more	  effective	  than	  that	  when	  given	  in	  higher	  pulsed	  doses	  at	  the	  onset	  of	  MCT	  exposure	  (Langleben	  and	  Reid,	  1985),	  suggesting	  the	  presence	  of	  ongoing	  inflammation.	  A	  further	  study	  in	  1984	  by	  Hilliker	  and	  Roth	   similarly	   administered	   dexamethasone	   before	   MCT	   as	   well	   as	   at	   later	   time-­‐points;	   this	  study	  was	  notable	  because	  it	  gave	  dexamethasone	  at	  much	  lower	  dose	  than	  the	  Bhargava	  study	  (Hilliker	   and	   Roth,	   1984).	   The	   main	   novel	   feature	   of	   my	   study	   was	   that	   it	   demonstrated	   a	  reversal	  of	  PH	  end-­‐points	  at	  two	  late	  time-­‐points,	  beyond	  the	  onset	  of	  the	  ‘proliferative	  phase’	  and	  the	  development	  of	  PH.	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An	   important	   factor	   to	   consider	   is	   the	   human	   equivalent	   dose	   of	   dexamethasone.	   Using	   the	  recently	  described	  formula	  based	  on	  body	  surface	  area	  for	  rats	  and	  humans	  (human	  equivalent	  dose	   =	   rat	   dose	   x	   0.16)	   (Reagan-­‐Shaw	   et	   al.,	   2008),	   the	   human	   equivalent	   of	   5mg/kg	   of	  dexamethasone	   is	   0.8mg/kg	   or	   56mg/day	   in	   a	   70kg	   adult.	   Even	   the	   lower	   dose	   range	   in	   our	  study	   (1.25mg/kg/48	   hourly)	   is	   14mg	   dexamethasone	   alternate	   days,	   which	   is	   equivalent	   to	  93mg	   prednisolone.	   To	   put	   this	   into	   context,	   the	   usual	   adult	   clinical	   dose	   for	   acute	   flares	   of	  rheumatological	   conditions	   is	   40-­‐60mg	   prednisolone	   daily,	  weaned	   to	   a	  maintenance	   dose	   of	  10-­‐15mg/day,	  with	  pulses	  of	  high	  dose	  methylprednisolone	  of	  1mg/kg	  added	  for	  1-­‐3	  days	  in	  the	  presence	  of	  significant	  organ	  involvement	  (Mackworth-­‐Young	  et	  al.,	  1988).	  Indeed,	  I	  noted	  the	  effect	   of	   MCT	   on	   weight	   loss	   in	   the	   MCT	   group,	   which	   has	   also	   been	   previously	   reported	   in	  studies	  of	   severe	  MCT-­‐induced	  PH	   (‘cachexia’)	   from	  day	  25	   in	  association	  with	  an	   increase	   in	  respiratory	  rate	  and	  a	  lack	  of	  physical	  activity	  (Schermuly	  et	  al.,	  2004)(Hessel	  et	  al.,	  2006).	  The	  addition	  of	  dexamethasone	  caused	  further	  weight	  loss	  in	  a	  dose-­‐dependent	  manner.	  	  
Although	  I	  lacked	  a	  ‘dexamethasone-­‐alone’	  group	  (see	  limitations),	  previous	  studies	  have	  shown	  that	  a	  similar	  dose	  of	  dexamethasone	  itself	  caused	  significant	  weight	  loss	  in	  rats	  over	  2	  weeks	  (Bhargava	  et	  al.,	  1999)	  and	  that	  the	  combination	  of	  MCT	  and	  dexamethasone	  caused	  even	  more	  marked	   weight	   loss	   (Hilliker	   and	   Roth,	   1984).	   Given	   the	   marked	   weight	   loss	   in	   the	  dexamethasone-­‐treated	  rats,	   it	  was	  likely	  that	  a	  very	  high	  GC	  dose	  was	  used.	  Interestingly,	  the	  similar	   (and	   efficacious)	   experiments	   using	   NF-­‐κB	   inhibitors	   (discussed	   below)	   did	   not	   see	  significant	   loss	   in	   weight	   (Sawada	   et	   al.,	   2007).	   In	   addition,	   it	   was	   likely	   that	   rats	   in	   the	  preliminary	  experiments	  that	  died	  with	  hypotension	  soon	  after	  the	  induction	  of	  anaesthesia	  had	  relative	  adrenal	  suppression,	  even	  though	  dexamethasone	  has	  relatively	  less	  mineralocorticoid	  effect	   compared	   to	  other	  GC	   (see	   chapter	  1).	   In	   the	   clinical	   setting,	  patients	   taking	  more	   than	  20mg	  prednisolone	   or	   2mg	  dexamethasone	  daily	   for	  more	   than	  3	  weeks,	   or	  with	   evidence	   of	  Cushingoid	   symptoms,	   are	   likely	   to	  have	   relative	  adrenal	   suppression.	  Although	  performed	   in	  clinical	  practice,	  the	  evidence	  supporting	  increased	  perioperative	  steroid	  cover	  is	  weak.	  It	  stems	  from	   cases	   reported	   in	   the	   1950s	   where	   patients	   developed	   perioperative	   adrenal	   failure	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following	   cessation	   of	   long	   terms	   steroids	   (Salem	   et	   al.,	   1994);	   two	   small	   and	   inconclusive	  clinical	  trials	  followed	  these	  reports	  (Yong	  et	  al.,	  2009).	  The	  high	  dexamethasone	  doses	  used	  in	  my	   study	   were	   selected	   based	   on	   preliminary	   experiments	   using	   5mg/kg/day	   and	   from	   a	  literature	   search	   of	   GC	   use	   in	   other	   models.	   I	   also	   tried	   to	   avert	   the	   detrimental	   effects	   on	  adrenal	   suppression	   by	   using	   alternate-­‐day	   dosing.	   Some	   previous	   studies	   looking	   at	   the	  ‘preventative	   phase’	   did	   use	   lower	   doses,	   notably	   Hilliker	   used	   dexamethasone	  0.027mg/kg/day	   (i.p.)	   for	   14	   days,	   which	   was	   deemed	   to	   have	   minimal	   effects	   on	   adrenal,	  thymus	  and	  body	  weight	  in	  rats	  treated	  for	  4	  days	  (Hilliker	  and	  Roth,	  1984).	  It	  would	  be	  useful	  to	   repeat	   experiments	   using	   my	   ‘late	   phase’	   treatment	   protocol	   using	   much	   lower	  dexamethasone	  doses.	  	  
The	  reversal	  of	  established	  disease	  is	  of	  clinical	  relevance.	  Indeed,	  several	  preclinical	  studies	  of	  PAH	  therapies	  used	  the	  early	  preventative	  vs.	  late	  treatment	  approach,	  for	  example	  the	  study	  of	  sildenafil	  by	  Schermuly	  et	  al	   (Schermuly	  et	  al.,	  2004),	  although	  many	  of	   the	  MCT	  studies	  have	  used	   a	   protocol	   where	   the	   agent	   of	   interest	   was	   co-­‐applied	   with	   MCT	   e.g.	   in	   studies	   of	   the	  endothelin	   receptor	   antagonist	   bosentan	   (Prie	   et	   al.,	   1997)	   and	   prostacyclin	   (Sakuma	   et	   al.,	  1999).	   The	   results	   presented	   here	   show	   a	   significant	   improvement	   in	   all	   standard	   invasive	  haemodynamic	  end	  points	  and,	  importantly,	  a	  reversal	  to	  normal	  values	  at	  the	  two	  higher	  doses	  of	  dexamethasone.	   Interestingly,	   the	  haemodynamic	   improvements	  with	  dexamethasone	  were	  even	  more	  marked	  in	  proportion	  compared	  to	  the	  published	  study	  where	  sildenafil	  was	  given	  to	  the	  same	  model	  using	  the	  same	  protocol	  (sildenafil	  100µg/kg	  daily	  from	  day	  14-­‐28)	  (Table	  4.8).	  	  





































Table	  4.1.	  	  Haemodynamic	  data	  in	  our	  dexamethasone	  study	  in	  comparison	  with	  a	  
previous	   published	   sildenafil	   study	   in	   monocrotaline-­‐induced	   pulmonary	  
hypertension.	  My	  dexamethasone	   study	   (summarised	   in	   grey	   box)	   followed	   a	   similar	   protocol	   as	   an	   earlier	  study	  of	  sildenafil	  by	  Schermuly	  et	  al	  (lower	  box)	  (Schermuly	  et	  al.,	  2004):	  Both	  used	  the	  same	  model	  and	  monocrotaline	  (MCT)	  dose,	  and	  administered	  the	  drug	  daily	  from	  day	  14-­‐28	  prior	  to	  haemodynamic	  assessment	  at	  day	  28.	  The	  table	  illustrates	  the	  mean	  values	  for	  RVSP	  (top	  line)	  and	   RV/LVS	   (lower	   line)	   at	   baseline,	   28	   days	   after	   MCT,	   and	   following	   treatment	   with	   both	  dexamethasone	   and	   sildenafil.	   In	   these	   similarly	   designed	   studies,	   compared	   to	   MCT	   alone,	  there	  appeared	  a	  greater	  %	  reduction	  in	  haemodynamics	  in	  my	  dexamethasone	  study	  compared	  with	   the	  sildenafil	   study,	   suggesting	   that	  dexamethasone	  was	  more	  effective	   than	  sildenafil	   in	  the	  MCT	  model.	  
As	   introduced	   in	   chapter	   1,	   glucocorticoids	   (GC)	   activate	   cytosolic	   GC	   receptors,	   which	   bind	  specific	  glucocorticoid	  response	  elements	  (GRE)	  in	  the	  promoter/enhancer	  of	  responsive	  genes.	  Through	  the	  GRE,	  GC	  either	  transactivate	  anti-­‐inflammatory	  genes	  or,	  at	   lower	  concentrations,	  physically	  interact	  with	  and	  inhibit	  (transrepress)	  the	  interaction	  of	  inflammatory	  transcription	  factors	   (including	   NF-­‐κB)	   with	   the	   GR,	   blocking	   subsequent	   inflammatory	   gene	   expression	  (Barnes,	  1998).	  A	  major	  limitation	  of	  GC	  is	  their	  side	  effect	  profile,	  which	  largely	  relates	  to	  their	  non-­‐genomic	   effects.	   One	   approach	   to	   reduce	   this	   has	   been	   to	   specifically	   inhibit	   the	   most	  important	  genomic	  pathways	   through	  which	  GC	  act,	   that	  being	  NF-­‐κB.	  Knowing	   that	  NF-­‐κB	   is	  activated	  in	  the	  MCT-­‐induced	  PH	  model,	  several	  specific	  NF-­‐κB	  inhibitors	  have	  been	  assessed	  at	  various	   time	  points:	  Published	  studies	  have	  demonstrated	   the	  prevention	  of	   the	  onset	  of	  PAH	  when	  NF-­‐κB	  inhibitors	  were	  used	  early	   in	   the	  model	  (Sawada	  et	  al.,	  2007,	  Huang	  et	  al.,	  2008)	  although	   as	   yet	   only	   one	   study	   using	   a	   nanoparticle	   NF-­‐κB	   decoy	   has	   successfully	   reversed	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established	   PH	   (Kimura	   et	   al.,	   2009).	   Sawada	   et	   al	   administered	   daily	   PDTC	   (pyrrolidine	  dithiocarbamate,	   a	   non-­‐selective	   NF-­‐κB	   inhibitor)	   from	   day	   3-­‐16,	   at	   which	   point	   PH	   was	  improved;	   perivascular	   infiltrating	   ED-­‐1	   positive	   cells	   (macrophages)	   were	   reduced;	  phosphorylated	   p65	   in	   EC	   and	   mononuclear	   cells	   was	   reduced	   and	   lung	   IкB-­‐α	   protein	   was	  increased	  (Sawada	  et	  al.,	  2007).	  Huang	  et	  al	  gave	  PDTC	  either	  as	  a	  ‘preventative	  phase’	  (day	  0-­‐14)	  protocol	  or	  a	  ‘late	  treatment	  protocol’	  from	  day	  14-­‐28.	  The	  former	  reduced	  haemodynamic	  severity	   with	   an	   associated	   recovery	   of	   IкB-­‐α;	   however	   the	   later	   phase	   treatment	   did	   not	  improve	   haemodynamics	   or	   change	   IкB-­‐α	   levels	   which	   remained	   low	   and	   no	   different	   to	  untreated	  MCT	  rats	  at	  day	  28	  (Huang	  et	  al.,	  2008).	  This	  suggests	   that	   the	  recovery	  of	   IкB-­‐α	   is	  essential	  to	  enable	  effective	  inhibition	  of	  NF-­‐κB,	  at	  least	  in	  this	  model.	  Most	  recently,	  Kimura	  et	  
al	  used	  an	  NF-­‐κB	  decoy	  (a	  nanoparticle	  targeting	  the	  NF-­‐κB	  binding	  site	  in	  the	  promoter	  region	  of	  NF-­‐κB–responsive	  genes,	   thus	   inhibiting	  NF-­‐κB	  binding),	   in	  a	   ‘prevention	  group’	  where	   the	  decoy	  was	  co-­‐administered	  with	  MCT	  at	  day	  0	  and	  in	  a	  treatment	  group	  where	  the	  decoy	  was	  administered	  once	  on	  day	  21,	  before	  assessment	  at	  day	  28.	  Even	  at	  this	  later	  time	  point,	  the	  NF-­‐
κB	   decoy	   significantly	   improved	   PAH	   haemodynamics,	   in	   association	   with	   a	   reduction	   in	  pulmonary	  arteriolar	  muscularisation,	  a	  reduction	  in	  MCP-­‐1,	  TNF-­‐α,	  IL1-­‐β,	  IL-­‐6	  and	  ICAM	  gene	  expression,	   and	  a	   reduction	   in	   the	   infiltration	  of	  ED-­‐1	  expressing	  cells.	   In	  addition,	   the	  NF-­‐κB	  decoy	   administered	   at	   day	   21	   significantly	   improved	   survival	   assessed	   at	   day	   35	   (n=33	   per	  group,	   p<0.001),	   and	   reduced	   serum-­‐induced	   proliferation	   when	   administered	   to	   normal	  human	  PASMC	   in	  culture	   (Kimura	  et	  al.,	  2009).	  This	   last	   study	  using	  a	  potent	   selective	  NF-­‐κB	  inhibitor,	  together	  with	  the	  results	  from	  our	  dexamethasone	  study,	  which	  were	  both	  efficacious	  using	  ‘therapeutic	  dosing’	  imply	  that	  NF-­‐κB	  activation	  is	  implicated	  not	  just	  in	  the	  development	  of,	  but	  also	  the	  progression	  of,	  MCT-­‐induced	  PH.	  	  
In	  my	  study,	  the	  improvements	  in	  pulmonary	  haemodynamics	  were	  associated	  with	  significant	  reductions	  in	  all	  measured	  indices	  of	  pulmonary	  arterial	  and	  arteriolar	  remodelling.	  There	  was	  a	   significant	   effect	   on	   the	   smooth	   muscle	   and	   adventitial	   mass	   following	   dexamethasone	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treatment.	   Whether	   the	   reduction	   in	   smooth	   muscle	   cell	   layer	   might	   reflect	   a	   reduction	   in	  PASMC	  proliferation	  and/or	  an	  increase	  in	  their	  apoptosis	  is	  explored	  in	  the	  next	  chapter.	  	  	  
4.4.1	  Clinical	  application	  
The	   clinical	   experience	   so	   far	   of	   GC	   in	   patients	   with	   PAH	   is	   mainly	   limited	   to	   those	   with	  associated	   ‘inflammatory’	   conditions	   where	   immunosuppression	   was	   otherwise	   indicated,	  including	   PAH	   associated	   with	   connective	   tissue	   diseases	   (Sanchez	   et	   al.,	   1999)	   and	   SLE	  (Karmochkine	  et	  al.,	  1996).	   Interestingly	   this	   improvement	   in	  PAH	  was	  observed	  especially	   in	  those	   with	   earlier,	   less	   severe	   PAH	   (Jais	   et	   al.,	   2008),	   perhaps	   suggesting	   that	  immunosuppressive	   therapies	   may	   be	   more	   effective	   in	   proliferating	   ‘active’	   lesions	   in	   early	  disease	   than	   in	   those	  with	   established	   ‘fixed’	   pulmonary	   vascular	   lesions	   –	   or	   just	   that	   these	  patients	  had	   less	  severe	  disease.	  There	  has	  been	  a	  single	  case	  report	  where	  prednisolone	  was	  given	  to	  a	  patient	  with	  idiopathic	  PAH	  (Ogawa	  et	  al.,	  2011)	  but	  this	  class	  of	  drug	  has	  not	  been	  formally	  studied	  in	  these	  patients.	  	  
4.4.2	  Limitations	  of	  results	  
A	  major	  limitation	  was	  the	  lack	  of	  a	  ‘dexamethasone	  alone’	  control	  group.	  This	  was	  because	  the	  initial	  experiments	  were	  planned	  to	  determine	  haemodynamic	  effect,	  and	  such	  as	  group	  was	  not	  deemed	   to	   apply	   to	   the	   ‘3	   R’s’	   principle	   of	   ‘replacement;	   reduction	   and	   refinement’.	   It	   was	  therefore	   deemed	   that	   treating	   10	   rats	   with	   dexamethasone	   alone	   would	   have	   caused	  unnecessary	  harm.	  Further	   limitations	  related	  to	  the	   lack	  of	  cardiac	  output	  data	  thus	   I	  had	  no	  index	  of	  pulmonary	  vascular	  resistance;	  and	  that	  pulmonary	  haemodynamics	  should	  also	  have	  measured	  at	  day	  14	  to	  see	  true	  reversal	  to	  the	  time-­‐point	  at	  which	  dexamethasone	  was	  given.	  Additional	  factors	  such	  as	  hypoxia,	  known	  to	  occur	  in	  MCT-­‐induced	  PH,	  could	  influence	  NF-­‐κB	  activation;	  oxygen	  saturations	  could	  be	  measured	  in	  future	  experiments.	  A	  final	  comment	  is	  that	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these	  experiments	  were	  performed	  in	  2008	  in	  Paris.	  Since	  this	  time	  in	  the	  UK	  at	  least,	  ‘survival’	  is	  not	  considered	  a	  humane	  end	  point,	  and	  alternative	  physiological	  parameters	  are	  now	  used.	  	  	  
4.4.3	  Summary	  and	  future	  work	  
I	  have	   shown	   that	  administration	  of	  dexamethasone	   in	   late	   stages	  of	   the	  MCT-­‐induced	  PH	  rat	  model	   reversed	   PH	   haemodynamic	   severity,	   pulmonary	   vascular	   remodelling	   and	   arteriolar	  muscularisation.	  However,	  the	  marked	  weight	  loss	  and	  likely	  adrenal	  suppression	  suggest	  these	  doses	  are	  not	   clinically	  useful:	  Further	  studies	  using	   lower	  dexamethasone	  doses	  would	  be	  of	  interest,	  as	  well	  as	  non-­‐GC	  alternatives,	   such	  as	   the	  effect	  of	   IKK-­‐2	   inhibition.	   Indeed	   in	  many	  chronic	  inflammatory	  diseases	  such	  as	  asthma,	  IKK-­‐2	  has	  been	  proposed	  as	  a	  novel	  therapeutic	  target	   and	   are	   expected	   to	   have	   fewer	   side	   effects	   compared	   to	  GC.	   	  However,	   concerns	   exist	  regarding	   the	   potential	   for	   widespread	   immunosuppressive	   effects.	   Preclinical	   studies	   in	  asthma	  suggest	  that	  IKK-­‐2	  inhibitors	  have	  beneficial	  and	  equivalent	  efficacy	  to	  GC.	  	  For	  example,	  the	  efficacy	  of	   the	  IKK-­‐2	   inhibitor	  TPCA	  was	  demonstrated	   in	  an	   inhaled	  ovalbumin	  rat	  model	  and	  in	  human	  airway	  SMC	  (Birrell	  et	  al.,	  2005).	  In	  addition,	  the	  IKK-­‐2	  inhibitor	  PHA-­‐408	  dose-­‐dependently	   attenuated	   cell	   infiltration	   and	   cytokine	   production	   in	   an	   inhaled	   LPS-­‐induced	  model	  of	  airway	  inflammation	  in	  rats	  (Sommers	  et	  al.,	  2009).	  	  
Following	  this	  chapter,	  which	  focussed	  on	  the	  pulmonary	  vascular	  and	  haemodynamic	  effects	  of	  dexamethasone	  on	  survival	   in	  MCT-­‐induced	  PH,	  I	  then	  questioned	  potential	  anti-­‐inflammatory	  and	  ant-­‐proliferative	  mechanisms	  in	  PASMC	  in	  the	  model,	  in	  the	  following	  chapter.	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CHAPTER	  5:	  DEXAMETHASONE	  EXERTS	  ANTI-­‐
REMODELLING	  EFFECTS	  IN	  PULMONARY	  ARTERIAL	  
SMOOTH	  MUSCLE	  CELLS	  
	  
5.1	  Rationale	  
In	   chapter	   4	   I	   demonstrated	   that	   dexamethasone	   reversed	   pulmonary	   hypertension	   in	  established	  monocrotaline	  (MCT)-­‐induced	  pulmonary	  hypertension	  (PH)	  in	  rats.	  There	  was	  an	  associated	   significant	   reduction	   of	   smooth	   muscle	   medial	   thickness	   following	   all	   doses	   of	  dexamethasone	  treatment.	  I	  therefore	  sought	  to	  determine	  contributing	  mechanisms	  including	  the	  effects	  of	  dexamethasone	  on	  pulmonary	  arterial	  smooth	  muscle	  cell	  (PASMC)	  growth.	  	  
The	   main	   components	   of	   vascular	   remodelling	   in	   PAH	   are	   medial	   thickening	   of	   pulmonary	  arteries	   and	   arterioles,	   and	   neomuscularisation	   of	   non-­‐muscularised	   arterioles.	   These	   result	  from	   an	   imbalance	   between	   PASMC	   proliferation	   and	   apoptosis,	   promoting	   proliferation	   and	  increased	  cell	  survival.	  Several	  studies	  have	  shown	  that	  in	  culture,	  PASMC	  isolated	  from	  patients	  with	  PAH	  proliferate	  more	  readily	  than	  those	  from	  controls	  (Morrell	  et	  al.,	  2001,	  Eddahibi	  et	  al.,	  2001,	  Ogawa	  et	   al.,	   2005).	   In	  PASMC	  derived	   from	  patients	  with	  bone	  morphogenetic	  protein	  receptor	  (BMPR)-­‐II	  mutations,	  the	  response	  to	  normally	  growth-­‐inhibitory	  stimuli	  was	  reduced,	  with	   contributing	   mechanisms	   including	   unopposed	   p38	   MAPK/ERK	   signalling	   (Yang	   et	   al.,	  2005b).	  In	  addition,	  in	  the	  MCT-­‐PH	  model,	  proliferation	  of	  the	  vascular	  smooth	  muscle	  layer	  has	  been	  shown	  to	  be	  a	  very	  early	  step	  in	  the	  development	  of	  PH	  (Guignabert	  et	  al.,	  2005).	  	  
Stimuli	   that	   increase	   PASMC	   proliferation	   in	   PAH	   include	   blood-­‐borne	   and	   locally	   derived	  mitogens,	   such	  as	  platelet-­‐derived	  growth	   factor	   (PDGF)	  (Schermuly	  et	  al.,	  2005,	  Perros	  et	  al.,	  2008),	   fibroblast	   growth	   factor	   (Xin	   et	   al.,	   1994)	   (FGF)	   and	   epidermal	   growth	   factor	   (EGF)	  (Ushio-­‐Fukai	   et	   al.,	   2001);	   serotonin	   (Eddahibi	   et	   al.,	   2001);	   vasoactive	   mediators	   with	   an	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abundance	  of	  the	  mitogen	  endothelin-­‐1	  (ET-­‐1)	  over	  nitric	  oxide	  and	  prostacyclin;	  hypoxia	  and	  mechanical	   stress.	   These	   stimuli	   activate	   a	   cascade	   of	   intracellular	   signalling	   events	   with	  different	  growth	  factors	  affecting	  the	  cell	  cycle	  at	  varying	  stages.(Scott	  et	  al.,	  1997)	  In	  vascular	  cells,	  these	  pathways	  include	  activation	  of	  intracellular	  calcium	  flux	  e.g.	  by	  hypoxia	  or	  ET-­‐1	  and	  subsequent	   activation	   of	   kinases	   such	   as	   protein	   kinase	   C;	   phosphatidyl-­‐inositol-­‐3-­‐kinase	  [PI3K],	  MAP	  kinases	  e.g.	  p38	  MAPK	   (Welsh	  et	   al.,	   2001)	  and	   tyrosine	  kinases	   that	   are	  usually	  associated	  with	  growth	  factor	  receptors	  which	  display	  intrinsic	  tyrosine	  kinase	  activity	  (Scott	  et	  al.,	  1997).	  In	  addition,	  NF-­‐κB	  signalling	  is	  implicated	  in	  the	  control	  of	  cell	  proliferation	  in	  cancer	  cells	  (Karin	  and	  Lin,	  2002,	  Hoshi	  et	  al.,	  2000)	  as	  well	  as	  in	  human	  PASMC	  (Ogawa	  et	  al.,	  2008b).	  
To	   date,	   therapies	   used	   in	   the	   treatment	   of	   PAH	   have	   focused	   on	   vasodilating	   properties	   of	  compounds	  such	  as	  nitric	  oxide	  and	  prostacyclin	  and	  reducing	  the	  vasoconstrictor	  properties	  of	  ET-­‐1.	  However,	  there	  is	  growing	  interest	  in	  the	  anti-­‐proliferative	  effects	  of	  therapies	  to	  reverse	  vascular	   remodelling.	   These	   may	   be	   co-­‐incidental	   anti-­‐proliferative	   actions	   of	   the	   classical	  vasodilating	   compounds	  above,	  or	  newer	  agents	  designed	   to	   suppress	  proliferative	  pathways.	  Indeed,	   prostacyclin	   (Wharton	   et	   al.,	   2000),	   sildenafil	   (Wharton	   et	   al.,	   2005)	   and	   endothelin	  receptor	   antagonists	   (Davie	   et	   al.,	   2002)	   exert	   anti-­‐proliferative	   properties	   on	   PASMC.	   In	  addition,	   PDGF	   receptor	   inhibitors	   e.g.	   imatinib	   (Schermuly	   et	   al.,	   2005,	   Perros	   et	   al.,	   2008),	  HMG	   CoA	   reductase	   inhibitors	   (statins)	   (Ali	   et	   al.,	   2011)	   and	   activators	   of	   voltage	   gated	  potassium	  channels	  (Kv)	  reduce	  PASMC	  proliferation	  (McMurtry	  et	  al.,	  2004)	  (Platoshyn	  et	  al.,	  2000).	   For	   example,	   dichloroacetate,	   a	   metabolic	   modulator	   that	   increases	   mitochondrial	  oxidative	  phosphorylation,	  reduced	  experimental	  PAH	  (McMurtry	  et	  al.,	  2004)	  since	  loss	  of	  Kv	  in	   PAH	   causes	   PASMC	   depolarization	   and	   calcium	   and	   K+	   influx,	   which	   stimulates	   PASMC	  proliferation	   (Platoshyn	   et	   al.,	   2000).	   Finally,	   as	   mentioned	   earlier,	   high	   concentrations	   of	  prednisolone	  was	  shown	  to	  inhibit	  PDGF-­‐	  and	  serum-­‐stimulated	  proliferation	  in	  human	  PASMC	  (Ogawa	  et	  al.,	  2005).	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Further	   to	   exaggerated	   proliferation,	   decreased	   apoptosis	   has	   been	   implicated	   in	   the	  development	  and	  maintenance	  of	  severe	  PAH.	  Gene	  microarray	  studies	  of	   lungs	   from	  patients	  with	   PAH	   demonstrated	   a	   decrease	   in	   the	   proapoptotic/antiapoptotic	   gene	   expression	   ratio	  (Geraci	   et	   al.,	   2001).	   In	   normal	   human	   PASMC,	   where	   bone	   morphogenetic	   proteins	   (BMPs)	  usually	  inhibit	  proliferation	  (Yang	  et	  al.,	  2005b),	  BMP	  2	  and	  7	  also	  induced	  apoptosis	  and	  down-­‐regulated	  the	  anti-­‐apoptotic	  protein	  bcl-­‐2;	  by	  contrast,	  BMP-­‐induced	  apoptosis	  was	  inhibited	  in	  PASMC	   from	   iPAH	   (Zhang	   et	   al.,	   2003).	   In	   animal	   experiments,	   the	   induction	   of	   apoptosis	   of	  hypertrophied	   PASMC	   in	   intact	   pulmonary	   vessels	   prevented	   the	   progression	   of	   medial	  hypertrophy	   (Cowan	   et	   al.,	   1999,	   Cowan	   et	   al.,	   2000).	   Further	   to	   BMPR-­‐II	   dysfunction,	  downregulation	  of	   the	  Kv	   channel	   axis	   is	   also	   involved	   in	   suppression	  of	  PASMC	  apoptosis	   in	  PAH,	  relating	  to	  a	  tonic	  inhibition	  of	  caspases	  (McMurtry	  et	  al.,	  2004).	  	  
Following	   from	   the	   experiments	   in	   our	   MCT-­‐PH	   model,	   I	   hypothesized	   that	   dexamethasone	  would	  lead	  to	  both	  a	  reduction	  in	  PASMC	  proliferation	  and	  an	  increase	  in	  apoptosis.	  In	  addition,	  I	   assessed	   the	   effects	   of	   dexamethasone	   on	   stimulated	   PASMC	   in	   terms	   of	   IL-­‐6	   and	   CXCL8	  release	  and	  NF-­‐κB	  activation.	  I	  selected	  to	  measure	  these	  cytokines	  as	  both	  IL-­‐6	  (Humbert	  et	  al.,	  1995,	   Pendergrass	   et	   al.,	   2010,	   Soon	   et	   al.,	   2010)	   and	  CXCL8	   (Soon	   et	   al.,	   2010,	  Damas	   et	   al.,	  2004)	   plasma	   levels	   are	   elevated	   in	   patients	   with	   PAH,	   and	   there	   is	   evidence	   that	   they	  (especially	  IL-­‐6)	  contribute	  to	  remodelling,	  as	  reviewed	  in	  chapter	  1.	  For	  example,	  IL-­‐6	  induces	  proliferation	   in	   rat	   SMC	   through	   endogenous	   PDGF	   production	   (Ikeda	   et	   al.,	   1991)	   and	   of	  PASMC	   in	  mice	   through	  upregulation	  of	  VEGF	  receptor	  expression	   (Steiner	  et	  al.,	  2009).	  Lung	  IL-­‐6	  levels	  are	  elevated	  in	  the	  MCT-­‐PH	  rat	  model	  (Bhargava	  et	  al.,	  1999),	  and	  its	  overexpression	  or	  administration	  leads	  to	  PH	  in	  rodent	  models	  (Steiner	  et	  al.,	  2009,	  Miyata	  et	  al.,	  1995).	  	  
In	   the	   final	   experiments	   in	   this	   chapter,	   we	   hypothesized	   that	   the	   above	   effects	   of	  dexamethasone	  on	  cytokine	  release	  were	  through	  an	  NF-­‐κB-­‐dependent	  pathway.	  To	  do	  this	  we	  assessed	   the	   activation	   of	   NF-­‐κB	   in	   PASMC	   using	   a	   TransAm	   assay;	   we	   also	   treated	   human	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PASMC	  with	  a	  specific	  NF-­‐κB	  inhibitor	  to	  attempt	  to	  recreate	  the	  effects	  of	  dexamethasone	  on	  cytokine	  release.	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5.2	  Experimental	  protocols	  
5.2.1	  Pulmonary	  arterial	  smooth	  muscle	  cell	  culture	  
PASMC	  were	  isolated	  from	  control	  and	  day-­‐21	  MCT-­‐exposed	  rats	  and	  from	  normal	  human	  lung	  excised	   from	  patients	  undergoing	  surgery	   for	   lung	  cancer	  as	  described	   in	  chapter	  2.	   	  Both	  rat	  and	  human	  cells	  were	  used	  at	  passage	  3-­‐6	  in	  DMEM/10%	  FCS.	  	  	  
5.2.2	  Proliferation	  assays	  
The	   effects	   of	   dexamethasone	   (10-­‐8	   to	   10-­‐5M,	   Sigma	   Aldrich)	   on	   10%	   FCS-­‐stimulated	  proliferation	   were	   assessed	   by	   manual	   counting	   of	   DAPI-­‐stained	   cells	   and	   by	   [methyl-­‐3H]-­‐thymidine	   incorporation,	   expressed	   as	   counts	   per	   minute	   per	   well	   (Chapter	   2).	   Controls	  included	   the	   effects	   of	   dexamethasone	   alone	   on	  unstimulated	   cells,	   and	   for	   thymidine	   assays,	  also	   included	   water-­‐soluble	   clinical	   grade	   dexamethasone	   (Merck)	   (although	   we	   could	   not	  control	   for	   the	   excipients,	   sodium	   metabisulphite	   and	   sodium	   methylparahydroxybenzoate).	  The	  effects	  of	  the	  diluent	  for	  dexamethasone,	  ethanol	  (Sigma	  Aldrich),	  were	  also	  assessed.	  	  
5.2.3	  Apoptosis	  in	  vitro	  assays	  
The	  effects	  of	  dexamethasone	  (10-­‐8	  to	  10-­‐6M)	  on	  apoptosis	  in	  PASMC	  isolated	  from	  control	  and	  MCT-­‐exposed	  rats	  were	  assessed	  using	  several	  methods	  including	  Hoechst	  33342	  staining	  and	  an	   ELISA-­‐based	   assay	   to	   detect	   DNA	   fragmentation;	   rat	   lung	   tissue	   was	   also	   analysed	   using	  immunohistochemistry	  for	  both	  apoptosis	  markers	  and	  for	  NF-­‐κB	  activation.	  	  
5.2.3.1	  Hoechst	  33342	  staining	  
Hoechst	  33342	  is	  a	  water-­‐soluble,	  blue	  fluorescent	  dye	  that	  targets	  DNA	  in	  live	  cells	  and	  stains	  condensed	   apoptotic	   condensed	  nuclei	  with	  high	   intensity.	   It	   is	  more	   cell-­‐permeable	   and	   less	  toxic	  to	  cells	  than	  DAPI.	  Rat	  PASMC	  were	  plated	  at	  2.5x104	  cells/well	  in	  8-­‐well	  permanox	  Lab-­‐
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Tek	  slides	  with	  5μg/ml	  Hoechst	  stain	  for	  20	  min	  at	  20°C	  for	  48h	  and	  72h:	  Cells	  were	  maintained	  in	   DMEM/10%	   FCS	   (negative	   control),	   with	   H2O2	   (100-­‐800nM)	   and	   100μM	   dichloroacetate	  (DCA)	  in	  0%	  DMEM	  as	  positive	  controls.	  In	  dexamethasone	  experiments,	  cells	  were	  maintained	  in	   DMEM	   containing	   10%	   FCS	   (as	   a	   negative	   control)	   or	   0%	   FCS	   and	   treated	   with	  dexamethasone	   for	   48	   and	   72	   hours.	   Individual	   nuclei	   were	   counted	   in	   5	   randomly	   selected	  fields	   for	   each	   well	   (>90	   cells/field).	   The	   number	   of	   apoptotic	   cells	   exhibiting	   condensed	  nuclear	  fluorescence	  was	  determined	  and	  expressed	  as	  a	  proportion	  of	  the	  total	  cells.	  	  	  
5.2.3.2	  ELISA	  for	  DNA	  fragmentation	  
The	   Cell	   Death	   Detection	   ELISA	   Plus	   kit	   (Roche)	   was	   used	   to	   detect	   cytoplasmic	   histone-­‐associated-­‐DNA	   fragments.	   PASMC	  were	   plated	   at	   5x104	   cells	   per	  well	   in	   24-­‐well	   plates,	   and	  500ul	  per	  well	  used	  for	  analysis	  according	  to	  the	  manufacturer’s	  instructions.	  	  
5.2.4	  Rat	  lung	  immunohistochemistry	  
Lung	   specimens	   were	   resected	   from	   rats	   following	   right	   heart	   catheterisation;	   5μm	   thick	  paraffin-­‐embedded	   rat	   lung	   sections	  were	   immunostained	   by	  Dr	   Jie	   Zhu	   (JZ,	   Royal	   Brompton	  Hospital).	  Lung	  sections	  were	  incubated	  with	  peroxidase	  blocking	  solution	  (Dako,	  Cambridge).	  After	   incubation	   with	   the	   primary	   antibody,	   rabbit	   anti-­‐active	   caspase-­‐3	   (1:50)	   (Abcam,	  ab2302),	   NF-­‐κB	   p65	   (1:200)	   immunohistochemistry	   (Cell	   Signaling,	   C22B4)	   and	   rabbit	   anti-­‐phospho-­‐IKKα/β	  (1:40)	  (Cell	  Signaling,	  2697)	  primary	  antibodies,	  sections	  were	  incubated	  with	  polyclonal	  goat	  anti-­‐rabbit	  horseradish	  (ready	  to	  use)	  peroxidase	  (HRP)-­‐conjugated	  secondary	  antibody	   (Dako)	   followed	   by	   incubation	   with	   diaminobenzidine	   (DAB)	   and	   peroxide	   buffer	  (Dako)	  to	  produce	  a	  brown	  stain.	  For	  IKK,	  cytoplasmic	  IKKα	  was	  detected	  when	  phosphorylated	  at	   Ser176/180,	   and	   for	   IKKβ	   when	   phosphorylated	   at	   Ser177/181.	   The	   p38	   MAP	   kinase	  antibody	  similarly	  detected	  phosphorylation	  (of	  Thr180	  and	  Tyr182	  residues);	  and	  the	  caspase	  3	   antibody	   was	   specific	   for	   the	   cleaved	   activated	   form.	   Slides	   were	   counterstained	   with	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hematoxylin	  and	  eosin	   to	  provide	  nuclear	  and	  morphological	  detail	   and	  mounted	   in	   synthetic	  resin	   mountant.	   Non-­‐specific	   rabbit	   IgG	   (Sigma-­‐Aldrich)	   at	   the	   same	   concentration	   as	   those	  used	  above	  was	  used	  as	  a	  control	  primary	  antibody.	  	  
In-­‐situ	   detection	   of	   end-­‐labelled	   nucleotides	   (rather	   than	   classic	   in-­‐situ	   hybridization	   (ISH)	  which	  detects	  RNA)	  was	  performed	  on	  paraffin-­‐embedded	   lung	  sections	  using	  a	  VasoTACS	  kit	  (R&D	  systems)	  to	  detect	  DNA	  fragmentation	  in	  vascular	  tissue.	  DNA	  cleavage	  by	  endonucleases	  during	  apoptosis	  results	  in	  3’	  ends	  of	  cleaved	  DNA	  fragments,	  which	  can	  be	  detected	  in	  situ	  by	  their	  binding	  the	  enzyme	  terminal	  deoxynucleotidyl	  transferase	  (TdT),	  which	  adds	  nucleotides	  at	   the	  sites	  of	  DNA	  breaks.	  The	   incorporation	  of	  biotinylated	  nucleotides	  allows	  chromosomal	  DNA	   fragmentation	   to	   be	   visualized	   by	   binding	   streptavidin-­‐horseradish	   peroxidase	   (HRP)	  followed	  by	  a	  reaction	  with	  TACS	  Blue	  LabelTM	  to	  generate	  a	  dark	  blue	  precipitate	  in	  cell	  nuclei.	  This	   is	   due	   to	   the	   application	   of	   haemalum	   (a	   complex	   formed	   from	   aluminium	   ions	   and	  oxidized	  haematoxylin),	  which	  colours	  cell	  nuclei	  dark	  blue	  when	  viewed	  under	  a	  standard	  light	  microscope.	  Counterstaining	  was	  performed	  with	  eosin,	  staining	  other	  (eosinophilic)	  structures	  red	   or	   pink.	   These	   experiments	   were	   performed	   exactly	   according	   to	   the	   manufacturer’s	  instructions	  by	  JZ	  (Royal	  Brompton	  Hospital).	  	  
5.2.5	  Immunohistochemical	  scoring	  
Slides	  were	  numbered	  and	  coded	  and	  performed	  by	  blinded	  assessors	  (LCP	  and	  JZ).	  Cells	  within	  pulmonary	  vessels	  were	  identified	  using	  light	  microscopy.	  For	  each	  pulmonary	  artery	  (at	  least	  10	  per	  subject),	  standard	  morphometric	  end	  points	  were	  also	  measured.	  For	  apoptosis	  staining,	  percentage	   (e.g.	   caspase-­‐3)	   cytoplasmic	  positivity	  was	   counted	   for	   each	  PASMC	  over	   the	   total	  number	  of	  cells	  counted.	  For	  the	  NF-­‐κB	  stained	  lung	  sections,	  percentage	  nuclear	  p65	  positivity	  was	  scored	  for	  each	  EC	  and	  PASMC	  over	  the	  total	  number	  counted	  for	  each	  cell	  type.	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5.2.6	  Quantitative	  real-­‐time	  reverse	  transcription	  polymerase	  chain	  
reaction	  (RT-­‐qPCR)	  of	  rat	  lung	  and	  PASMC	  
qRT-­‐PCR	  was	  performed	  on	  rat	  lung	  homogenates	  from	  control	  rats;	  rats	  with	  MCT-­‐induced	  PH;	  and	  dexamethasone-­‐treated	   (5mg/kg/day,	  days	  14-­‐28)	  MCT-­‐exposed	   rats.	  RNA	  was	  extracted	  from	   rat	   lungs	   with	   the	   total	   RNA	   isolation	   minikit	   (Agilent	   technologies,	   France)	   and	   then	  eluted	  from	  silica	  columns	  and	  reverse-­‐transcribed	  using	  Omniscript	  Reverse	  Transcription	  kit	  (Qiagen,	   Courtaboeuf,	   France)	   exactly	   as	   described	   by	   the	   manufacturer.	   Constitutively	  expressed	  β-­‐actin	  was	  selected	  as	  an	  internal	  housekeeping	  gene	  control	  for	  the	  comparative	  CT	  method	   for	   relative	   gene	   quantification.	   BMPR2,	   IL-­‐6,	   and	   β-­‐actin	   mRNA	   expression	   was	  quantified	  by	  RT-­‐PCR	  with	  TaqMan	  Gene	  Expression	  Assays	  (β-­‐actin	  [Rn00667869_m1],	  BMPR2	  [Rn01437210_m1],	  IL-­‐6	  [Rn00561420_m1],	  and	  TaqMan	  Universal	  PCR	  Master	  Mix	  followed	  in	  an	  ABI	  Prism7000	  Sequence	  Detection	  System	  (Applied	  Biosystems,	  Courtaboeuf,	  France)	  using	  PCR	  conditions	  as	  described	  in	  the	  general	  methods.	  qRT-­‐PCR	  was	  also	  performed	  on	  rat	  PASMC	  (plated	  at	  a	  density	  of	  5000/well	  in	  96-­‐well	  plates)	  isolated	  from	  control	  rats	  and	  from	  rats	  21	  days	   after	   MCT,	   using	   the	   same	   primers.	   	   Cells	   were	   stimulated	   with	   10%	   FCS/DMEM,	   and	  treated	  with	  dexamethasone	  (10-­‐7	  M).	  	  
5.2.7	  Measurement	  of	  cytokine	  release	  from	  human	  PASMC	  	  
Human	  PASMC	  were	  plated	  in	  96-­‐well	  plates	  (5000	  cells/well)	  and	  cultured	  in	  DMEM/10%	  FCS	  until	   90%	   confluent;	   cells	   were	   starved	   overnight	   and	   then	   10%	   FCS/DMEM	   used	   as	   the	  stimulus	   in	   the	  presence	  and	  absence	  of	  dexamethasone	   (10-­‐8	   to	  10-­‐6M)	  or	  an	   IKK-­‐2	   inhibitor	  (AS602868,	  0-­‐3μM	  (0	  -­‐	  3x10-­‐6M)).	  After	  24	  hours,	  the	  supernatant	  was	  aspirated	  off	  and	  stored	  at	   -­‐20°C	   and	  MTT	   viability	   assays	  were	   performed	   on	   the	   cells.	   IL-­‐6	   and	   CXCL8	  ELISAs	  were	  later	  performed	  on	  the	  stored	  supernatants.	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5.3	  Results	  &	  Figures	  
5.3.1	  Effect	  of	  dexamethasone	  on	  rat	  PASMC	  proliferation 
































DMEM (%)     0        0       0        0      10      10      10     10 





















DMEM (%)     0        0       0        0      10      10      10     10 
Dex xx10M    -        -7       -6      -5       -        -7        -6      -5  
E F
 
Figure	  5.1.	  	  Dexamethasone	  reduced	  cell	  counts:	  DAPI-­‐stained	  pulmonary	  arterial	  
smooth	  muscle	  cell	  (PASMC)	  nuclei.	  PASMC	  from	  control	  rats	  and	  from	  day	  21	  monocrotaline	  (MCT)-­‐exposed	  rats	  were	  stimulated	  with	  0%	  or	  10%	  serum	  and	  treated	  with	  dexamethasone	  (10-­‐7M	  to	  10-­‐5M)	  for	  24	  hours,	  when	  cells	  were	  stained	  with	  DAPI.	  Photographs	  show	  representative	  examples	  of	  multiple	  images	  of	  the	  effect	  of	  treatment	  with	  dexamethasone	  with	  10%	  FCS/DMEM	  on	  control	  rat	  PASMC	  (A-­‐D)	  (Magnification	   x	   400).	   Numbers	   of	   PASMC	   from	   control	   (E)	   and	   MCT-­‐treated	   rats	   (F)	   were	  counted	  by	  an	  assessor	  blinded	  to	  the	  groups.	  Data	  are	  presented	  as	  the	  percentage	  change	  in	  cell	  numbers	  of	  untreated	  PASMC,	  reported	  as	  the	  mean	  values	  from	  8-­‐10	  images	  of	  fields	  saved	  for	  each	  condition.	  n=2	  rats	  per	  group.	  
A:#10%#(MCT)# B:#10%#+#Dex17#M#
C:#10%#+#Dex#16#M# D:#10%#+#Dex15#M#
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Subsequent	  experiments	  assessed	  a	  more	  physiological	  concentration	  range	  of	  dexamethasone	  (10-­‐8M	  to	  10-­‐6M)	  based	  on	  a	  study	  of	  binding	  affinities	  of	  dexamethasone	  to	  the	  cytoplasmic	  GR	  in	   a	   rat	   hepatoma	   cell	   line	   (Baxter	   and	   Tomkins,	   1971).	   	   The	   effects	   of	   dexamethasone	   was	  assessed	   on	   10%	   serum-­‐stimulated	   3H-­‐thymidine	   uptake,	   which	   showed	   a	   reduction	   in	   3H-­‐thymidine	  uptake	  at	  all	  dexamethasone	  concentrations	  with	  a	  maximal	  effect	  seen	  at	  10-­‐7M	   in	  control	   cells	   (70262±14969	   vs.	   1683±1253	   counts	   per	   minute	   (cpm),	   p<0.01),	   which	  represented	   a	   reduction	   from	   100%	   to	   2.4%	   of	  mean	   values.	   	  MCT-­‐exposed	   cells	  were	  more	  resistant	   to	   10-­‐8M	   dexamethasone-­‐induced	   suppression	   of	   proliferation	   compared	   to	   control	  cells	  (17298±5511	  vs.	  50603±11833cpm,	  p<0.05).	  	  No	  significant	  difference	  in	  effects	  was	  seen	  at	   10-­‐7M	   dexamethasone	   (1683±1253	   vs.	   7996±4709cpm,	   p=NS)	   (Figure	   5.2).	   To	   investigate	  whether	   the	   dexamethasone	   diluent	   (ethanol)	   was	   affecting	   the	   results,	   further	   experiments	  were	  performed	   to	  assess	   the	  effects	  of	   increasing	   concentration	  of	   clinically	   available	  water-­‐soluble	   dexamethasone	   (Figure	   5.2B),	   and	   effects	   of	   ethanol	   alone	   at	   equivalent	   dilutions	   in	  control	  PASMC	  (Figure	  5.2B	  and	  C).	  Although	  only	  performed	  in	  n=2,	  these	  preliminary	  results	  suggested	  that	  water-­‐soluble	  dexamethasone	  reduced	  3H-­‐thymidine	  uptake	  (although	  without	  a	  concentration-­‐dependent	   effect)	   (Figure	   5.2B).	   Experiments	   using	   ethanol,	   also	   at	   n=2,	  suggested	   a	   slight	   reduction	  with	   ethanol	   10-­‐4M	   (which	   corresponded	   to	   the	   concentration	  of	  ethanol	   present	   in	   10-­‐7M	   dexamethasone)	   –	   suggesting	   it	  was	   not	   the	   sole	   factor	   causing	   the	  reduction	   in	   proliferation.	   The	   highest	   ethanol	   concentration	  was	   toxic	   to	   cells	   (Figure	   5.2C).	  Finally,	   it	   needs	   to	  be	   commented	  upon	   that	   I	  was	  unable	   to	   control	   for	   the	   excipients	   in	   the	  commercially	  available	  clinical	  soluble	  dexamethasone.	  











Figure	  5.2.	  Dexamethasone	  inhibits	  DNA	  synthesis	  (3H-­‐thymidine	  incorporation)	  
in	  cultured	  rat	  pulmonary	  arterial	  smooth	  muscle	  cells	  (PASMC).	  PASMC	  were	   isolated	   from	  control	  rats	   (A,	   left	  side)	  and	  21-­‐day	  monocrotaline	  (MCT)-­‐treated	  rats	  (A,	  right	  side)	  and	  stimulated	  with	  10%	  serum	  (10%	  FCS)	  before	  being	  treated	  for	  24h	  with	  dexamethasone	   (10-­‐8M	   to	  10-­‐6M).	  Proliferation	  assessed	  by	   3H-­‐thymidine	  uptake	  expressed	  as	  counts	  per	  minute	   (cpm).	  The	  effects	  of	   (B)	  water-­‐soluble	  dexamethasone	  and	   (C)	   ethanol	  on	  10%	  FCS-­‐induced	  3H-­‐thymidine	  uptake	  at	  24	  hours	  are	  also	  shown.	  Results	  represent	  mean	  ±	  SEM	   of	   n=5	   rats	   (controls)	   and	   n=7	   MCT-­‐exposed	   cells	   (A),	   *p<0.05,	   **p<0.01.	   	   N=2	   in	  experiments	  presented	  in	  B	  and	  C.	  	  
5.3.2	  Effects	  of	  dexamethasone	  on	  rat	  PASMC	  apoptosis	  
5.3.2.1	  Immunohistochemistry	  apoptosis	  studies	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Figure	  5.3.	  	  Dexamethasone	  increased	  caspase-­‐3	  immunohistochemistry	  scores	  in	  
rat	  pulmonary	  artery	  smooth	  muscle	  cells	  (PASMC)	  in	  vivo.	  Caspase-­‐3	   immunostaining	   was	   performed	   on	   rat	   lung	   resected	   at	   day	   28	   in	   control	   (A)	  (showing	   caspase-­‐negative	   PASMC,	   unfilled	   arrow),	   monocrotaline	   (MCT,	   showing	   caspase-­‐negative	   PASMC,	   unfilled	   arrow)	   (B)	   and	   MCT+	   day	   14-­‐28	   dexamethasone	   (5mg/kg/day)	  (showing	   caspase-­‐positive	   PASMC,	   filled	   arrow)	   (C).	   Images	   are	   representative	   of	   n=5	   per	  group.	  D:	  antibody-­‐negative	  staining	  control	  in	  a	  control	  rat.	  	  Caspase-­‐3	  immunohistochemistry	  scoring	  was	  performed	  by	  an	  assessor	  blinded	  to	  the	  groups	  and	  presented	  as	  (E)	  percentage	  of	  caspase-­‐3	  positive	  PASMC	  over	  total	  PASMC	  and	  (F)	  the	  numbers	  of	  caspase-­‐3-­‐positive	  PASMC	  per	  mm2.	  Results	   represent	  median	   (interquartile	   range)	   of	   5	   rats	   per	   group	   compared	  using	  Mann	  Whitney	  U	  test.	  *p<0.05,	  **p<0.01,	  ***p<0.001.	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In-­‐situ	  detection	  of	  DNA	  fragmentation	  was	  also	  analysed	  on	  lungs	  resected	  from	  control,	  MCT	  and	  MCT+dexamethasone-­‐treated	   rats	   at	   day	   28.	   An	   increase	   in	   the	   haemalum	  dye	   (a	  mix	   of	  haematoxylin	   and	   aluminium	   ions)	   causing	   blue	   nuclear	   staining	   indicative	   of	   apoptosis	   was	  demonstrated	   in	  MCT	  rats	  at	  day	  28	   (Figure	  5.4).	  Blinded	  morphometric	   scoring	   showed	   that	  the	   percentage	   of	   PASMC	   scoring	   positive	   increased	   in	   lung	   sections	   from	   rats	  with	  MCT-­‐PH	  from	   controls	   (5.3±2.8	   vs.	   38.8±6.1,	   p<0.001)(Figure	   5.4A),	   and	   was	   further	   increased	   in	  dexamethasone-­‐treated	  MCT	  rats	  (38.8±6.1	  vs.	  59.9±3.9,	  p<0.05)(Figure	  5.4B).	  	  	  






















Figure	   5.4.	   	   Dexamethasone	   increased	   apoptosis	   assessed	   by	   in-­‐situ	   DNA	  
fragmentation	  detection	   in	  pulmonary	  artery	  smooth	  muscle	  cell	   (PASMC)	   layer	  
in	  monocrotaline	  (MCT)	  and	  dexamethasone-­‐treated	  rats.	  In-­‐situ	  detection	  of	  DNA	  fragmentation	  was	  performed	  on	   lung	  sections	   from	  control	  rats	  and	  on	  lungs	  resected	  from	  rats	  28	  days	  following	  MCT,	  with	  and	  without	  dexamethasone	  treatment	  (5mg/kg/day	   from	   day	   14-­‐28).	   Representative	   examples	   in	   (A)	   a	   control	   rat,	   (B)	   nuclease-­‐positive	  cells	  in	  an	  MCT-­‐treated	  rat	  (black	  arrow),	  (C)	  negative-­‐stained	  cells	  (unfilled	  arrow)	  in	  a	   rat	   at	   day	   28	   following	  MCT	   and	   (D)	   in	   a	   rat	   at	   day	   28	   following	  MCT	   and	   dexamethasone	  treatment	   (showing	  positive	  stained	  cells,	  black	  arrow).	  Results	  are	  representative	  of	  n=5	  per	  group	   (for	  A,	   C	   and	  D).	   Slides	   are	   counterstained	  with	   haematoxylin	   and	   eosin.	  Magnification	  x200.	   Scoring	   was	   performed	   by	   an	   assessor	   blinded	   to	   the	   groups	   for	   percentage	   positive	  PASMC	  over	  total	  number	  of	  counted	  cells	  (E).	  Results	  represent	  median	  (interquartile	  range)	  of	  n=5	  per	  group,	  compared	  by	  Mann	  Whitney	  tests,	  *p<0.05	  ***P<0.001.	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5.3.2	  In-­‐vitro	  PASMC	  apoptosis	  studies	  
Serum	  withdrawal	   induced	  a	  characteristic	  apoptotic	  response	   in	  PASMC,	  as	  demonstrated	  by	  nuclear	  condensation	  with	  Hoechst	  33342	  staining	  (Figure	  5.5)	  and	  DNA	  fragmentation	  (Figure	  5.6	   –	   see	   next	   paragraph).	   Firstly	   Hoechst	   staining	   results	   are	   described:	   Dexamethasone	  increased	   0%	   FCS-­‐induced	   PASMC	   apoptosis	   as	   determined	   by	   Hoechst	   33342	   staining	   in	   a	  time-­‐	  and	  concentration-­‐dependent	  manner.	  Selected	  examples	  of	  images	  are	  shown	  in	  Figures	  5.5A-­‐D,	   and	   quantified	   in	   Figures	   5.5E-­‐F.	   At	   48	   hours,	   dexamethasone	   increased	   0%	   FCS-­‐induced	  apoptosis	  of	  control	  rat	  PASMC	  (5.4±1.8	  vs.	  8.85±0.68	  (p=0.16)	   for	  dex10-­‐7M;	  5.4±1.8	  vs.	  17.6±0.8	   for	  dex10-­‐6M	   (p<0.001))	   (Figure	  5.5F);	   at	  72	  hours,	  dex10-­‐7M	  and	  dex10-­‐6M	  both	  increased	  apoptosis	   in	  control	  cells	   (17.5±1.9	  vs.	  36.1±7.2	   for	  dex10-­‐7M;	  17.5±1.9	  vs.	  37.6±1.9	  for	  dex10-­‐6M,	  p<0.01	   for	  both)	   (Figure	  5.5G).	  When	  control	  PASMC	  were	   compared	  with	   cells	  isolated	   from	   day	   21-­‐MCT-­‐exposed	   rats	   at	   72	   hours,	   serum	   starvation	   alone	   significantly	  increased	   apoptosis	   in	   both	   groups,	   and	   dexamethasone	   increased	   apoptosis	   even	   further	   in	  control	  cells	  (16.2±1.18	  vs.	  37.6±2.38	  at	  dex10-­‐6M;	  16.2±1.18	  vs.	  37.6±1.91	  for	  dex10-­‐7M,	  p<0.01	  for	  both)	  and	   in	  cells	   from	  MCT	  rats	   (14.5±0.79	  vs.	  35.1±7.2,	   (p=0.1);	  14.5±0.79	  vs.	  42.5±9.93	  (p<0.05))	  (Figure	  5.5H).	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Figure	  5.5.	  	  Effects	  of	  control	  and	  experimental	  conditions	  on	  apoptosis	  assessed	  
by	  Hoescht-­‐33342	  nuclear	  condensation	  of	  rat	  PASMC.	  	  PASMC	  from	  control	  rats	  were	  treated	  for	  48-­‐72	  hours	  in	  10%	  FCS/DMEM	  as	  a	  negative	  control	  (A),	   then	   with	   800nM	   hydrogen	   peroxide	   (H2O2)	   as	   a	   positive	   control	   (B),	   serum	   starvation	  alone	  (0%	  FCS)	  (C)	  and	  with	  dexamethasone	  (10-­‐7M)	  and	  0%	  and	  10%	  FCS	  +	  dex	  then	  stained	  with	  Hoechst	   33342.	   Images	   are	   representative	   of	   n=3-­‐4	  per	   group.	  Magnification	   x400.	  Data	  were	   quantified	   by	   analysing	   5-­‐8	   images	   for	   each	   condition.	   Control	   conditions	   used	   control	  cells	  stimulated	  with	  10%	  FCS	  (negative	  control),	  dichloroacetate	  (DCA,	  100µM)	  and	  increasing	  concentrations	   (100-­‐800nM)	   hydrogen	   peroxide	   (H202)	   (positive	   controls)	   for	   48	   hours	   to	  induce	   apoptosis	   (E).	   Effects	   of	   10%	  FCS	   and	   dexamethasone	   plus	   0%	  FCS	  were	   assessed	   on	  apoptosis	  in	  control	  PASMC	  at	  48h	  (F),	  in	  both	  control	  cells	  at	  48	  and	  72	  hours	  (G),	  and	  effects	  of	  dexamethasone	   at	   72h	  were	   compared	   in	   control	   PASMC	  with	   day	   21-­‐MCT-­‐exposed	   rats	   (H).	  Results	   represent	   mean±SEM	   from	   n=3-­‐5	   per	   group,	   compared	   using	   1-­‐way	   ANOVA	   and	  Bonferroni’s	  post-­‐test.	  *p<0.05,	  **p<0.01,	  ***p<0.001.	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Further	  to	  the	  effects	  on	  nuclear	  condensation	  using	  Hoechst	  staining,	  the	  release	  of	  fragmented	  DNA	  into	  the	  cytoplasm	  was	  measured	  using	  an	  ELISA-­‐based	  assay.	  These	  results	  also	  showed	  that	  dexamethasone	   significantly	   increased	  apoptosis	   in	   a	   time-­‐	   and	   concentration-­‐dependent	  manner	  in	  serum-­‐starved	  rat	  PASMC,	  especially	  in	  control	  cells,	  reaching	  a	  plateau	  after	  72hrs	  with	   10-­‐7M	   dexamethasone	   (48h:	   0.36±0.06	   vs.	   0.56±0.02	   (10-­‐8M,	   p=NS);	   1.67±0.14	   (10-­‐7M,	  p<0.05);	   1.17±0.19	   (10-­‐6M,	   p<0.01);	   72h:	   0.40±0.05	   vs.	   1.26±0.27	   (10-­‐8M,	   p<0.01);	   1.28±0.15	  (10-­‐7M,	  p<0.01);	  1.51±0.19	  (x10-­‐6M,	  p<0.01)	  (Figure	  5.6A)	  Dexamethasone	  increased	  apoptosis	  in	  both	  PASMC	  from	  control	  rats	  and	  from	  rats	  exposed	  to	  MCT	  for	  21	  days	  at	  both	  48	  and	  72	  hours,	   and	   there	   was	   significantly	   less	   apoptosis	   induced	   in	   cells	   from	   MCT-­‐treated	   rats	  compared	   to	   control	   rats	   in	   terms	   of	   absolute	   values	   (Figure	   5.6B	   and	   C).	   However,	   when	  expressed	  as	  the	  proportion	  of	  apoptosis	  from	  baseline	  serum	  starvation	  the	  difference	  was	  no	  longer	  significant	  (Figure	  5.6D	  and	  E).	  






Figure	  5.6.	  	  Dexamethasone	  increased	  apoptosis	  in	  rat	  pulmonary	  arterial	  smooth	  
muscle	  cells	  (PASMC),	  measured	  by	  a	  DNA	  fragmentation	  ELISA.	  Rat	   PASMC	   were	   isolated	   from	   control	   rats	   and	   from	   rats	   21	   days	   after	   exposure	   to	  monocrotaline	   (MCT)	   and	   treated	   with	   an	   increasing	   concentration	   of	   dexamethasone	   (Dex)	  and	   appropriate	   controls.	   Apoptosis	   was	   increased	   from	   baseline	   in	   serum-­‐starved	   cells	  (0%FCS)	  in	  control	  PASMC	  at	  48h	  (grey	  bars)	  and	  72h	  (black	  bars)	  by	  Dex	  (10-­‐8M	  to	  10-­‐6M)	  at	  both	  time	  points	  (A).	  When	  control	  and	  MCT-­‐exposed	  cells	  were	  compared	  at	  48	  hours	  (B)	  and	  72	   hours	   (C),	   10-­‐7M	   and	   dex10-­‐6M	   Dex	   increased	   apoptosis,	   with	   a	   significant	   difference	  observed	  between	  cell	  types.	  However	  the	  difference	  between	  cell	  types	  was	  not	  apparent	  when	  data	  were	   normalised	   to	   baseline	   serum	   starvation	   levels	   at	   48	   hours	   (D)	   and	   72	   hours	   (E).	  Results	  represent	  mean±SEM	  from	  n=3-­‐5,	  compared	  using	  1-­‐way	  ANOVA	  and	  Bonferroni’s	  post-­‐test.	  *p<0.05,	  **p<0.01,	  ***p<0.001.	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5.3.3	  Effect	  of	  dexamethasone	  on	  NF-­‐κB	  activation	  in	  rat	  pulmonary	  
vascular	  cells	  
Morphometric	  analysis	  of	  PASMC	  and	  endothelial	  cells	  (EC)	  in	  lung	  sections	  showed	  an	  increase	  in	  nuclear	  p65	  activation	  in	  lung	  from	  rats	  with	  MCT-­‐induced	  PH	  at	  day	  28	  compared	  to	  control	  rats	  (PASMC:	  16.1±2.27	  vs.	  55.7±5.02	  (p<0.001);	  EC:	  15.3±3.46	  vs.	  84.4±5.75,	  p<0.001)(Figure	  5.7).	  Nuclear	  p65	  activation	  was	  reduced	  following	  day	  14-­‐28	  dexamethasone	  treatment	  of	  the	  rats,	   at	   all	  doses	   studied	   compared	   to	  MCT	  alone	   (PASMC:	  55.7±5.02	  vs.	  36.4±3.53	   (Dex	  1.25,	  p<0.001);	   26.8±2.63	   (Dex	   2.5,	   p<0.001)	   and	   29.1±2.37	   (Dex	   5,	   p<0.001);	   EC:	   84.4±5.75	   vs.	  38.8±4.9	  (Dex	  1.25);	  30.23±3.34	  (Dex	  2.5)	  and	  22.1±3.64	  (Dex	  5),	  p<0.001	  for	  all	  doses)	  (Figure	  5.7).	  The	  effects	  of	  dexamethasone	  on	  medial	  thickness	  was	  also	  measured	  in	  these	  sections	  and	  showed	   the	   same	  results	   as	   those	   in	  Figure	  4.3.	   In	  addition,	  preliminary	   immunostaining	  was	  performed	  for	  IKK-­‐α/β	  on	  rat	  lung	  sections	  (Figure	  5.8),	  which	  suggested	  an	  increased	  staining	  in	   endothelial	   cells	   (and	   very	   faintly	   in	   PASMC)	   in	   MCT-­‐exposed	   rats	   compared	   to	   controls,	  which	   appeared	   to	   be	   reduced	   in	   dexamethasone-­‐treated	   rats.	   These	   have	   not	   yet	   been	  quantified.	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Figure	   5.7.	   	   Dexamethasone	   reduced	   nuclear	   p65	   in	   lung	   vascular	   cells	   in	   rats	  
with	  monocrotaline	  (MCT)-­‐induced	  pulmonary	  hypertension	  (PH).	  Rats	  with	  MCT-­‐induced	  PH	  were	  treated	  with	  dexamethasone	  (Dex,	  5mg/kg/day)	  from	  day	  14-­‐28.	   At	   day	   28,	   immunohistochemical	   staining	   for	   p65	   (brown)	   with	   haematoxylin	   &	   eosin	  counterstaining	   was	   performed	   on	   lung	   sections	   from	   rats	   from	   untreated	   controls	   (p65-­‐ve	  cells,	   unfilled	   arrow)	   (A),	   day	   28	   MCT	   rats	   (p65+ve	   cells,	   filled	   black	   arrow)	   (B)	   and	  dexamethasone-­‐treated	   MCT-­‐exposed	   rats	   (p65-­‐ve	   cells,	   unfilled	   arrow)	   (C).	   An	   antibody-­‐negative	  control	   is	  shown	  in	  slide	  D.	  Blinded	  morphometric	  scoring	  showed	  the	  percentage	  of	  total	  nuclear	  p65-­‐positive	  PASMC	  (E)	  and	  in	  endothelial	  cells	  (F)	  increased	  with	  MCT	  increased	  in	  MCT	  rats	  and	  was	   reduced	   in	  all	  dexamethasone-­‐treated	  groups.	  Results	   represent	  mean	  ±	  SEM	  of	  n=5	  per	  group,	  compared	  using	  Kruskal	  Wallis	  and	  Dunn’s	  post-­‐test.	  *p<0.01,	  **p<0.01,	  ***p<0.001.	  	  	  
	  





Figure	   5.8.	   	   Dexamethasone	   reduced	   monocrotaline-­‐induced	   enhancement	   of	  
phospho-­‐IKK-­‐α/β	  immunostaining	  in	  vascular	  cells	  in	  rat	  lungs.	  Immunohistochemistry	   for	   IKK-­‐α/β	   (brown)	  was	   performed	   on	   lung	   sections	   from	   rats	   from	  untreated	   control	   rats	   (A);	   day	   28	   monocrotaline	   rats	   (B)	   and	   monocrotaline	   and	  dexamethasone	   day	   14-­‐28-­‐treated	   rats	   (C).	   These	   preliminary	   data	   suggest	   an	   increase	   in	  nuclear	  NF-­‐κB	  p65+	  in	  the	  EC	  layer	  in	  MCT	  rats	  (black	  arrow),	  and	  very	  faint	  staining	  in	  PASMC	  (black	   arrow)	   (B),	   which	   was	   reduced	   in	   dexamethasone-­‐treated	   rats	   (unfilled	   arrow)	   (C).	  Sections	  represent	  n=4-­‐5	  per	  group	  (A-­‐C);	  and	  were	  counterstained	  with	  haematoxylin	  &	  eosin.	  	  Antibody-­‐negative	  control	  is	  shown	  in	  slide	  D.	  	  	  
5.3.4	  Effects	  of	  dexamethasone	  on	  IL-­‐6,	  CXCL8	  and	  BMPR-­‐II	  in	  rat	  MCT-­‐
induced	  PH	  
5.3.4.1	  Effect	  of	  dexamethasone	  on	  adventitial	  infiltration	  of	  IL-­‐6-­‐expressing	  
inflammatory	  cells	  in	  rat	  MCT-­‐induced	  PH	  	  
Twenty-­‐eight	  days	  after	  MCT	  administration,	   there	  was	  weak	  staining	  of	   IL-­‐6	   in	  control	   lungs	  (Figure	   5.9A)	  whereas	   adventitial	   infiltrating	   inflammatory	   cells,	   which	   look	  morphologically	  like	   macrophages	   but	   no	   specific	   macrophage	   markers	   were	   used,	   displayed	   a	   strong	   IL-­‐6	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expression	   in	   MCT-­‐exposed	   rats	   (Figure	   5.9B).	   Lungs	   from	   dexamethasone	   (5mg/kg/day)-­‐treated	  rats	  exhibited	   the	  same	   faint	   IL-­‐6	  staining	  as	   seen	   in	  control	   lungs	  with	  an	  associated	  regression	   in	   vascular	   remodelling	   (5.9C).	   In	   addition,	   endothelial	   cells	   stained	   for	   IL-­‐6	   in	  control	   (5.9A)	   and	   in	   dexamethasone-­‐treated	   rat	   lungs	   (5.9C),	   although	   the	   EC	   layer	  was	   not	  clearly	   visible	   in	  MCT-­‐treated	   rat	   lungs	   (5.9B).	   	   It	   is	   difficult	   to	   comment	   on	   the	   relative	   IL-­‐6	  staining	  in	  PASMC.	  These	  slides	  were	  representative	  of	  n=4-­‐5	  per	  group.	  The	  images	  were	  a	  gift	  from	  Dr	  Peter	  Dorfmuller,	  and	  I	  have	  not	  yet	  had	  time	  to	  quantify	  the	  data.	  
	  
Figure	  5.9.	  	  Dexamethasone	  reduced	  infiltration	  of	  IL-­‐6-­‐expressing	  inflammatory	  
cells	  in	  monocrotaline	  (MCT)-­‐induced	  pulmonary	  hypertension	  (PH).	  Rats	  with	  MCT-­‐induced	  PH	  were	   treated	  with	  dexamethasone	   (5mg/kg/day,	   days	  14-­‐28)	   and	  IL-­‐6	   immunohistochemistry	   (red/brown)	   performed	   on	   paraffin-­‐embedded	   rat	   lung	   tissue.	  Control	   rat	   lung	   (A)	   shows	   normal	   lung	   parenchyma	   and	   no	   inflammatory	   cells	   with	   IL-­‐6	  staining;	   28	   days	   following	   MCT	   exposure	   there	   is	   extensive	   vascular	   narrowing	   of	   small	  muscular	  pulmonary	  arteries	  and	  adventitial	  infiltrating	  inflammatory	  cells	  display	  strong	  IL-­‐6	  expression	   (B).	   Dexamethasone-­‐treated	   lung	   sections	   at	   day	   28	   show	   a	   normal	   medial	   wall	  thickness	   of	   small	   pulmonary	   arteries	   and	   exhibiting	   a	   similar	   weak	   IL-­‐6	   staining	   as	   seen	   in	  control	  rats	  (C).	  	  Sections	  were	  counterstained	  with	  haematoxylin	  and	  eosin.	  A	  negative	  control	  with	  omission	  of	  primary	  antibody	  is	  also	  shown	  (D).	  Results	  are	  representative	  of	  4-­‐5	  animals	  per	  group.	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5.3.4.2	  Effect	  of	  dexamethasone	  on	  IL-­‐6	  and	  BMPR-­‐II	  mRNA	  in	  rat	  whole	  lung	  	  







































































































Figure	   5.10.	   	   Dexamethasone	   (Dex)	   reduced	   whole	   lung	   interleukin	   (IL)-­‐6	   and	  
increased	  bone	  morphogenetic	   protein	   receptor	   (BMPR)-­‐II	  mRNA	  expression	   in	  
monocrotaline	  (MCT)-­‐induced	  pulmonary	  hypertension	  (PH).	  Rats	  with	  MCT-­‐induced	  PH	  were	  treated	  with	  dexamethasone	  (Dex,	  1.25,	  2.5	  and	  5mg/kg/day)	  (day	   14-­‐28).	   Reverse	   transcriptase	   polymerase	   chain	   reaction	   (RT-­‐PCR)	   of	   whole	   lung	  homogenates	  was	  performed	  on	  frozen	  lung	  tissue	  from	  day	  28	  animals.	   	  Compared	  to	  control	  rats	   receiving	  no	  MCT	  or	  dexamethasone,	  MCT	  upregulated	   IL-­‐6	  mRNA	  expression	  which	  was	  significantly	  reduced	  by	  Dex	  1.25	  (A).	  BMPR-­‐II	  mRNA	  was	  significantly	  reduced	  in	  MCT-­‐treated	  rats	   and	   was	   increased	   by	   Dex	   in	   a	   dose-­‐dependent	   manner	   (B).	   Results	   represent	   data	  normalised	  to	  β-­‐actin	  mRNA	  control	  values	  for	  mean	  ±	  SEM	  of	  3-­‐5	  animals	  per	  group,	  compared	  using	  Kruskal	  Wallis	  and	  Dunn’s	  post-­‐test.	  *p<0.05	  **p<0.01.	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5.3.4.3	  Effect	  of	  dexamethasone	  on	  IL-­‐6	  and	  BMPR-­‐II	  mRNA	  in	  rat	  PASMC	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Figure	   5.11.	   	   Dexamethasone	   (Dex)	   reduced	   IL-­‐6	   but	   had	   no	   effect	   on	   BMPR-­‐II	  
mRNA	  in	  serum-­‐stimulated	  rat	  pulmonary	  arterial	  smooth	  muscle	  cells	  (PASMC).	  PASMC	  were	   isolated	   from	  control	  and	   from	  21	  day-­‐monocrotaline-­‐treated	  rats.	   	  PASMC	  were	  stimulated	  by	  10%	  FCS	  in	  the	  presence	  and	  absence	  of	  dexamethasone	  (Dex,	  10-­‐8M	  and	  10-­‐7M)	  for	  24	  hours.	  	  RNA	  was	  then	  extracted	  and	  reverse	  transcriptase	  polymerase	  chain	  reaction	  (RT-­‐PCR)	  performed.	  There	  was	  no	  significant	  difference	  in	  baseline	  IL-­‐6	  mRNA	  expression	  although	  Dex	   induced	   a	   significant	   reduction	   in	   IL-­‐6	   mRNA	   in	   both	   cell	   types	   (A).	   BMPR-­‐II	   mRNA	  expression	  was	  unaltered	  in	  MCT	  rats	  vs.	  control	  cells	  at	  baseline	  and	  there	  was	  no	  significant	  change	   following	  Dex	   exposure	   (B).	   Results	   represent	  mean±SEM	   from	  data	   normalised	   to	   β-­‐actin	  mRNA	  and	  compared	  with	  baseline	  conditions	  in	  control	  PASMC	  from	  n=4	  per	  group.	  	  Data	  was	  analysed	  by	  Kruskal	  Wallis	  with	  Dunn’s	  post-­‐test	  analysis.	  ***p<0.001.	  	  
5.3.5	  Effect	  of	  dexamethasone	  and	  IKK-­‐2	  inhibition	  on	  IL-­‐6	  and	  CXCL8	  
release	  from	  human	  PASMC	  
The	  following	  experiments	  were	  performed	  on	  human	  PASMC	  in	  order	  to	  study	  more	  clinically	  relevant	  cells.	  Control	  human	  PASMC	  were	  isolated	  from	  normal	  lung	  from	  patients	  undergoing	  surgery	   for	   solitary	   pulmonary	   nodule	   resection.	   I	   performed	   two	  main	   sets	   of	   experiments:	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initially	  using	  dexamethasone	  and	  then	  a	  specific	  inhibitor	  of	  IKK-­‐2,	  AS602868	  (kindly	  provided	  by	   Serono	   International	   SA,	   Geneva,	   Switzerland).	   The	   first	   experiments	   demonstrated	   a	  concentration-­‐dependent	   reduction	   in	   both	   TNF-­‐α-­‐stimulated	   IL-­‐6	   and	   CXCL8	   release	   by	  dexamethasone.	   IL-­‐6	  release	  was	   increased	   from	  baseline	  by	  TNFα	  (4962±581	  to	  13056±624,	  p<0.001)	  and	  was	  reduced	  by	  dexamethasone	  to	  11495±675	  (10-­‐10M,	  p=NS);	  8233±553	  (10-­‐9M,	  p<0.001);	  5534±228	  (10-­‐8M,	  p<0.001);	  4795±396	  (10-­‐7M,	  p<0.001);	  3822±691	  (10-­‐6M,	  p<0.001)	  (Figure	  5.12A).	  CXCL-­‐8	  release	  was	  increased	  by	  TNFα	  (866±127	  to	  13018±464,	  p<0.001)	  and	  was	   reduced	   by	   dexamethasone	   to	   13431±842	   (10-­‐10M,	   p=NS);	   12056±8574	   (10-­‐9M,	   p=NS);	  7854±442	   (10-­‐8M,	   p<0.001);	   6954±477	   (10-­‐7M,	   p<0.001);	   6283±494	   (10-­‐6M,	   p<0.001)	   (Figure	  5.12B).	   I	   proceeded	   to	   perform	   TransAm	   assays	   using	   a	   selected	   single	   concentration	   of	  dexamethasone	   (10-­‐7M)	   to	   show	   this	  was	   indeed	   an	   effect	   centred	   upon	   inhibition	   of	   NF-­‐κB.	  These	   showed	   an	   increase	   following	   TNFα	   simulation	   (0.027±0.025	   to	   0.44±0.022,	   p<0.001)	  and	  a	  significant	  reduction	  in	  the	  presence	  of	  10-­‐7M	  dexamethasone	  (0.33±0.02	  to	  0.31±0.062,	  p<0.01)	  (Figure	  5.13).	  
The	  second	  set	  of	  experiments	  using	  the	  IKK-­‐2	  inhibitor	  showed	  a	  reduction	  in	  IL-­‐6	  and	  CXCL8	  release	   from	   TNF-­‐α-­‐stimulated	   PASMC	   in	   a	   concentration-­‐dependent	   manner,	   similar	   to	   the	  reduction	   seen	   with	   dexamethasone.	   Release	   of	   IL-­‐6	   was	   increased	   by	   TNF-­‐α	   (3450±887	   to	  7856±657,	   p<0.001)	   and	   was	   reduced	   by	   AS602868	   to	   6460±626	   (0.1μM,	   NS);	   4739±553	  (0.3μM,	   p<0.001);	   3647±429	   (1μM,	   p<0.001);	   2014±307	   (3μM,	   p<0.001).	   CXCL8	   release	   was	  enhanced	   by	   TNFα	   (702±266	   to	   8701±775,	   p<0.001)	   and	   was	   reduced	   by	   AS602868	   to	  6587±450	  (0.1μM,	  p<0.001);	  4393±338	  (0.3μM,	  p<0.001);	  2107±159	  (1μM,	  p<0.001);	  534±68.6	  (3μM,	  p<0.001)	   (Figure	  5.14A-­‐B).	  Of	  note,	   in	  both	   the	  dexamethasone	  and	   the	   IKK-­‐2	   inhibitor	  experiments,	  baseline	  IL-­‐6	  release	  was	  significantly	  reduced	  at	  the	  higher	  drug	  concentrations	  even	  before	  the	  addition	  of	  TNF-­‐α.	  For	  all	  these	  experiments,	  PASMC	  viability	  was	  assessed	  by	  MTT	  and	  showed	  no	  change	  across	  all	  conditions	  (Figure	  5.12C	  and	  5.14C).	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Figure	  5.12.	  	  Dexamethasone	  (Dex)	  reduced	  interleukin	  (IL)-­‐6	  and	  CXCL8	  release	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Figure	   5.13.	   	   Dexamethasone	   (Dex)	   inhibits	   tumour	   necrosis	   factor-­‐α 	   (TNFα)-­‐
induced	  activation	  of	  nuclear	  factor	  (NF)-­‐κB	  in	  pulmonary	  arterial	  smooth	  muscle	  
cells	  (PASMC).	  	  PASMC	   from	  3	  control	   subjects	  were	  stimulated	  with	  TNF-­‐α	   (0-­‐10ng/ml)	   in	   the	  presence	  and	  absence	  of	  dexamethasone	  (Dex,	  10-­‐7M)	  for	  1	  hour.	  	  NF-­‐κB	  p65	  DNA	  binding	  in	  nuclear	  extracts	  was	  measured	  by	  TransAm	  assay.	  Data	  are	   reported	  as	   the	  mean	  ±	  SEM.	   *p<0.05,	   ***p<0.001	  using	  Kruskal	  Wallis	  and	  Dunn’s	  post-­‐test	  analysis.	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Figure	  5.14.	  	  IKK-­‐2	  inhibition	  reduced	  interleukin	  (IL)-­‐6	  and	  CXCL8	  release	  from	  
human	  pulmonary	  arterial	  smooth	  muscle	  cells	  (PASMC).	  Human	  PASMC	  were	  plated	  at	  5000/well	  in	  96-­‐well	  plates;	  starved	  overnight	  in	  SCF-­‐free	  media	  and	   treated	   with	   tumour	   necrosis	   factor	   (TNF)-­‐α	   (10ng/ml)	   with	   and	   without	   the	   IKK-­‐2	  inhibitor	  AS602868	  (0-­‐1μM)	  for	  24h.	  IL-­‐6	  (A)	  and	  CXCL8	  (B)	  release	  into	  the	  supernatants	  was	  measured	   by	   ELISA.	   MTT	   assays	   were	   also	   performed	   to	   assess	   cell	   viability	   (C).	   Results	  represent	   mean±SEM	   for	   n=4,	   compared	   using	   1-­‐way	   ANOVA	   and	   Bonferroni’s	   post-­‐test.	  *p<0.05,	  ***p<0.001.	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5.4	  Discussion	  
Firstly,	  I	  showed	  that	  dexamethasone	  reduced	  proliferation	  in	  rat	  PASMC.	  There	  was	  a	  relative	  resistance	  to	  dexamethasone	  in	  PASMC	  from	  rats	  exposed	  to	  MCT	  compared	  to	  control	  PASMC	  from	  normal	   rats.	   Secondly,	   I	   showed	   that	   dexamethasone	   increased	   apoptosis	   in	   rat	   PASMC,	  with	   no	   difference	   in	   induced	   apoptosis	   between	   cells	   from	   controls	   and	  MCT-­‐PH	   rats,	  when	  data	  were	   normalised.	   Thirdly,	   I	   provide	   evidence	   for	   increased	   IL-­‐6	   expression	   in	   rats	  with	  MCT-­‐induced	  PH,	  using	  lung	  immunohistochemistry,	  whole	  lung	  and	  PASMC	  qRT-­‐PCR;	  this	  IL-­‐6	  activity	   was	   suppressed	   by	   dexamethasone	   in	   PASMC	   and	   lung	   tissue.	   Furthermore,	  dexamethasone	  up-­‐reversed	  the	  MCT-­‐induced	  reduction	  in	  BMPR-­‐II	  mRNA	  in	  whole	  lung	  from	  rats	   with	   dexamethasone-­‐treated	   MCT-­‐induced	   PH.	   	   However,	   this	   was	   not	   seen	   in	   PASMC.	  Fourthly,	  I	  showed	  that	  NF-­‐κB	  activation	  was	  increased	  by	  MCT	  in	  lung	  endothelial	  and	  PASMC	  cells	  as	  determined	  by	  p65	  nuclear	  translocation	  in	  lung	  tissue	  in	  MCT-­‐treated	  rats,	  and	  that	  this	  was	  reduced	  by	   in	  vivo	  dexamethasone	   treatment.	  Finally,	   I	   showed	   that	   treatment	  of	  normal	  human	   PASMC	   in	   culture	   with	   dexamethasone	   and	   an	   IKK-­‐2	   inhibitor	   both	   led	   to	   a	  concentration-­‐dependent	   reduction	   in	   IL-­‐6	   and	   CXCL8	   release.	   The	   restoration	   of	   the	  proliferation/apoptosis	   imbalance	   by	   dexamethasone,	   which	   may	   in	   part	   relate	   to	   NF-­‐κB	  inhibition	   and	   a	   reduction	   in	   PASMC	   cytokine	   release,	   may	   contribute	   to	   the	   reversal	   of	  established	  PH	  by	  dexamethasone	  seen	  in	  the	  rat	  MCT-­‐induced	  PH	  model.	  
My	  initial	  cell	  counting	  and	  proliferation	  experiments	  showed	  that	  dexamethasone	  reduced	  cell	  number	   and	   thymidine	  uptake	   in	   a	   concentration-­‐dependent	  manner.	   There	  was	   an	   apparent	  nadir	  at	  10-­‐7M	  dexamethasone	  and	  less	  effect	  seen	  at	  10-­‐6M,	  which	  we	  have	  not	  fully	  explained,	  but	  we	   thought	   could	   in	   part	   relate	   to	   the	   effects	   of	   the	   diluent	   for	   dexamethasone,	   ethanol.	  Further	  experiments	  using	  a	  clinically	  available	  water-­‐soluble	  formulation	  showed	  that	  the	  anti-­‐proliferative	  effects	  of	  dexamethasone	  (without	  ethanol)	  persisted	  therefore	  these	  effects	  were	  unlikely	   to	   be	   solely	   an	   ethanol	   effect.	   Another	   explanation	   could	   relate	   to	   the	   differences	   in	  dexamethasone-­‐induced	   gene	   transactivation	   and	   transrepression	   profiles	   at	   the	   different	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concentrations	  tested	  (Adcock	  et	  al.,	  1999).	  Further	  to	  this,	  it	  would	  be	  useful	  to	  perform	  these	  proliferation	  experiments	  at	  even	  lower	  concentrations	  of	  dexamethasone.	  
A	   single	   previous	   study	   examined	   the	   effects	   of	   prednisolone	   on	   human	   PASMC	   proliferation	  showed	   that	   high	   concentrations	   (2x10-­‐5	   to	   2x10-­‐3M	   -­‐	   equating	   to	   dexamethasone	   3x10⁻⁵	   to	  3x10⁻⁴M)	   significantly	   inhibited	   PDGF-­‐stimulated	   thymidine	   uptake	   in	   PASMC	   from	   PAH	  patients,	  even	  more	  so	  than	  in	  control	  PASMC.	  This	  was	  associated	  with	  inhibition	  of	  G0/G1	  to	  S	  phase	  cell	  cycle	  progression,	  inhibition	  of	  PDGF-­‐induced	  PASMC	  migration	  (Ogawa	  et	  al.,	  2005),	  and	   reduced	   NF-­‐κB	   activation	   (discussed	   later)	   (Ogawa	   et	   al.,	   2008b).	   Interestingly,	   other	  immunosuppressive	  agents	  including	  azathioprine,	  rapamycin	  and	  cyclosporin	  had	  no	  effect	  on	  PASMC	  proliferation	  (Ogawa	  et	  al.,	  2005).	  	  
The	   inhibitory	   effects	   of	   GC	   on	   10%	   FCS-­‐stimulated	   SMC	   proliferation	   were	   also	   studied	   in	  systemic	  vascular	  SMC	  (Longenecker	  et	  al.,	  1982,	  Voisard	  et	  al.,	  1994),	  where	  high	  GC	  doses	  led	  to	   marked	   alterations	   in	   the	   expression	   of	   actin	   and	   vimentin	   microtubules	   (Voisard	   et	   al.,	  1994).	   The	   same	   authors	   assessed	   the	   effects	   of	   dexamethasone	   (10-­‐10	   to	   10-­‐7M)	   on	   collagen	  production	  by	  systemic	  SMC	  and	  showed	  that	  dexamethasone	  (10-­‐7M)	  induced	  a	  2-­‐fold	  increase	  in	   hydroxproline	   in	   proliferating	   cells,	   while	   inhibiting	   collagen	   production	   in	   confluent	   cells	  (Leitman	  et	  al.,	  1984).	  The	  authors	  suggested	  that	  if	  GC	  had	  similar	  effects	  in	  vivo,	  the	  formation	  of	  a	   less	  cellular,	  more	   fibrous	   lesion	  may	  even	  delay	   the	  regression	  of	  atherosclerotic	   lesions	  once	   formed.	   It	   is	   of	   course	   difficult	   to	   compare	   studies	   of	   systemic	   with	   pulmonary	   arterial	  SMC.	  However,	  it	  is	  likely	  that	  GC	  exert	  complex	  and	  varying	  effects	  on	  different	  cell	  types.	  	  
There	  have	  been	  very	  few	  studies	  specifically	  using	  PASMC	  and	  none	  as	  yet	  using	  distal	  PASMC,	  which	  are	  known	  to	  proliferate	  more	  than	  proximal	  cells	  (Wharton	  et	  al.,	  2000).	  It	  must	  also	  be	  noted	  that	  even	  within	  the	  medial	  layer,	  subpopulations	  of	  PASMCs	  exist	  (Frid	  et	  al.,	  1994),	  and	  that	  a	  mitogenic	  stimulus	  (e.g.	  hypoxia)	  might	  stimulate	  proliferation	  in	  certain	  PASMC	  within	  the	  media	   and	   not	   others	   (Wohrley	   et	   al.,	   1995).	  We	   have	   shown	   that	   GC	   inhibited	  NF-­‐κB	   in	  control	  PASMC	  in	  culture	  and	  in	  vivo.	  We	  do	  not	  yet	  know	  whether	  additional	  GC	  effects	  such	  as	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inhibition	  of	  MAP	  kinases	  are	  important	  in	  the	  control	  of	  PASMC	  proliferation.	  In	  addition,	  the	  effect	  of	  dexamethasone	  on	  cell	  cycle	  regulation	  in	  PASMC	  requires	  further	  evaluation	  at	  more	  physiological	  doses	  than	  previously	  studied	  here	  and	  by	  Ogawa	  et	  al	  (Ogawa	  et	  al.,	  2005).	  
My	   results	   suggest	   that	   dexamethasone	   (at	   10-­‐8M	   only)	   suppressed	   proliferation	   less	  efficaciously	   in	   cells	   isolated	   from	  MCT-­‐treated	   animals	   compared	   to	   those	   from	   control	   rats.	  Indeed,	  it	  is	  known	  that	  PASMC	  from	  PAH	  patients	  proliferate	  more	  readily	  than	  control	  PASMC	  (Morrell	   et	   al.,	   2001,	   Eddahibi	   et	   al.,	   2001,	   Ogawa	   et	   al.,	   2005)	   although	   we	   (and	   others	   -­‐	  Dewachter	   L,	   personal	   communication)	   did	   not	   observe	   a	   baseline	   difference	   in	   our	  MCT	   rat	  cells.	   Increased	   PASMC	   proliferation	   in	   PAH	   occurs	   due	   to	   several	   mechanisms	   including	  upregulated	  ET-­‐1,	  PDGF	  (Schermuly	  et	  al.,	  2005,	  Perros	  et	  al.,	  2008),	  5-­‐HT	  signalling	  (Eddahibi	  et	   al.,	   2001),	   down-­‐regulated	   NO	   and	   prostacyclin	   signalling,	   and	   importantly,	   BMPR-­‐II	  dysfunction.	   Usually	   growth-­‐inhibitory	  members	   of	   the	   BMPR-­‐II	   pathway	   such	   as	   TGF-­‐β	   and	  BMP	  2,	  4	   and	  7	  enhance	  proliferation	   in	   cells	   from	  PAH	  patients	   (Morrell	   et	   al.,	   2001),	  which	  relates	   to	   dysfunctional	   Smad	   and	   p38	   MAP	   kinase	   signalling	   (Yang	   et	   al.,	   2005b)	   and,	   as	  recently	  shown,	  other	  pathways	  including	  NF-­‐κB	  (Davies	  et	  al.,	  2012).	  	  
Further	   to	   the	   reduction	   in	   PASMC	   proliferation,	   we	   showed	   using	   several	   methods	   that	  dexamethasone	  induced	  PASMC	  apoptosis.	  Previously,	  many	  compounds	  relevant	  to	  PAH	  have	  been	  shown	  to	  induce	  PASMC	  apoptosis,	  and	  it	  is	  a	  recognised	  anti-­‐remodelling	  process	  –	  these	  include	   nitric	   oxide	   (Krick	   et	   al.,	   2002),	   dichloroacetate	   (Michelakis	   et	   al.,	   2002),	   imatinib	  (Schermuly	  et	  al.,	  2005)	  and	  statins	  (Ali	  et	  al.,	  2011).	  In	  a	  study	  of	  human	  PASMC	  by	  Wharton	  et	  
al,	   a	   similar	   proportion	   of	   PASMC	   underwent	   apoptosis	   in	   the	   face	   of	   serum	   starvation,	   and	  sildenafil	   required	   the	   additional	   stimulus	   of	   serum	   starvation	   to	   induce	   apoptosis.	   As	   in	   our	  study,	   they	   observed	   no	   difference	   in	   sildenafil-­‐induced	   apoptosis	   and	   also	   showed	   an	  additional	  lack	  of	  difference	  in	  proliferation	  between	  cells	  from	  control	  subjects	  or	  PAH	  patients	  (Wharton	  et	  al.,	  2005).	  In	  other	  settings,	  physiological	  concentrations	  of	  GC	  promote	  apoptosis	  in	   certain	  white	   blood	   cells	   including	   eosinophils	   and	   immature	   thymocytes	   (although	   not	   in	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neutrophils),	  hence	  their	  use	  in	  asthma	  and	  lymphoid	  diseases	  respectively	  (McColl	  et	  al.,	  2007).	  Apoptosis	  is	  a	  physiological	  process	  in	  certain	  cells	  during	  the	  resolution	  of	  inflammation,	  which	  maintaining	  beneficial	  neutrophil-­‐dependent	  anti-­‐microbial	  responses	  (McColl	  et	  al.,	  2007).	  For	  example,	   GC-­‐induced	   eosinophil	   apoptosis	   was	   demonstrated	   in	   a	   rat	   peritoneal	  model,	   with	  maximal	   effects	   at	   10-­‐6M	   dexamethasone	   (Nittoh	   et	   al.,	   1998).	   Mechanisms	   of	   GC-­‐induced	  apoptosis	   in	   these	   cells	   is	   likely	   to	   be	   through	   the	   GR	   as	   it	   is	   blocked	   by	   the	   GR	   antagonist	  mifepristone	   (Meagher	   et	   al.,	   1996),	   and	   further	   to	   this,	   mechanisms	   are	   likely	   to	   be	   both	  through	  transrepression	  of	  survival	  genes,	  transactivation	  of	  death	  genes,	  with	  resultant	  effects	  on	  mitochondrial	  pathway-­‐regulated	  apoptosis,	  as	  well	  as	  Bcl-­‐2	  proteins	   (McColl	  et	  al.,	  2007).	  For	  example,	  GC	  could	   induce	  apoptosis	   in	  T-­‐cell	   leukaemia	  cell	   lines	  expressing	  mutant	  DNA-­‐binding	  and	  transactivation-­‐defective	  GRs,	  which	  retained	  the	  ability	  to	  repress	  NF-­‐κB	  and	  AP-­‐1	  (Helmberg	  et	  al.,	  1995).	  	  
As	  previously	  discussed,	   IL-­‐6	   is	   implicated	   as	   a	   causal	   agent	   in	  both	  human	  PAH	   (Soon	   et	   al.,	  2010,	  Humbert	  et	  al.,	  1995)	  and	  rodent	  PH	  models	  (Miyata	  et	  al.,	  1995)	  (Steiner	  et	  al.,	  2009).	  In	  keeping	  with	  previous	  studies	  (Bhargava	  et	  al.,	  1999,	  Miyata	  et	  al.,	  1995),	   I	  showed	  that	  MCT-­‐induced	  PH	   increases	   IL-­‐6	  expression.	  We	   further	  demonstrated	   that	  dexamethasone	   reduced	  IL-­‐6	  expression	  in	  all	  the	  cell	  and	  tissue	  samples	  measured.	  My	  immunohistochemistry	  results	  suggested	  that	   the	  prominent	  source	  of	   IL-­‐6,	  at	   least	  at	   the	  time	  of	  assessment	  at	  day	  28,	  was	  from	   perivascular	   inflammatory	   cells.	   Further	   to	   IL-­‐6,	   I	   would	   also	   like	   to	   have	   performed	  additional	  experiments	  to	  assess	  CXCL8	  expression	  (using	  rat	  CXCL8,	  CINC-­‐1).	  In	  hypoxic	  mice	  with	  PH,	  IL-­‐6	  was	  also	  increased	  in	  the	  vascular	  wall	  (Savale	  et	  al.,	  2009).	  My	  later	  experiments	  with	  PASMC,	  and	  others	  where	  stimulated	  PASMC	  (and	  EC)	  released	  IL-­‐6	  (Steiner	  et	  al.,	  2009,	  Hagen	   et	   al.,	   2007),	   suggest	   that	   PASMC	   also	   play	   an	   active	   role	   in	   pulmonary	   vascular	  inflammation	  via	  the	  NF-­‐κB	  dependent	  release	  of	  chemokines	  and	  pro-­‐inflammatory	  cytokines.	   
IL-­‐6	   has	   been	   shown	   to	   be	   directly	   pro-­‐proliferative	   in	   vascular	   SMC	   (Ikeda	   et	   al.,	   1991),	  supporting	  an	  autocrine	  role.	  In	  a	  gastric	  cancer	  cell	  line,	  IL-­‐6	  even	  directly	  inhibited	  apoptosis	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through	   inhibition	   of	   JNK	   signalling	   and	   subsequent	   cell	   death	   (Lin	   et	   al.,	   2001).	   Hagen	   et	   al	  identified	   a	   regulatory	   loop	   involving	   both	   the	   IL-­‐6	   and	   the	   BMP	   pathways,	   in	   which	  upregulated	   IL-­‐6	   was	   seen	   in	   mice	   and	   PASMC	   lacking	   functional	   BMPR-­‐II	   and	   that	   IL-­‐6	  administration	   in	   vivo	   increased	   BMP	   pathway	   activity	   (Hagen	   et	   al.,	   2007).	   Furthermore,	  pulmonary	   arterial	   EC	   co-­‐treated	   with	   IL-­‐6	   and	   MCT	   in	   vitro	   increased	   proliferation	   due	   to	  enhanced	  activation	  of	  STAT3	  (Mathew	  et	  al.,	  2004).	   	  Persistent	  activation	  of	  STAT3	  has	  been	  shown	   to	   reduce	  BMPR-­‐II	   expression	   (Brock	  et	  al.,	   2009).	   	  Although	  asymptomatic	  BMPR-­‐II+/-­‐	  mice	  do	  not	  develop	  PH	  spontaneously,	  under	  inflammatory	  stress	  they	  are	  more	  susceptible	  to	  PH	   than	   wild-­‐type	   mice	   (Song	   et	   al.,	   2005),	   and	   that	   mice	   expressing	   a	   dominant	   negative	  BMPR-­‐II	   in	   smooth	  muscle	   develop	   elevated	  RV	   pressures,	  with	   an	   increase	   in	   cytokines	   and	  markers	  of	  immune	  response,	  when	  the	  transgene	  is	  activated	  (Tada	  et	  al.,	  2007).	  This	  provides	  further	  support	   for	  BMPR-­‐II	  dysfunction	  and	  resulting	   loss	  of	  activity	  causing	  unopposed	   IL-­‐6	  production	  in	  the	  context	  of	  an	  inflammatory	  stimulus.	  	  
I	  hypothesized	  that	  NF-­‐κB	  could	  be	  a	  link	  through	  which	  dexamethasone	  reduced	  cytokines	  and	  PASMC	   survival.	   Indeed,	   we	   showed	   that	   specific	   inhibition	   of	   NF-­‐κB	   suppressed	   IL-­‐6	   and	  CXCL8	   release	   to	   similar	   extent	   as	   dexamethasone,	   and	   inhibited	   PASMC	   nuclear	   p65	  translocation	   by	   TransAm	   assay.	   NF-­‐κB	   is	   known	   to	   have	   important	   pro-­‐survival	   effects	   on	  immune	   and	   non-­‐immune	   cells.	   For	   example	   in	   vascular	   SMC,	   various	   stimuli	   including	   basic	  fibroblast	  growth	   factor	  (βFGF)	   increase	  proliferation	  and	  NF-­‐κB	  activation.	  Using	  an	  a	  NF-­‐κB	  reporter	   gene	   assay,	   addition	   of	   an	   ERK	   (a	   pro-­‐proliferative	  MAPK)	   inhibitor	   reduced	   NF-­‐κB	  transcriptional	  activity	  as	  well	  as	  proliferation	   induced	  by	  βFGF,	  suggesting	  that	  ERK	  1/2	  was	  important	  in	  NF-­‐κB	  activation	  and	  SMC	  proliferation	  modulation	  of	  IκBα	  degradation	  (Hoshi	  et	  al.,	  2000).	   In	   systemic	  vascular	  cells	   from	  mice	  overexpressing	   IκBα,	  proliferation	   in	  systemic	  vascular	   fibroblasts	   was	   reduced,	   with	   an	   associated	   reduction	   in	   cyclin	   D1	   expression.	  However,	   the	  same	  was	  not	  seen	  in	  systemic	  vascular	  SMC,	  suggesting	  a	  cell-­‐type	  specific	  role	  for	  NF-­‐κB	  in	  the	  regulation	  of	  proliferation	  (Mehrhof	  et	  al.,	  2005).	  In	  human	  PASMC,	  Ogawa	  et	  al	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showed	   that	   PDGF-­‐induced	   NF-­‐κB	   activation	   and	   PASMC	   proliferation	   was	   inhibited	   by	  prednisolone	  (Ogawa	  et	  al.,	  2008b).	  	  
My	   results	   suggest	   that	   at	   least	   one	   of	   the	   mechanisms	   by	   which	   dexamethasone	   induced	  apoptosis	   could	   be	   via	   NF-­‐κB	   inhibition	   –	   although	   as	   my	   experiments	   showed	   that	  dexamethasone	   only	   partly	   suppressed	   NF-­‐κB	   activity,	   it	   does	   suggest	   there	   may	   also	   be	  additional	  mechanisms,	  which	  could	   include	  AP-­‐1	  or	  MAPK	   inhibition	  (Helmberg	  et	  al.,	  1995).	  There	   have	   been	  no	   similar	   studies	  where	  GC	  have	   induced	   apoptosis	   in	   other	   vascular	   SMC,	  although	  NF-­‐κB	   is	   implicated	   in	   protecting	   against	   apoptosis	   in	   several	   cell	   types	   –	   including	  those	  lacking	  NF-­‐κB	  components	  such	  as	  IKK-­‐2	  (Karin	  and	  Lin,	  2002).	  The	  association	  of	  NF-­‐κB	  with	   apoptosis	   regulation	   was	   first	   noted	   in	   RelA-­‐/-­‐	   mice	   that	   developed	   fatal	   hepatocyte	  apoptosis	   (Beg	   et	   al.,	   1995).	   	   NF-­‐κB	   also	   regulates	   apoptosis	   in	   aortic	   SMC,	   where	   elevating	  endogenous	   IκBα	   levels,	   by	   overexpression	  or	   by	   inhibiting	   its	   degradation	  with	  proteasomal	  inhibitors,	  increased	  apoptosis	  (Erl	  et	  al.,	  1999).	  It	  is	  understood	  that	  products	  of	  certain	  NF-­‐κB	  target	  genes	  inhibit	  apoptosis.	  These	  gene	  products	  include	  caspase-­‐8-­‐c-­‐FLIP,	  cellular	  inhibitors	  of	  apoptosis	  (c-­‐IAPS),	  A1	  (also	  known	  as	  Bfl1),	  TNFR-­‐associated	   factor	  1	  (TRAF1)	  and	  TRAF2.	  Caspase-­‐8-­‐c-­‐FLIP,	  cIAPS	  and	  A1	  act	  in	  concert	  to	  block	  apoptosis	  at	  multiple	  steps	  in	  apoptotic	  signalling	  (Karin	  and	  Lin,	  2002).	  	  
Indeed,	  NF-­‐κB	  aides	  the	  long	  term	  survival	  of	  lymphocytes	  and	  epithelial	  cells,	  as	  TNF-­‐α	  induces	  an	  increase	  their	  apoptosis	  in	  the	  absence	  of	  NF-­‐κB	  (Senftleben	  et	  al.,	  2001,	  Baldwin,	  2001).	  As	  cancers	   of	   these	   cell	   types	   show	   constitutive	   activation	   of	   NF-­‐κB,	   it	   is	   thought	   that	   the	   anti-­‐apoptotic	   function	  of	  NF-­‐κB	   is	   a	   likely	  major	  obstacle	   to	   the	   effectiveness	  of	   cancer	   therapies	  (Baldwin,	   2001).	   Indeed,	   constitutive	   activation	   of	   NF-­‐κB	   was	   demonstrated	   in	   PASMC	   from	  patients	  with	  heritable	  PAH	  (HPAH)	  (Davies	  et	  al.,	  2012).	  Here,	  Davies	  et	  al	  also	  suggest	  that	  IL-­‐6	   and	   CXCL8	   play	   a	   role	   in	   the	   resistance	   of	   PASMC	   to	   growth-­‐inhibition	   by	   TGF-­‐β	   in	   HPAH	  PASMC.	  Microarray	  analysis	  revealed	  an	  increase	  in	  TGF-­‐β-­‐induced	  IL-­‐6	  and	  CXCL8	  expression.	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This	  was	   reversed	   by	  NF-­‐κB	   inhibition	   using	   BMS-­‐345541,	   an	   IKK-­‐2	   inhibitor,	   and	   SN-­‐50,	   an	  inhibitor	   of	   NF-­‐κB	   nuclear	   translocation,	   as	   was	   the	   ability	   of	   TGF-­‐β	   to	   evoke	   an	   anti-­‐proliferative	  effect	  on	  HPAH	  PASMC	  by	   IL-­‐6	  and	  CXCL-­‐8	  neutralising	  antibodies	   (Davies	  et	  al.,	  2012).	   These	   results	   suggest	   that	   BMPR-­‐II	   dysfunction	   is	   associated	   with	   increased	   NF-­‐κB	  signalling,	   IL-­‐6	   and	   CXCL8	   activity,	   and	   excessive	   PASMC	   proliferation.	   This	   nicely	   fits	   the	  hypothesis	   that	  dysregulated	  BMPR-­‐II	   signalng	   is	   followed	  by	   an	   inflammatory	   ‘second	  hit’	   in	  the	  pathogenesis	  of	  PAH.	  	  We	  showed	  that	  there	  was	  a	  reduction	  in	  lung	  BMPR-­‐II	  expression	  in	  MCT-­‐induced	  PH	  in	  rats	  confirming	  previous	  studies	  (Morty	  et	  al.,	  2007,	  Long	  et	  al.,	  2009).	  	  Our	  novel	   finding	  was	   that	  BMPR-­‐II	  mRNA	  was	   restored,	   although	  not	   normalised,	   in	  whole	   lung,	  although	   not	   in	   PASMC,	   following	   dexamethasone	   treatment	   in	   the	   MCT-­‐induced	   PH	   model.	  Along	   these	   lines	  of	   consideration,	  one	  of	  our	   further	  planned	  experiments	  would	  be	   to	  more	  specifically	   assess	   the	   effect	   of	   the	   IKK-­‐2	   inhibitor	   AS602868	   on	   the	   transcription	   and	  expression	  of	  BMPR-­‐II	  in	  PASMC.	  
My	   experiments	   had	   some	   discrepancies	   from	   predicted	   results.	   	   Firstly,	   the	   dose-­‐response	  effect	   of	   dexamethasone	   in	   my	   experiments	   on	   BMPR-­‐II	   and	   IL-­‐6	   mRNA	   expression	   was	   the	  opposite	   of	   that	   expected.	   This	   could	   relate	   to	   the	   relatively	   small	   numbers	   used	   in	   the	   PCR	  analysis	   compared	   to	   the	   functional	   in	  vivo	   study.	  Secondly	  we	  hypothesised	   that	   the	  changes	  would	   have	   been	   reflected	   in	   PASMC	   but	   they	   were	   not.	   This	   suggests	   that	   the	   GC-­‐induced	  changes	  in	  BMPR-­‐II	  were	  not	  localised	  to	  PASMC	  but	  to	  other	  cells,	  perhaps	  to	  EC,	  which	  would	  be	   interesting	   to	   examine.	   It	   would	   also	   be	   good	   to	   demonstrate	   a	   similar	   change	   in	   protein	  levels	  in	  whole	  lung	  and	  then,	  if	  possible,	  to	  perform	  IHC	  to	  identify	  the	  cell	  type	  which	  is	  most	  involved	  in	  these	  GC-­‐induced	  alterations	  in	  BMPR-­‐II.	  	  I	  did	  attempt	  to	  do	  this	  but	  was	  unable	  to	  obtain	  a	  good	  enough	  anti-­‐rat	  antibody	  for	  BMPR-­‐II.	  
Together	  these	  results	  do	  suggest	  that	  the	  use	  of	  GC	  interrupts	  the	  NF-­‐κB/BMPR-­‐II-­‐IL-­‐6/CXCL8	  negative	  feedback	  loop,	  i.e.	  inducing	  a	  reduction	  in	  NF-­‐κB;	  an	  increase	  in	  BMPR-­‐II	  and	  thereafter	  a	   fall	   in	   inflammatory	  cytokine	  transcription.	  This	  could	  be	  through	  a	  dexamethasone-­‐induced	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reduction	  in	  IL-­‐6-­‐expressing	  inflammatory	  cells	  or	  a	  direct	  effect	  on	  PASMC.	  GCs	  are	  known	  to	  inhibit	   NF-­‐κB	   activation	   through	   direct	   interaction	   of	   the	   GR	   with	   p65	   in	   the	   nucleus	   thus	  inhibiting	  transcription	  of	  inflammatory	  genes.	  The	  mechanisms	  by	  which	  glucocorticoids	  might	  increase	  BMPR-­‐II	  gene	  expression	  are	  unclear	  (Donn	  et	  al.,	  2007),	  and	   it	  will	  be	   interesting	  to	  determine	  how	  GC	  may	  regulate	  BMPR-­‐II	  and	  in	  which	  cells.	  
In	   conclusion,	   I	   have	   demonstrated	   that	   dexamethasone	   exerted	   anti-­‐remodelling	   effects	   on	  PASMC	  in	  the	  rat	  MCT	  PH	  model	  both	  through	  an	  inhibition	  of	  proliferation	  and	  an	  induction	  of	  apoptosis	   in	   these	   cells.	   The	   effects	   on	   proliferation,	   but	   not	   apoptosis,	   were	   relatively	  suppressed	  in	  PASMC	  isolated	  from	  rats	  exposed	  to	  MCT,	  suggesting	  a	  relative	  GC	  resistance	  in	  the	  model.	   In	   rat	  whole	   lung,	  we	   showed	   that	   IL-­‐6	   expression	  was	  prominent	   in	  perivascular	  inflammatory	   cells,	   and	   that	   this	  was	   reduced	  by	  dexamethasone	   treatment.	  When	  moving	   to	  human	   PASMC,	   we	   showed	   that	   TNF-­‐induced	   IL-­‐6	   and	   CXCL8	   release	   was	   inhibited	   by	   both	  dexamethasone	  and	  by	  IKK-­‐2	  inhibition	  suggesting	  that	  dexamethasone	  was	  acting	  by	  inhibiting	  NF-­‐κB.	  	  
5.4.2	  Clinical	  application	  
My	   results	   showing	   anti-­‐remodelling	   effects	   of	   dexamethasone	   in	   the	   MCT	   model	   provide	   a	  rationale	   for	   clinical	   trials	  using	  GC	   in	  patients	  with	   iPAH,	   as	  well	   as	  patients	  with	  associated	  inflammatory	   causes	   of	   PAH.	   The	   fact	   that	   IKK-­‐2	   inhibition	   exerted	   similar	   effects	   as	  dexamethasone	   on	   cytokine	   release,	   at	   least	   in	   control	   human	   cells,	   is	   encouraging	   as	   these	  agents	   are	   likely	   to	   have	   less	   systemic	   side	   effects	   than	   GC	   although	   they	   may	   lead	   to	  opportunistic	  infections	  due	  to	  complete	  suppression	  of	  the	  innate	  immune	  system	  with	  chronic	  treatment.	   In	  my	  view,	  before	  consideration	  of	  proceeding	  to	  clinical	   trials,	   these	  experiments	  using	  GC	  and	  IKK	  inhibition	  need	  to	  be	  repeated	  in	  PASMC	  from	  PAH	  patients,	   including	  those	  with	  HPAH,	  and	  IKK	  inhibition	  studies	  performed	  in	  vivo	  in	  several	  models	  of	  PAH.	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5.4.3	  Future	  experiments	  
Firstly,	  I	  am	  planning	  to	  perform	  experiments	  to	  assess	  whether	  NF-­‐κB	  inhibition	  might	  induce	  apoptosis	  in	  human	  PASMC.	  If	  this	  held	  true,	  it	  would	  fit	  with	  the	  hypothesis	  that	  activation	  of	  NF-­‐κB	   was	   a	   cell	   survival	   factor	   and	   a	   mechanism	   of	   the	   pro-­‐apoptotic	   property	   of	  dexamethasone	   that	   I	   have	   demonstrated.	   Secondly,	   as	  mentioned,	   I	  would	   like	   to	   assess	   the	  effects	   of	   IKK-­‐2	   inhibition	   on	   BMPR-­‐II	   expression,	   to	   see	   if	   the	   effects	   induced	   by	  dexamethasone	  on	  cytokine	  release	  might	  be	  influenced	  by	  a	  loop	  containing	  NF-­‐κB	  and	  BMPR-­‐II	   –	   as	  proposed	   in	   the	   study	  by	  Davies	  et	  al	   (Davies	  et	   al.,	   2012).	   In	  addition,	   I	  would	   like	   to	  assess	  the	  effects	  of	  dexamethasone	  and	  IKK-­‐2	  inhibition	  on	  cytokine	  release	  from	  PASMC	  from	  patients	  with	  BMPR-­‐II	  mutations	   –	   further	   to	   those	  on	   control	   PASMC	   -­‐	   to	   see	   if	   they	  display	  relative	   resistance	   to	   the	   suppressive	   effects	   of	   both	   dexamethasone	   and	   IKK-­‐2	   inhibition	   on	  cytokine	   release	   and	   proliferation/apoptosis.	   In	   addition	   it	  would	   be	   useful	   to	   determine	   the	  potential	   mechanisms	   by	   which	   dexamethasone	   is	   reducing	   proliferation	   and	   increasing	  apoptosis	   (including	   the	   observed	   difference	   between	   control	   and	   pulmonary	   hypertensive	  PASMC).	   For	   example,	   that	   the	   effect	   is	   mediated	   via	   the	   GR	   using	   mifepristone;	   that	   other	  important	   transcription	   factors	   including	   AP-­‐1	   may	   be	   repressed;	   the	   actions	   on	   cell	   cycle	  proteins	  such	  as	  c-­‐myc	  and	  cyclin	  D	  and	  whether	  inhibiting	  anti-­‐apoptotic	  NF-­‐κB-­‐regulated	  gene	  products	   such	   as	   the	   ‘IAP’	   proteins	   and	   surviving	   increases	   apoptosis.	   Finally	   it	   might	   be	  interesting	   to	   assess	   the	   effects	   of	   dexamethasone	   on	   apoptosis	   early	   vs.	   late	   in	   the	   MCT-­‐induced	  PH	  model,	   to	  hypothesise	   that	   earlier	   induction	  of	   apoptosis	   is	  more	  efficacious	   than	  that	  occurring	  later.	  
Laura	  Price	  PhD:	  Inflammation	  in	  Pulmonary	  Arterial	  Hypertension	   184	  
CHAPTER	  6:	  INFLAMMATORY	  CELL	  BEHAVIOUR	  IN	  
PATIENTS	  WITH	  IDIOPATHIC	  PULMONARY	  ARTERIAL	  
HYPERTENSION	  
	  
6.1	  Rationale	   	  
Circulating	   plasma	   cytokines	   and	   chemokines	   are	   elevated	   in	   patients	   with	   idiopathic	   PAH	  (Humbert	  et	  al.,	  1995,	  Soon	  et	  al.,	  2010,	   Itoh	  et	  al.,	  2006,	  Selimovic	  et	  al.,	  2009),	  with	  some	  of	  these	  -­‐	  notably	  IL-­‐6	  (Selimovic	  et	  al.,	  2009,	  Soon	  et	  al.,	  2010),	  CXCL-­‐8,	  IL-­‐10	  and	  IL-­‐12	  (Soon	  et	  al.,	   2010)	   independently	   associated	  with	  mortality.	   Further	   to	   these	   baseline	   plasma	   studies,	  there	  have	  been	  no	  studies	  comparing	  the	  release	  of	  cytokines	   from	  cells	   from	  idiopathic	  PAH	  patients	   with	   those	   from	   control	   subjects,	   in	   order	   to	   test	   the	   hypothesis	   that	   patients’	   cells	  might	   release	   both	   higher	   levels	   of	   cytokines	   at	   baseline	   and	   following	   activation	   with	  inflammatory	   stimuli.	   Given	   that	   pulmonary	   vascular	   and	   inflammatory	   cells	   are	   relatively	  inaccessible	  in	  patients	  with	  PAH,	  I	  selected	  to	  study	  peripheral	  blood	  circulating	  inflammatory	  cells	  to	  examine	  whether	  those	  from	  patients	  might	  behave	  differently	  from	  those	  isolated	  from	  control	   subjects,	   thereby,	   potentially,	   detecting	   an	   altered	   inflammatory	   phenotype.	   To	  investigate	   this,	   I	   isolated	   peripheral	   blood	  mononuclear	   cells	   (PBMC)	   and	   also	   used	   a	  whole	  blood	  (WB)	  assay.	  The	  PBMC	  layer	  contains	  cells	  of	  relevance	  to	  PAH	  including	  monocytes	  (so	  following	  from	  our	  previous	  evidence	  for	  activation	  of	  lung	  macrophages	  in	  chapter	  3),	  as	  well	  as	  other	  cells	  implicated	  in	  the	  disease	  process	  including	  lymphocytes	  and	  mast	  cells	  (Heath	  and	  Yacoub,	   1991,	   Perros	   et	   al.,	   2012,	  Tuder	   et	   al.,	   1994).	   In	   addition,	  WB	  assays	  were	  used,	   as	   a	  model	   containing	  all	   the	  necessary	  serum	   factors	   required	   for	   cell	   activation.	  WB	  assays	  have	  been	  used	  in	  many	  studies	  and	  are	  considered	  useful	  predictors	  of	  cytokine	  release	  from	  human	  blood	  in	  preclinical	  studies	  of	  monoclonal	  antibodies	  (Walker	  et	  al.,	  2011).	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Relatively	  little	  is	  known	  about	  circulating	  inflammatory	  cells	  in	  PAH.	  Their	  homing	  to	  diseased	  pulmonary	  arteries	  is	  influenced	  by	  chemokines	  released	  by	  endothelial	  (and	  other)	  cells,	  which	  may	  occur	  via	  prominent	  vasa	  vasorum	   in	  diseased	  pulmonary	  arteries	  (Montani	  et	  al.,	  2011).	  The	   relative	   contribution	   of	   the	   monocyte/macrophage	   population	   seen	   in	   PAH	   i.e.	   from	  resident	  lung	  cells	  and/or	  circulating	  blood	  monocytes	  is	  not	  certain.	  As	  discussed	  in	  Chapter	  1,	  an	  increase	  in	  CD14+	  monocytes	  in	  pulmonary	  arterial	  adventitia	  is	  seen	  in	  human	  iPAH	  (Savai	  et	   al.,	   2012b)	   with	   elevated	   plasma	   and	   lung	   tissue	   levels	   of	   monocyte	   chemoattractants	  including	   MCP-­‐1	   (Itoh	   et	   al.,	   2006),	   fracktalkine	   (Balabanian	   et	   al.,	   2002)	   and	   RANTES	  (Dorfmuller	  et	  al.,	  2002).	  Further	  evidence	  for	  a	  potential	  role	  for	  the	  recruitment	  and	  activation	  of	  monocytes	  was	   suggested	  by	  a	   recent	   study	   in	   the	  MCT-­‐induced	  PH	  model	  where	  blocking	  monocyte	  recruitment	  led	  to	  regression	  of	  PH	  (Savai	  et	  al.,	  2012b).	  
Having	  demonstrated	  an	  increase	  in	  NF-­‐κB	  activation	  in	  resident	  lung	  macrophages	  in	  Chapter	  3,	   I	   selected	   classical	   activators	   of	   NF-­‐κB	   for	   these	   experiments	   -­‐	   bacterial	   endotoxin	  (lipopolysaccharide,	   LPS)	   and	   tumour	   necrosis	   factor	   (TNF)-­‐α	   (Barnes	   and	   Karin,	   1997).	   In	  addition,	  these	  stimuli	  were	  selected	  as	  they	  are	  relevant	  to	  PAH	  pathophysiology.	  Plasma	  TNF-­‐α	  is	  produced	  by	  activated	  (M1)	  macrophages,	  and	  is	  elevated	  and	  associated	  with	  lower	  cardiac	  index	   in	   PAH	   (Itoh	   et	   al.,	   2006,	   Soon	   et	   al.,	   2010).	   In	   sheep,	   infusion	   of	   TNF-­‐α	   caused	   PH	   in	  association	   with	   an	   early	   pulmonary	   neutrophilic	   infiltration	   followed	   by	   a	   perivascular	  mononuclear	  cell	  infiltration,	  and	  peripheral	  blood	  leucopaenia	  (Johnson	  et	  al.,	  1991).	  In	  a	  more	  chronic	   model,	   TNF-­‐α-­‐overexpressing	   transgenic	   mice	   developed	   severe	   emphysema	   and	   PH	  with	  irreversible	  pulmonary	  vascular	  remodelling	  (Fujita	  et	  al.,	  2001).	  	  
There	  is	  some	  evidence	  implicating	  LPS	  in	  PAH.	  When	  ‘chronically’	   infused	  into	  sheep	  over	  14	  weeks,	  LPS	  reduced	  pulmonary	  vasoreactivity	  and	  PH	  developed	  from	  8	  weeks,	  reaching	  a	  50%	  increase	   in	   mPAP	   from	   18mmHg	   at	   baseline	   to	   28mmHg	   at	   week	   10,	   with	   perivascular	  infiltration	  of	  granulocytes,	  monocytes	  and	   lymphocytes,	  and	  pulmonary	  vascular	  remodelling	  (Meyrick	  and	  Brigham,	  1986).	  Microarray	  studies	  of	  PBMC	  showed	  an	  upregulation	  of	  Toll-­‐Like	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receptor	  (TLR)-­‐4	  in	  patients	  with	  idiopathic	  PAH	  (Bull	  et	  al.,	  2004);	  in	  addition,	  normal	  human	  PASMC	   (George	   et	   al.,	   2012,	   Yang	   et	   al.,	   2005a)	   and	   endothelial	   cells	   (George	   et	   al.,	   2012)	  express	  TLR-­‐4	  although	  PASMC	  do	  not	  express	  CD14	  (Yang	  et	  al.,	  2005a).	  Finally,	  a	  recent	  study	  (in	  abstract	   form)	  showed	  that	  mice	  heterozygous	  for	  a	  null	  allele	  resulting	  in	   loss	  of	  BMPR-­‐II	  function,	  and	  human	  PASMC	  from	  patients	  with	  a	  mutation	  in	  BMPR2,	  both	  had	  increased	  IL-­‐6	  and	   CXCL8	   at	   baseline	   and	   following	   stimulation	   with	   LPS,	   with	   increased	   phospho-­‐Stat3	  signalling	   and	   pro-­‐proliferative	   and	   pro-­‐survival	   effects	   of	   IL-­‐6	   seen	   in	   PASMC	   from	   patients	  with	  BMPR-­‐II	  mutations	  (Soon,	  2010).	  These	  studies	  thus	  provide	  a	  rationale	  for	  the	  use	  of	  LPS	  and	  TNF-­‐α	  as	  disease-­‐relevant	  stimuli.	  	  
As	   inflammatory	   end-­‐points,	   I	   measured	   activation	   of	   NF-­‐κB	   (using	   p65	   TransAm	   assays	   of	  PBMC	   nuclear	   extracts)	   and	   IL-­‐6	   and	   CXCL8	   expression,	   which	   as	   mentioned	   above	   are	  particularly	  implicated	  in	  PAH	  (Selimovic	  et	  al.,	  2009,	  Soon	  et	  al.,	  2010)	  (and	  see	  Chapter	  1).	  In	  addition	  I	  had	  shown	  in	  the	  previous	  chapter	  that	  IL-­‐6	  and	  CXCL8	  were	  elevated	  and	  reduced	  by	  dexamethasone	   treatment	   in	   the	   rat	   MCT-­‐PH	   model.	   I	   investigated	   the	   effect	   of	   in	   vitro	  dexamethasone	  on	  inhibition	  of	  cytokine	  response,	  as	  steroids	  are	  known	  to	  work	  largely	  on	  the	  NF-­‐κB	  pathway,	  as	  well	  as	  being	  a	  potential	  therapeutic	  option.	  One	  obvious	  confounding	  factor	  was	   medications,	   especially	   “advanced	   PAH	   therapies”	   such	   as	   sildenafil,	   bosentan	   and	  prostacyclin.	   For	   instance	   sildenafil,	   a	   phosphodiesterase	   type-­‐5	   (PDE-­‐5)	   inhibitor,	   is	   a	  commonly	   used	   PH	   therapy	   that	   augments	   nitric	   oxide	   (NO)	   signalling	   (through	   inhibition	   of	  PDE-­‐5	   thus	   augmenting	   cyclic	   GMP);	   NO	   is	   known	   to	   inhibit	   cytokine	   release	   from	   alveolar	  macrophages	  from	  PAH	  patients	  by	  inhibiting	  NF-­‐κB	  p65	  nuclear	  translocation	  (Raychaudhuri	  et	  al.,	  1999).	  Following	  from	  this,	  I	  was	  also	  interested	  to	  assess	  the	  potential	  effects	  of	  sildenafil	  on	  NF-­‐κB-­‐induced	  CXCL8	  release,	  as	  a	  potential	  confounding	  factor.	  
My	  experimental	  aims	  for	  this	  chapter	  were	  therefore	  as	  follows:	  
1. To	   determine	   whether	   inflammatory	   cells	   behave	   in	   a	   hyper-­‐responsive,	  hyporesponsive	  or	  equivalent	  manner	   following	   stimuli	  known	   to	  activate	  NF-­‐κB	   (LPS	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and	   TNF-­‐α),	   in	   WB	   and	   PBMC	   isolated	   from	   PAH	   patients	   compared	   to	   those	   from	  controls.	  
2. To	  assess	  whether	  inflammatory	  cells	  from	  PAH	  patients	  (in	  WB	  and	  PBMC)	  behave	  in	  a	  dexamethasone-­‐resistant	  manner	  compared	  to	  those	  from	  controls.	  
3. To	  perform	  preliminary	   experiments	   to	   investigate	   the	   effect	   of	   sildenafil	   on	   cytokine	  release	  from	  WB.	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6.2	  Experimental	  protocols	  
6.2.1	  Selection	  of	  patients	  &	  controls	  
Ethical	   approval	   for	   venesection	   from	  patients	   and	  healthy	  volunteers	  was	  obtained	   from	   the	  Royal	   Brompton	   Hospital	   Cardiovascular	   Biomedical	   Research	   Unit	   Tissue	   Bank	   Ethics	  Committee,	  reference	  09/H0504/104.	  Cytokine	  release	  from	  PMBC	  has	  been	  shown	  to	  be	  age-­‐dependent;	  precise	  age	  matching	  of	  controls	  was	  therefore	  essential.	  In	  addition,	  subjects	  who	  had	   taken	  non-­‐steroidal	   anti-­‐inflammatory	  drugs	  within	  1	  month	  of	   the	   study	  were	  excluded.	  Concomitant	   clinical	   data	   was	   collected	   for	   patients	   including	   full	   blood	   count,	   C-­‐reactive	  protein	   (CRP),	   brain	   natriuretic	   peptide	   (BNP),	   and	   PH	   clinical	   endpoints	   including	   NYHA	  functional	  class;	  6-­‐minute	  walk	  test,	  invasive	  pulmonary	  haemodynamic	  and	  echocardiographic	  data.	  	  
6.2.2	  Venesection	  
The	   required	   volume	   of	   whole	   blood	   was	   pre-­‐determined	   knowing	   that	   the	   yield	   from	   the	  selected	   methods	   of	   PBMC	   isolation	   was	   1-­‐2	   million	   cells	   per	   ml.	   Venous	   blood	   (45ml	   per	  subject)	  was	  taken	  in	  commercial	  vacutainers	  (BD	  bioscience)	  containing	  sodium	  citrate	  (0.1M)	  from	  all	  subjects.	  Processing	  of	  fresh	  whole	  blood	  was	  performed	  at	  room	  temperature	  ideally	  within	   30	   minutes	   of	   blood	   taking	   aseptically	   in	   a	   “class	   II”	   biological	   safety	   hood.	   Cellular	  mechanical	   stress	   was	   avoided	   (gentle	   pipetting;	   avoidance	   of	   air	   bubbles),	   and	   all	   culture	  media	  was	  warmed	  prior	  to	  use	  for	  at	  least	  15	  minutes	  at	  37°C.	  	  
6.2.3	  Treatment	  of	  whole	  blood	  (WB)	  and	  peripheral	  blood	  
mononuclear	  cells	  (PBMC)	  	  
LPS	   (0-­‐1μg/ml)	   (a	   single	   batch	   of	   E.	   Coli	   O26:B6	   (Sigma	   Aldrich,	   St	   Louis)	   used	   in	   all	  experiments),	  recombinant	  human	  TNF-­‐α	  (0-­‐10ng/ml)	  (R&D	  systems),	  LPS	  1μg/ml	  and	  TNF-­‐α	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10ng/ml	  ±	  dexamethasone	  (0.1-­‐1μM)	  (Sigma,	  dissolved	  in	  ethanol)	  and	  LPS	  1μg/ml	  ±	  sildenafil	  (1μM,	  Pfizer,	  dissolved	  in	  water)	  were	  prepared	  in	  volume	  of	  10μl	  in	  serum	  free	  RPMI	  medium.	  Whole	   citrated	   blood	   (190μl)	   was	   plated	   into	   wells	   of	   a	   96-­‐well	   plate	   and	   pre-­‐prepared	  treatments	  added	  (10μl	  per	  well)	  for	  24h	  at	  37°C	  in	  5%	  CO2.	  	  Following	  PBMC	  isolation	  from	  the	  remainder	   of	   the	   WB,	   100μl	   of	   suspended	   PBMC	   (containing	   105	   PBMC)	   and	   90µl	   10%	  FCS/RPMI	  was	  plated	  with	  10μl	  of	   treatments	   to	  make	  up	   to	  200μl	  per	  well	   (so	  all	   treatment	  were	  diluted	  1:20)	  for	  24	  hours	  at	  37°C.	  	  Plates	  were	  then	  centrifuged	  at	  1000xg	  for	  5	  minutes;	  plasma	   aspirated	   from	   WB	   and	   PBMC,	   then	   samples	   frozen	   at	   -­‐20°C.	   	   Alamar	   blue	   viability	  assays	   were	   immediately	   performed	   on	   the	   PBMC	   plates	   (see	   Chapter	   2),	   and	   ELISA	   assays	  performed	  at	  a	  later	  date.	  	  	  
6.2.4	  IL-­‐6	  and	  CXCL8	  ELISAs	  and	  NF-­‐κB	  assays	  
ELISA	  assays	  for	  IL-­‐6	  and	  CXCL8	  were	  performed	  on	  frozen	  supernatants	  from	  WB	  and	  PBMC	  in	  duplicate	   according	   to	   the	  manufacturer’s	   instructions	   (R&D	  Systems,	   see	  Chapter	  2).	   Control	  samples	  required	  1:2	  dilutions;	  stimulated	  samples	  required	  1:10	  to	  1:50	  dilutions	  to	  maintain	  measurements	  within	  the	  linear	  part	  of	  the	  standard	  curves.	  	  
Nuclear	  extracts	  of	  PMBC	  were	  prepared	  and	  frozen	  at	  -­‐80°C	  as	  described	  in	  chapter	  2;	  protein	  content	  was	   determined	   by	   the	  Bradford	   assay;	   and	  NF-­‐κB	  DNA	  binding	   assay	   performed	   on	  thawed	  nuclear	  extracts	  using	  TransAm®	  Kits	  (DNA-­‐binding	  ELISAs,	  Active	  Motif	  ®),	  according	  to	  the	  manufacturer’s	  instructions.	  	  	  
6.2.5	  Data	  analysis	  
Data	   analysis	  was	  performed	  using	  Microsoft	  Excel	   for	  data	  preparation	   and	  GraphPad	  Prism	  5.0	  for	  statistical	  analysis.	  Data	  were	  assessed	  for	  adherence	  to	  a	  normal	  distribution	  using	  the	  Kolmogorov-­‐Smirnov	  method.	  For	  each	  concentration-­‐response	  curve,	  the	  individual	  values	  for	  EC50,	  Emax	  and	  Imax	  were	  tabulated	  from	  Prism-­‐calculated	  values,	  with	  Emax	  or	  Imax	  defined	  as	  the	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maximum	   or	   minimum	   effect,	   i.e.	   the	   top	   or	   bottom	   value	   depending	   on	   whether	   an	  agonist/inhibitor	  was	  used;	  and	  EC50	  the	  concentration	  of	  agonist/antagonist	  required	  to	  induce	  or	  inhibit	  half	  of	  the	  maximum	  biological	  response,	  respectively.	  The	  term	  IC50	  was	  not	  used,	  as	  complete	   inhibition	   was	   not	   achieved.	   The	   mean	   or	   median	   values	   were	   compared	   using	  Student	   t-­‐tests	   or	  Mann	  Whitney	   tests	   for	   parametric	   or	   non-­‐parametric	   data	   as	   appropriate.	  Multiple	  comparisons	  were	  performed	  using	  one-­‐way	  ANOVA	  (for	  parametric	  data)	  or	  Kruskal	  Wallis	  (for	  non-­‐parametric	  data),	  with	  appropriate	  post-­‐tests,	  and	  for	  comparing	  ranked	  values	  normalised	  to	  baseline,	  the	  Wilcoxon	  signed	  rank	  test	  and	  signed	  rank	  pairs	  test	  were	  used	  for	  parametric	  and	  non-­‐parametric	  data	  respectively.	  Values	  of	  p<0.05	  were	  considered	  statistically	  significant.	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6.3	  Results	  &	  Figures	  	  
6.3.1	  Clinical	  and	  demographic	  data	  
Patients	  with	  idiopathic	  PAH	  (n=12)	  were	  selected	  at	  random,	  and	  control	  subjects	  (n=9)	  were	  carefully	   age-­‐matched	   (36.2±2.7	   vs.	   36.5±3.7	   in	   PAH,	   p=NS).	   	   All	   subjects	   were	   non-­‐smokers	  (Table	  6.1).	  Clinical	  and	  haemodynamic	  characteristics	  of	  PAH	  patients	  are	  displayed	   in	  Table	  6.2.	  Of	   note,	   all	   PAH	  patients	  were	   on	   advanced	  PAH	   therapies	   including	   endothelin	   receptor	  antagonists	  (bosentan,	  ambrisentan);	  type	  5	  phosphodiesterase	  inhibitors	  (sildenafil,	  tadalafil)	  and/or	   prostacyclins	   (iloprost,	   prostacyclin).	   One	   patient	   was	   also	   receiving	   daily	   imatinib	  400mg	   (a	   tyrosine	   kinase	   inhibitor	   and	   PDGF	   receptor	   antagonist)	   as	   part	   of	   a	   clinical	   trial	  based	   at	   Papworth	   Hospital,	   UK.	   No	   patients	   were	   taking	   conventional	   anti-­‐inflammatory	  therapies	  within	  3	  months	  of	  the	  study.	  In	  terms	  of	  clinical	  severity,	  5	  patients	  were	  NHYA	  class	  I-­‐II	  (defined	  as	  ‘non-­‐severe’)	  and	  7	  patients	  were	  NYHA	  class	  III-­‐IV	  (classed	  as	  ‘severe’).	  Invasive	  and	   non-­‐invasive	   hemodynamic	   characteristics	   are	   listed;	   BNP	  was	   raised	   at	   372±134.4ng/L	  	  (normal	  values	  36.6	  (7-­‐163)	  ng/L),	  indicating	  the	  presence	  of	  RV	  dysfunction	  in	  all	  patients;	  and	  there	   were	   no	   measured	   abnormalities	   in	   peripheral	   white	   cell	   counts	   (performed	   by	   the	  hospital	   laboratory	   on	   the	   day	   of	   research	   blood	   taking)	   in	   PAH	   patients.	   Finally,	   CRP	   was	  elevated	  from	  baseline	  values	  in	  PAH	  patients	  (12.7	  ±	  9.8	  mg/L)	  (Table	  6.2).	  	  	  
	   Controls	   PAH	  Number	   9	   12	  Age	  (years)	   36.2	  ±	  2.7	   36.5	  ±	  3.7	  #	  Female	  (Male)	   5	  (4)	   8	  (4)	  Smoking	  status	   No	   No	  
	  
Table	  6.1.	  	  Demographics	  of	  controls	  and	  PAH	  patients.	  Abbreviations:	  PAH	  pulmonary	  arterial	  hypertension,	  #	  not	  significant	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   PH	  diagnosis	   Idiopathic	  (11)	  &	  heritable	  PAH	  (1)	  Scimitar	  syndrome	  (n=1)	  Secundum	  ASD	  (n=1)	  Post-­‐partum	  presentation	  (n=1)	  PH	  medication	   Bosentan	  (n=8);	  ambrisentan	  (n=2)	  Sildenafil	  (n=8),	  tadalafil	  (n=2)	  Iloprost	  nebulizer	  (n=1)	  Intravenous	  prostacyclin	  (n=1)	  Imatinib	  (n=1)	  Additional	  relevant	  medication	   Naproxen	  3	  months	  earlier	  (n=1)	  NYHA	  functional	  class	  (n)	   Class	  I	  (1),	  II	  (4),	  III	  (6),	  class	  IV	  (1)	  6-­‐minute	  walk	  distance	  (m)	   370	  ±	  17.6	  Right	  heart	  catheterization	  data	  (n=12)	  mPAP	  (mmHg)	  RAP	  (mmHg)	  Cardiac	  output	  (Fick)	  (l/min)	  PVR	  (Woods	  unit)	  
	  72	  ±	  5	  11	  ±	  3	  3.9	  ±	  1.9	  11.9	  ±	  6.1	  Recent	  echocardiography	  data	  	  RVSP	  (mmHg)	  PAT	  (m/s)	   	  150.3	  ±	  9.1	  65.6	  ±	  5.1	  BNP	  (ng/L)	  C-­‐reactive	  protein	  (mg/L)	  (NR	  <5mg/L)	  Total	  WCC	  (x109/L)	  (NR	  4.8-­‐10.8	  x109/L)	  Differential	  WCC	  (x109/L)	  Neutrophils	  (NR	  4-­‐11	  x109/L)	  Lymphocytes	  (NR	  1-­‐4	  x109/L)	  Monocytes	  (NR	  0.1-­‐1	  x109/L)	  Eosinophils	  (NR	  0-­‐0.5	  x109/L)	  Basophils	  (NR	  0-­‐0.2	  x109/L)	  
372	  ±	  134.4	  12.7	  ±	  9.8	  7.1	  ±	  0.87	  	  4.8	  ±	  0.77	  1.5	  ±	  0.28	  0.58	  ±	  0.08	  0.13	  ±	  0.02	  0.04	  ±	  0.02	  
	  
	  
Table	  6.2.	  	  Clinical	  Characteristics	  of	  PAH	  patients.	  Data	  are	  mean	  ±	  SEM	  Abbreviations:	   PH	   -­‐	   pulmonary	   hypertension;	   PAH	   -­‐	   pulmonary	   arterial	   hypertension;	   ASD	   -­‐	  atrial	  septal	  defect;	  CRP	  -­‐	  C-­‐reactive	  protein;	  BNP	  -­‐	  brain	  natriuretic	  peptide;	  NYHA	  -­‐	  New	  York	  Heart	  Association;	  mPAP	  -­‐	  mean	  pulmonary	  arterial	  pressure;	  RAP	  -­‐	  right	  atrial	  pressure;	  PVR	  -­‐	  pulmonary	   vascular	   resistance;	   RVSP	   -­‐	   right	   ventricular	   systolic	   pressure;	   PAT	   -­‐	   pulmonary	  arterial	  acceleration	  time;	  m/s	  -­‐	  meters	  per	  second;	  WCC	  -­‐	  white	  cell	  count;	  NR	  -­‐	  normal	  range.	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6.3.2	  LPS	  and	  TNF-­‐α	  Stimulation	  Experiments	  
6.3.2.1	  Baseline	  cytokine	  release	  


































































Figure	  6.1.	  	  Baseline	  cytokine	  release	  from	  whole	  blood	  cells	  (WB)	  and	  peripheral	  
blood	  mononuclear	  cells	  (PBMC).	  WB	  (A	  &	  B)	  and	  PBMC	  (C	  &	  D)	  were	  incubated	  at	  37°C	  for	  24h	  and	  supernatants	  stored	  at	  -­‐20°C	  before	  detection	  of	   interleukin	  (IL)-­‐6	  (A	  &	  C)	  and	  CXCL8	  (B	  &	  D)	   levels	  by	  ELISA.	   	  Results	  are	  presented	  as	  the	  mean±SEM	  of	  8-­‐10	  individual	  samples.	  	  	  *	  p<0.05	  vs.	  controls	  compared	  using	  Mann	  Whitney	  tests.	  	  PAH	  –	  pulmonary	  arterial	  hypertension.	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6.3.2.2	  LPS-­‐induced	  CXCL8	  release	  from	  whole	  blood	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Figure	   6.2.	   	   	   Concentration-­‐dependent	   induction	   of	   CXCL8	   release	   from	   whole	  
blood	  following	  lipopolysaccharide	  (LPS)	  stimulation.	  	  Whole	   blood	   (WB)	   was	   stimulated	   with	   LPS	   (0-­‐1µg/ml)	   for	   24h	   and	   CXCL8	   within	   the	  supernatants	   measured	   by	   ELISA.	   No	   difference	   in	   maximal	   (Emax)	   or	   concentration	   (EC50)	  response	  was	  seen	  between	  control	  subjects	  and	  patients	  with	  pulmonary	  arterial	  hypertension	  (PAH)	  (A).	  	  When	  PAH	  patients	  were	  subdivided	  into	  non-­‐severe	  (NS)	  and	  severe	  PAH	  there	  was	  a	  trend	  towards	  a	  difference	  in	  EC50	  but	  not	  Emax	  (B)	  but	  this	  did	  not	  reach	  statistical	  significance	  (C).	   	  C	  shows	  mean±SEM	  Emax	  (left	  panel)	  and	  EC50	  values	  (right	  panel)	  for	  data	  from	  9	  control	  subjects	  and	  8	  patients	  with	  PAH.	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6.3.2.3	  LPS-­‐induced	  IL-­‐6	  release	  from	  whole	  blood	  
IL-­‐6	  release	   from	  WB	  increased	   in	  a	  concentration-­‐dependent	  manner	   from	  both	  controls	  and	  PAH	  patients	  following	  LPS	  stimulation	  for	  24h	  (Figure	  6.2).	  	  There	  was	  a	  significant	  difference	  between	   the	   Emax	   between	   the	   control	   subjects	   and	   patients	   with	   PAH	   (24815±2362	   vs.	  15259±1570	  pg/ml,	  p<0.01).	  	  There	  was	  no	  difference	  in	  EC50	  for	  LPS	  induction	  of	  IL-­‐6	  between	  the	  2	   groups.	   	  However,	   there	  was	  a	   significance	  difference	   in	  Emax	   observed	  between	   control	  and	   severe	   PAH	   (24815±2362	   vs.	   13571±1861	   pg/ml,	   p<0.01)	   but	   not	   between	   control	   and	  non-­‐severe	   PAH	   (24815±2362	   vs.	   18214±2427	   pg/ml)	   when	   PAH	   subjects	   were	   separated	  according	  to	  disease	  severity	  (Figure	  6.2).	  	  There	  was	  no	  significant	  difference	  in	  Emax	  between	  severe	  and	  non-­‐severe	  PAH	  patients.	  









































































Figure	   6.2.	   	   Concentration-­‐dependent	   effect	   of	   lipolysaccharide	   (LPS)	   on	  
interleukin	   (IL)-­‐6	   release	   from	   whole	   blood	   obtained	   from	   pulmonary	   arterial	  
hypertension	  (PAH)	  subjects	  and	  controls.	  Whole	   blood	   (WB)	  was	   stimulated	  with	   LPS	   (0-­‐1µg/ml)	   for	   24h	   then	   IL-­‐6	   in	   the	   supernatant	  measured	  by	  ELISA.	  Figure	   (A)	   shows	  a	   significant	  difference	   in	   the	  maximal	  LPS	   response	   in	  subjects	  with	  PAH	  compared	  to	  control	  subjects.	  	  When	  PAH	  patients	  were	  subdivided	  into	  non-­‐severe	   (NS)	   and	   severe	  PAH	   there	  was	   a	   significant	   difference	   in	  Emax	   (B).	   	   Individual	   patient	  data	   for	   Emax	   (C)	   and	   EC50	   (D)	   are	   also	   shown.	   Results	   represent	  mean	   ±	   SEM	   from	   controls	  (n=8)	  vs.	  non-­‐severe	  PAH	  patients	  (n=4)	  vs.	  severe	  PAH	  (n=6).	  	  **p<0.01.	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6.3.2.4	  LPS-­‐induced	  CXCL8	  release	  from	  PBMC	  


















































Figure	  6.3.	  	  Concentration-­‐dependent	  effect	  of	  lipopolysaccharide	  (LPS)	  on	  CXCL8	  
release	   from	   peripheral	   blood	   mononuclear	   cells	   (PBMC)	   from	   pulmonary	  
arterial	  hypertension	  (PAH)	  subjects	  and	  controls.	  PBMC	   were	   treated	   with	   LPS	   (0-­‐1ug/ml)	   for	   24h,	   and	   plasma	   levels	   of	   CXCL8	   measured	   by	  ELISA	  (A).	  	  In	  (B)	  the	  data	  were	  normalised	  to	  baseline	  in	  each	  group.	  Results	  are	  expressed	  as	  mean	  ±	  SEM	  from	  controls	  (n=8)	  vs.	  PAH	  patients	  (n=9).	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Figure	  6.4.	  	  Concentration-­‐dependent	  effect	  of	  lipopolysaccharide	  (LPS)	  on	  CXCL8	  
release	   from	  peripheral	   blood	  mononuclear	   cells	   (PBMC)	   from	   severe	   and	  non-­‐
severe	  (NS)	  pulmonary	  arterial	  hypertension	  (PAH)	  subjects	  and	  controls.	  PBMC	  from	  severe	  and	  NS	  PAH	  patients	  and	  controls	  were	  stimulated	  with	  LPS	  (0-­‐1ug/ml)	  for	  24h	   and	   levels	   of	   CXCL8	   released	   were	   measured	   by	   ELISA	   (A).	   	   There	   was	   no	   significant	  difference	   in	   the	  maximal	   (Emax)(B)	   or	   concentration	   response	   (logEC50)(C)	   across	   the	  patient	  groups.	  	  Results	  expressed	  as	  mean	  ±	  SEM	  from	  controls	  (n=8)	  vs.	  PAH	  patients	  (n=9).	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6.3.2.5	  LPS-­‐induced	  IL-­‐6	  release	  from	  PBMC	  




























































Figure	   6.5.	   	   Concentration-­‐dependent	   effect	   of	   lipopolysaccharide	   (LPS)	   on	  
interleukin	  (IL)-­‐6	  release	  from	  peripheral	  blood	  mononuclear	  cells	  (PBMC)	  from	  
pulmonary	  arterial	  hypertension	  (PAH)	  subjects	  and	  controls.	  PBMC	   were	   treated	   with	   LPS	   (0-­‐1ug/ml)	   for	   24h	   and	   levels	   of	   IL-­‐6	   detected	   in	   the	   culture	  supernatant	  measured	  by	  ELISA.	   	   There	  was	   a	   significant	   reduction	   in	   the	   production	   of	   IL-­‐6	  from	  cells	  from	  PAH	  subjects	  compared	  with	  controls	  (A).	  	  The	  maximal	  response	  (Emax)	  (B)	  and	  the	   concentration	   response	   (logEC50)(C)	   were	   both	   significantly	   altered	   in	   cells	   from	   PAH	  patients	  compared	  with	  controls.	  	  Results	  expressed	  as	  mean	  ±	  SEM	  from	  controls	  (n=6)	  vs.	  PAH	  patients	  (n=9).	  *p<0.05,	  **p<0.01.	  	  	  











































Figure	  6.6.	  	  No	  effect	  of	  lipopolysaccharide	  (LPS)	  stimulation	  on	  peripheral	  blood	  
mononuclear	  cell	  (PBMC)	  viability.	  	  The	  viability	  of	  PBMC	  following	  LPS	  treatment	  (0-­‐1	  µg/ml)	  was	  assessed	  using	  the	  Alamar	  blue	  assay.	  Results	  represent	  mean	  ±	  SEM	  from	  n=5	  controls	  (A)	  and	  n=6	  PAH	  patients	  (B).	  	  	  
6.3.2.6	  TNF-­‐α-­‐induced	  CXCL8	  release	  from	  PBMC	  













	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  6.7.	  	  Tumour	  necrosis	  factor-­‐α	  (TNF-­‐α)	  induces	  a	  concentration-­‐dependent	  
induction	  of	  CXCL8	  release	  from	  peripheral	  blood	  mononuclear	  cells	  (PBMC)	  from	  
pulmonary	  arterial	  hypertension	  (PAH)	  subjects	  and	  controls.	  PBMC	  were	   stimulated	  with	  TNF-­‐α	   (0-­‐10ng/ml)	   for	   24h,	   following	  which	  CXCL8	   levels	   in	   the	  culture	  medium	  were	  measured	  by	  ELISA.	  As	  CXCL8	  levels	  were	  significantly	  different	  between	  groups	   at	   baseline	   (A),	   data	   were	   normalised	   i.e.	   expressed	   as	   the	   increment	   from	   baseline	  CXCL8	  release	  for	  each	  subject	  (B).	  There	  was	  a	  significant	  difference	  in	  the	  maximal	  response	  (Emax)(C)	   but	   not	   the	   concentration	   response	   (EC50)(D)	   between	   the	   two	   groups.	   	   Results	   are	  expressed	  as	  mean	  ±	  SEM	  from	  control	  (n=6)	  vs.	  PAH	  patients	  (n=6).	  *p<0.05.	  	  
6.3.3	  Dexamethasone	  Suppression	  Experiments	  
6.3.3.1	  Dexamethasone	  inhibited	  CXCL8	  release	  from	  LPS-­‐stimulated	  whole	  
blood	  (WB)	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1μg/ml)-­‐stimulated	  WB.	  There	  was	  no	  significant	  difference	  between	  controls	  and	  PAH	  patients	  (Figure	  6.10A)	  or	  when	  patients	  were	  divided	  according	   to	   severity	  by	  NYHA	   functional	   class	  (with	  functional	  class	  III-­‐IV	  defining	  severe	  PAH)	  (Figure	  6.8B).	  	  There	  was	  no	  difference	  in	  Imax	  between	   controls,	   ‘all-­‐PAH’	   combined,	   non-­‐severe	   and	   severe	   PAH	   patients	   (5.36±1.10	   vs.	  2.20±1.68	   vs.	   3.78±1.15	   vs.	   1.15±2.71	   (%	   suppression	   of	   1mg/ml	   LPS-­‐stimulated	   release	   in	  pg/ml),	  p=NS	  between	  all	  groups)	  (Figure	  6.8C).	  In	  addition,	  there	  was	  no	  significant	  difference	  in	   dexamethasone	   EC50	   between	   controls,	   ‘all-­‐PAH’	   combined,	   non-­‐severe	   and	   severe	   PAH	  patients:	  (-­‐8.54	  (-­‐9.6	  to	  -­‐8.23)	  vs.	  -­‐8.7	  (-­‐9.08	  to	  -­‐8.04)	  vs.	  -­‐8.69	  (-­‐9.03	  to	  -­‐7.96)	  vs.	  -­‐8.80	  (-­‐10.4	  to	  -­‐8.04)	  log[M],	  p=NS	  between	  all	  groups)	  (Figure	  6.8D).	  	  








































































































































Figure	   6.8.	   	   Concentration-­‐dependent	   suppression	   of	   lipopolysaccharide	   (LPS)-­‐
stimulated	  CXCL8	  release	  from	  whole	  blood	  by	  dexamethasone.	  Whole	  blood	  (WB)	  was	  stimulated	  with	  LPS	  (0-­‐1µg/ml)	  ±	  dexamethasone	  (10-­‐10	  -­‐	  10-­‐6M)	  for	  24h	  and	  CXCL8	  within	  the	  supernatants	  measured	  by	  ELISA.	  No	  difference	  in	  the	  maximal	  inhibition	  (Imax)	   or	   concentration	   (EC50)	   response	  was	   seen	   between	   control	   subjects	   and	   patients	  with	  
Laura	  Price	  PhD:	  Inflammation	  in	  Pulmonary	  Arterial	  Hypertension	   203	  
pulmonary	  arterial	  hypertension	   (PAH)	   (A),	  or	  when	  PAH	  patients	  were	  subdivided	   into	  non-­‐severe	  (NS)	  and	  severe	  PAH	  (B).	  Figure	  (C)	  shows	  mean±SEM	  Imax	  and	  (D)	  median	  (interquartile	  range)	   for	   EC50	   values	   for	   data	   normalised	   to	   baseline	   LPS	   without	   dexamethasone,	   from	   9	  control	  subjects	  and	  10	  patients	  with	  PAH	  (4	  NS,	  6	  severe	  PAH).	  	  
	  
6.3.3.2	  Dexamethasone	  inhibited	  IL-­‐6	  release	  from	  LPS-­‐stimulated	  whole	  
blood	  	  
Addition	   of	   dexamethasone	   resulted	   in	   a	   concentration-­‐dependent	   reduction	   in	   IL-­‐6	   release	  from	  LPS-­‐stimulated	  WB.	  There	  was	  no	  difference	   in	   the	  extent	  of	  suppression	  of	   IL-­‐6	  release	  between	  control	  subjects	  and	  PAH	  patients	  (Figure	  6.9A)	  or	  between	  groups	  when	  PAH	  patients	  were	  subdivided	  according	  to	  PAH	  (where	  severe	  PAH	  was	  defined	  by	  NYHA	  functional	  class	  III-­‐IV)	  (Figure	  6.9B):	  This	  was	  assessed	  by	  the	  dexamethasone	  Imax	  which	  was	  no	  different	  between	  controls,	  ‘all	  PAH’,	  non-­‐severe	  PAH	  and	  severe	  PAH	  as	  follows:	  (6.669	  (0.3320-­‐	  7.165)	  %	  vs.	  3.49	  (1.9-­‐12.5)	   %	   3.89	   (1.71	   -­‐	   8.15)	   %	   vs.	   3.10	   (1.78-­‐	   15.96)	   (%	   suppression	   of	   1mg/ml	   LPS-­‐stimulated	   release	   in	   pg/ml),	   p=NS	   between	   groups)	   (Figure	   6.9C).	   In	   addition,	   there	  was	   no	  significant	  difference	  in	  the	  log	  EC50	  for	  dexamethasone	  between	  controls,	  ‘all	  PAH’,	  non-­‐severe	  PAH	  and	  severe	  PAH	  as	  follows:	  (-­‐8.13	  (-­‐8.3	  to	  -­‐8.04)	  vs.	  -­‐8.45	  (-­‐8.9	  to	  -­‐8.08)	  vs.	  -­‐8.9	  (-­‐9.7	  to	  -­‐8.22)	  vs.	  -­‐8.17	  (-­‐8.4	  to	  -­‐8.05)	  log[M],	  p=NS	  between	  groups)	  (Figure	  6.9D).	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Figure	   6.9.	   	   Concentration-­‐dependent	   suppression	   of	   lipopolysaccharide	   (LPS)-­‐
stimulated	  interleukin	  (IL)-­‐6	  release	  from	  whole	  blood	  by	  dexamethasone.	  Whole	  blood	  (WB)	  was	  stimulated	  with	  LPS	  (0-­‐1µg/ml)	  ±	  dexamethasone	  (10-­‐10	  -­‐	  10-­‐6M)	  for	  24h	  and	   IL-­‐6	  within	   the	  supernatants	  measured	  by	  ELISA.	  No	  difference	   in	   the	  maximal	   inhibition	  (Imax)	   or	   concentration	   (EC50)	   response	  was	   seen	   between	   control	   subjects	   and	   patients	  with	  pulmonary	  arterial	  hypertension	   (PAH)	   (A),	  or	  when	  PAH	  patients	  were	  subdivided	   into	  non-­‐severe	   (NS)	   and	   severe	   PAH	   (B).	   (C)	   shows	   Imax	   and	   (D)	   EC50	   values	   with	   data	   reported	   as	  median	   (interquartile	   range)	   normalised	   to	   baseline	   LPS	   without	   dexamethasone,	   from	   10	  control	  subjects	  and	  12	  patients	  with	  PAH	  (expressed	  as	  ‘all	  PAH’	  combined	  and	  separated	  into	  non-­‐severe	  (n=5)	  and	  n=7	  severe	  PAH).	  	  
	  
6.3.3.3	  Dexamethasone	  inhibited	  IL-­‐8	  release	  from	  LPS-­‐stimulated	  PBMC	  
Dexamethasone	  induced	  a	  concentration-­‐dependent	  reduction	   in	  CXCL8	  release	  from	  PBMC	  in	  both	  control	  subjects	  and	  PAH	  patients.	  However,	  no	  difference	  was	  seen	  between	  the	  groups	  overall	   (Figure	   6.10A),	   including	  when	   subdivided	   into	   those	  with	  more	   severe	   PAH	   (divided	  according	   to	   NYHA	   class)	   (Figure	   6.10B).	   There	   was	   no	   difference	   in	   dexamethasone	   Imax	  between	   controls,	   ‘all	   PAH’,	   non-­‐severe	   and	   severe	   PAH	   patients	   (29.9±5.22	   vs.	   27.9±5.2	   vs.	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22.5±9.27	   vs.	   32.1±54.57	   (%	   suppression	   of	   1mg/ml	   LPS-­‐stimulated	   release	   in	   pg/ml),	   p=NS	  between	  all	  groups)	  (Figure	  6.10C).	  	  In	  addition,	  there	  was	  also	  no	  difference	  in	  log	  EC50	  values	  between	  controls,	   ‘all	  PAH’,	  non-­‐severe	  and	  severe	  PAH	  patients	  (-­‐8.55±0.54	  vs.	  -­‐8.7±0.15	  vs.	  -­‐8.76±0.24	  vs.	  -­‐8.59±0.20	  log[M],	  p=NS	  between	  all	  groups)	  (Figure	  6.10C).	  Finally,	  the	  changes	  in	   CXCL8	   release	   were	   not	   likely	   to	   reflect	   an	   effect	   of	   ethanol,	   the	   dexamethasone	   diluent	  (Figure	  6.11),	  or	  a	  reduction	  in	  PMBC	  viability	  (Figure	  6.12).	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Figure	  6.10.	   	  Concentration-­‐dependent	   suppression	  of	   lipopolysaccharide	   (LPS)-­‐
stimulated	   CXCL8	   release	   from	   peripheral	   blood	   mononuclear	   cells	   (PBMC)	   by	  
dexamethasone.	  PBMC	  were	   stimulated	   with	   LPS	   (0-­‐1µg/ml)	   in	   the	   presence	   and	   absence	   of	   dexamethasone	  (Dex,	   10-­‐10	   -­‐	   10-­‐6M)	   for	   24h	   and	   CXCL8	   within	   the	   supernatants	   measured	   by	   ELISA.	   No	  difference	  in	  the	  maximal	   inhibition	  (Imax)	  or	  concentration	  (EC50)	  response	  was	  seen	  between	  control	   subjects	   and	   PAH	   patients	   subdivided	   into	   non-­‐severe	   (NS)	   and	   severe	   PAH	   (A).	   (B)	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LPS 1µg/ml    +  +   +   +   +   +   -    -    -    -   -    -    -    -    -   -
Ethanol/M       -  -7  -6  -5  -4  -3  -    -    -    -   -   -7  -6  -5  -4  -3
Dex/M             -   -    -    -    -    -  -10 -9  -8  -7  -6  -   -    -    -    - 	  
Figure	   6.11.	   	   No	   effect	   of	   dexamethasone	   alone;	   ethanol	   alone,	   or	   ethanol	   on	  
lipopolysaccharide	   (LPS)-­‐induced	   CXCL8	   release	   from	   peripheral	   blood	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Figure	   6.12.	   	   No	   effect	   of	   lipopolysaccharide	   (LPS)	   stimulation	   on	   peripheral	  
blood	  mononuclear	  cell	  (PBMC)	  viability.	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Viability	   of	   PBMC	   following	   LPS	   (0-­‐1µg/ml),	   dexamethasone	   (Dex,	   10-­‐10	   –	   10-­‐6M)	   and	   ethanol	  (10-­‐7	  –	  10-­‐3M,	  diluent)	   treatment	  was	  assessed	  using	   the	  Alamar	  blue	  assay.	  Results	  represent	  mean	  ±	  SEM	  from	  n=5	  controls	  (A)	  and	  n=6	  PAH	  patients	  (B).	  	  	  
6.3.3.4	  Dexamethasone	  inhibited	  IL-­‐6	  release	  from	  LPS-­‐stimulated	  PBMC	  
Dexamethasone	   reduced	   IL-­‐6	   release	   from	   PBMC	   in	   a	   concentration-­‐dependent	  manner	   from	  both	   PAH	   patients	   and	   controls.	   There	   was	   no	   significant	   difference	   in	   the	   extent	   of	   IL-­‐6	  suppression	  between	  control	  subjects	  and	  PAH	  patients	  (Figure	  6.13A).	  However,	  when	  patients	  were	   subdivided	   according	   to	   PAH	   severity	   by	  NYHA	   functional	   class,	   a	   significant	   difference	  was	  detected	   in	   the	  dexamethasone	   Imax	  between	  severe	  and	  non-­‐severe	  PAH	  patients	   (Figure	  6.13B):	   Imax	   was	   18.3±2.3	   in	   controls,	   20.1±5.5	   (%	   suppression	   of	   1mg/ml	   LPS-­‐stimulated	  release	  in	  pg/ml)	  in	  ‘all	  PAH’	  (p=NS	  between	  controls	  and	  ‘all	  PAH’),	  9.4±5.1	  in	  non-­‐severe	  PAH	  and	  30.9±7.1%	  in	  severe	  PAH	  (p<0.05	  between	  NS	  and	  severe	  PAH;	  p=NS	  between	  controls	  and	  severe	  PAH)	  (Figure	  6.13C).	  The	  log	  EC50	  for	  dexamethasone	  was	  not	  different	  between	  groups	  (-­‐8.43±0.29	  in	  controls	  vs.	  -­‐8.2±0.32	  log[M]	  in	  ‘all	  PAH’,	  p=NS;	  -­‐8.39±0.2	  in	  non-­‐severe	  PAH	  vs.	  -­‐8.02±0.63	  log[M]	  in	  severe	  PAH,	  p=NS	  between	  all	  groups)	  (Figure	  6.13D).	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Figure	  6.13.	   	  Concentration-­‐dependent	   suppression	  of	   lipopolysaccharide	   (LPS)-­‐
stimulated	   interleukin	   (IL)-­‐6	   release	   from	   peripheral	   blood	   mononuclear	   cells	  
(PBMC)	  by	  dexamethasone.	  PBMC	  were	  stimulated	  with	  LPS	  (0-­‐1µg/ml)	  ±	  dexamethasone	  (10-­‐10	  -­‐	  10-­‐6M)	  for	  24h	  and	  IL-­‐6	  within	   the	   supernatants	  measured	   by	   ELISA.	   There	  was	   no	   difference	   between	   groups	  when	  controls	  were	   compared	  with	  patients	   grouped	   together	   (A);	   however	   a	   significant	  difference	  was	   detected	   between	   PAH	   patients	   with	   non-­‐severe	   (NS)	   and	   severe	   PAH	   (B)	   in	   the	  dexamethasone	  maximal	   inhibition	   (Imax)	   (C),	   although	   not	   the	   concentration	   (EC50)	   response	  (D).	  Data	   are	   reported	  as	  mean±SEM	   for	  Emax	   and	  EC50	   values	   for	  data	  normalised	   to	  baseline	  LPS	  without	  dexamethasone	  from	  6	  control	  subjects	  and	  10	  patients	  with	  PAH	  (5	  NS,	  5	  severe	  PAH).	  *	  p<0.05.	  	  	  
6.3.3.5	  Dexamethasone	  reduced	  TNF-­‐α-­‐induced	  CXCL8	  release	  from	  PBMC	  
Dexamethasone	  suppressed	  TNF-­‐α-­‐induced	  CXCL8	  release	  from	  PBMC,	  with	  no	  difference	  seen	  between	  controls	  and	  PAH	  patients	  (Figure	  6.14A)	  in	  terms	  of	  dexamethasone	  Imax	  (52.1	  (35.7-­‐58.24)	   vs.	   42.9	   (23.3-­‐77.9)	   (%	   suppression	   of	   1mg/ml	   LPS-­‐stimulated	   release	   in	   pg/ml),	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p=0.69)	  (Figure	  6.14B).	  Interestingly,	  the	  ability	  of	  dexamethasone	  to	  suppress	  TNF-­‐α-­‐induced	  CXCL8	  release	  as	  measured	  by	   Imax	   in	   these	  experiments	  was	   less	  marked	   than	   that	  seen	  with	  LPS	   stimulated	   cells.	   	   The	   Imax	   for	   CXCL8	   release	   was	   suppressed	   to	   29.9±5.2%	   in	   controls,	  22.5±9.3%	  in	  non-­‐severe	  PAH	  and	  to	  32.1±54.6%	  from	  PBMC	  isolated	  from	  patients	  with	  severe	  PAH	  (Figure	  6.11).	  Finally,	   these	  TNF-­‐α	  experiments	  demonstrated	  no	  significant	  difference	  in	  log	  EC50	  for	  dexamethasone	  between	  control	  subjects	  and	  PAH	  patients	  (-­‐8.9	  (-­‐9.41	  to	  -­‐8.15)	  vs.	  -­‐9.41	  (-­‐10.1	  to	  -­‐9.0)	  logM,	  p=0.18)	  (Figure	  6.14C).	  





























































































Figure	   6.14.	   	   Concentration-­‐dependent	   suppression	   of	   tumour	   necrosis	   factor	  
(TNF)-­‐α-­‐stimulated	   CXCL8	   release	   from	   peripheral	   blood	   mononuclear	   cells	  
(PBMC)	  by	  dexamethasone.	  PBMC	   were	   stimulated	   with	   TNF	   (0-­‐10ng/ml)	   ±	   dexamethasone	   (10-­‐10	   -­‐	   10-­‐6M)	   for	   24h	   and	  CXCL8	   within	   the	   supernatants	   measured	   by	   ELISA.	   There	   was	   no	   significant	   difference	  between	   control	   subjects	   and	   PAH	   patients	   (A)	   in	   the	   maximal	   inhibition	   (Imax)	   (B)	   and	  concentration	   (EC50)	   response	   (C)	   to	   dexamethasone.	   Data	   are	   reported	   as	   median	  (interquartile	   range)	   for	   Imax	   and	   EC50	   values	   for	   data	   normalised	   to	   baseline	   LPS	   without	  dexamethasone,	  from	  4	  control	  subjects	  and	  4	  patients	  with	  PAH.	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6.3.3.6	  Dexamethasone	  inhibited	  NF-­‐κB	  activation	  in	  control	  PBMC	  


























Figure	   6.15.	   	   Dexamethasone	   inhibits	   tumour	  necrosis	   factor-­‐α 	   (TNFα)-­‐induced	  
activation	   of	   nuclear	   factor	   (NF)-­‐κB	   in	   peripheral	   blood	   mononuclear	   cells	  
(PBMC).	  	  PBMC	   from	   4	   control	   subjects	  were	   stimulated	  with	   TNF-­‐α	   (0-­‐10ng/ml)	   in	   the	   presence	   and	  absence	   of	   dexamethasone	   (Dex,	   10-­‐7M)	   for	   1hr.	   	  NF-­‐κB	  p65	  DNA	  binding	   in	   nuclear	   extracts	  was	  measured	  by	  TransAm	  assay.	  Data	  are	  reported	  as	  the	  mean	  ±	  SEM.	  **p<0.01	  using	  1-­‐way	  ANOVA	  and	  Bonferroni’s	  post-­‐test	  analysis.	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6.3.4	  Confounding	  effects	  of	  PAH	  therapies:	  Effects	  of	  sildenafil	  	  
6.3.4.1	  Effects	  of	  increasing	  concentration	  of	  sildenafil	  on	  LPS-­‐induced	  CXCL8	  
release	  from	  whole	  blood	  from	  PAH	  patients	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Figure	   6.16.	   	   Sildenafil	   reduced	   CXCL8	   release	   from	   lipopolysaccharide	   (LPS)-­‐
stimulated	  whole	  blood	  from	  control	  subjects	  and	  patients	  with	  PAH	  (pulmonary	  
arterial	  hypertension).	  	  Whole	  blood	  from	  controls	  (A)	  and	  PAH	  subjects	  (B)	  was	  stimulated	  with	  LPS	  (0-­‐1μg/ml),	  with	  and	  without	  the	  addition	  of	  1-­‐10μM	  sildenafil,	  and	  in	  (B)	  the	  addition	  of	  dexamethasone	  (Dex,	  10-­‐7M),	   and	   CXCL8	   within	   the	   supernatants	   measured	   by	   ELISA.	   Sildenafil	   reduced	   CXCL8	  release	   in	   a	   concentration-­‐dependent	  manner	   from	   control	   (A)	   and	   PAH	  patient	  whole	   blood	  (B),	  where	  dexamethasone	  reduced	  CXCL8	  release	  further	  (B).	  Results	  reported	  as	  mean	  ±	  SEM	  from	  n=4	   control	   and	  PAH	   subjects,	   and	   only	   n=2	   for	   addition	   of	   sildenafil	   1-­‐10μM.	   Statistics	  were	  not	  performed	  where	  n=2.	  *p<0.05	  ***p<0.001.	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6.4	  Discussion	  
I	  detected	  no	  difference	  in	  baseline	  IL-­‐6	  and	  CXCL8	  release	  following	  incubation	  of	  whole	  blood	  at	   37°C	   for	   24	   hours	   between	   PAH	   patients	   and	   controls.	   Several	   previous	   published	   studies	  measured	  plasma	  cytokine	  levels	  from	  frozen	  plasma	  samples	  prepared	  within	  an	  hour	  of	  blood	  sampling	   (Humbert	   et	   al.,	   1995,	   Soon	   et	   al.,	   2010)	   although	   none	   recorded	   levels	   after	  incubation	   of	   WB	   for	   24	   hours.	   Compared	   to	   these	   studies,	   IL-­‐6	   levels	   recorded	   here	   were	  within	  the	  same	  range	  in	  terms	  of	  absolute	  values	  although	  CXCL8	  levels	  were	  higher	  (Humbert	  et	  al.,	  1995,	  Soon	  et	  al.,	  2010).	  These	  previous	  studies	  however	  mostly	  demonstrated	  significant	  differences	  between	  PAH	  patients	  and	  controls	  (Humbert	  et	  al.,	  1995,	  Itoh	  et	  al.,	  2006,	  Selimovic	  et	   al.,	   2009,	   Soon	   et	   al.,	   2010)	   although	   several	   PAH	   patients	   had	   cytokine	   levels	   within	   the	  normal	   range.	   Indeed	   there	   have	   been	   several	   smaller	   studies	  where	   no	   difference	  was	   seen	  between	  patients	  and	  controls,	   for	  example	   in	  terms	  of	   IL-­‐1,	   IL-­‐6	  (Raychaudhuri	  et	  al.,	  2002a)	  (Miyata	  et	  al.,	  1993)	  and	  MIP1-­‐α	  release	  (Raychaudhuri	  et	  al.,	  2002a).	  The	  spectrum	  of	  baseline	  cytokine	   release	  within	   the	  patient	  population	   could	  explain	  why	  we	  did	  not	   see	  a	   significant	  difference	  in	  our	  study.	  In	  addition,	  I	  had	  performed	  a	  power	  calculation	  and	  determined	  that	  I	  would	  need	  a	  sample	  size	  of	  at	  least	  10	  per	  group	  to	  detect	  a	  difference	  (e.g.	  in	  IL-­‐6)	  of	  50pg/ml	  between	   PAH	   patients	   and	   controls	   at	   0.80	   power	   (Humbert	   et	   al.,	   1995).	   However	   if	   I	   had	  based	  our	  predicted	  calculation	  on	  the	  more	  recent	  study	  by	  Soon	  et	  al	  where	  a	  much	  smaller	  difference	  was	  detected	  (Soon	  et	  al.,	  2010)	  a	  much	  larger	  sample	  size	  would	  have	  been	  needed.	  Despite	  the	  lack	  of	  cytokine	  elevation	  in	  baseline	  plasma	  IL-­‐6	  and	  CXCL8	  levels	  the	  PAH	  patients	  studied	  here	  did	  have	  elevated	  baseline	   levels	  of	  CRP	  compared	   to	  published	  data.	   	  However,	  unfortunately	  CRP	  levels	  were	  not	  measured	  in	  the	  control	  subjects	  in	  the	  study	  reported	  here	  and	   so	   further	   studies	   using	   samples	   from	   controls	  must	   be	   performed.	   	   CRP	   is	   a	   circulating	  acute	   phase	   response	   protein	  whose	   transcription	   is	  mainly	   regulated	   in	   hepatocytes	   by	   IL-­‐6	  (Labarrere	  and	  Zaloga,	  2004).	  In	  a	  study	  of	  104	  mostly	  NYHA	  class	  II-­‐III	  PAH	  patients	  by	  Quarck	  
et	   al,	   levels	   of	  CRP	  were	   significantly	   elevated	  at	  4.4mg/L	   in	   compared	   to	  2.3mg/L	   in	   control	  subjects,	  and	  CRP>5mg/L	  predicted	  worse	  survival	  and	  increased	  adverse	  events	  (Quarck	  et	  al.,	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2009).	   Several	   mechanisms	   have	   been	   proposed	   for	   this	   effect	   in	   the	   setting	   of	   systemic	  vascular	  disease	  where	  minimal	  elevations	  in	  CRP	  predict	  cardiovascular	  events	  in	  patients	  with	  atherosclerosis	  (Labarrere	  and	  Zaloga,	  2004).	  These	  include	  CRP-­‐induced	  activation	  of	  NF-­‐κB	  in	  saphenous	  vein	  EC	  (Verma	  et	  al.,	  2003),	  which	  results	   in	  EC	  activation	  including	  expression	  of	  adhesion	  molecules	  such	  as	  MCP-­‐1	  (Labarrere	  and	  Zaloga,	  2004).	  	  
My	  findings	  in	  the	  PBMC	  baseline	  experiments	  were	  in	  contrast	  to	  the	  whole	  blood	  results:	  IL-­‐6	  and	  CXCL8	  release	  at	  baseline	  following	   incubation	  at	  37°C	  for	  24	  hours	  was	   indeed	  higher	   in	  PBMC	  isolated	  from	  PAH	  patients	  compared	  to	  controls.	  No	  comparative	  experiments	  have	  been	  performed	  in	  PAH	  patients	  to	  date,	  although	  a	  recent	  study	  compared	  CXCL8,	   IL-­‐6,	  and	  TNF-­‐α	  release	   from	  WB	   and	   PBMC	   from	   healthy	   volunteers	   plated	   at	   a	   comparable	   density	   to	   our	  study.	  This	  study	  showed	  that	  at	  24	  hours	  following	  LPS	  stimulation	  (1µg/ml),	  PBMCs	  released	  markedly	   more	   cytokines	   compared	   to	   WB	   (e.g.	   35000±6300	   versus	   2372±512pg/ml	   for	  CXCL8)	  (Stebbings	  et	  al.,	  2007)	  	  -­‐	  consistent	  with	  the	  higher	  levels	  seen	  in	  the	  PBMC	  compared	  to	  the	  WB	  experiments	  reported	  here.	  	  
My	  next	  observation	  relates	  to	  the	  findings	  from	  the	  stimulated	  WB	  and	  PBMC	  experiments.	  The	  main	  findings	  were	  that	  release	  of	  IL-­‐6	  was	  significantly	  lower	  from	  LPS-­‐stimulated	  whole	  blood	  and	  PBMC	  in	  PAH	  patients	  compared	  to	  controls;	  the	  message	  was	  similar	  (but	  non-­‐significant)	  for	   CXCL8.	   In	   addition,	   TNF-­‐α-­‐stimulated	   PBMC	   from	   PAH	   patients	   released	   less	   CXCL8	  compared	   to	   controls	   (IL-­‐6	   results	   for	   the	   TNF-­‐α-­‐stimulated	   experiments	   are	   on-­‐going).	   This	  could	   be	   interpreted	   as	   relative	   ‘hyporesponsiveness’	   of	   stimulated	  WB	   and	   PBMC	   from	  PAH	  patients	   compared	   to	   controls.	   In	   addition,	   there	   seemed	   to	   be	   a	   difference	   in	   the	   stimulated	  release	  of	  IL-­‐6	  compared	  with	  CXCL8	  (discussed	  below).	  Monocyte	  ‘hyporesponsiveness’	  to	  LPS	  has	  been	  previously	  described	  in	  one	  previous	  study	  of	  patients	  with	  iPAH	  (Raychaudhuri	  et	  al.,	  2002a).	  Here,	  monocytes	  derived	  from	  PBMC	  isolated	  from	  8	  patients	  with	  severe	  iPAH	  showed	  no	   difference	   in	   baseline	  NF-­‐κB	   activation	   compared	   to	   controls,	   yet	  monocyte	   IL-­‐6,	   GM-­‐CSF,	  MIP1-­‐α	   and	   VEGF	   RNA	   was	   lower	   than	   from	   controls.	   To	   potentially	   explain,	   the	   authors	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demonstrated	  a	  reduction	  in	  monocyte	  CD14	  and	  HLA-­‐DR	  in	  PAH	  patients	  (Raychaudhuri	  et	  al.,	  2002a).	  
Further	   to	   this	  monocyte	  study,	  Wang	  et	  al	   similarly	  showed	  that	  dendritic	  cells	   (DC)	  derived	  from	  PBMC	  from	  21	  iPAH	  patients	  were	  fewer	  in	  number	  (especially	  myeloid	  DC)	  and	  expressed	  immature	  cell	   surface	  markers	   (CD1a)	  and	   less	  co-­‐stimulatory	  molecules	   (CD86)	  compared	   to	  controls	  (Wang	  et	  al.,	  2009),	  despite	  these	  cells	  being	  activated	  in	  the	  lung	  in	  PAH	  (Perros	  et	  al.,	  2007b).	  In	  another	  study	  of	  tertiary	  lymphoid	  follicles	  by	  Perros	  et	  al,	  examination	  of	  circulating	  lymphocytes	  showed	  a	  relative	  depletion	  of	  T	  cells	  (especially	  T	  helper	  cells)	  in	  the	  circulating	  population,	  in	  contrast	  with	  a	  marked	  increase	  in	  lymphocyte	  accumulation	  in	  lymphoid	  follicles	  in	   PAH	   lung	   tissue,	   which	   interestingly	   were	   seen	  more	   commonly	   in	   patients	   with	   BMPR-­‐II	  mutations	  (Perros	  et	  al.,	  2012).	   It	  has	  been	  suggested	  that	  enhanced	  recruitment	  of	  precursor	  DC	   into	   inflamed	  tissue	  occurs,	  resulting	   in	  a	  reduction	   in	  circulating	  precursors	  (Liberman	  et	  al.,	  2012).	  Together	  these	  studies	  in	  circulating	  monocytes,	  DC	  and	  lymphocytes,	  together	  with	  our	   findings	   in	   PBMC	   in	   conjunction	   with	   lung	   tissue	   macrophages	   being	   activated,	   might	  suggest	   that	   a	   recruitment	   of	   activated	   inflammatory	   cells	   to	   the	   lung	   is	   occurring,	   with	   the	  remaining	  peripheral	  cells	  being	  less	  immune-­‐responsive.	  	  
Systemic	  immune	  hyporesponsiveness	  has	  been	  previously	  reported	  in	  certain	  other	  acute	  and	  chronic	   inflammatory	   conditions.	   In	   patients	  with	   sepsis,	   LPS-­‐stimulated	  monocytes	   released	  less	  TNF-­‐α	  and	  IL-­‐1β	  compared	  to	  those	  from	  healthy	  subjects,	  which	  positively	  correlated	  with	  sepsis	  severity	  (Hilliker	  et	  al.,	  1984).	  In	  sepsis,	  ‘endotoxin	  tolerance’	  has	  been	  proposed	  to	  relate	  to	   the	   release	   of	   monocyte	   inhibitory	   substances	   by	   infecting	   organisms	   (e.g.	   IL-­‐10,	  prostaglandin	  E2,	  TGF-­‐β1)	  as	  well	  as	  reduced	  class	  II	  MHC	  expression	  (HLA-­‐DR)	  (Hilliker	  et	  al.,	  1984),	   which	   has	   been	   associated	   with	   higher	   sepsis	   mortality	   (Hilliker	   and	   Roth,	   1984).	   In	  patients	   compared	   before	   and	   after	   elective	   gastrectomy	   surgery,	   LPS-­‐stimulated	   PBMC	  released	   less	   TNF-­‐α	   and	   IL-­‐6	   following	   LPS	   stimulation	   compared	   to	   those	   isolated	   pre-­‐operatively,	   and	   expressed	   less	   HLA-­‐DR	   and	   CD14	   (Hilliker	   et	   al.,	   1983a).	   In	   more	   chronic	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diseases	  such	  as	  in	  the	  granulomatous	  inflammation	  in	  sarcoidosis,	  peripheral	  anergy	  was	  seen	  in	  lymphocytes	  and	  DC	  in	  patients	  with	  active	  untreated	  disease	  compared	  to	  controls,	  with	  the	  allogeneic	   responses	   also	   correlating	   with	   disease	   severity	   (Hilliker	   et	   al.,	   1983b).	   Raised	  plasma	   levels	   of	   IL-­‐10	   are	   indeed	   seen	   in	   patients	   with	   iPAH	   (Soon	   et	   al.,	   2010).	   Adenoviral	  overexpression	   of	   IL-­‐10	   prevented	   MCT-­‐induced	   PH	   in	   rats	   and	   inhibits	   TGF-­‐β1-­‐induced	   rat	  PASMC	  proliferation	  (Ito	  et	  al.,	  2007).	  In	  addition,	  monocytes	  from	  PAH	  patients	  expressed	  less	  CD14	   and	   HLA-­‐DR	   as	   mentioned	   (Raychaudhuri	   et	   al.,	   2002a)	   –	   suggesting	   potential	  ‘hyporesponsiveness’	  mechanisms.	  	  
An	   important	  potential	  confounding	  factor	   in	  my	  experiments	  was	  the	  effect	  of	  advanced	  PAH	  therapies.	   In	   preliminary	   experiments,	   I	   showed	   that	   increasing	   concentrations	   of	   sildenafil	  reduced	   CXCL8	   release	   from	   WB.	   This	   is	   in	   keeping	   with	   one	   of	   the	   explanations	   by	  Raychaudhuri	  et	  al	  that	  many	  (although	  not	  all)	  of	  their	  patients	  were	  taking	  prostacyclins,	  one	  of	   which	   (treprostinil)	   inhibited	   cytokine	   release	   through	   inhibition	   of	   NF-­‐κB	   nuclear	   p65	  translocation	   in	   alveolar	   macrophages	   (Raychaudhuri	   et	   al.,	   2002b).	   Although	   there	   is	   no	  evidence	   that	   sildenafil	   directly	   inhibits	   NF-­‐κB	   activation,	   it	   is	   worthwhile	   noting	   that	   nitric	  oxide	   whose	   actions	   are	   modulated	   by	   sildenafil	   also	   inhibits	   cytokine	   release	   and	   NF-­‐κB	  activation	  in	  alveolar	  macrophages	  (Raychaudhuri	  et	  al.,	  1999).	  	  	  
My	   dexamethasone	   experiments	   demonstrated	   a	   concentration-­‐dependent	   GC	   sensitivity	   in	  terms	  of	  suppression	  of	   IL-­‐6	  and	  CXCL8	   in	  both	  WB	  and	  PBMC.	   It	   is	  of	  note	   that	   for	  both	   IL-­‐6	  and	  CXCL8,	  there	  was	  a	  difference	  in	  GC	  sensitivity	  between	  WB	  and	  PBMC:	  Imax	  was	  suppressed	  to	  a	  greater	  degree	  in	  the	  WB	  assays	  compared	  to	  the	  PBMC	  experiments.	  Similar	  comparative	  experiments	   have	   not	   been	   performed	   and	   explanations	  might	   include	   the	   presence	   of	   other	  more	   GC-­‐sensitive	   cells	   in	  WB;	   the	   presence	   of	   additional	   necessary	   cofactors	   or	   relative	   GC	  resistance	   of	   PBMCs	  when	  plated	   at	   high	  density.	   Transcription	   factors	   transrepressed	  by	  GC	  include	  AP-­‐1,	  STATs,	  NFAT	  and	  NF-­‐κB	  (Adcock,	  2001).	  Indeed,	  many	  of	  the	  gene	  products	  that	  are	   upregulated	   in	   PAH	   are	   primarily	   regulated	   by	   NF-­‐κB	   (Soon	   et	   al.,	   2010,	   Humbert	   et	   al.,	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1995,	  Itoh	  et	  al.,	  2006),	  and	  NF-­‐κB	  can	  be	  upregulated	  by	  PAH-­‐relevant	  mechanisms	  including	  pro-­‐inflammatory	  cytokines,	  oxidants	  and	  viral	  infections	  (Papi	  and	  Johnston,	  1999,	  Barnes	  and	  Karin,	   1997)	   and	   CRP	   (Verma	   et	   al.,	   2003).	   Given	   that	   GC	   are	   effective	   in	   certain	   other	  inflammatory	   lung	   diseases,	   I	   therefore	   hypothesised	   that	   dexamethasone	   was	   reducing	  cytokine	  release	  by	  inhibiting	  NF-­‐κB	  in	  PAH.	  In	  asthma,	  NF-­‐κB	  is	  activated	  in	  airway	  epithelial	  cells,	  and	   these	  cells	  are	  a	  source	  of	   inflammatory	  mediators	   in	  asthma	  (Hart	  et	  al.,	  1998).	  GC	  inhibited	   NF-­‐κB	   activation	   in	   PBMC	   (Adcock	   et	   al.,	   1995a)	   and	   in	   lung	   tissue	   from	   normal	  individuals	  (Adcock	  et	  al.,	  1994).	  This	  however	  was	  not	  seen	  to	  occur	  in	  alveolar	  macrophages	  or	  in	  bronchial	  biopsies	  from	  asthmatic	  patients	  taking	  inhaled	  GC,	  even	  though	  these	  induced	  both	  clinical	  improvement	  and	  an	  anti-­‐inflammatory	  effect	  on	  eosinophils	  (Hart	  et	  al.,	  2000).	  In	  LPS	   and	   TNF-­‐stimulated	   aortic	   endothelial	   cells,	   dexamethasone	   inhibited	   NF-­‐κB-­‐dependent	  gene	   expression.	   This	   was	   likely	   to	   act	   by	   direct	   interaction	   with	   GR	   in	   these	   cells	   i.e.	  transrepression	   since	   no	   increase	   in	   IκBα	   was	   seen	   in	   these	   cells	   in	   contrast	   to	   PBMC	   and	  lymphocytes	  (Brostjan	  et	  al.,	  1996).	  	  
My	  p65	  TransAm	  results	   in	  control	  PBMC	  demonstrated	  dexamethasone-­‐induced	   inhibition	  of	  nuclear	   translocation	  or	  direct	  DNA	  binding	  of	  NF-­‐κB	  p65	   in	  vitro.	   It	  will	   be	  useful	   in	   further	  experiments	   to	   compare	   with	   PAH	   patients	   samples	   to	   see	   if	   the	   difference	   in	   IL-­‐6	   /	   CXCL8	  sensitivity	  is	  related	  to	  differences	  in	  p65	  DNA	  binding.	  These	  PBMC	  results	  are	  consistent	  with	  my	   p65	   PASMC	   immunohistochemistry	   findings	   in	   Chapter	   5,	   where	   NF-­‐κB	   activation	   was	  increased	   in	   both	   PAEC	   and	   PASMC	   in	  MCT-­‐induced	   PH,	   and	  was	   reduced	   in	   both	   cell	   types	  following	  in	  vivo	  dexamethasone	  treatment;	  also	  the	  p65	  TransAm	  results	  in	  controls.	  It	  will	  also	  be	  useful	  in	  further	  studies	  to	  measure	  p65	  DNA	  binding	  in	  the	  rat	  lungs	  to	  determine	  whether	  the	  increased	  p65	  nuclear	  translocation	  is	  related	  to	  an	  increase	  in	  IKK,	  and	  to	  assess	  effects	  of	  a	  specific	   IKK2	   inhibitor	   on	   this	   NF-­‐κB	   classical	   pathway.	   Direct	   binding	   of	   p65	   to	   native	  inflammatory	   gene	   promoters	   using	   chromatin	   immunoprecipitation	   experiments	   may	   also	  provide	  further	  evidence	  for	  GC	  mechanisms	  in	  rat	  lung	  tissues	  and	  cells.	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My	   PBMC	   (although	   not	   the	   WB)	   experiments	   demonstrated	   a	   difference	   between	   PAH	   and	  control	   subjects	   in	   dexamethasone	   responsiveness	   between	   the	   cytokines	   IL-­‐6	   and	   CXCL8:	  There	  was	  greater	  suppression	  of	  IL-­‐6	  release	  from	  PBMC	  in	  control	  subjects	  compared	  to	  PAH	  patients,	   whereas	   there	   was	   no	   significant	   difference	   in	   response	   between	   controls/PAH	  subjects	  for	  suppression	  of	  CXCL8	  release	  –	  or	  for	  either	  mediator	  release	  from	  whole	  blood.	  I	  can	  only	  hypothesise	  that	  the	  lack	  of	  difference	  in	  the	  WB	  assays	  compared	  to	  the	  PBMC	  assays	  may	  reflect	   the	   increased	  PBMC	  cell	  density,	  as	  mentioned	  above	  (Stebbings	  et	  al.,	  2007).	  The	  fact	  that	  PBMC	  from	  PAH	  patients	  released	  higher	   levels	  of	  both	  IL-­‐6	  and	  CXCL8	  at	  baseline	  is	  consistent	   with	   the	   body	   of	   evidence	   implicating	   IL-­‐6	   (and	   CXCL8)	   in	   PAH	   as	   reviewed	   in	  chapter	  1.	  Indeed,	  I	  (and	  others)	  showed	  that	  IL-­‐6	  expression	  is	  increased	  in	  MCT	  PH	  lung;	  that	  IL-­‐6	  itself	  induces	  PASMC	  proliferation	  (Ikeda	  et	  al.,	  1991)	  and	  that	  IL-­‐6	  overexpression	  caused	  PH	   in	  mice	  (Steiner	  et	  al.,	  2009).	   IL-­‐6	  released	   from	   inflammatory	  cells	   is	  considered	   likely	   to	  have	  an	  important	  pro-­‐survival	  effect	  on	  vascular	  cells.	  Furthermore,	  Hagen	  et	  al	  established	  a	  feedback	   loop	  with	  BMPR-­‐II	  dysfunction	  and	  enhanced	  IL-­‐6	  signalling	   in	  PASMC	  (Hagen	  et	  al.,	  2007).	  
Further	  reasons	  why	  dexamethasone	  suppressed	  IL-­‐6	  release	  from	  PBMC	  isolated	  from	  control	  subjects	  compared	  to	  cells	  from	  patients	  is	  not	  entirely	  clear.	  If	  NF-­‐κB	  was	  the	  only	  target	  of	  GC,	  one	  may	  also	  expect	  a	  similar	  suppression	  of	  CXCL8	  in	  these	  experiments.	  In	  a	  previous	  study,	  a	  differential	   response	   (by	   budesonide)	  was	   described	   in	   LPS-­‐stimulated	   alveolar	  macrophages	  (AM)	  and	  blood	  monocytes	  isolated	  from	  healthy	  volunteers	  with	  GM-­‐CSF	  secretion	  being	  more	  potently	   inhibited	   than	   IL-­‐I	   or	   IL-­‐6	   (Linden	   and	  Brattsand,	   1994).	   This	   differential	   effect	  was	  postulated	  to	  relate	  to	  a	  difference	  in	  the	  relative	  abundance	  and/or	  activation	  of	  transcription	  factors	  and	  a	  difference	  in	  promoter	  and	  enhancer	  structure	  between	  the	  various	  inflammatory	  mediators	  (Linden	  and	  Brattsand,	  1994).	  Recent	  evidence	  from	  Hager	  and	  Colleagues	  (Biddie	  et	  al.,	  2011)	  indicates	  that	  subtle	  changes	  in	  promoter	  context,	  e.g.	  base	  pair	  sequences	  around	  the	  GR	  tethering/binding	  site,	  can	  affect	  steroid	  responsiveness	  whether	  regulating	  gene	  induction	  or	  repression.	  	  Different	  stimuli	  may	  also	  induce	  inflammatory	  gene	  expression	  in	  different	  cell	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types	   to	   the	   same	   extent	   but	   utilize	   different	   panels	   of	   transcription	   factors	   due	   to	   intrinsic	  differences	  in	  intracellular	  signalling	  pathways	  (Beck	  et	  al.,	  2009).	  The	  response	  of	  an	  individual	  gene	  to	  steroid	  treatment	  will	  therefore	  be	  cell	  and	  stimulus	  dependent.	  
This	  finding	  can	  be	  described	  as	  relative	  GC	  resistance	  to	  suppression	  of	  IL-­‐6	  compared	  to	  cells	  from	  control	   subjects.	  GC	   resistance	   is	  not	  a	  well-­‐recognised	  concept	   in	  PAH,	  although	   is	  well	  described	   in	   several	   conditions	   (notably	   inflammatory	   bowel	   disease,	   arthritis,	   COPD	   and	   in	  some	   severe	   asthmatics).	   In	   all	   conditions	   described,	   GC	   resistance	   is	   thought	   to	   reflect	   a	  number	   of	   heterogeneous	   molecular	   mechanisms	   (see	   chapter	   1).	   These	   include	   GR	  modification	   (e.g.	   by	   phosphorylation,	   acetylation	   or	   ubiquitination),	   defective	   histone	  acetylation	  (see	  below),	  a	  failure	  of	  Treg	  cells	  to	  secrete	  IL-­‐10	  in	  response	  to	  GC,	  or	  alteration	  of	  GR	  affinity	  to	  GC.	  For	  example,	  GR	  expression	  or	  receptor	  affinity	  may	  be	  reduced	  through	  the	  effects	  of	  several kinases	  that	  phosphorylate	  the	  GR	  (such	  as	  by	  excessive	  activation	  of	  p38	  MAP	  kinase	  (Galliher-­‐Beckley	  et	  al.,	  2011)	  or	  c-­‐Jun	  N-­‐terminal	  kinase	  (JNK)),	  which	  alters	  GR	  function	  (Barnes	   and	  Adcock,	   2009).	   Changes	   in	  GR	  phopshorylation	   status	   at	   distinct	   sites	  may	  affect	  the	  ability	  of	  GR	  to	  bind	   to	  GREs	  or	   interact	  correctly	  with	  other	   transcription	   factors	  such	  as	  NF-­‐κB	   or	   cofactors	   (Adcock	   et	   al.,	   1995b).	   For	   example	   AP-­‐1	   (a	   heterodimer	   of	   Fos	   and	   Jun	  proteins)	   can	   be	   activated	   by	   cytokines	   through	   the	   JNK	   pathway.	   JNK	   is	   over-­‐activated	   in	  PBMCs	   and	   bronchial	   biopsy	   samples	   from	   patients	   with	   GC-­‐resistant	   asthma	   and	   there	   is	  higher	   expression	   of	   c-­‐Fos	   compared	   to	   cells	   and	   samples	   from	   patients	   with	   GC-­‐sensitive	  disease.	  In	  addition,	  in	  PBMCs	  from	  patients	  with	  GC-­‐resistant	  asthma	  there	  is	  no	  fall	  in	  JNK	  or	  c-­‐Jun	  activity	  after	  high	  doses	  of	  oral	  GC	  (Adcock	  et	  al.,	  1995b).	  	  
In	  both	  asthma	  and	  COPD,	  reduced	  HDAC2	  has	  been	  shown	  to	  cause	  GC	  insensitivity	  by	  either	  targeting	   acetylated	   GR	   and	   altering	   its	   ability	   to	   associate	   with	   NF-­‐κB	   p65,	   modifying	   p65	  acetylation	  or	  by	  affecting	  local	  histone	  acetylation	  status	  thereby	  affecting	  inflammatory	  gene	  expression	   (Dewint	   et	   al.,	   2008).	   LPS-­‐stimulated	   IL-­‐6	   and	   CXCL8	   release	   from	   PBMCs	   from	  patients	  with	  severe	  asthma	  is	  relatively	  resistant	  to	  the	  effects	  of	  dexamethasone	  compared	  to	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the	   effect	   of	   dexamethasone	   in	   cells	   from	  non-­‐severe	   asthmatics	   (Hew	  et	   al.,	   2006).	   This	  was	  suggested	   to	  be	   associated	  with	   the	   reduced	  HDAC	  activity	   seen	   in	   the	   severe	   asthmatic	   cells	  (Hew	  et	  al.,	  2006).	  In	  COPD,	  Ito	  et	  al	  showed	  that	  reduction	  of	  HDAC2	  plays	  a	  critical	  role	  in	  GC	  insensitivity	   in	   repressing	   a	   subset	   of	   NF-­‐κB-­‐induced	   inflammatory	   genes	   without	   affecting	  GRE-­‐induced	   gene	   expression	   (Ito	   et	   al.,	   2006).	   Importantly,	   overexpression	   of	   HDAC2	   in	  alveolar	  macrophages	  from	  COPD	  patients	  restored	  GC	  sensitivity	  in	  these	  cells	  (Ito	  et	  al.,	  2006).	  In	   PAH,	   Gambaryan	   et	   al	   provide	   preliminary	   evidence	   implicating	   reduced	   HDAC	   activity	   in	  whole	   lung	  specimens	   from	  patients	  with	   iPAH	  (Gambaryan,	  2012).	   It	  would	  be	   interesting	   to	  see	   if	  resistance	  to	  IL-­‐6	  suppression	  by	  dexamethasone	  in	  PBMC	  from	  PAH	  patients	  related	  to	  reduced	  HDAC	  activity.	  Detailed	  measurement	  of	  HAT/HDAC	  activity	   in	   these	  cells	  along	  with	  transcriptome	   analysis	   using	   gene	   arrays	   or	   deep	   sequencing	   and	   the	   use	   of	   selective	   HAT	  inhibitors	  (Nicodeme	  et	  al.,	  2010)	  may	  provide	  evidence	  for	  which	  genes	  are	  regulated	  by	  which	  mechanism	  in	  these	  cells	  –	  knowing	  that	  CXCL8	  is	  HDAC2–dependent	  in	  macrophages	  (Charron	  et	  al.,	  2009).	  
Finally,	  the	  potential	  influence	  of	  BMPR-­‐II	  signalling	  on	  GC	  responsiveness	  was	  suggested	  by	  a	  study	   by	   Donn	   et	   al,	   where	   gene	   expression	   profiling	   of	   healthy	   lymphocytes	   revealed	   that	  BMPR-­‐II	  was	  a	  steroid-­‐sensitising	  gene	  (Donn	  et	  al.,	  2007).	  In	  this	  study,	  the	  authors	  compared	  the	   circulating	   genes	   between	   the	   10%	   of	   participants	   with	   the	   highest	   and	   lowest	   GC	  responsiveness	   (assessed	   using	   a	   clinical	   dexamethasone	   suppression	   test)	   and	   identified	   24	  genes	   that	   were	   different	   between	   the	   groups.	   The	   most	   discriminant	   gene	   identified	   was	  BMPR-­‐II,	   which	   enhanced	   GC	   responsiveness	   when	   transfected	   into	   Hela	   cells	   (Donn	   et	   al.,	  2007).	   This	   is	   interesting	   knowing	   that	   BMPR-­‐II	   dysfunction	   is	   likely	   to	   predispose	   to	   the	  development	  of	  inflammation	  in	  PAH	  (Soon,	  2010)	  -­‐	  it	  could	  be	  hypothesised	  that	  dysfunctional	  BMPR-­‐II	   also	   predisposes	   to	   relative	   GC	   resistance.	   We	   showed	   that	   that	   dexamethasone	  inhibited	  NF-­‐κB	  activation	  at	  baseline	   in	  control	  PBMC.	   It	  was	  previously	  suggested	   in	  a	  small	  study	  that	  no	  difference	  in	  NF-­‐κB	  activation	  in	  PBMC	  existed	  at	  baseline	  between	  PAH	  patients	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and	  controls	  (Raychaudhuri	  et	  al.,	  2002a),	  although	  an	  increase	  in	  NF-­‐κB	  activation	  was	  noted	  in	  alveolar	  macrophages	  (Raychaudhuri	  et	  al.,	  1999),	  HPAH	  PASMC	  (Davies	  et	  al.,	  2012),	  and	  in	  my	  results	   in	  both	   lung	  vascular	  and	   inflammatory	  cells	   in	  chapter	  3.	   It	  may	  therefore	  be	  that	  the	  peripherally	  accessible	  cells	  are	  not	  truly	  representative	  of	  PAH	  whereas	  vascular	  cells	  from	  the	   lungs	   are.	   Additional	   experiments	   would	   be	   needed	   to	   compare	   with	   PBMC	   in	   patients	  harbouring	  BMPR-­‐II	  mutations	  to	  see	  if	  they	  exhibit	  more	  marked	  GC	  resistance	  in	  vitro	  as	  well	  as	  comparing	  patients	  with	  more	  severe	  and	  less	  severe	  disease.	  	  Ideally,	  it	  will	  be	  necessary	  to	  extend	  this	  hypothesis	  further	  to	  lung-­‐derived	  rather	  than	  circulating	  cells.	  	  
Finally,	   it	   must	   be	   remembered	   that	   there	   are	   probable	   additional	   steroid	   sensitive	  inflammatory	   pathways	   that	   are	   upregulated	   in	   PAH	   in	   addition	   to	   NF-­‐κB	   and,	   therefore,	  possible	   targets	   for	   inhibition	   by	   GC.	   For	   example,	   AP-­‐1	   was	   upregulated	   in	   a	   model	   of	  bleomycin–induced	  PH	  in	  mice	  (Ortiz	  et	  al.,	  2002)	  (although	  not	  yet	  studied	  in	  MCT-­‐induced	  PH)	  and	   is	   a	   known	   GC-­‐sensitive	   transcription	   factor	   in	   cytokine-­‐stimulated	   PBMC	   (Adcock	   et	   al.,	  1995a).	  Study	  of	  such	  additional	  inflammatory	  pathways	  would	  be	  of	  interest	  in	  iPAH.	  	  	  
6.4.1	  Limitations	  of	  results	  
Many	  of	  the	  limitations	  have	  been	  discussed	  already.	  The	  major	  limitations	  were	  the	  variability	  of	   PBMC	   isolation	   techniques	   and	   the	   confounding	   nature	   of	   PH	   therapies	   that	   are	   known	   to	  inhibit	  inflammation	  (and	  specifically	  that	  inhibit	  NF-­‐κB).	  Cytokine	  release	  from	  our	  PBMC	  was	  much	   more	   variable	   (hence	   the	   large	   error	   bars	   e.g.	   in	   Figure	   6.4),	   with	   a	   less	   robust	  concentration-­‐response	   curve	   to	   the	   stimuli	   compared	   to	   our	   whole	   blood	   assays.	   This	   may	  have	  related	  to	  the	  inherent	  variations	  in	  PBMC	  isolation	  including	  time	  from	  sampling	  to	  PBMC	  isolation;	   ambient	   temperature;	   the	   presence	   of	   subclinical	   infections;	   handling	   of	   PBMC	  (including	  differences	  in	  plastics)	  leading	  their	  baseline	  activation;	  and	  unintentional	  variations	  in	   PBMC	   seeding	   density.	   These	   factors	   were	   minimised	   as	   much	   as	   possible,	   and	   when	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differences	  between	  groups	  were	  significant	  at	  baseline,	  data	  were	  expressed	  as	  the	  increment	  from	  baseline	  un-­‐stimulated	  values.	  	  
6.4.2	  Clinical	  implications	  
The	  relative	  hyporesponsiveness	  to	  an	  inflammatory	  stimulus	  is	   likely	  to	  be	  a	  reflection	  of	  the	  inflammatory	   cells’	   recruitment	   to	   the	   lung.	  Although	   this	   is	   interesting,	   it	   is	   unlikely	   to	   have	  much	  direct	  clinical	  relevance	  other	  than	  to	  conclude	  that	  by	  stimulating	  patients’	  cells,	  we	  are	  (unfortunately)	  unlikely	   to	  more	  easily	  detect	  patients	  with	  an	   ‘inflammatory	  phenotype’	  who	  could	  potentially	  be	  targeted	  with	  anti-­‐inflammatory	  therapies	  than	  previous	  baseline	  cytokine	  biomarker	  studies.	  The	  fact	  that	  dexamethasone	  suppressed	  IL-­‐6	  and	  CXCL8	  from	  patients	  and	  control	   subjects	   suggests	   that	   dexamethasone	  works	   to	   suppress	   inflammation	   in	   circulating	  inflammatory	  cells.	  This	   is	  potentially	   relevant	   for	   future	  GC	  studies	   in	  PAH	  patients	  although	  the	   more	   relevant	   cells	   to	   study	   appear	   to	   be	   those	   from	   the	   lung	   vasculature.	   Finally,	   we	  provide	   some	   evidence	   for	   relative	   steroid	   resistance	   (at	   least	   towards	   LPS-­‐induced	   IL-­‐6	  release)	   in	  patients’	  PBMC,	  which	  should	  be	   further	  explored.	   It	  will	  be	  clinically	   important	   to	  know	   if	   patients	   are	   clinically	   GC	   responsive	   or	   GC	   resistant,	   and	   to	   target	   research	   and	  potential	  therapies	  to	  the	  correct	  patient	  phenotype.	  	  	  
6.4.3	  Summary	  and	  future	  directions	  
Firstly,	   the	   potential	   mechanisms	   of	   the	   relative	   ‘hyporesponsiveness’	   could	   be	   further	  investigated	   by	   sequential	   studies	   of	   both	   the	   lung	   and	   the	   systemic	   compartments,	   and	  peripherally	  accessible	  cells	  could	  be	  stimulated	  to	  see	  if	  differences	  were	  explained	  by	  altered	  NF-­‐κB	   activation.	   From	   the	   dexamethasone	   experiments,	   the	   implication	   that	   IL-­‐6	   differed	   in	  terms	   of	   GC	   sensitivity	   should	   be	   explored	   in	   larger	   studies	   of	   pulmonary	   vascular	   cells.	   In	  addition,	   the	   reduction	   in	   LPS-­‐induced	   cytokine	   release	  with	   sildenafil	   suggests	   an	   additional	  ‘anti-­‐inflammatory’	  mechanism	  for	  sildenafil,	  and	  it	  would	  be	  interesting	  to	  assess	  whether	  this	  is	   through	   inhibition	  of	  NF-­‐κB.	  Due	   to	   time	  constraints,	   the	   following	  are	  outstanding:	  1)	  CRP	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experiments	  in	  control	  subjects,	  2)	  ELISAs	  for	  IL-­‐6	  release	  from	  TNF-­‐α-­‐stimulated	  PBMC	  and	  3)	  a	  Luminex	  assay	  to	  measure	  further	  cytokines	  and	  growth	  factors	  on	  stored	  samples,	  including	  IL-­‐1β,	  IL-­‐10,	  TNF-­‐α,	  MCP-­‐1,	  fractalkine	  and	  RANTES.	  Finally,	  it	  would	  be	  of	  interest	  to	  perform	  a	  controlled	   trial	   of	   steroid	   or	   sildenafil,	   and	   to	   look	   at	   inflammatory	  mediator	   expression	   and	  peripheral	  blood	  cell	  activation	  status	  pre-­‐	  and	  post-­‐treatment.	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CHAPTER	  7.	  OVERALL	  DISCUSSION	  AND	  FUTURE	  
DIRECTIONS	  
The	   findings	   in	   this	   thesis	   confirmed	   my	   hypothesis	   that	   NF-­‐κB,	   at	   least	   in	   part,	   drives	   the	  inflammatory	   response	   in	   PAH	   and	   that	   inhibition	   of	   this	   pathway	   can	   reverse	   vascular	  remodelling	  and	  may	  thus	  provide	  novel	  treatments	  in	  PAH.	  I	  showed	  that	  NF-­‐κB	  was	  activated	  in	  patients	  with	  end-­‐stage	  iPAH;	  and	  that	  this	  NF-­‐κB	  activation	  was	  especially	  localised	  to	  lung	  macrophages,	  also	  B	  and	  T	  lymphocytes,	  and	  notably	  EC	  and	  PASMC.	  These	  are	  novel	  findings	  in	  lung	   specimens	   from	   patients	   with	   iPAH.	   In	   the	   MCT-­‐induced	   PH	   rat	   model,	   I	   demonstrated	  activation	   of	   NF-­‐κB	   located	   to	   lung	   vascular	   cells	   (EC	   and	   PASMC)	   and	   confirmed	   previous	  findings	   that	   the	   cytokine	   IL-­‐6	  was	  upregulated	   and	  BMPR-­‐II	   down-­‐regulated	   in	   this	  model.	   I	  showed	   that	   the	   synthetic	   GC	   dexamethasone	   reversed	   established	   PH	   in	   this	  model	  with	   an	  associated	   reduction	   in	   NF-­‐κB	   activation,	   IL-­‐6	   expression	   and	   a	   restoration	   of	   BMPR-­‐II	  expression.	  I	  showed	  potential	  anti-­‐remodelling	  mechanisms	  including	  that	  dexamethasone	  was	  anti-­‐proliferative	   and	   pro-­‐apoptotic	   effects	   in	   both	   rat	   and	   in	   human	   PASMC	   and	   that	  dexamethasone	   reduced	   CXCL8	   and	   IL-­‐6	   release	   in	   an	   NF-­‐κB-­‐dependent	   manner.	   Finally	   I	  showed	  in	  whole	  blood	  assays	  and	  PBMC	  that	  circulating	  inflammatory	  cells	  from	  patients	  were	  relatively	  hyporesponsive	  to	  LPS	  and	  TNF-­‐α	  in	  terms	  of	  cytokine	  release,	  compared	  to	  control	  cells;	  that	  dexamethasone	  reduced	  CXCL8	  and	  IL-­‐6	  release	  and	  that	  IL-­‐6	  release	  from	  PAH	  PBMC	  were	  relatively	  resistant	  to	  the	  effects	  of	  dexamethasone	  compared	  to	  control	  PBMC.	  
NF-­‐κB	  can	  be	  considered	  a	  key	  transcription	  factor	  as	  it	  regulates	  the	  expression	  of	  chemokines	  and	   cytokines	   that	   are	   elevated	   in	   PAH.	  Disease	   relevant	   stimuli	   for	  NF-­‐κB	   activation	   include	  certain	   cytokines,	   bacterial,	   parasitic	   and	   viral	   infections,	   and	   potentially	   other	   inflammatory	  stimuli	   including	  toxic	  insults	  and	  drugs.	  The	  time-­‐course	  of	  the	  inflammatory	  insult	   in	  PAH	  is	  uncertain.	   Animal	   models	   suggest	   the	   presence	   of	   an	   early	   inflammatory	   phase	   in	   terms	   of	  inflammatory	   cell	   infiltrate	   and	   also	  NF-­‐κB	   activation.	   	   Hence,	  NF-­‐κB	   has	   been	   considered	   an	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early	   insult	   that	   is	   likely	   to	   lead	   to	   exaggerated	   remodelling	   through	   mechanisms	   such	   as	  dysfunctional	  BMPR-­‐II	  signalling.	  	  It	  is	  however	  difficult	  to	  determine	  the	  sequence	  of	  events	  in	  human	  disease	  as	  we	  do	  not	  have	  access	  to	  lung	  samples	  from	  patients	  with	  less	  severe	  disease.	  	  It	   is	   important	   to	   study	   these	   lung	   samples	   rather	   than	   peripherally	   accessible	   inflammatory	  cells	  as	  highlighted	  in	  chapter	  6.	  	  In	  addition,	  we	  do	  not	  know	  whether	  the	  inflammatory	  insult	  is	   a	   single	   event,	   such	   as	   a	   viral	   infection,	   or	   an	   ongoing	   self-­‐perpetuating	   inflammatory	  stimulus.	   Indeed,	   it	   is	   unclear	   whether	   inflammation	   is	   one	   of	   multiple	   single	   hits	   in	   the	  pathogenesis	   of	   remodelling	   such	   as	   in	   the	  multi-­‐hit	   process	   of	   carcinogenesis	   or	   an	   ongoing	  process	  that	  parallels	  the	  remodelling.	  My	  results	  suggest	  that	  the	  latter	  may	  be	  more	  likely	  as	  we	   showed	   that	   even	   in	   these	   patients	   with	   end	   stage	   PAH	   marked	   NF-­‐κB	   activation.	   This	  suggests	   that	   in	  human	  disease,	   inflammation	  may	  be	  even	  more	  prominent	   than	   in	   the	   ‘early	  inflammatory’	  model	  we	  selected	  to	  study.	  	  It	  would	  be	  interesting	  to	  ascertain	  the	  contribution	  and	   time-­‐course	   of	   NF-­‐κB	   activation	   and	   inflammation	   in	   alternative	   models	   of	   PH	   where	  inflammation	  is	  prominent	  such	  as	  the	  murine	  schistosomiasis-­‐induced	  PH	  model	  (Crosby	  et	  al.,	  2011).	  	  
In	  this	  thesis,	  I	  quantified	  an	  increase	  in	  lung	  macrophages	  in	  PAH,	  and	  that	  these	  macrophages	  showed	  more	  NF-­‐κB	  activation	   than	  macrophages	   in	  control	   lungs.	  Although	   little	   is	  currently	  known	  about	  these	  lung	  macrophages	  in	  PAH;	  MCP-­‐1	  and	  other	  chemokines	  are	  elevated	  in	  lung	  from	  PAH	  patients	  particularly	  to	  the	  EC	  (Itoh	  et	  al.,	  2006)	  (Balabanian	  et	  al.,	  2002,	  Dorfmuller	  et	  al.,	  2002)	  and	  increase	  the	  chemoattraction	  of	  monocytes	  in	  iPAH	  (Sanchez	  et	  al.,	  2007).	  We	  do	   not	   know	   what	   types	   of	   macrophages	   these	   cells	   are;	   nor	   their	   origin	   –	   whether	   from	  resident	   lung	   monocytes	   or	   circulating	   precursors.	   As	   in	   other	   diseases	   including	  atherosclerosis	  and	  cancer,	  it	  would	  be	  interesting	  to	  ascertain	  the	  macrophage	  subtype	  in	  PAH;	  the	   level	   of	   function;	   and	   to	   postulate	   the	   impact	   of	   changing	   their	   function.	   For	   example	   in	  atherosclerosis,	  CD68+CD14+	  cells	  reside	  within	  active	  plaques	  whereas	  CD68+CD14-­‐	  cells	  are	  seen	   in	   disease-­‐free	   areas	   (Waldo	   et	   al.,	   2008)	   suggesting	   differences	   in	   their	   monocyte	  precursors;	  and	  several	  pathogens	  and	  tumours	  can	  enhance	  the	  anti-­‐inflammatory	  responses	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of	  macrophages	  (the	  ‘M1	  to	  M2	  switch’)	  (Mantovani	  et	  al.,	  2013).	  Whatever	  their	  subtype,	  these	  lung	  macrophages	  are	  likely	  to	  be	  a	  major	  source	  of	  TNF-­‐α	  which	  is	  implicated	  in	  PAH	  (Soon	  et	  al.,	  2010)	  and	  both	  an	  activator	  of	  NF-­‐κB	  and	  a	  gene	  product	  of	  NF-­‐κB	  activation	  (Barnes	  and	  Karin,	  1997).	  
In	  Chapter	  3	  I	  also	  showed	  that	  the	  EC	  were	  particularly	  activated	  in	  terms	  of	  NF-­‐κB	  to	  an	  even	  greater	   extent	   than	   in	   PASMC.	   In	   PAH,	   EC	  have	   been	   shown	   to	   be	   a	   source	   of	   several	  NF-­‐κB-­‐dependent	  chemokines	   including	   fractalkine	  and	  RANTES	  (Balabanian	  et	  al.,	  2002,	  Dorfmuller	  et	  al.,	  2002)	  that	  attract	  inflammatory	  cells	  to	  the	  pulmonary	  vascular	  lesion.	  Further	  to	  these,	  it	  would	   be	   interesting	   to	   counterstain	   human	   PAH	   tissue	  with	   CXCL8	   (or	   of	   CINC-­‐1	   in	   the	   rat	  model)	   to	   determine	   the	   main	   cell	   source	   of	   this	   implicated	   NF-­‐κB-­‐regulated	   mediator.	   We	  showed	   that	   dexamethasone	   suppressed	   CXCL8	   release	   from	   cultured	   PASMC	   and	   circulating	  PBMC	  in	  an	  NF-­‐κB-­‐dependent	  manner,	  but	  beyond	  the	  suppression	  of	   its	  release	   from	  PASMC	  being	   suppressed	   by	   dexamethasone	   in	   an	   NF-­‐κB-­‐dependent	   manner,	   we	   have	   not	   yet	   fully	  explored	   additional	   mechanisms	   through	   which	   this	   chemokine	   may	   impact	   on	   PAH	  pathogenesis.	   It	   is	   known	   to	   be	   pro-­‐proliferative	   to	   systemic	   SMC	   (Li	   et	   al.,	   2003),	   and	   an	  important	  angiogenic	  chemokine	  acting	  upon	  multiple	   intracellular	  pathways	  important	   in	  the	  promotion	  of	  vascular	  cell	  growth.	  Further	  studies	  using	  PASMC	  would	  be	  important.	  	  
IL-­‐6	   is	   the	   cytokine	   most	   implicated	   in	   PAH	   pathogenesis.	   Further	   to	   plasma	   levels	   being	  elevated	  in	  patients	  (Soon	  et	  al.,	  2010,	  Itoh	  et	  al.,	  2006),	  it	  is	  directly	  proliferative	  to	  PASMC	  in	  culture	   (Ikeda	   et	   al.,	   1991)	   and	   known	   to	   act	   (in	   other	   cells)	   through	   activation	   of	   JAK	   STAT	  signalling	  which	   augments	   cell	   survival	   -­‐	   being	  both	  pro-­‐proliferative	   and	  anti-­‐apoptotic.	   IL-­‐6	  can	   also	   activate	   NF-­‐κB	   in	   epithelial	   cells	   (Wang	   et	   al.,	   2003)	   potentially	   creating	   a	   positive	  feedback	  loop.	  	  However,	  we	  do	  not	  know	  that	  this	  is	  the	  case	  specifically	  in	  PASMC.	  This	  sort	  of	  positive	   feedback	   loop	   for	   ongoing	   NF-­‐κB	   activation	   is	   already	   well	   described	   for	   IL1-­‐β	   and	  TNF-­‐α	  (Barnes	  and	  Karin,	  1997)	  and	  might	  be	  a	  potential	  mechanism	  for	  the	  ongoing	  persistent	  NF-­‐κB	   activation	   in	   PAH.	   I	   confirmed	   previous	   findings	   that	   dexamethasone	   reduced	   the	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elevated	   IL-­‐6	   mRNA	   in	   lung	   from	   rats	   with	   MCT-­‐induced	   PH	   (Bhargava	   et	   al.,	   1999);	   I	   also	  showed	  that	  the	  dexamethasone-­‐induced	  fall	  in	  IL-­‐6	  mRNA	  in	  PASMC	  from	  day-­‐21	  MCT-­‐exposed	  rats	  was	   less	  marked	   than	   that	   in	   control	  PASMC	   suggesting	   a	   relative	  GC	   resistance	   in	   these	  cells.	   Using	   immunohistochemistry,	   I	   observed	   a	   dexamethasone-­‐induced	   reduction	   in	   IL-­‐6	  expressing	   cells	   in	   the	   rat	   model	   and	   that	   the	   main	   source	   of	   IL-­‐6	   was	   the	   perivascular	  inflammatory	  cells.	   	  Morphologically	  these	  cells	  were	  monocytes/macrophages.	  In	  addition,	  EC	  stained	   strongly	   for	   IL-­‐6,	   suggesting	   these	   cells	   are	   also	   a	  major	   source	   of	   IL-­‐6	  which	  would	  contribute	  to	  the	  NF-­‐κB	  IHC	  findings	  in	  EC.	  I	  also	  showed	  that	  cultured	  PASMC	  released	  IL-­‐6:	  It	  is	   likely,	   therefore,	   that	   the	   raised	   plasma	   levels	   of	   IL-­‐6	   are	   derived	   from	   a	  multitude	   of	   cell	  types.	  	  
I	   showed	   that	   physiological	   concentrations	   of	   dexamethasone	   inhibited	   proliferation	   in	   rat	  PASMC.	  This	  adds	  to	  the	  findings	  in	  human	  PASMC	  from	  iPAH	  patients	  by	  Ogawa	  et	  al	  who	  used	  very	   high	   concentrations	   of	   prednisolone	   to	   the	   same	   effect	   (Ogawa	   et	   al.,	   2005).	   I	   further	  demonstrated	  using	  several	  methods	   that	  dexamethasone	   induced	  PASMC	  apoptosis.	  This	   is	  a	  novel	   finding	   in	   SMC,	   although	   is	  well	   recognised	   in	   lymphoid	   cells	   and	   certain	   granulocytes	  including	  eosinophils,	  and	  is	  a	  likely	  anti-­‐remodelling	  mechanism	  in	  PASMC	  as	  demonstrated	  by	  other	   PAH	   therapies.	   Interestingly,	   NF-­‐κB	   is	   an	   important	   inhibitor	   of	   apoptosis,	   as	   first	  recognised	   in	  RelA-­‐deficient	  mice	  with	  hepatocyte	  apoptosis	  (Beg	  et	  al.,	  1995)	  and	  has	   indeed	  been	   demonstrated	   to	   regulate	   apoptosis	   in	   rat	   and	   human	   aortic	   SMC	   where	   elevating	  endogenous	   IκBα	   levels,	   either	   by	   adenovirus-­‐mediated	   overexpression	   or	   by	   inhibiting	   its	  degradation	   with	   proteasomal	   inhibitors,	   increased	   apoptosis	   (Erl	   et	   al.,	   1999).	   In	   general,	  activation	  of	  NF-­‐κB	  protects	  cells	  from	  apoptosis	  by	  increasing	  the	  expression	  of	  anti-­‐apoptotic	  proteins	   such	   ascellular	   inhibitor	   of	   apoptosis	   protein	   1	   (c-­‐IAP1),	   c-­‐IAP2,	   TNF	   receptor-­‐	  associated	  factor	  1	  (TRAF1)	  and	  TRAF2.	  However,	   the	  effects	  can	  vary	  between	  cell	   types	  and	  NF-­‐κB	   can	   even	   sensitise	   some	   cells	   to	   death-­‐inducing	   stimuli	   (Dutta	   et	   al.,	   2006).	   How	  dexamethasone	  induced	  apoptosis	  in	  our	  PASMC	  is	  not	  certain	  but	  my	  initial	  hypothesis	  would	  
Laura	  Price	  PhD:	  Inflammation	  in	  Pulmonary	  Arterial	  Hypertension	   227	  
be	  that	  an	  increase	  in	  cell	  death	  signals	  results	  through	  inhibition	  of	  NF-­‐κB.	  This	  is	  my	  proposed	  first	   step	   in	   unravelling	   this	  mechanism:	  We	   have	   experiments	   planned	   in	   human	   PASMC	   to	  assess	   the	   effects	   of	   an	   IKK2	   inhibitor,	   which	   would	   increase	   IκBα	   levels,	   on	   apoptosis,	   and	  ideally	  to	  measure	  some	  of	  the	  NF-­‐κB-­‐regulated	  gene	  products	  mentioned	  above.	  
In	  human	  PASMC	  and	  PBMC	  experiments,	  I	  showed	  that	  dexamethasone	  reduced	  CXCL8	  and	  IL-­‐6	   release,	   which	   was	   by	   GC-­‐induced	   transrepression	   of	   these	   NF-­‐κB	   target	   genes,	   as	   I	  demonstrated	  using	  p65	  TransAms	  in	  both	  cell	  types.	  The	  resulting	  anti-­‐remodelling	  effects	  of	  dexamethasone	  and	  IKK2	   inhibition	  could	  either	  be	  a	  global	  effect	  on	  NF-­‐κB	  and/or	  a	  specific	  effect	  relating	  to	  suppression	  of	  specific	  cytokines	  or	  chemokines	  including	  IL-­‐6	  and	  CXCL8.	  In	  several	  conditions,	  blockade	  of	  IL-­‐6	  has	  been	  studied	  using	  monoclonal	  antibodies.	  For	  example	  in	  multiple	  myeloma,	   IL-­‐6	   plays	   a	   central	   role	   in	   pathogenesis	   and	   confers	   resistance	   to	   GC-­‐induced	  apoptosis.	  An	  IL-­‐6	  monoclonal	  antibody	  (siltuximab)	  led	  to	  a	  clinical	  response	  in	  some	  patients	  with	  refractory	  disease	  despite	  infections	  in	  over	  half	  of	  patients;	  of	   interest	  was	  that	  responses	  were	  even	  seen	  in	  dexamethasone-­‐refractory	  disease	  (Voorhees	  et	  al.,	  2013).	  In	  PAH,	  an	  IL-­‐6	  mAb	  (tocilizumab)	  has	  been	  used	  to	  treat	  a	  single	  case	  of	  Castleman’s	  PAH	  (associated	  with	  a	  lymphoproliferative	  disease)	  who	  was	  resistant	  to	  conventional	  advanced	  PAH	  therapies	  and	  also	  steroids.	  She	  showed	  significant	  clinical	  improvement	  for	  6	  months	  (Arita	  et	  al.,	  2010).	  Whether	  blocking	  IL-­‐6	  has	  an	  additional	  effect	  on	  GC-­‐induced	  inhibition	  of	  proliferation	  and/or	  induction	  of	  PASMC	  apoptosis	  is	  of	  interest	  in	  the	  context	  of	  my	  results.	  
An	  important	  question	  is	  whether	  PAH	  is	  a	  ‘GC	  sensitive’	  disease?	  	  In	  my	  experiments,	  the	  MCT	  model	  was	  GC	  sensitive	  in	  vivo,	  and	  in	  most	  respects	  in	  vitro	  -­‐	  except	  that	  MCT-­‐exposed	  PASMC	  were	   relatively	   dexamethasone	   resistant	   (only	   at	   10-­‐8M)	   in	   terms	   of	   dexamethasone-­‐induced	  inhibition	   of	   proliferation.	   Despite	   this,	   the	   MCT	  model	   was	   GC	   sensitive	   overall	   in	   terms	   of	  haemodynamic	   parameters,	   remodelling	   and	   survival	   –	   although	   very	   high	   human	   dose	  equivalents	  of	  dexamethasone	  were	  used	  (approximating	  to	  90mg	  prednisolone	  per	  day),	  with	  associated	  marked	   side	   effects	   including	   severe	   weight	   loss	   (cachexia)	   and	   probably	   adrenal	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suppression.	   It	   is	   likely	   that	   GC	   act	   in	   so	   many	   ways,	   reducing	   the	   downstream	   effects	   of	  multiple	   cytokines	   and	  mediators	   that	   enable	   the	   clinical	   effect	   –	   such	   that	   individual	   in	   vitro	  findings	   are	   less	   relevant	   than	   the	   global	   in	   vivo	   effect.	   In	   other	   settings,	  MCT-­‐induced	   PH	   is	  suggested	   to	   not	   be	   an	   ideal	  model	   of	   human	  disease,	   notably	   it	   does	   not	   recapitulate	   all	   the	  histopathological	  aspects	  of	  human	  iPAH	  including	  the	  most	  severe	  plexiform	  lesions	  (Stenmark	  et	  al.,	  2009)	  –	  it	  might	  be	  these	  are	  impossible	  to	  reverse,	  unlike	  the	  impressive	  dissolution	  we	  saw	  of	  the	  medial	  thickening	  (that	  we	  showed	  was	  also	  reversible	  in	  vitro	  by	  reversing	  PASMC	  proliferation/apoptosis).	   MCT-­‐induced	   PH	   could	   be	   considered	   a	   better	   model	   of	   a	   more	  obviously	   GC	   sensitive	   subtype	   of	   PAH	   for	   example	   SLE-­‐induced	   PAH	   (Jais	   et	   al.,	   2008)	   	   –	  although	   controlled	   clinical	   trials	   have	   not	   yet	   been	   performed	   in	   iPAH.	   My	   human	   ex	   vivo	  experiments	  also	  showed	  at	  least	  some	  evidence	  for	  GC	  resistance	  in	  terms	  of	  IL-­‐6	  release	  from	  PBMC.	   This	   is	   of	   interest	   especially	   as	   I	   also	   demonstrated	   GC	   resistance	   to	   IL-­‐6	   mRNA	   and	  proliferation	  in	  MCT-­‐exposed	  PASMC.	  However,	  we	  also	  showed	  an	  overall	  hyporesponsiveness	  in	  the	  circulating	  cell	  population	  –	  in	  PBMC	  from	  my	  study	  and	  also	  in	  derived	  monocytes	  and	  DC	   in	  others	  (Wang	  et	  al.,	  2009,	  Raychaudhuri	  et	  al.,	  2002a).	   	   It	   is	  unclear,	   therefore,	  whether	  these	  cells	  are	  a	  true	  representation	  of	  GC	  resistance	  in	  iPAH.	  I	  believe	  we	  need	  to	  examine	  lung-­‐derived	  cells,	  and	  in	  addition	  a	  robust	  clinical	  end	  point.	  	  
GC	  resistance	  in	  other	  diseases	  is	  a	  clinical	  diagnosis	  defined	  by	  a	  lack	  of	  response	  to	  GC,	  as	  is	  the	   case	   in	   a	   subgroup	   of	   severe	   asthmatics	   (in	   some	   patients	   with	   severe	   disease	   and	   in	  smokers),	   as	   well	   as	   in	   patients	   with	   COPD	   and	   rheumatoid	   arthritis	   (Barnes	   Adcock	   Lancet	  2009).	  Of	  note	   in	  patients	  with	  severe	  asthma,	  circulating	  PBMC	  showed	  relative	  resistance	  to	  GC-­‐induced	   suppression	   of	   cytokine	   release	   (Hew	   et	   al.,	   2006)	   –	   suggesting	   in	   these	   airway	  diseases,	  peripheral	  circulating	  inflammatory	  cells	  are	  more	  representative	  of	  the	  lung	  disease.	  The	  GC	  resistance	  in	  our	  PBMC	  experiments	  to	  IL-­‐6	  is	  potentially	  interesting	  and	  might	  present	  a	  way	  of	  detecting	  GC	  sensitivity	  through	  use	  of	  a	  peripherally	  accessible	  assay	  although	  it	  was	  not	  mirrored	  by	  changes	  CXCL8.	  Further	  analysis	  of	  samples	  using	  a	  Luminex	  assay	  to	  detect	  a	  larger	   panel	   of	  mediators	  will	   be	   enlightening.	   Of	   note,	   dexamethasone	   suppression	   tests	   are	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considered	  to	  be	  the	  most	  useful	  clinical	  predictor	  of	  GC	  sensitivity,	  and	  would	  be	  very	  useful	  to	  perform	  in	  PAH	  patients	  –	  although	  would	  be	  logistically	  difficult	  in	  a	  research	  setting	  as	  require	  an	   overnight	   period.	   If	   GC	   resistance	   is	   a	   true	   feature	   of	   at	   least	   a	   subgroup	   of	   PAH	   patients	  mechanisms	  might	   include	   a	   excess	   of	  HAT	   and	   a	   reduction	   in	  HDAC	  which	   has	   indeed	   been	  demonstrated	  by	  Gambaryan	  et	  al	   in	  whole	   lung	   from	   iPAH	  patients	   (Gambaryan,	  2012).	  This	  association	  of	  HDAC	  with	  GC	  responsiveness	  was	  demonstrated	  by	  Cosio	  et	  al	  where	  low	  HDAC	  activity	   in	   alveolar	  macrophages	   from	   COPD	   patients	   was	   restored	   using	   theophylline	   which	  restored	  the	  ability	  of	  dexamethasone	  to	  suppress	  LPS-­‐stimulated	  cytokine	  release	  (Cosio	  et	  al.,	  2004).	  This	  data	  importantly	  showed	  that	  GC	  resistance	  is	  potentially	  reversible	  –	  by	  drugs	  such	  as	   theophylline	   (although	   not	   an	   ideal	   drug	   in	   PAH)	   and	   also	   by	   antioxidants	   (Barnes	   and	  Adcock,	  2009).	  Additional	  pathways	  in	  other	  chronic	  lung	  diseases	  suggest	  treatment	  strategies	  to	  reverse	  the	  underlying	  GC	  resistance	  including	  inhibition	  of	  other	  upregulated	  inflammatory	  pathways	  e.g.	  AP-­‐1	  or	  p38	  MAP	  kinase	  or	  the	  use	  of	  vitamin	  D	  to	  restore	  IL-­‐10	  function	  (Barnes	  and	  Adcock,	  2009).	  
To	  ultimately	  determine	  GC	  sensitivity	  in	  PAH	  would	  involve	  a	  clinical	  trial	  of	  GC	  in	  patients.	  In	  other	  diseases	  where	  GC	  are	  used,	   clinical	   samples	   included	  bronchial	  biopsy	  specimens	   from	  patients	   (e.g.	   with	   asthma),	   upon	  which	   nuclear	   p65	   TransAms	   have	   been	   performed,	   which	  have	   been	   used	   in	   assessing	   the	   tissue	   response	   to	   systemic	   GC	   treatment.	   These	   and	   BAL	  samples	  are	  now	  almost	   impossible	   to	  obtain	   from	  PAH	  patients,	  hence	  the	  challenge	   in	   these	  patients	   (and	   the	  potential	   appeal	   of	  PBMCs/derived	   cells).	  Thus	   far,	   clinical	   evidence	   for	   the	  use	  of	  GC	  in	  PAH	  is	  based	  on	  case	  series	  in	  associated	  PAH	  such	  as	  lupus-­‐	  and	  MCTD-­‐associated	  PAH	  (Karmochkine	  et	  al.,	  1996,	  Tanaka	  et	  al.,	  2002,	  Jais	  et	  al.,	  2008,	  Goupille	  et	  al.,	  1994),	  MCTD	  (Jais	  et	  al.,	  2008,	  Dahl	  et	  al.,	  1992)	  and	  rarer	  associated	  inflammatory	  conditions	  such	  as	  POEMS	  syndrome	  (Jouve	  et	  al.,	  2007).	  There	  are	  sporadic	  reports	  of	  prednisolone	  use	  in	  patients	  with	  iPAH.	   For	   example,	   a	   34-­‐year-­‐old	   woman	   on	   prostacyclin	   was	   treated	   with	   1mg/kg/day	  prednisolone	  for	  coexistent	  idiopathic	  thrombocytopaenia	  purpura.	  Upon	  starting	  prednisolone,	  her	   echocardiographic	   parameters	   and	  WHO	   functional	   class	   improved	   (from	   class	   III	   to	   II),	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with	   a	   return	   of	   PH	   symptoms	   on	   tapering	   prednisolone	   (Ogawa	   et	   al.,	   2011).	   To	   consider	   a	  controlled	   trial	   of	   GC	   in	   iPAH	   a	   precise	   PAH-­‐specific	   definition	   of	   GC	   sensitivity/resistance	  would	  first	  have	  to	  be	  defined	  and,	  further	  to	  classical	  PH	  end	  points,	  appropriate	  inflammatory	  end	   points	   selected.	   The	   timing,	   dose	   and	   length	   of	   treatment	   time	   would	   need	   careful	  consideration,	   and	   it	   would	   be	   useful	   to	   look	   at	   the	   early	   experience	   in	   patients	   with	   other	  diseases	  such	  as	  multiple	  myeloma.	  We	  are	  now	  seeing	  that	  NF-­‐κB	  activation	  is	  prominent	  even	  in	   late	  stages	  of	  disease	  –	  which	  contrasts	  with	  studies	   in	  animal	  models.	  There	  are	  currently	  patients	  with	  CTD-­‐PAH	  who	  are	  taking	  prednisolone	  as	  part	  of	  their	  treatment,	  and	  may	  present	  a	   patient	   group	  where	   this	   could	   be	   assessed	   in	   the	   context	   of	   a	   controlled	   trial	   to	   establish	  robust	   endpoints	   –	   which	   should	   include	   circulating	   cytokines	   and	   CRP.	   Finally,	   I	   have	  presented	  data	   that	   support	   specific	   inhibition	  of	  NF-­‐κB	   to	  be	  potentially	  useful	   in	  PAH;	   such	  inhibitors	  are	   indeed	  on	   the	  horizon	  although	   there	  are	  concerns	  about	   the	  possibility	  of	   side	  effects	  particularly	  the	  risk	  of	  opportunistic	  infections.	  	  Potential	  ideas	  include	  the	  use	  of	  more	  specific	  targeting	  of	  inflammation	  including	  individual	  cytokines;	  the	  more	  localised	  delivery	  of	  drug	   e.g.	   inhaled	   corticosteroids	   and	   the	   selection	   of	   patients	   with	   a	   marked	   inflammatory	  phenotype	   –	   selecting	   those	  with,	   for	   example,	   very	   high	   circulating	   cytokine	   or	   CRP	   plasma	  levels.	  	  	  
I	  would	  like	  to	  finally	  conclude	  that	  I	  have	  demonstrated	  evidence	  for	  widespread	  activation	  of	  NF-­‐κB	  in	  end-­‐stage	  disease	  in	  patients	  with	  iPAH,	  which	  challenges	  the	  concept	  of	  inflammation	  solely	  being	  an	  early	  ‘hit’;	  and	  contributed	  to	  the	  hypothesis	  that	  the	  anti-­‐remodelling	  effects	  of	  dexamethasone	   can	   be	   explained	   by	   NF-­‐κB	   inhibition.	   In	   addition,	   I	   showed	   that	   circulating	  inflammatory	   cells	   from	   PAH	   patients	   are	   hyporesponsive	   and	   may	   not	   be	   such	   as	   useful	  inflammatory	   signal	   in	   this	   pulmonary	   disease.	   Finally,	   I	   show	   that	   the	   MCT-­‐induced	   PH	   rat	  model	   is	   GC	   sensitive,	   although	   present	   some	   evidence	   for	   GC	   resistance	   in	   human	   cells	   –	   at	  least	  in	  terms	  of	  IL-­‐6	  release.	  This	  work	  needs	  expanding	  by	  studying	  lung-­‐derived	  cells,	  tissue	  and	  ultimately	  patients	  to	  fully	  ascertain	  whether	  iPAH	  is	  a	  GC	  sensitive	  or	  resistant	  condition.	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